Q9BXB4	184	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9ULL5	1169	Natural variant	R	1.0	description:in NOC; dbSNP
Q00LT1	2	Natural variant	C	1.0	description:in RP36; loss of palmitoylation; reduced protein stability; fails to localize to the photoreceptor outer segment; dbSNP
Q00LT1	25	Natural variant	P	1.0	description:in RP36; no effect on protein level
Q00LT1	30	Natural variant	V	1.0	description:in RP36; unknown pathological significance; no effect on protein stability; dbSNP
P07949	20	Natural variant	P	1.0	description:in HSCR1; sporadic form
P07949	618	Natural variant	C	1.0	description:in MEN2A and MTC; familial form; dbSNP
P07949	618	Natural variant	C	1.0	description:in MEN2A; dbSNP
P07949	618	Natural variant	C	1.0	description:in MEN2A, MTC and HSCR1; dbSNP
P07949	618	Natural variant	C	1.0	description:in MEN2A, HSCR1 and MTC; familial and sporadic forms; dbSNP
P07949	618	Natural variant	C	1.0	description:in MEN2A and MTC; familial form; dbSNP
P07949	620	Natural variant	C	1.0	description:in MEN2A and MTC; familial form; dbSNP
P07949	620	Natural variant	C	1.0	description:in MEN2A and MTC; familial and sporadic forms; dbSNP
P07949	620	Natural variant	C	1.0	description:in MEN2A, MTC and HSCR1; familial and sporadic forms; dbSNP
P07949	620	Natural variant	C	1.0	description:in MEN2A and MTC; familial form; dbSNP
P07949	620	Natural variant	C	1.0	description:in MEN2A and HSCR1; dbSNP
P07949	620	Natural variant	C	1.0	description:in MEN2A; dbSNP
P07949	626	Natural variant	Q	1.0	description:in HSCR1; sporadic form; dbSNP
P07949	630	Natural variant	C	1.0	description:in MEN2A and MTC; familial form; dbSNP
P07949	630	Natural variant	C	1.0	description:in MTC; sporadic form; dbSNP
P07949	630	Natural variant	C	1.0	description:in MTC; familial and sporadic forms; dbSNP
P07949	631	Natural variant	D	1.0	description:in thyroid carcinoma; somatic mutation; dbSNP
P07949	634	Natural variant	C	1.0	description:in MEN2A
P07949	634	Natural variant	C	1.0	description:in MEN2A and pheochromocytoma; dbSNP
P07949	634	Natural variant	C	1.0	description:in MEN2A and pheochromocytoma; dbSNP
P07949	634	Natural variant	C	1.0	description:in MEN2A, pheochromocytoma and MTC; familial form; also found as somatic mutation in a sporadic thyroid carcinoma; dbSNP
P07949	634	Natural variant	C	1.0	description:in MEN2A, pheochromocytoma and MTC; familial form; dbSNP
P07949	634	Natural variant	C	1.0	description:in MEN2A, pheochromocytoma and MTC; familial form; dbSNP
P07949	634	Natural variant	C	1.0	description:in MEN2A, pheochromocytoma and MTC; familial form; dbSNP
P07949	679	Natural variant	P	1.0	description:in HSCR1
P07949	690	Natural variant	S	1.0	description:in HSCR1; sporadic form
P07949	694	Natural variant	R	1.0	description:in HSCR1; dbSNP
P07949	830	Natural variant	G	1.0	description:in HSCR1; dbSNP
P07949	1039	Natural variant	P	1.0	description:in HSCR1; dbSNP
P07949	1049	Natural variant	P	1.0	description:in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP
P07949	1052	Natural variant	L	1.0	description:in HSCR1; dbSNP
P07949	1059	Natural variant	N	1.0	description:in HSCR1
P07949	1061	Natural variant	L	1.0	description:in HSCR1; dbSNP
P07949	1062	Natural variant	Y	1.0	description:in HSCR1; dbSNP
P07949	1064	Natural variant	M	1.0	description:in HSCR1; familial form; dbSNP
P07949	1067	Natural variant	P	1.0	description:in a patient with renal agenesis; unknown pathological significance; prevents phosphorylation in response to GDNF; dbSNP
P07949	1112	Natural variant	F	1.0	description:in a bladder transitional cell carcinoma sample; somatic mutation
Q9HCK4	945	Natural variant	I	1.0	description:in VUR2; dbSNP
Q9HCK4	1236	Natural variant	A	1.0	description:in VUR2; dbSNP
Q9NVV4	478	Natural variant	N	1.0	description:in SPAX4; dbSNP
O95340	10	Natural variant	E	1.0	description:decreased sulfate assimilation; dbSNP
Q96QU1	1611	Natural variant	N	1.0	description:in USH1F; dbSNP
Q96QU1	1867	Natural variant	T	1.0	description:in USH1F
Q96IS3	87	Natural variant	R	1.0	description:in ARMD6; increased transactivation and DNA-binding activity; dbSNP
Q96IS3	137	Natural variant	G	1.0	description:in CORD11; decreased interaction with Crx and transactivation activity; dbSNP
Q96IS3	140	Natural variant	P	1.0	description:in CORD11; decreased interaction with Crx and increased transactivation activity
Q9Y6N7	1055	Natural variant	S	1.0	description:in a breast cancer sample; dbSNP
Q9Y6N7	1533	Natural variant	E	1.0	description:in a breast cancer sample; dbSNP
Q96PC5	437	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q8N5Y2	308	Natural variant	L	1.0	description:in MRXSBA; unknown pathological significance; dbSNP
Q8NCK7	443	Natural variant	P	1.0	description:risk factor for NIDDM when associated with I-113, G-127 and S-340; reduced pyruvate transmembrane transporter activity, loss of interaction with BSG and decreased localization to plasma membrane when associated with I-113, G-127 and S-340; dbSNP
Q969G2	389	Natural variant	P	1.0	description:in CPHD4; dbSNP
P20264	407	Natural variant	R	1.0	description:in SNIBFIS; no effect on nuclear location; no effect on transcriptional activation function; no effect on homodimerization
P20264	407	Natural variant	R	1.0	description:in SNIBFIS; no effect on nuclear location; increased transcriptional activation function; no effect on homodimerization
P11086	9	Natural variant	N	1.0	description:slight increase in protein expression and enzyme activity with octopamine as substrate; dbSNP
P47736	609	Natural variant	Y	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9NPG4	1091	Natural variant	G	1.0	description:in DMJDS1; unknown pathological significance; dbSNP
O43316	141	Natural variant	R	1.0	description:in KPD; associated with disease susceptibility; dbSNP
O43316	172	Natural variant	R	1.0	description:in MODY9; the mutant sequence represses the activity of the insulin and glucagon promoters by only 35% compared to 50% and 57% respectively with wild-type sequence
P27918	3	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
P27918	414	Natural variant	Y	1.0	description:in PFD; type III; significantly decreases Complement C3 beta chain binding; dbSNP
O14827	538	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9H792	611	Natural variant	H	1.0	description:in a bladder carcinoma NOS sample; somatic mutation
Q9H792	1035	Natural variant	S	1.0	description:in a metastatic melanoma sample; somatic mutation
Q9H792	1145	Natural variant	P	1.0	description:in a metastatic melanoma sample; somatic mutation
O75360	73	Natural variant	R	1.0	description:in CPHD2; familial; no detectable DNA binding observed with the mutant protein in electromobility shift assays; whereas in vitro translated PROP1 and the mutant proteins were similar in their expression and electrophoretic properties; dbSNP
O75360	73	Natural variant	R	1.0	description:in CPHD2; familial; dbSNP
O60828	224	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
O60828	244	Natural variant	P	1.0	description:probable disease-associated variant found in a patient with autism; dbSNP
Q02962	2	Natural variant	D	1.0	description:in PAPRS
Q02962	150	Natural variant	T	1.0	description:in FSGS7; dbSNP
Q02962	164	Natural variant	T	1.0	description:in FSGS7; dbSNP
Q02962	189	Natural variant	G	1.0	description:in FSGS7; transactivation activity is dramatically decreased in presence of TLE4; dramatically enhances interaction with TLE4; dbSNP
Q02962	295	Natural variant	A	1.0	description:in PAPRS; dbSNP
Q02962	296	Natural variant	L	1.0	description:in PAPRS
Q02962	298	Natural variant	P	1.0	description:in PAPRS; dbSNP
Q02962	329	Natural variant	T	1.0	description:in PAPRS
Q02962	387	Natural variant	S	1.0	description:found in a patient with bilateral optic nerve colobomas; uncertain pathological significance; dbSNP
Q99946	94	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q5UIP0	1784	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q5UIP0	1955	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q96RG2	11	Natural variant	E	1.0	description:in a metastatic melanoma sample; somatic mutation; dbSNP
Q86XR5	22	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UMZ3	281	Natural variant	R	1.0	description:in DFNB84A
Q6ZVN8	80	Natural variant	C	1.0	description:in HFE2A; dbSNP
P41220	2	Natural variant	Q	1.0	description:rare variant; unknown pathological significance; decreased down-regulation of angiotensin-activated signaling pathway; decreased RGS2 protein abundance; dbSNP
P41220	2	Natural variant	Q	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P41220	3	Natural variant	S	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P41220	4	Natural variant	A	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P41220	5	Natural variant	M	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P41220	18	Natural variant	K	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P41220	23	Natural variant	G	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P41220	40	Natural variant	D	1.0	description:unknown pathological significance; decreased down-regulation of angiotensin-activated signaling pathway; reduced localization at the cell membrane; dbSNP
P41220	44	Natural variant	R	1.0	description:unknown pathological significance; decreased down-regulation of angiotensin-activated signaling pathway; reduced localization at the cell membrane; dbSNP
P41220	50	Natural variant	Q	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P41220	55	Natural variant	P	1.0	description:likely benign variant; no effect on down-regulation of angiotensin-activated signaling pathway; dbSNP
P48378	37	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
P48378	110	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9BXM0	651	Natural variant	D	1.0	description:in CMT4F; dbSNP
Q9BXM0	1335	Natural variant	R	1.0	description:found in a patient with a complex hereditary motor and sensory neuropathy form associated with dysarthria, joints hypermobility and cerebellar signs; unknown pathological significance; dbSNP
Q9NQV8	261	Natural variant	F	1.0	description:in EPM10; does not affect interaction with EPM2A and NHLRC1; dbSNP
Q13635	1242	Natural variant	E	1.0	description:in squamous cell carcinoma; dbSNP
Q13635	1438	Natural variant	E	1.0	description:in BCNS; sporadic NBCCS
Q92698	63	Natural variant	P	1.0	description:in a colon adenocarcinoma sample; dbSNP
Q6ZRF8	603	Natural variant	G	1.0	description:associated with prolonged QT interval in heart's electrical cycle; behaves like wild-type in terms of protein expression, subcellular location and shortening of heart's action potential duration, when expressed in neonatal rabbit cardiomyocytes; dbSNP
Q07001	398	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q07001	402	Natural variant	E	1.0	description:in CMS3C; results in reduced expression of the AChR at the cell surface; impairs normal clustering of the AChR channel with RAPSN; dbSNP
Q9UKV5	605	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q15059	161	Natural variant	A	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
Q02388	1347	Natural variant	G	1.0	description:in RDEB; localized type; mild; dbSNP
Q02388	1364	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q02388	1366	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q02388	1519	Natural variant	G	1.0	description:in TBDN; dbSNP
Q02388	1522	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	1557	Natural variant	G	1.0	description:in DDEB
Q02388	1595	Natural variant	G	1.0	description:in NDNC8; dbSNP
Q02388	1604	Natural variant	G	1.0	description:in RDEB; dbSNP
Q02388	1652	Natural variant	G	1.0	description:in RDEB; mitis type; dbSNP
Q02388	1703	Natural variant	G	1.0	description:in RDEB; dbSNP
Q02388	1772	Natural variant	R	1.0	description:in RDEB; dbSNP
Q02388	1776	Natural variant	G	1.0	description:in DDEB
Q02388	1782	Natural variant	G	1.0	description:in RDEB; mitis type; dbSNP
Q02388	1791	Natural variant	G	1.0	description:in EBP; dbSNP
Q02388	1812	Natural variant	G	1.0	description:in RDEB
Q02388	1815	Natural variant	G	1.0	description:in NDNC8; dbSNP
Q02388	1845	Natural variant	G	1.0	description:in RDEB
Q02388	1981	Natural variant	K	1.0	description:in RDEB; mild form
Q02388	1982	Natural variant	G	1.0	description:in RDEB
Q02388	2003	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	2006	Natural variant	G	1.0	description:in DDEB
Q02388	2006	Natural variant	G	1.0	description:in DDEB; interferes with collagen VII folding and secretion; dbSNP
Q02388	2008	Natural variant	R	1.0	description:in RDEB; dbSNP
Q02388	2008	Natural variant	R	1.0	description:in RDEB; dbSNP
Q02388	2009	Natural variant	G	1.0	description:in RDEB
Q02388	2015	Natural variant	G	1.0	description:in DDEB; interferes with collagen VII folding and secretion; dbSNP
Q02388	2025	Natural variant	G	1.0	description:in RDEB; mitis type; dbSNP
Q02388	2028	Natural variant	G	1.0	description:in DDEB
Q02388	2028	Natural variant	G	1.0	description:in DDEB and EBP; dbSNP
Q02388	2031	Natural variant	G	1.0	description:in RDEB; severe phenotype; dbSNP
Q02388	2034	Natural variant	G	1.0	description:in DDEB and EBDSC; interferes with collagen VII folding and secretion; dbSNP
Q02388	2034	Natural variant	G	1.0	description:in DDEB
Q02388	2037	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	2040	Natural variant	G	1.0	description:in DDEB
Q02388	2040	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	2040	Natural variant	G	1.0	description:in DDEB
Q02388	2043	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	2043	Natural variant	G	1.0	description:in DDEB; localized type; dbSNP
Q02388	2046	Natural variant	G	1.0	description:in DDEB
Q02388	2049	Natural variant	G	1.0	description:in RDEB
Q02388	2055	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	2063	Natural variant	R	1.0	description:in RDEB; dbSNP
Q02388	2064	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	2069	Natural variant	R	1.0	description:in RDEB; dbSNP
Q02388	2070	Natural variant	G	1.0	description:in DDEB
Q02388	2073	Natural variant	G	1.0	description:in RDEB; mitis type
Q02388	2076	Natural variant	G	1.0	description:in DDEB; also in recessive forms; dbSNP
Q02388	2079	Natural variant	G	1.0	description:in DDEB
Q02388	2079	Natural variant	G	1.0	description:in DDEB; associated with squamous cell carcinoma
Q02388	2132	Natural variant	G	1.0	description:in RDEB; dbSNP
Q02388	2192	Natural variant	G	1.0	description:in RDEB
Q02388	2207	Natural variant	G	1.0	description:in DDEB
Q02388	2221	Natural variant	G	1.0	description:in RDEB
Q02388	2242	Natural variant	G	1.0	description:in EBP; dbSNP
Q02388	2251	Natural variant	G	1.0	description:in TBDN; also found in isolated toenail dystrophy; dbSNP
Q02388	2263	Natural variant	G	1.0	description:in RDEB
Q02388	2287	Natural variant	G	1.0	description:in RDEB; also found in isolated toenail dystrophy; dbSNP
Q02388	2296	Natural variant	G	1.0	description:in RDEB
Q02388	2316	Natural variant	G	1.0	description:in RDEB
Q02388	2348	Natural variant	G	1.0	description:in DDEB/RDEB; mild form
Q02388	2351	Natural variant	G	1.0	description:in a patient with dystrophic epidermolysis bullosa; mitis type; dbSNP
Q02388	2366	Natural variant	G	1.0	description:in RDEB; mitis type; dbSNP
Q02388	2369	Natural variant	G	1.0	description:in EBP
Q02388	2557	Natural variant	G	1.0	description:in RDEB
Q02388	2569	Natural variant	G	1.0	description:in RDEB; severe and mitis type
Q02388	2575	Natural variant	G	1.0	description:in RDEB; dbSNP
Q02388	2622	Natural variant	R	1.0	description:in RDEB; dbSNP
Q02388	2623	Natural variant	G	1.0	description:in PR-DEB; dominant; dbSNP
Q02388	2653	Natural variant	G	1.0	description:in RDEB; mitis type; dbSNP
Q02388	2671	Natural variant	G	1.0	description:in RDEB
Q02388	2674	Natural variant	G	1.0	description:in RDEB
Q02388	2674	Natural variant	G	1.0	description:in RDEB; mitis type
Q02388	2713	Natural variant	G	1.0	description:in DDEB; dbSNP
Q02388	2713	Natural variant	G	1.0	description:in EBP
Q02388	2740	Natural variant	G	1.0	description:in RDEB
Q02388	2749	Natural variant	G	1.0	description:in RDEB; dbSNP
Q02388	2775	Natural variant	G	1.0	description:in RDEB; mitis type; dbSNP
Q02388	2791	Natural variant	R	1.0	description:in DDEB; dbSNP
Q02388	2798	Natural variant	M	1.0	description:in RDEB; dbSNP
P16220	102	Natural variant	D	1.0	description:found in a patient with multiple congenital anomalies; does not affect CREB1 phosphorylation at S-119; fails to interact with CREBBP; dbSNP
P00451	19	Natural variant	S	1.0	description:in HEMA
P00451	22	Natural variant	R	1.0	description:in HEMA; severe
P00451	24	Natural variant	Y	1.0	description:in HEMA
P00451	25	Natural variant	Y	1.0	description:in HEMA; mild
P00451	26	Natural variant	L	1.0	description:in HEMA; severe
P00451	26	Natural variant	L	1.0	description:in HEMA; severe; dbSNP
P00451	30	Natural variant	E	1.0	description:in HEMA; mild; dbSNP
P00451	33	Natural variant	W	1.0	description:in HEMA; moderate
P00451	35	Natural variant	Y	1.0	description:in HEMA; mild/severe; dbSNP
P00451	35	Natural variant	Y	1.0	description:in HEMA; severe
P00451	41	Natural variant	G	1.0	description:in HEMA; severe/moderate; dbSNP
P00451	48	Natural variant	R	1.0	description:in HEMA; severe
P00451	48	Natural variant	R	1.0	description:in HEMA; dbSNP
P00451	129	Natural variant	E	1.0	description:in HEMA; severe
P00451	130	Natural variant	G	1.0	description:in HEMA; severe; dbSNP
P00451	132	Natural variant	E	1.0	description:in HEMA; severe; dbSNP
P00451	133	Natural variant	Y	1.0	description:in HEMA; mild; dbSNP
P00451	135	Natural variant	D	1.0	description:in HEMA; severe; dbSNP
P00451	135	Natural variant	D	1.0	description:in HEMA; severe sporadic
P00451	137	Natural variant	T	1.0	description:in HEMA; severe
P00451	137	Natural variant	T	1.0	description:in HEMA; moderate; dbSNP
P00451	138	Natural variant	S	1.0	description:in HEMA; mild
P00451	141	Natural variant	E	1.0	description:in HEMA; severe familial; dbSNP
P00451	145	Natural variant	D	1.0	description:in HEMA; moderate; dbSNP
P00451	147	Natural variant	V	1.0	description:in HEMA; severe
P00451	340	Natural variant	E	1.0	description:in HEMA; dbSNP
P00451	345	Natural variant	V	1.0	description:in HEMA; dbSNP
P00451	345	Natural variant	V	1.0	description:in HEMA; severe; dbSNP
P00451	348	Natural variant	C	1.0	description:in HEMA; severe; dbSNP
P00451	348	Natural variant	C	1.0	description:in HEMA; moderate; dbSNP
P00451	348	Natural variant	C	1.0	description:in HEMA; mild/severe
P00451	365	Natural variant	Y	1.0	description:in HEMA; mild; dbSNP
P00451	739	Natural variant	E	1.0	description:in HEMA; mild; dbSNP
P00451	742	Natural variant	Y	1.0	description:in HEMA; mild
P00451	947	Natural variant	P	1.0	description:in HEMA; dbSNP
P00451	1012	Natural variant	V	1.0	description:in HEMA
P00451	1057	Natural variant	E	1.0	description:in HEMA; moderate; dbSNP
P00451	1066	Natural variant	H	1.0	description:in HEMA
P00451	1336	Natural variant	Q	1.0	description:in HEMA
P00451	1460	Natural variant	N	1.0	description:in HEMA
P00451	1610	Natural variant	A	1.0	description:in HEMA; dbSNP
P00451	1698	Natural variant	I	1.0	description:in HEMA; mild
P00451	1699	Natural variant	Y	1.0	description:in HEMA; severe
P00451	1699	Natural variant	Y	1.0	description:in HEMA; moderate; dbSNP
P00451	1701	Natural variant	E	1.0	description:in HEMA; mild
P00451	1705	Natural variant	Q	1.0	description:in HEMA; mild sporadic
P00451	1708	Natural variant	R	1.0	description:in HEMA; East Hartford; severe/moderate/mild; abolishes thrombin cleavage at the light chain; dbSNP
P00451	1708	Natural variant	R	1.0	description:in HEMA; mild; abolishes thrombin cleavage at the light chain; dbSNP
P00451	1714	Natural variant	T	1.0	description:in HEMA; moderate
P00451	1715	Natural variant	R	1.0	description:in HEMA; mild; dbSNP
P00451	1720	Natural variant	A	1.0	description:in HEMA
P00451	1723	Natural variant	E	1.0	description:in HEMA; severe; dbSNP
P00451	1727	Natural variant	D	1.0	description:in HEMA; mild
P00451	1728	Natural variant	Y	1.0	description:in HEMA; moderate; dbSNP
P00451	1740	Natural variant	R	1.0	description:in HEMA; mild
P81408	358	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q15910	185	Natural variant	D	1.0	description:decreased histone methyltransferase activity; dbSNP
P11362	4	Natural variant	W	1.0	description:in HH2; unknown pathological significance; dbSNP
P11362	96	Natural variant	S	1.0	description:in HH2; unknown pathological significance
P11362	97	Natural variant	G	1.0	description:in HH2
P11362	99	Natural variant	Y	1.0	description:in HH2; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression; dbSNP
P11362	101	Natural variant	C	1.0	description:in HH2
P11362	102	Natural variant	V	1.0	description:in HH2; dbSNP
P11362	116	Natural variant	V	1.0	description:in HH2; dbSNP
P11362	117	Natural variant	N	1.0	description:in HH2; some patients also carry GNRHR mutations; dbSNP
P11362	125	Natural variant	S	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP
P11362	129	Natural variant	D	1.0	description:in HH2; dbSNP
P11362	795	Natural variant	V	1.0	description:in HH2; also found in a family member with isolated anosmia; dbSNP
O95872	314	Natural variant	T	1.0	description:found in a clear cell renal carcinoma case; somatic mutation
P38567	5	Natural variant	K	1.0	description:found in a renal cell carcinoma sample; somatic mutation
O75626	84	Natural variant	P	1.0	description:found in an activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) cell line; protein instability caused by increased susceptibility to proteasomal degradation
P30566	2	Natural variant	A	1.0	description:in ADSLD; severe; dbSNP
P30566	3	Natural variant	A	1.0	description:in ADSLD; severe
Q8N196	296	Natural variant	A	1.0	description:in BOR2; dbSNP
Q8N196	365	Natural variant	G	1.0	description:in BOR2; dbSNP
Q8N196	552	Natural variant	T	1.0	description:in BOR2; affects Eya1 binding and the ability to activate gene transcription; dbSNP
Q9HB58	425	Natural variant	L	1.0	description:may be associated with increased susceptibility to tuberculosis; dbSNP
Q9UGU0	512	Natural variant	K	1.0	description:in DDVIBA; unknown pathological significance
Q9UGU0	1557	Natural variant	P	1.0	description:in DDVIBA; unknown pathological significance
Q9UGU0	1937	Natural variant	P	1.0	description:in DDVIBA; unknown pathological significance
Q9UGU0	1942	Natural variant	P	1.0	description:in DDVIBA; unknown pathological significance
Q13009	678	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q13485	13	Natural variant	N	1.0	description:rare variant; found in a patient with pulmonary hypertension; unknown pathological significance; dbSNP
P48431	51	Natural variant	W	1.0	description:in MCOPS3; unknown pathological significance
Q9C004	77	Natural variant	T	1.0	description:in HH17; phenotype consistent with Kallmann syndrome; dbSNP
Q9C004	82	Natural variant	D	1.0	description:in HH17; without anosmia; dbSNP
Q15475	249	Natural variant	P	1.0	description:in BOR; uncertain pathological significance; dbSNP
O15273	70	Natural variant	R	1.0	description:in CMH25; dbSNP
O15273	87	Natural variant	R	1.0	description:found in a patient with dilated cardiomyopathy; unknown pathological significance; dbSNP
O15273	90	Natural variant	P	1.0	description:in CMH25; unknown pathological significance; dbSNP
O15273	132	Natural variant	E	1.0	description:probable disease-associated variant found in a patient with dilated cardiomyopathy; impairs the interaction with CSRP3, TTN and MYOZ2; dbSNP
O15273	137	Natural variant	T	1.0	description:in CMH25; increased interaction with TTN and MYOZ2; dbSNP
O15273	153	Natural variant	R	1.0	description:in CMH25; dbSNP
O00300	182	Natural variant	D	1.0	description:in PDB5; dbSNP
Q6ZMH5	304	Natural variant	M	1.0	description:in MYP24; affects the BMP/TGF-beta pathway by suppressing expression of SMAD1; loss of function mutation; dbSNP
Q01196	174	Natural variant	R	1.0	description:in FPDMM; impaired phosphorylation; dbSNP
Q5TH74	254	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
P17987	7	Natural variant	V	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9UP52	22	Natural variant	V	1.0	description:in HFE3; dbSNP
P04155	32	Natural variant	T	1.0	description:in a gastric carcinoma sample; somatic mutation
P04155	32	Natural variant	T	1.0	description:in a gastric carcinoma sample; somatic mutation
P04155	34	Natural variant	A	1.0	description:in a gastric carcinoma sample; somatic mutation; abolishes inhibition of gastric cancer cell growth; abolishes inhibition of apoptosis in gasterointestinal epithelial cells; increases invasive activity in epithelial cells; dbSNP
P04155	37	Natural variant	E	1.0	description:in a gastric carcinoma sample; somatic mutation; abolishes inhibition of gastric cancer cell growth; abolishes inhibition of apoptosis in gasterointestinal epithelial cells; increases invasive activity in epithelial cells
P04155	46	Natural variant	V	1.0	description:in a gastric adenoma sample; somatic mutation
P04155	55	Natural variant	G	1.0	description:in a gastric carcinoma sample; somatic mutation; dbSNP
O60216	481	Natural variant	G	1.0	description:found in a radiation-sensitive cancer patient; dbSNP
Q92736	414	Natural variant	R	1.0	description:in CPVT1; dbSNP
Q9NP59	248	Natural variant	Q	1.0	description:associated with mild anemia and a tendency to iron loading; dbSNP
Q9NP59	267	Natural variant	G	1.0	description:in HFE4; dbSNP
Q9NP59	270	Natural variant	D	1.0	description:in HFE4; dbSNP
P55011	979	Natural variant	E	1.0	description:in DFNA78; dbSNP
P55011	980	Natural variant	E	1.0	description:in DELMNES; dbSNP
P55011	981	Natural variant	D	1.0	description:in DFNA78; reduced chloride transmembrane transport; dbSNP
P55011	988	Natural variant	P	1.0	description:in DFNA78; reduced chloride transmembrane transport; dbSNP
Q01826	323	Natural variant	M	1.0	description:in KTZSL
Q01826	366	Natural variant	S	1.0	description:no effect on DNA-binding or transcriptional repression
Q01826	573	Natural variant	A	1.0	description:no effect on DNA-binding or transcriptional repression
Q01826	577	Natural variant	H	1.0	description:in KTZSL
Q01826	619	Natural variant	Q	1.0	description:in KTZSL; unknown pathological significance
O43597	119	Natural variant	R	1.0	description:in IGAN3; no effect on protein expression; negatively regulates ERK1 and ERK2 cascade; dbSNP
P05106	778	Natural variant	S	1.0	description:in GT2; variant Strasbourg-1; dbSNP
Q9BXM7	92	Natural variant	C	1.0	description:in PARK6; dbSNP
Q9BXM7	196	Natural variant	P	1.0	description:in PARK6; dbSNP
P06400	358	Natural variant	R	1.0	description:in RB
P06400	358	Natural variant	R	1.0	description:in RB; dbSNP
P06400	616	Natural variant	K	1.0	description:in RB
P06400	635	Natural variant	A	1.0	description:in RB
P06400	803	Natural variant	N	1.0	description:in RB
Q66K14	1086	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q9BWX1	369	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
O43157	1891	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q9NYY3	14	Natural variant	S	1.0	description:in an ovarian Endometrioid carcinoma sample; somatic mutation; dbSNP
Q7Z3Z2	6	Natural variant	W	1.0	description:in an individual with an atypical late-onset form of retinitis pigmentosa; does not affect ability to suppress GUCY2D activity induced by GCAPA; dbSNP
Q96DA2	192	Natural variant	G	1.0	description:in WSMN; impaired localization to cytoplasmic vesicles; dbSNP
Q9BXA9	143	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
Q9H156	601	Natural variant	S	1.0	description:does not affect synaptogenesis; no effect on localization to cell membrane; dbSNP
P00441	55	Natural variant	T	1.0	description:in ALS1; reduces tendency to form fibrillar aggregates; dbSNP
P00441	66	Natural variant	N	1.0	description:in ALS1; dbSNP
P00441	68	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	68	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	73	Natural variant	G	1.0	description:in ALS1; dbSNP
P00441	77	Natural variant	D	1.0	description:in ALS1; dbSNP
P00441	81	Natural variant	H	1.0	description:in ALS1; sporadic form; interferes with zinc binding; requires 2 nucleotide substitutions
P00441	85	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	85	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	86	Natural variant	G	1.0	description:in ALS1; ubiquitinated by RNF19A; interferes with zinc-binding; ubiquitinated by MARCH5; leading to the degradation of mitochondrial SOD1; dbSNP
P00441	87	Natural variant	N	1.0	description:in ALS1; dbSNP
P00441	88	Natural variant	V	1.0	description:in ALS1; dbSNP
P00441	90	Natural variant	A	1.0	description:in ALS1; dbSNP
P00441	90	Natural variant	A	1.0	description:in ALS1; dbSNP
P00441	91	Natural variant	D	1.0	description:in ALS1; does not seem to be linked with a decrease in activity; dbSNP
P00441	91	Natural variant	D	1.0	description:in ALS1; dbSNP
P00441	94	Natural variant	G	1.0	description:in ALS1; increases tendency to form fibrillar aggregates; ubiquitinated by RNF19A; dbSNP
P00441	94	Natural variant	G	1.0	description:in ALS1; dbSNP
P00441	94	Natural variant	G	1.0	description:in ALS1; dbSNP
P00441	94	Natural variant	G	1.0	description:in ALS1; 30% of wild-type activity; dbSNP
P00441	94	Natural variant	G	1.0	description:in ALS1; dbSNP
P00441	96	Natural variant	A	1.0	description:in ALS1; dbSNP
P00441	98	Natural variant	V	1.0	description:in ALS1; increases tendency to form fibrillar aggregates; dbSNP
P00441	101	Natural variant	E	1.0	description:in ALS1; dbSNP
P00441	101	Natural variant	E	1.0	description:in ALS1; dbSNP
P00441	102	Natural variant	D	1.0	description:in ALS1; dbSNP
P00441	102	Natural variant	D	1.0	description:in ALS1; dbSNP
P00441	105	Natural variant	I	1.0	description:in ALS1; dbSNP
P00441	106	Natural variant	S	1.0	description:in ALS1; dbSNP
P00441	107	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	109	Natural variant	G	1.0	description:in ALS1; dbSNP
P00441	112	Natural variant	C	1.0	description:in ALS1; dbSNP
P00441	113	Natural variant	I	1.0	description:in ALS1; dbSNP
P00441	113	Natural variant	I	1.0	description:in ALS1; dbSNP
P00441	114	Natural variant	I	1.0	description:in ALS1; destabilizes dimeric protein structure and increases tendency to form fibrillar aggregates; dbSNP
P00441	115	Natural variant	G	1.0	description:in ALS1; dbSNP
P00441	116	Natural variant	R	1.0	description:in ALS1; dbSNP
P00441	119	Natural variant	V	1.0	description:in ALS1; dbSNP
P00441	119	Natural variant	V	1.0	description:in ALS1
P00441	125	Natural variant	D	1.0	description:in ALS1; dbSNP
P00441	125	Natural variant	D	1.0	description:in ALS1; dbSNP
P00441	126	Natural variant	D	1.0	description:in ALS1; dbSNP
P00441	127	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	134	Natural variant	E	1.0	description:in ALS; dbSNP
P00441	135	Natural variant	S	1.0	description:in ALS1; reduced metal binding; increases tendency to form fibrillar aggregates; dbSNP
P00441	140	Natural variant	N	1.0	description:in ALS1; dbSNP
P00441	145	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	145	Natural variant	L	1.0	description:in ALS1; dbSNP
P00441	146	Natural variant	A	1.0	description:in ALS1; dbSNP
P00441	147	Natural variant	C	1.0	description:in ALS1; dbSNP
P00441	148	Natural variant	G	1.0	description:in ALS1; dbSNP
P00441	149	Natural variant	V	1.0	description:in ALS1; dbSNP
P00441	149	Natural variant	V	1.0	description:in ALS1; dbSNP
P00441	150	Natural variant	I	1.0	description:in ALS1; dbSNP
P00441	152	Natural variant	I	1.0	description:in ALS1; dbSNP
P22105	29	Natural variant	R	1.0	description:in EDSCLL; dbSNP
P22105	1244	Natural variant	T	1.0	description:in VUR8
P26367	178	Natural variant	Q	1.0	description:in AN1
P26367	292	Natural variant	S	1.0	description:in BONH; significant impairment of ability to activate transcription
P26367	321	Natural variant	A	1.0	description:shows about two-fold higher binding efficiency than the normal wild-type protein; transcriptional activation ability is about 89% of that of the wild-type protein
P26367	353	Natural variant	S	1.0	description:in AN1; dbSNP
P26367	363	Natural variant	S	1.0	description:in ASGD5
P26367	375	Natural variant	P	1.0	description:in AN1; reduced DNA binding ability; dbSNP
P26367	378	Natural variant	Q	1.0	description:in optic nerve aplasia
P26367	381	Natural variant	M	1.0	description:in BONH
P26367	391	Natural variant	T	1.0	description:in BONH; dbSNP
P26367	395	Natural variant	G	1.0	description:in AN1
P26367	422	Natural variant	Q	1.0	description:in AN1 and ocular anterior segment anomalies; loss of DNA binding ability; dbSNP
Q92834	436	Natural variant	G	1.0	description:in RP3; dbSNP
Q96S37	75	Natural variant	I	1.0	description:in RHUC1; unknown pathological significance; reduced urate transport; decreased localization to cell membrane; dbSNP
Q96S37	90	Natural variant	R	1.0	description:in RHUC1; strongly reduced urate transport; dbSNP
Q4U2R8	50	Natural variant	R	1.0	description:lower Vmax; increase in substrate affinity and increase in the affinity for the nucleoside phosphonate analogs cidofovir, adefovir and tenofovir; dbSNP
Q9UGP8	568	Natural variant	E	1.0	description:in PCLD2
O60880	102	Natural variant	V	1.0	description:in XLP1; reduced protein stability and strongly reduced affinity for SLAMF1, decreases interaction with FYN
Q9UPX8	1101	Natural variant	A	1.0	description:found in a child with developmental disabilities; unknown pathological significance; dbSNP
Q9Y566	2026	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q8IY92	378	Natural variant	P	1.0	description:likely benign variant; does not modify the functional properties of the protein
Q8IY92	952	Natural variant	A	1.0	description:requires 2 nucleotide substitutions; dbSNP
Q8IY92	1550	Natural variant	R	1.0	description:does not modify the functional properties of the protein; dbSNP
Q8IY92	1834	Natural variant	N	1.0	description:does not modify the functional properties of the protein; dbSNP
Q07890	1092	Natural variant	P	1.0	description:in NS9; unknown pathological significance; dbSNP
Q96N96	89	Natural variant	R	1.0	description:found in two consanguineous families with intellectual disability; unknown pathological significance; dbSNP
P49842	89	Natural variant	D	1.0	description:recurrent gain-of-function variant found in metastatic melanoma; promotes NRAS signaling; somatic mutation; dbSNP
Q5JTZ9	50	Natural variant	F	1.0	description:in LKENP; deleterious only under stress conditions; dbSNP
P01308	84	Natural variant	G	1.0	description:in PNDM4; uncertain pathological significance; dbSNP
P01308	89	Natural variant	R	1.0	description:in PNDM4; dbSNP
P01308	89	Natural variant	R	1.0	description:in HPRI; impairs post-translational cleavage; dbSNP
P01308	89	Natural variant	R	1.0	description:in HPRI; Kyoto; dbSNP
P01308	90	Natural variant	G	1.0	description:in PNDM4; dbSNP
P01308	92	Natural variant	V	1.0	description:in Wakayama; dbSNP
P01308	96	Natural variant	C	1.0	description:in PNDM4; dbSNP
P01308	96	Natural variant	C	1.0	description:in PNDM4; dbSNP
P01308	101	Natural variant	S	1.0	description:in PNDM4; dbSNP
P01308	103	Natural variant	Y	1.0	description:in PNDM4; dbSNP
P01308	108	Natural variant	Y	1.0	description:in PNDM4; dbSNP
Q9UBS0	443	Natural variant	T	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP
Q93074	1974	Natural variant	Q	1.0	description:found in a family with X-linked intellectual disability; unknown pathological significance; dbSNP
Q13508	334	Natural variant	P	1.0	description:found in patients with non-obstructive azoospermia; unknown pathological significance; dbSNP
Q13563	807	Natural variant	R	1.0	description:in PKD2; dbSNP
Q9H6I2	17	Natural variant	Q	1.0	description:in VUR3
Q9H6I2	178	Natural variant	G	1.0	description:in VUR3; dbSNP
Q9H6I2	259	Natural variant	Y	1.0	description:in VUR3; increased levels of the mutant protein that is associated with increased suppression of CTNNB1 signaling of the Wnt pathway compared to wild-type; dbSNP
Q9NSC7	207	Natural variant	T	1.0	description:found in patients with Inflammatory bowel disease; unknown pathological significance; does dot affect protein sialyltransferase activity; dbSNP
P40763	716	Natural variant	T	1.0	description:in ADMIO1; dbSNP
Q9HCD6	1689	Natural variant	H	1.0	description:in IDDALDS; unknown pathological significance; dbSNP
P36897	26	Natural variant	A	1.0	description:in allele TGFBR1*10A
Q15583	157	Natural variant	S	1.0	description:in HPE4; dbSNP
Q15583	236	Natural variant	Q	1.0	description:in HPE4; dbSNP
Q15583	280	Natural variant	T	1.0	description:in HPE4; dbSNP
Q15583	291	Natural variant	S	1.0	description:in HPE4; dbSNP
Q9UPN9	580	Natural variant	M	1.0	description:in a glioblastoma multiforme sample; somatic mutation
Q9UPN9	811	Natural variant	E	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q9UPN9	885	Natural variant	P	1.0	description:in a glioblastoma multiforme sample; somatic mutation
Q96M63	248	Natural variant	A	1.0	description:in CILD20; expressed at very low levels in patients' nasal epithelial cells; the genetic variation producing this missense variant predominantly affects splicing; dbSNP
Q9NQ40	266	Natural variant	R	1.0	description:in BVVLS1; unknown pathological significance; dbSNP
Q9BZR6	377	Natural variant	R	1.0	description:in SCZD; associated with disease susceptibility; unable to mediate down-regulation of axonal growth; does not affect interaction with MAG, RTN4, OMG, NGFR and LINGO1; dbSNP
Q9BZR6	377	Natural variant	R	1.0	description:in SCZD; associated with disease susceptibility; unable to mediate down-regulation of axonal growth; does not affect interaction with MAG, RTN4, OMG, NGFR and LINGO1; dbSNP
Q9BZR6	399	Natural variant	R	1.0	description:in SCZD; unknown pathological significance; dbSNP
Q9Y6X0	854	Natural variant	S	1.0	description:in AML
Q9Y6X0	858	Natural variant	E	1.0	description:in ACML; somatic mutation in ACML and other myeloid malignancies; dbSNP
Q9Y6X0	868	Natural variant	D	1.0	description:in SGMFS; dbSNP
Q9Y6X0	868	Natural variant	D	1.0	description:in myeloid malignancies
Q9Y6X0	868	Natural variant	D	1.0	description:in SGMFS, ACML, JMML and MDS; also found in other myeloid malignancies; somatic mutation; dbSNP
Q9Y6X0	868	Natural variant	D	1.0	description:in myeloid malignancies
Q9Y6X0	869	Natural variant	S	1.0	description:in MDS and myeloid malignancies
Q9Y6X0	869	Natural variant	S	1.0	description:in myeloid malignancies
Q9Y6X0	870	Natural variant	G	1.0	description:in SGMFS; dbSNP
Q9Y6X0	870	Natural variant	G	1.0	description:in AML
Q9Y6X0	870	Natural variant	G	1.0	description:in SGMFS, ACML, MDS and AML; somatic mutation in ACML and other myeloid malignancies; results in higher protein levels; cells expressing this mutant exhibit higher proliferation rates than those expressing the wild-type protein; dbSNP
Q9Y6X0	870	Natural variant	G	1.0	description:in myeloid malignancies
Q9Y6X0	871	Natural variant	I	1.0	description:in AML; dbSNP
Q9Y6X0	871	Natural variant	I	1.0	description:in SGMFS and ACML; somatic mutation in ACML and other myeloid malignancies; dbSNP
Q9Y6X0	873	Natural variant	T	1.0	description:in MDS and myeloid malignancies
Q9Y6X0	874	Natural variant	D	1.0	description:in myeloid malignancies
Q9Y6X0	880	Natural variant	D	1.0	description:in myeloid malignancies
Q9Y6X0	880	Natural variant	D	1.0	description:in myeloid malignancies
Q9Y6X0	880	Natural variant	D	1.0	description:in myeloid malignancies
Q9Y6X0	908	Natural variant	D	1.0	description:in myeloid malignancies; dbSNP
Q9Y6X0	1162	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q15465	6	Natural variant	R	1.0	description:in HPE3
Q15465	17	Natural variant	L	1.0	description:in HPE3
Q15465	26	Natural variant	P	1.0	description:in HPE3
Q15465	27	Natural variant	G	1.0	description:in HPE3
Q15465	31	Natural variant	G	1.0	description:in HPE3; the same mutation in the mouse sequence introduces a cleavage site for a furin-like protease resulting in abnormal protein processing; cleavage at this site removes 11 amino acids from the N-terminal domain and reduces affinity of Shh for Ptch1 and signaling potency in assays using chicken embryo neural plate explants and mouse C3H10T1/2 stem cells; dbSNP
Q15465	39	Natural variant	L	1.0	description:in HPE3; dbSNP
Q15465	280	Natural variant	S	1.0	description:in HPE3
Q15465	290	Natural variant	G	1.0	description:in HPE3; sporadic; dbSNP
Q15465	296	Natural variant	G	1.0	description:in HPE3; unknown pathological significance; dbSNP
Q15465	411	Natural variant	G	1.0	description:in HPE3; unknown pathological significance
Q15465	416	Natural variant	T	1.0	description:in HPE3; unknown pathological significance; dbSNP
Q15465	424	Natural variant	P	1.0	description:in HPE3; familial; dbSNP
Q15465	435	Natural variant	Y	1.0	description:in HPE3
Q15465	436	Natural variant	S	1.0	description:in HPE3; sporadic
Q15465	456	Natural variant	G	1.0	description:in HPE3; unknown pathological significance
Q9Y448	24	Natural variant	S	1.0	description:in SCC; impaired chromatid cohesion; dbSNP
Q15468	798	Natural variant	L	1.0	description:in MCPH7; dbSNP
Q9NRP7	1185	Natural variant	P	1.0	description:in an ovarian endometrioid sample; somatic mutation
P02786	20	Natural variant	Y	1.0	description:in IMD46; increases protein expression; increases cell surface expression on T and B cells; increases soluble form level; impairs receptor internalization; impairs transferrin transport; impairs T and B cell proliferation as well as B cell class-switching; interacts with STEAP3; doesn't affect receptor internalization in erythroid precursor cells; dbSNP
Q02548	183	Natural variant	G	1.0	description:in ALL3; confers susceptibility to ALL3; reduced transcription factor activity; dbSNP
P35398	18	Natural variant	S	1.0	description:in a colorectal cancer sample, somatic mutation; dbSNP
P22626	302	Natural variant	D	1.0	description:in IBMPFD2; dbSNP
P78563	498	Natural variant	T	1.0	description:in NEDHYMS; unknown pathological significance; altered ratio of alternative splicing
P12755	21	Natural variant	L	1.0	description:in SGS; dbSNP
P12755	28	Natural variant	S	1.0	description:in SGS
P12755	31	Natural variant	S	1.0	description:in SGS
P12755	32	Natural variant	L	1.0	description:in SGS
P12755	32	Natural variant	L	1.0	description:in SGS; dbSNP
P12755	34	Natural variant	G	1.0	description:in SGS
P12755	34	Natural variant	G	1.0	description:in SGS; dbSNP
P12755	34	Natural variant	G	1.0	description:in SGS; dbSNP
P12755	34	Natural variant	G	1.0	description:in SGS; dbSNP
P12755	34	Natural variant	G	1.0	description:in SGS; dbSNP
P12755	35	Natural variant	P	1.0	description:in SGS; dbSNP
P12755	35	Natural variant	P	1.0	description:in SGS; dbSNP
Q14524	9	Natural variant	G	1.0	description:in LQT3; dbSNP
Q14524	18	Natural variant	R	1.0	description:in BRGDA1 and LQT3; unknown pathological significance; dbSNP
Q14524	18	Natural variant	R	1.0	description:rare variant; found in a patient with long QT syndrome; unknown pathological significance; dbSNP
Q14524	27	Natural variant	R	1.0	description:in BRGDA1 and LQT3; dbSNP
Q14524	30	Natural variant	E	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	43	Natural variant	R	1.0	description:in LQT3; does not affect baseline kinetics of sodium currents; causes an unusual hyperpolarizing shift of the activation kinetics after lidocaine treatment; dbSNP
Q14524	48	Natural variant	E	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	52	Natural variant	P	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	53	Natural variant	R	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	70	Natural variant	N	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	462	Natural variant	E	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	462	Natural variant	E	1.0	description:in LQT3; dbSNP
Q14524	470	Natural variant	N	1.0	description:in ATFB10; dbSNP
Q14524	501	Natural variant	D	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	512	Natural variant	T	1.0	description:in PFHB1A; voltage-dependent activation and inactivation of the I-512 channel is shifted negatively by 8 to 9 mV and had enhanced slow activation and slower recovery from inactivation commpared to the wild-type channel; the double mutant R-558/I-512 channel shows that R-558 eliminates the negative shift induced by I-512 but only partially restores the kinetic abnormalities; dbSNP
Q14524	514	Natural variant	G	1.0	description:in BRGDA1 and PFHB1A; dbSNP
Q14524	526	Natural variant	R	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	530	Natural variant	F	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	532	Natural variant	F	1.0	description:in SIDS and BRGDA1; dbSNP
Q14524	535	Natural variant	R	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	543	Natural variant	F	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	552	Natural variant	G	1.0	description:in BRGDA1; dbSNP
Q14524	558	Natural variant	H	1.0	description:channels properties are similar to wild-type; the double mutant R-558/I-512 channel shows that R-558 eliminates the negative shift induced by Ile-512 but only partially restores the kinetic abnormalities; can modulate the gating defects caused by Ala-2006 and other mutations; dbSNP
Q14524	567	Natural variant	L	1.0	description:in BRGDA1; dbSNP
Q14524	569	Natural variant	R	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	571	Natural variant	S	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	572	Natural variant	A	1.0	description:in LQT3 and ATFB10; likely benign variant; dbSNP
Q14524	572	Natural variant	A	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	572	Natural variant	A	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	573	Natural variant	Q	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	579	Natural variant	G	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	615	Natural variant	G	1.0	description:in LQT3 and BRGDA1; drug-induced LQT syndrome; dbSNP
Q14524	619	Natural variant	L	1.0	description:in LQT3 and BRGDA1; dbSNP
Q14524	620	Natural variant	R	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	632	Natural variant	T	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	637	Natural variant	P	1.0	description:in LQT3; dbSNP
Q14524	639	Natural variant	G	1.0	description:in LQT3; dbSNP
Q14524	640	Natural variant	P	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	647	Natural variant	A	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	648	Natural variant	P	1.0	description:in LQT3 and BRGDA1; dbSNP
Q14524	654	Natural variant	E	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	655	Natural variant	E	1.0	description:in ATFB10; dbSNP
Q14524	661	Natural variant	R	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	997	Natural variant	A	1.0	description:in LQT3; also found in patients with atrial fibrillation; sodium current characterized by slower decay and a 2- to 3-fold increase in late sodium current; dbSNP
Q14524	997	Natural variant	A	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	1004	Natural variant	C	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	1023	Natural variant	R	1.0	description:in BRGDA1; dbSNP
Q14524	1053	Natural variant	E	1.0	description:in BRGDA1, ATFB10 and LQT3; abolishes binding to ANK3 and also prevents accumulation of SCN5A at cell surface sites in ventricular cardiomyocytes; dbSNP
Q14524	1055	Natural variant	D	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	1069	Natural variant	T	1.0	description:in LQT3; dbSNP
Q14524	1079	Natural variant	S	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	1084	Natural variant	G	1.0	description:in SIDS; unknown pathological significance; dbSNP
Q14524	1100	Natural variant	A	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	1103	Natural variant	S	1.0	description:may confer susceptibility to acquired arrhythmia; dbSNP
Q14524	1113	Natural variant	A	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	1114	Natural variant	D	1.0	description:in LQT3; dbSNP
Q14524	1131	Natural variant	T	1.0	description:in ATFB10; dbSNP
Q14524	1140	Natural variant	S	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	1166	Natural variant	D	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	1739	Natural variant	R	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	1740	Natural variant	G	1.0	description:in BRGDA1; dbSNP
Q14524	1743	Natural variant	G	1.0	description:in BRGDA1; dbSNP
Q14524	1743	Natural variant	G	1.0	description:in BRGDA1; decreases expression at the cell membrane; yields nearly undetectable currents in transfected cells; dbSNP
Q14524	1935	Natural variant	G	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	1938	Natural variant	E	1.0	description:in BRGDA1; unknown pathological significance; dbSNP
Q14524	1949	Natural variant	A	1.0	description:in LQT3; dbSNP
Q14524	1951	Natural variant	V	1.0	description:in BRGDA1 and LQT3; also found in patients with atrial fibrillation; unknown pathological significance; dbSNP
Q14524	1951	Natural variant	V	1.0	description:in ATFB10; dbSNP
Q14524	1958	Natural variant	R	1.0	description:found in a patient with long QT syndrome; unknown pathological significance; dbSNP
Q14524	1968	Natural variant	I	1.0	description:in BRGDA1; dbSNP
Q14524	1977	Natural variant	Y	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q14524	1987	Natural variant	N	1.0	description:in ATFB10; dbSNP
Q14524	2004	Natural variant	F	1.0	description:in LQT3 and BRGDA1; also found in patients with atrial fibrillation; results in channels with decreased peak and persistent current amplitudes; increased closed-state and slow inactivation; decelerated recovery from inactivation; dbSNP
Q14524	2004	Natural variant	F	1.0	description:in BRGDA1 and LQT3; dbSNP
Q14524	2006	Natural variant	P	1.0	description:found in a patient with long QT syndrome; unknown pathological significance; causes an increase of persistent sodium current and produces a depolarizing shift in voltage dependence of inactivation; dbSNP
Q14524	2012	Natural variant	R	1.0	description:in LQT3; unknown pathological significance; dbSNP
Q9NPC8	241	Natural variant	P	1.0	description:in a renal hypodysplasia patient; dbSNP
Q9NPC8	276	Natural variant	D	1.0	description:in a renal hypodysplasia patient; dbSNP
O43759	222	Natural variant	D	1.0	description:in a patient affected by schizophrenia
Q5JUK2	31	Natural variant	C	1.0	description:in SPGF32; unknown pathological significance; does not have any significant effect on its transactivation; dbSNP
Q5JUK2	177	Natural variant	P	1.0	description:in SPGF32; unknown pathological significance; does not have any significant effect on its transactivation; dbSNP
Q96DX7	155	Natural variant	G	1.0	description:in AN3; affects function and results in increased negative regulation of PAX6 expression compared to wild-type; dbSNP
Q9Y210	88	Natural variant	F	1.0	description:in FSGS2; unknown pathological significance
Q9Y210	270	Natural variant	S	1.0	description:in FSGS2; dbSNP
Q9UHF7	952	Natural variant	R	1.0	description:in TRPS1; prevents the transport into the nucleus and thus reduces the nuclear TRPS1 concentration consistent with haploinsufficiency; dbSNP
Q9UHF7	952	Natural variant	R	1.0	description:in TRPS1; prevents the transport into the nucleus and thus reduces the nuclear TRPS1 concentration consistent with haploinsufficiency; dbSNP
P78332	353	Natural variant	S	1.0	description:in a non-small cell lung cancer cell line; dbSNP
Q9BQY4	68	Natural variant	G	1.0	description:found in infertile men; unknown pathological significance; decreased induction of target genes expression; dbSNP
Q9BQY4	227	Natural variant	G	1.0	description:found in infertile men; unknown pathological significance; decreased induction of target genes expression; dbSNP
Q9BQY4	235	Natural variant	D	1.0	description:found in infertile men; unknown pathological significance; dbSNP
Q8TA86	170	Natural variant	D	1.0	description:in RP9; dbSNP
Q14108	471	Natural variant	E	1.0	description:may act as a modifier of Gaucher disease; dbSNP
P15923	8	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
O14746	170	Natural variant	V	1.0	description:in PFBMFT1; the mutant protein is demonstrated to cause decreased telomerase activity; dbSNP
O14746	202	Natural variant	A	1.0	description:in PFBMFT1 and AA; severe and moderate; associated with disease susceptibility; shorter telomeres; dbSNP
O14746	299	Natural variant	V	1.0	description:associated with acute myeloid leukemia; dbSNP
O14746	412	Natural variant	H	1.0	description:in PFBMFT1, AA and DKCB4; severe and moderate; associated with susceptibility to acute myelogenous leukemia; the mutant protein has 36% residual activity; dbSNP
O14746	441	Natural variant	E	1.0	description:in AA; associated with susceptibility to acute myeloid leukemia
O14746	1062	Natural variant	A	1.0	description:increased incidence in sporadic acute myeloid leukemia; dbSNP
O14746	1110	Natural variant	T	1.0	description:in PFBMFT1; unknown pathological significance; impaired telomerase activity; dbSNP
O14746	1127	Natural variant	F	1.0	description:in DKCA2; severe; shortened telomeres but no effect on telomerase catalytic activity nor on binding to TERC; dbSNP
Q5H8A4	270	Natural variant	G	1.0	description:in NEDHSCA
Q5H8A4	271	Natural variant	M	1.0	description:in NEDHSCA
Q5H8A4	278	Natural variant	G	1.0	description:in NEDHSCA
O15055	662	Natural variant	S	1.0	description:in FASPS1; reduced in vitro phosphorylation by CSNK1E; dbSNP
O15055	823	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q99959	26	Natural variant	D	1.0	description:may be associated with increased susceptibility to arrhythmogenic right ventricular cardiomyopathy; dbSNP
Q99959	59	Natural variant	Q	1.0	description:in ARVD9; unknown pathological significance; decreased interaction with DSP; dbSNP
Q99959	62	Natural variant	Q	1.0	description:in ARVD9; unknown pathological significance; decreased protein stability; decreased interaction with DSP; does not affect subcellular location to the desmosomes; dbSNP
Q99959	137	Natural variant	E	1.0	description:in ARVD9; dbSNP
Q99959	169	Natural variant	S	1.0	description:in ARVD9; dbSNP
Q99959	489	Natural variant	G	1.0	description:in ARVD9; unknown pathological significance; dbSNP
Q99959	654	Natural variant	K	1.0	description:in ARVD9; impairs protein stability; dbSNP
Q99959	673	Natural variant	G	1.0	description:in ARVD9; unknown pathological significance; dbSNP
P28062	8	Natural variant	G	1.0	description:in allele LMP7C; dbSNP
Q04118	53	Natural variant	P	1.0	description:in Gl-8; requires 2 nucleotide substitutions
O14522	905	Natural variant	D	1.0	description:in a colorectal cancer
Q9NPD5	292	Natural variant	I	1.0	description:in a colorectal cancer sample; somatic mutation
P48436	169	Natural variant	H	1.0	description:in CMD1; decreased 75% transactivational activity
P48436	169	Natural variant	H	1.0	description:in CMD1; mild form overlapping with small patella syndrome; decreased 50% transactivational activity; dbSNP
P48436	170	Natural variant	P	1.0	description:in CMD1; dbSNP
P48436	170	Natural variant	P	1.0	description:in CMD1
P48436	173	Natural variant	K	1.0	description:in CMD1; dbSNP
O43151	752	Natural variant	R	1.0	description:in BEFAHRS; unknown pathological significance; no effect on methylcytosine dioxygenase activity; dbSNP
O43151	1677	Natural variant	P	1.0	description:in BEFAHRS; dbSNP
Q15569	539	Natural variant	H	1.0	description:in breast cancer samples; infiltrating ductal carcinoma; somatic mutation; dbSNP
Q5SWA1	134	Natural variant	P	1.0	description:found in a patient with isolated coloboma; unknown pathological significance; dbSNP
Q92932	716	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9UMX9	272	Natural variant	E	1.0	description:associated with variability of hair, eye and skin pigmentation; in Caucasians associated with dark hair, skin and eye color; strong protective effect for melanoma risk; dbSNP
Q9NZ71	1124	Natural variant	H	1.0	description:in PFBMFT3; dbSNP
Q9C0A6	175	Natural variant	S	1.0	description:in MRD23
Q9C0A6	1071	Natural variant	Y	1.0	description:in MRD23; unknown pathological significance
O15047	269	Natural variant	Q	1.0	description:in EPEDD; affects the development of synapses in a mouse model overexpressing the human protein harboring this variant
O15047	913	Natural variant	R	1.0	description:in EPEDD; affects the development of synapses in a mouse model overexpressing the human protein harboring this variant
O15047	1369	Natural variant	G	1.0	description:in EPEDD; affects the development of synapses in a mouse model overexpressing the human protein harboring this variant; dbSNP
O15047	1392	Natural variant	R	1.0	description:in EPEDD; affects the development of synapses in a mouse model overexpressing the human protein harboring this variant; dbSNP
O15047	1499	Natural variant	Y	1.0	description:in NEDSID; causes DNA damage repair defects associated with nucleolytic degradation of nascent DNA at stalled replication forks
Q9UBP0	44	Natural variant	S	1.0	description:acts as a disease modifier; patients carrying a mutated allele of spastin and L-44 on the other allele are affected by severe spastic paraplegia with an early age of onset; may decrease the activity of the alternative promoter which directs the synthesis of isoform 3 and isoform 4; dbSNP
Q9UBP0	45	Natural variant	P	1.0	description:acts as a disease modifier; patients carrying a mutated allele of spastin and Q-45 on the other allele are affected by severe spastic paraplegia with an early age of onset; dbSNP
Q9UBP0	95	Natural variant	A	1.0	description:in SPG4; dbSNP
Q9UBP0	97	Natural variant	P	1.0	description:in SPG4; unknown pathological significance; dbSNP
Q9UBP0	201	Natural variant	V	1.0	description:in SPG4; unknown pathological significance; dbSNP
Q9UBP0	287	Natural variant	T	1.0	description:in SPG4
Q9UBP0	293	Natural variant	P	1.0	description:in SPG4; dbSNP
Q9UBP0	309	Natural variant	R	1.0	description:in SPG4; dbSNP
Q9UBP0	314	Natural variant	L	1.0	description:in SPG4; unknown pathological significance; dbSNP
Q8IUC6	141	Natural variant	R	1.0	description:inhibition of IFNB induction
Q8IUC6	157	Natural variant	T	1.0	description:no effect on IFNB induction; dbSNP
Q8IUC6	186	Natural variant	S	1.0	description:in IIAE6; no effect on IFNB induction; dbSNP
Q8IUC6	302	Natural variant	V	1.0	description:no effect on IFNB induction
Q8IUC6	377	Natural variant	T	1.0	description:no effect on IFNB induction; dbSNP
Q8IUC6	386	Natural variant	L	1.0	description:no effect on IFNB induction
Q8IUC6	595	Natural variant	M	1.0	description:no effect on IFNB induction; dbSNP
Q8IUC6	598	Natural variant	G	1.0	description:no effect on IFNB induction; dbSNP
Q8IUC6	702	Natural variant	Q	1.0	description:no effect on IFNB induction
P58753	9	Natural variant	A	1.0	description:does not affect NF-kappa-B activation and TNF production; dbSNP
P58753	13	Natural variant	R	1.0	description:does not affect NF-kappa-B activation and TNF production; dbSNP
P58753	55	Natural variant	S	1.0	description:does not affect NF-kappa-B activation and TNF production; dbSNP
P13866	615	Natural variant	H	1.0	description:in GGM; slightly decreased activity
P51531	1241	Natural variant	Q	1.0	description:in NCBRS
P51531	1546	Natural variant	D	1.0	description:associated with schizophrenia in some populations; results in reduced localization to the nucleus; decreased interaction with chromatin; dbSNP
P51649	36	Natural variant	G	1.0	description:no effect on succinate-semialdehyde dehydrogenase activity; dbSNP
Q9UGM6	13	Natural variant	W	1.0	description:in NEMMLAS and PKDYS3; hypomorphic variant, clinically relevant when present in trans with an amorphic variant; impaired mitochondrial localization; dbSNP
P10827	398	Natural variant	E	1.0	description:in CHNG6) (Ref.26
P10827	403	Natural variant	L	1.0	description:in CHNG6) (Ref.26
P23942	304	Natural variant	E	1.0	description:associated with D-338 on the same haplotype; dbSNP
P23942	305	Natural variant	G	1.0	description:in VMD3; dbSNP
P23942	338	Natural variant	G	1.0	description:associated with Q-304 on the same haplotype; dbSNP
Q9UBY0	806	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
Q13428	1030	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q16585	11	Natural variant	Q	1.0	description:in LGMDR4; dbSNP
Q96KW9	25	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q15477	183	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q9Y6H5	621	Natural variant	R	1.0	description:found in patients with symptoms of Parkinson disease; unknown pathological significance; reduced number of cytoplasmic inclusions in cells expressing C-621 compared with cells expressing wild-type (wt) protein when subjected to proteasomal inhibition; C-621 transfected cells are more susceptible to staurosporine-induced cell death than cells expressing wt protein; dbSNP
Q13796	1245	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9BX79	638	Natural variant	R	1.0	description:in anophthalmia/microphthalmia; dbSNP
Q9BX79	644	Natural variant	T	1.0	description:in MCOPS9; loss of tyrosine phosphorylation; dbSNP
Q9BX79	655	Natural variant	R	1.0	description:in MCOPS9; dbSNP
Q6ZVD7	18	Natural variant	R	1.0	description:in PEE4; dbSNP
Q6ZVD7	825	Natural variant	N	1.0	description:in PEE4; dbSNP
Q96PV0	170	Natural variant	R	1.0	description:probable disease-associated variant found in a patient with drug-resistant generalized epilepsy, cognitive impairment and autism spectrum disorder; dbSNP
Q96PV0	195	Natural variant	A	1.0	description:probable disease-associated variant found in a patient with West syndrome; dbSNP
Q9BYW2	2	Natural variant	K	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	19	Natural variant	E	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	226	Natural variant	P	1.0	description:in ALL; unknown pathological significance; somatic mutation; dbSNP
Q9BYW2	267	Natural variant	V	1.0	description:in ALL; unknown pathological significance; somatic mutation; dbSNP
Q9BYW2	470	Natural variant	S	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	488	Natural variant	Y	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
Q9BYW2	499	Natural variant	T	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	761	Natural variant	M	1.0	description:in ALL; unknown pathological significance; somatic mutation; dbSNP
Q9BYW2	800	Natural variant	S	1.0	description:in AML; unknown pathological significance; somatic mutation; dbSNP
Q9BYW2	1076	Natural variant	S	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	1093	Natural variant	S	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	1171	Natural variant	T	1.0	description:in ALL; unknown pathological significance; somatic mutation; dbSNP
Q9BYW2	1351	Natural variant	D	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	1365	Natural variant	G	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	1397	Natural variant	D	1.0	description:in AML; unknown pathological significance; somatic mutation; dbSNP
Q9BYW2	1453	Natural variant	D	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	1815	Natural variant	L	1.0	description:in LLS; unknown pathological significance; dbSNP
Q9BYW2	1821	Natural variant	L	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	1915	Natural variant	V	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	1920	Natural variant	E	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	2122	Natural variant	R	1.0	description:in AML; unknown pathological significance; somatic mutation
Q9BYW2	2214	Natural variant	T	1.0	description:in ALL; unknown pathological significance; somatic mutation
Q9BYW2	2361	Natural variant	P	1.0	description:in ALL; unknown pathological significance; somatic mutation
O15041	703	Natural variant	S	1.0	description:found in a patient with CHARGE syndrome; unknown pathological significance; dbSNP
Q9BRG2	265	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q15858	10	Natural variant	Q	1.0	description:in PERYTHM; causes a hyperpolarizing shift of -5.3 mV for the midpoint of activation which is smaller than that seen in other mutations causing early-onset erythromelalgia mutations; also causes a faster rate of activation and slower deactivation compared to wild-type; expression of the mutant protein induced hyperexcitability in dorsal root ganglion neurons but the increase is smaller than that produced by Thr-859; dbSNP
Q15858	62	Natural variant	I	1.0	description:found in a patient with febrile seizures; unknown pathological significance; dbSNP
Q15858	641	Natural variant	N	1.0	description:found in patients with febrile seizures plus; unknown pathological significance; dbSNP
P48029	4	Natural variant	K	1.0	description:no effect on creatine transporter activity; dbSNP
P48029	26	Natural variant	G	1.0	description:no effect on creatine transporter activity; dbSNP
P48029	41	Natural variant	G	1.0	description:in CCDS1; unknown pathological significance; loss of creatine transporter activity; no effect on cell membrane localization
P48029	624	Natural variant	E	1.0	description:no effect on creatine transporter activity; dbSNP
P48029	629	Natural variant	V	1.0	description:no effect on creatine transporter activity; dbSNP
P04179	16	Natural variant	V	1.0	description:associated with a decreased susceptibility to diabetic nephropathy in Japanese and Chinese patients with type 2 diabetes; dbSNP
Q9P0W8	332	Natural variant	I	1.0	description:found in a patient with LCA3; dbSNP
Q7Z572	24	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q12772	273	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q96RU7	60	Natural variant	T	1.0	description:in a glioblastoma multiforme sample; somatic mutation; dbSNP
Q5JTV8	190	Natural variant	V	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P16234	1071	Natural variant	D	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP
P78527	500	Natural variant	G	1.0	description:in a metastatic melanoma sample; somatic mutation
O43900	558	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q8WZ75	510	Natural variant	D	1.0	description:in AOVD3; unknown pathological significance; dbSNP
Q8WZ75	622	Natural variant	D	1.0	description:in AOVD3; unknown pathological significance; dbSNP
Q8WZ75	749	Natural variant	A	1.0	description:in AOVD3; unknown pathological significance; requires 2 nucleotide substitutions; dbSNP
Q07889	1131	Natural variant	R	1.0	description:in a patient with Noonan syndrome; dbSNP
Q07889	1140	Natural variant	L	1.0	description:in a patient with Noonan syndrome; dbSNP
Q07889	1257	Natural variant	T	1.0	description:in a patient with Noonan syndrome; dbSNP
Q9H2G2	405	Natural variant	Q	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q9H2G2	604	Natural variant	E	1.0	description:in an ovarian serous carcinoma sample; somatic mutation; dbSNP
Q9UQ13	2	Natural variant	S	1.0	description:in NSLH1; creates a N-myristoylation site, resulting in myristoylation of the protein and aberrant targeting to the plasma membrane; dbSNP
P98175	396	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UHP9	7	Natural variant	P	1.0	description:in MPD7; unknown pathological significance
Q9UHP9	13	Natural variant	A	1.0	description:in MPD7; unknown pathological significance
Q9UHP9	27	Natural variant	P	1.0	description:in MPD7; unknown pathological significance
Q9UHP9	78	Natural variant	S	1.0	description:in MPD7; unknown pathological significance
Q7Z6B7	875	Natural variant	H	1.0	description:in NMTC2; does not affect the interaction with ROBO1; slightly increased GTPase activator activity; in SLIT2 and ROBO1-mediated inhibition of CDC42; dbSNP
P13631	430	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q6P4F7	605	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
P39023	11	Natural variant	H	1.0	description:rare variant found in a Diamond-Blackfan anemia patient; unknown pathological significance; dbSNP
Q96S53	11	Natural variant	G	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP
O00294	245	Natural variant	A	1.0	description:in RP14; dbSNP
O00294	261	Natural variant	K	1.0	description:in RP14
Q96PU4	87	Natural variant	I	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P0C7M4	68	Natural variant	G	1.0	description:found in infertile men; unknown pathological significance; decreased induction of target genes expression; dbSNP
P0C7M4	227	Natural variant	G	1.0	description:found in infertile men; unknown pathological significance; decreased induction of target genes expression
P0C7M4	235	Natural variant	D	1.0	description:found in infertile men; unknown pathological significance; dbSNP
Q92901	27	Natural variant	G	1.0	description:in CMD2D; unknown pathological significance; dbSNP
Q02878	100	Natural variant	K	1.0	description:in a colorectal cancer sample; somatic mutation
Q5VTB9	363	Natural variant	R	1.0	description:in HLD23; shows decreased beta-catenin binding
Q5VTB9	365	Natural variant	R	1.0	description:in HLD23; shows decreased beta-catenin binding
O43426	1018	Natural variant	Y	1.0	description:likely benign variant; no effect on inositol phosphate phosphatase activity
O43426	1383	Natural variant	S	1.0	description:in PARK20; unknown pathological significance; the patient also carries a heterozygous PINK1 truncating mutation; dbSNP
Q9NYJ8	208	Natural variant	P	1.0	description:in CHTD2; dbSNP
Q9NYJ8	230	Natural variant	Q	1.0	description:in CHTD2; dbSNP
Q702N8	1634	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q08499	190	Natural variant	S	1.0	description:in ACRDYS2; dbSNP
Q08499	225	Natural variant	P	1.0	description:in ACRDYS2; dbSNP
Q08499	226	Natural variant	F	1.0	description:in ACRDYS2; dbSNP
Q08499	227	Natural variant	A	1.0	description:in ACRDYS2
Q08499	228	Natural variant	Q	1.0	description:in ACRDYS2; dbSNP
Q08499	329	Natural variant	V	1.0	description:in ACRDYS2
P05166	17	Natural variant	L	1.0	description:in PA-2; likely benign variant; dbSNP
P05166	44	Natural variant	R	1.0	description:in PA-2
Q9Y5B6	538	Natural variant	R	1.0	description:found in a family with global developmental delay and myopathic hypotonia; unknown pathological significance
Q8WWQ0	1767	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
Q8N3A8	777	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
Q99697	58	Natural variant	P	1.0	description:in ASGD4
Q6N022	53	Natural variant	R	1.0	description:in ETM5; unknown pathological significance; dbSNP
Q6N022	518	Natural variant	R	1.0	description:in ETM5; unknown pathological significance; dbSNP
Q6N022	519	Natural variant	G	1.0	description:found in a patiend with developmental delay, cleft palate and proliferative retinopathy; unknown pathological significance; dbSNP
O15537	12	Natural variant	L	1.0	description:in XLRS1; dbSNP
O15537	13	Natural variant	L	1.0	description:in XLRS1; dbSNP
O43543	14	Natural variant	L	1.0	description:in SPGF50 and POF17; due to a nucleotide substitution that causes partial exon 2 skipping; patient cells contain both normally spliced transcripts and transcripts lacking exon 2; dbSNP
O43543	207	Natural variant	E	1.0	description:does not affect function in double-strand break repair via homologous recombination as shown in rescue assays of XRCC2-deficient cells; dbSNP
Q9P286	312	Natural variant	S	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
O60292	148	Natural variant	D	1.0	description:found in a patient with bilateral congenital cataracts; unknown pathological significance; lack of normal basal actin stress fiber formation; absence of SIPA1L3 and F-actin colocalization; dbSNP
Q9H2D6	1019	Natural variant	G	1.0	description:in DFNB28; dbSNP
Q9GZZ9	310	Natural variant	K	1.0	description:in SCAR24; does not affect cytoplasm localization; decreases protein stability; does not affect interaction with UFM1; dbSNP
Q9GZZ9	371	Natural variant	A	1.0	description:in DEE44; reduces UFM1 activating enzyme activity; reduces UFM1 activating enzyme activity; reduces UFM1-DDRGK1 formation; dbSNP
Q9GZZ9	389	Natural variant	D	1.0	description:in DEE44; no effect on UFM1 activating enzyme activity; dbSNP
P49754	13	Natural variant	E	1.0	description:in SCAR29; unknown pathological significance; no effect on protein expression
P42768	187	Natural variant	G	1.0	description:in WAS
P42768	236	Natural variant	A	1.0	description:in THC1
P42768	476	Natural variant	K	1.0	description:in WAS
P42768	477	Natural variant	R	1.0	description:in THC1
P42768	481	Natural variant	I	1.0	description:in THC1; dbSNP
Q52LW3	552	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q7Z5B4	346	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q96MS0	5	Natural variant	L	1.0	description:in HGPPS1; dbSNP
Q96MS0	66	Natural variant	I	1.0	description:in HGPPS1; dbSNP
Q8NBK3	20	Natural variant	L	1.0	description:in MSD; loss of activity; dbSNP
Q8IWU5	573	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q6N021	145	Natural variant	S	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation; dbSNP
Q6N021	308	Natural variant	A	1.0	description:in chronic myelomonocytic leukemia and acute myeloid leukemia samples; dbSNP
Q6N021	312	Natural variant	N	1.0	description:in an acute myeloid leukemia sample; somatic mutation
Q6N021	399	Natural variant	P	1.0	description:in myelodysplastic/myeloproliferative disorders; a patient positive for mutation F-617 in JAK2
Q6N021	460	Natural variant	S	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation; dbSNP
Q6N021	666	Natural variant	D	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation
Q6N021	817	Natural variant	S	1.0	description:in myelodysplastic/myeloproliferative disorders; dbSNP
Q6N021	941	Natural variant	P	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation; dbSNP
Q6N021	1718	Natural variant	V	1.0	description:in refractory anemia with ringed sideroblasts; somatic mutation in an acute myeloid leukemia sample; dbSNP
Q6N021	1757	Natural variant	H	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation
Q6N021	1811	Natural variant	C	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation
Q6N021	1828	Natural variant	Q	1.0	description:in a myeloproliferative disorder; somatic mutation
Q6N021	1869	Natural variant	G	1.0	description:in an essential thrombocythemia sample; dbSNP
Q6N021	1872	Natural variant	L	1.0	description:in a refractory anemia with excess blasts sample
Q6N021	1873	Natural variant	I	1.0	description:in myelodysplastic syndromes, myeloproliferative disorders and chronic myelomonocytic leukemia; somatic mutation in acute myeloid leukemia and chronic myelomonocytic leukemia samples; dbSNP
Q6N021	1875	Natural variant	C	1.0	description:in a myelodysplastic syndrome; somatic mutation
Q6N021	1881	Natural variant	H	1.0	description:in a myelodysplastic syndrome; somatic mutation
Q6N021	1881	Natural variant	H	1.0	description:in a myeloproliferative disorder; somatic mutation; also in a patient with systemic mastocytosis associated with chronic myelomonocytic leukemia; dbSNP
Q6N021	1896	Natural variant	R	1.0	description:in a primary acute myeloid leukemia sample; somatic mutation; reduces enzyme activity
Q6N021	1896	Natural variant	R	1.0	description:in a myeloproliferative disorder; somatic mutation
Q6N021	1898	Natural variant	S	1.0	description:in a secondary acute myeloid leukemia sample; somatic mutation; loss of enzyme activity; dbSNP
Q6N021	1913	Natural variant	G	1.0	description:in myelodysplastic syndromes; refractory cytopenia with multilineage dysplasia and ringed sideroblasts; somatic mutation in a patient
Q6N021	1919	Natural variant	A	1.0	description:in a myeloproliferative disorder; somatic mutation; dbSNP
Q6N021	1926	Natural variant	R	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation; dbSNP
Q6N021	1941	Natural variant	P	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation; dbSNP
Q6N021	1962	Natural variant	P	1.0	description:in a myelodysplastic syndrome; dbSNP
Q6N021	1966	Natural variant	R	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation; dbSNP
Q6N021	1974	Natural variant	R	1.0	description:in a chronic myelomonocytic leukemia sample; somatic mutation; dbSNP
P49815	963	Natural variant	V	1.0	description:in TSC2; unknown pathological significance; dbSNP
P49815	1084	Natural variant	D	1.0	description:in TSC2; dbSNP
P49815	1144	Natural variant	V	1.0	description:in TSC2; dbSNP
P49815	1200	Natural variant	R	1.0	description:in TSC2; dbSNP
P49815	1227	Natural variant	P	1.0	description:in TSC2
P49815	1240	Natural variant	R	1.0	description:in TSC2
P49815	1295	Natural variant	D	1.0	description:in TSC2
P49815	1315	Natural variant	P	1.0	description:in TSC2; dbSNP
P49815	1773	Natural variant	H	1.0	description:in TSC2; dbSNP
P49815	1783	Natural variant	E	1.0	description:in TSC2; dbSNP
O76024	58	Natural variant	A	1.0	description:in WFS1; dbSNP
O76024	797	Natural variant	D	1.0	description:in WFSL
O00470	272	Natural variant	R	1.0	description:found in a patient with susceptibility to restless legs syndrome; dbSNP
Q56UN5	500	Natural variant	I	1.0	description:in a breast pleomorphic lobular carcinoma sample; somatic mutation
Q9Y2H9	93	Natural variant	S	1.0	description:in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance; dbSNP
Q9Y2H9	98	Natural variant	G	1.0	description:in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance
Q9Y2H9	915	Natural variant	A	1.0	description:in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance
Q9Y2H9	1177	Natural variant	P	1.0	description:in a patient with neurodevelopmental abnormalities; de novo variant; unknown pathological significance
Q9Y2H9	1240	Natural variant	H	1.0	description:in an ovarian serous carcinoma sample; somatic mutation; dbSNP
O75962	1922	Natural variant	A	1.0	description:in MRD44; unknown pathological significance
O75962	1939	Natural variant	S	1.0	description:in MRD44; unknown pathological significance
Q96RL1	15	Natural variant	R	1.0	description:not associated with susceptibility to breast cancer; dbSNP
Q96RL1	353	Natural variant	M	1.0	description:not associated with susceptibility to breast cancer; dbSNP
Q96RL1	435	Natural variant	P	1.0	description:not associated with susceptibility to breast cancer; dbSNP
Q96RL1	511	Natural variant	C	1.0	description:not associated with susceptibility to breast cancer; dbSNP
P04156	102	Natural variant	P	1.0	description:in GSD and early-onset dementia; dbSNP
P04156	105	Natural variant	P	1.0	description:in GSD; dbSNP
P04156	117	Natural variant	A	1.0	description:linked to development of dementing Gerstmann-Straussler disease; dbSNP
P04156	127	Natural variant	G	1.0	description:variant that has been selected for in response to the Kuru epidemic and confers resistance to prion disease by acting as a 'dominant negative' inhibitor of prion conversion; is not only itself resistant to conformational conversion, but also inhibits conversion of wild-type proteins; confers protection against classical Creutzfeldt-Jakob disease (CJD) and Kuru in the heterozygous state, but can be infected with variant CJD prions, resulting from exposure to bovine spongiform encephalopathy prions; confers complete resistance to all prion strains when homozygous. Always associated with M-129 variant; dbSNP
P04156	129	Natural variant	M	1.0	description:confers relative protection against acquired, sporadic and some inherited prion diseases in the heterozygous state, possibly by preventing homodimerization; determines the disease phenotype in patients who have a PrP mutation at position 178; patients with M-129 develop FFI, those with V-129 develop CJD; dbSNP
P04156	131	Natural variant	G	1.0	description:in GSD; dbSNP
P04156	171	Natural variant	N	1.0	description:in schizoaffective disorder; dbSNP
P04156	178	Natural variant	D	1.0	description:in FFI and CJD; dbSNP
P04156	180	Natural variant	V	1.0	description:in CJD; dbSNP
P04156	183	Natural variant	T	1.0	description:in SENF and early-onset dementia; induces loss of glycosylation at N-181; dbSNP
P04156	187	Natural variant	H	1.0	description:in GSD; dbSNP
P04156	188	Natural variant	T	1.0	description:in early-onset dementia; dementia associated to prion diseases
P04156	196	Natural variant	E	1.0	description:in CJD
P04156	198	Natural variant	F	1.0	description:in GSD; atypical form with neurofibrillary tangles; dbSNP
P04156	200	Natural variant	E	1.0	description:in CJD; dbSNP
P04156	202	Natural variant	D	1.0	description:in GSD; dbSNP
P04156	203	Natural variant	V	1.0	description:in CJD; unknown pathological significance; dbSNP
P04156	208	Natural variant	R	1.0	description:in CJD; dbSNP
P04156	210	Natural variant	V	1.0	description:in CJD; dbSNP
P04156	211	Natural variant	E	1.0	description:in CJD; dbSNP
P04156	212	Natural variant	Q	1.0	description:in GSD; dbSNP
P04156	217	Natural variant	Q	1.0	description:in GSD; with neurofibrillary tangles; dbSNP
P04156	219	Natural variant	E	1.0	description:confers relative protection against sporadic Creutzfeldt-Jakob disease (CJD) in the heterozygous state; dbSNP
P04156	232	Natural variant	M	1.0	description:in CJD; dbSNP
Q9Y253	535	Natural variant	K	1.0	description:in XPV; dbSNP
Q9Y253	589	Natural variant	K	1.0	description:in XPV; dbSNP
Q9Y253	692	Natural variant	T	1.0	description:in XPV; dbSNP
Q96PX8	593	Natural variant	S	1.0	description:in TTM; unknown pathological significance; does not affect synaptogenesis; dbSNP
Q9BQB4	21	Natural variant	V	1.0	description:in CDD; affects protein secretion; dbSNP
Q9BQB4	21	Natural variant	V	1.0	description:in CDD; de novo mutation; affects protein secretion; dbSNP
Q14134	514	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q13049	299	Natural variant	R	1.0	description:in a patient with Bardet-Biedl syndrome; unknown pathological significance; dbSNP
Q59H18	798	Natural variant	M	1.0	description:in a head & Neck squamous cell carcinoma sample; somatic mutation; dbSNP
Q9HBA0	19	Natural variant	P	1.0	description:associated with lower sodium concentrations in serum; shows diminished response to hypotonic stress relative to wild-type; dbSNP
Q9HBA0	89	Natural variant	T	1.0	description:in MTD; lethal form; dbSNP
Q9HBA0	97	Natural variant	P	1.0	description:in HMN8; loss of function mutation; dbSNP
P07477	16	Natural variant	A	1.0	description:in PCTT; disrupts signal sequence cleavage site; dbSNP
Q9NVA1	44	Natural variant	W	1.0	description:in a breast cancer sample; somatic mutation
P04637	5	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation; abolishes strongly phosphorylation
P04637	6	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation; reduces interaction with ZNF385A
P04637	7	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	8	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	10	Natural variant	V	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	11	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	11	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	15	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	16	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation
P04637	17	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	24	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	28	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	31	Natural variant	V	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	33	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	34	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	35	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	36	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	37	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	37	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	39	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	39	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	42	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation
P04637	43	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	44	Natural variant	M	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	44	Natural variant	M	1.0	description:in a sporadic cancer; somatic mutation
P04637	44	Natural variant	M	1.0	description:in a sporadic cancer; somatic mutation
P04637	45	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	46	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	46	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	47	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	48	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation
P04637	49	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	49	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	49	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation
P04637	52	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation
P04637	53	Natural variant	W	1.0	description:in sporadic cancers; somatic mutation
P04637	53	Natural variant	W	1.0	description:in a sporadic cancer; somatic mutation
P04637	54	Natural variant	F	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	54	Natural variant	F	1.0	description:in a sporadic cancer; somatic mutation
P04637	56	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	56	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	58	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	58	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	59	Natural variant	G	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	59	Natural variant	G	1.0	description:in sporadic cancers; somatic mutation
P04637	59	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions
P04637	60	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	60	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	60	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	61	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	61	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation
P04637	62	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	63	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	63	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	65	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	66	Natural variant	M	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	66	Natural variant	M	1.0	description:in a sporadic cancer; somatic mutation
P04637	67	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	67	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	67	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	68	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	68	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	69	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	69	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	69	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	69	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	70	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	71	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	72	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions; dbSNP
P04637	72	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions
P04637	72	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	72	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	73	Natural variant	V	1.0	description:in a sporadic cancer; somatic mutation
P04637	73	Natural variant	V	1.0	description:in sporadic cancers; somatic mutation
P04637	73	Natural variant	V	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	74	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	75	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	75	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	75	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	76	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	76	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	77	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	78	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation
P04637	79	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	79	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	79	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation
P04637	80	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	80	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	81	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation
P04637	82	Natural variant	P	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	82	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	83	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	83	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	84	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation
P04637	84	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation
P04637	85	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	85	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	86	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	87	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	88	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	88	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	89	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	89	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	90	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	90	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	91	Natural variant	W	1.0	description:in a sporadic cancer; somatic mutation
P04637	92	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	92	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	92	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	93	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	93	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	94	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	94	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	95	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	95	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	96	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	96	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	96	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	97	Natural variant	V	1.0	description:in a sporadic cancer; somatic mutation
P04637	97	Natural variant	V	1.0	description:in a sporadic cancer; somatic mutation
P04637	97	Natural variant	V	1.0	description:in familial cancer not matching LFS; germline mutation and in a sporadic cancer; somatic mutation; dbSNP
P04637	98	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	98	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	99	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	99	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	100	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation
P04637	101	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	101	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	281	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	281	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	281	Natural variant	D	1.0	description:in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	281	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	281	Natural variant	D	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	281	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions
P04637	281	Natural variant	D	1.0	description:in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	281	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	282	Natural variant	R	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	282	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation
P04637	282	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	282	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	282	Natural variant	R	1.0	description:in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	282	Natural variant	R	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; does not induce SNAI1 degradation; dbSNP
P04637	283	Natural variant	R	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	283	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation
P04637	283	Natural variant	R	1.0	description:in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	283	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation
P04637	283	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation
P04637	283	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	284	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation
P04637	284	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	284	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation
P04637	284	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	285	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	285	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	285	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	285	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	285	Natural variant	E	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation
P04637	285	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	286	Natural variant	E	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	286	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	286	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	286	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	286	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions
P04637	286	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	286	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	287	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	287	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	287	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	287	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	287	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	288	Natural variant	N	1.0	description:in a sporadic cancer; somatic mutation
P04637	288	Natural variant	N	1.0	description:in sporadic cancers; somatic mutation
P04637	288	Natural variant	N	1.0	description:in sporadic cancers; somatic mutation
P04637	288	Natural variant	N	1.0	description:in sporadic cancers; somatic mutation
P04637	288	Natural variant	N	1.0	description:in sporadic cancers; somatic mutation
P04637	289	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	289	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	289	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	289	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	289	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	290	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	290	Natural variant	R	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	290	Natural variant	R	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation
P04637	291	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	291	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	291	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	291	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	291	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	291	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	292	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	292	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions
P04637	292	Natural variant	K	1.0	description:in LFS; germline mutation and in a sporadic cancer; somatic mutation; dbSNP
P04637	292	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	292	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	292	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	292	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	293	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation
P04637	293	Natural variant	G	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	293	Natural variant	G	1.0	description:in sporadic cancers; somatic mutation
P04637	293	Natural variant	G	1.0	description:in a brain tumor with no family history; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	294	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	294	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	294	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	294	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	294	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	294	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	295	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	295	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	295	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	295	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	296	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation; requires 2 nucleotide substitutions
P04637	296	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation
P04637	296	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation
P04637	296	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation
P04637	296	Natural variant	H	1.0	description:in a sporadic cancer; somatic mutation
P04637	296	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation
P04637	296	Natural variant	H	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	296	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	297	Natural variant	H	1.0	description:in a sporadic cancer; somatic mutation
P04637	297	Natural variant	H	1.0	description:in a sporadic cancer; somatic mutation
P04637	297	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation
P04637	297	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	297	Natural variant	H	1.0	description:in sporadic cancers; somatic mutation
P04637	298	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	298	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	298	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	298	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	298	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	299	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	299	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	299	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	299	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	300	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	300	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	300	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	300	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	301	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	301	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	301	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	301	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	301	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	302	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation
P04637	302	Natural variant	G	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	302	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	302	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation
P04637	303	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	303	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	303	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	303	Natural variant	S	1.0	description:in sporadic cancers; somatic mutation
P04637	304	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	304	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation
P04637	304	Natural variant	T	1.0	description:in a sporadic cancer; somatic mutation
P04637	304	Natural variant	T	1.0	description:in a sporadic cancer; somatic mutation
P04637	305	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	305	Natural variant	K	1.0	description:in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation
P04637	305	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation; loss of nuclear localization
P04637	305	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	305	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	306	Natural variant	R	1.0	description:in LFS; germline mutation and in a sporadic cancer; somatic mutation
P04637	306	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	307	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	307	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation
P04637	307	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation
P04637	308	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	308	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	309	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation
P04637	309	Natural variant	P	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	310	Natural variant	N	1.0	description:in a sporadic cancer; somatic mutation
P04637	310	Natural variant	N	1.0	description:in sporadic cancers; somatic mutation
P04637	311	Natural variant	N	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	311	Natural variant	N	1.0	description:in a sporadic cancer; somatic mutation
P04637	311	Natural variant	N	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	311	Natural variant	N	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	312	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation
P04637	312	Natural variant	T	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	313	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	313	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	313	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	313	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	314	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	315	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	315	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	315	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	316	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	316	Natural variant	P	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	317	Natural variant	Q	1.0	description:in a kidney cancer with no family history; germline mutation and in a sporadic cancer; somatic mutation; dbSNP
P04637	317	Natural variant	Q	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	317	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation
P04637	317	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation
P04637	317	Natural variant	Q	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	318	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	319	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	319	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	319	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	320	Natural variant	K	1.0	description:in sporadic cancers; somatic mutation
P04637	321	Natural variant	K	1.0	description:in kidney cancer; germline mutation
P04637	321	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	322	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	322	Natural variant	P	1.0	description:in sporadic cancers; somatic mutation
P04637	323	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions
P04637	323	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	323	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	323	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	323	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	324	Natural variant	D	1.0	description:in sporadic cancers; somatic mutation
P04637	324	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions
P04637	324	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation
P04637	325	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation
P04637	325	Natural variant	G	1.0	description:in sporadic cancers; somatic mutation
P04637	325	Natural variant	G	1.0	description:in LFS; germline mutation; dbSNP
P04637	326	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	327	Natural variant	Y	1.0	description:in a sporadic cancer; somatic mutation
P04637	327	Natural variant	Y	1.0	description:in a sporadic cancer; somatic mutation
P04637	328	Natural variant	F	1.0	description:in a sporadic cancer; somatic mutation
P04637	328	Natural variant	F	1.0	description:in sporadic cancers; somatic mutation
P04637	328	Natural variant	F	1.0	description:in a sporadic cancer; somatic mutation
P04637	329	Natural variant	T	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	329	Natural variant	T	1.0	description:in a sporadic cancer; somatic mutation
P04637	330	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	330	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	330	Natural variant	L	1.0	description:in sporadic cancers; somatic mutation
P04637	331	Natural variant	Q	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	331	Natural variant	Q	1.0	description:in sporadic cancers; somatic mutation
P04637	331	Natural variant	Q	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	332	Natural variant	I	1.0	description:in a sporadic cancer; somatic mutation
P04637	334	Natural variant	G	1.0	description:in sporadic cancers; somatic mutation
P04637	334	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	335	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation
P04637	335	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	335	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation
P04637	337	Natural variant	R	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	337	Natural variant	R	1.0	description:in LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	337	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	337	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	338	Natural variant	F	1.0	description:in a sporadic cancer; somatic mutation
P04637	338	Natural variant	F	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	339	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	339	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	341	Natural variant	F	1.0	description:in sporadic cancers; somatic mutation
P04637	342	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation
P04637	342	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	342	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	343	Natural variant	E	1.0	description:in sporadic cancers; somatic mutation
P04637	344	Natural variant	L	1.0	description:in LFS; germline mutation and in a sporadic cancer; somatic mutation; dbSNP
P04637	344	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	346	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	347	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	347	Natural variant	A	1.0	description:in sporadic cancers; somatic mutation
P04637	348	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	348	Natural variant	L	1.0	description:in a sporadic cancer; somatic mutation
P04637	349	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	352	Natural variant	D	1.0	description:in a sporadic cancer; somatic mutation
P04637	353	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	354	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation
P04637	354	Natural variant	Q	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	354	Natural variant	Q	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	356	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation
P04637	356	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation
P04637	358	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation
P04637	358	Natural variant	E	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	360	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	363	Natural variant	R	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	364	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	364	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	364	Natural variant	A	1.0	description:in a sporadic cancer; somatic mutation
P04637	365	Natural variant	H	1.0	description:in a sporadic cancer; somatic mutation
P04637	365	Natural variant	H	1.0	description:in a familial cancer not matching LFS; germline mutation and in a sporadic cancer; somatic mutation; dbSNP
P04637	366	Natural variant	S	1.0	description:in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation; dbSNP
P04637	370	Natural variant	K	1.0	description:in a sporadic cancer; somatic mutation
P04637	376	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	376	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
P04637	379	Natural variant	R	1.0	description:in sporadic cancers; somatic mutation; dbSNP
P04637	385	Natural variant	F	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	389	Natural variant	G	1.0	description:in a sporadic cancer; somatic mutation; dbSNP
P04637	392	Natural variant	S	1.0	description:in a sporadic cancer; somatic mutation
Q9NZL6	699	Natural variant	V	1.0	description:in a breast cancer sample; somatic mutation
O43623	119	Natural variant	D	1.0	description:in a patient with neural tube defects; dbSNP
Q9NQB0	465	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
Q96GM8	496	Natural variant	S	1.0	description:in PCH7; dbSNP
O75581	19	Natural variant	A	1.0	description:in STHAG7; impairs Wnt signaling; prevents transport to plasma membrane location; dbSNP
O75581	1415	Natural variant	V	1.0	description:found in a patient with congenital hydrocephalus; unknown pathological significance
Q9UHV7	326	Natural variant	T	1.0	description:in MRD61; dbSNP
Q9UHV7	326	Natural variant	T	1.0	description:in MRD61
Q9UHV7	327	Natural variant	P	1.0	description:in MRD61
Q9UHV7	327	Natural variant	P	1.0	description:in MRD61
Q9UHV7	540	Natural variant	P	1.0	description:in MRD61; unknown pathological significance
Q9UHV7	2060	Natural variant	Q	1.0	description:in MRD61; unknown pathological significance
Q9UHV7	2064	Natural variant	A	1.0	description:in MRD61; unknown pathological significance
P33527	296	Natural variant	E	1.0	description:in DFNA77; unknown pathological significance
P49810	62	Natural variant	R	1.0	description:in AD4; likely benign variant; dbSNP
P49810	71	Natural variant	R	1.0	description:in AD4; unknown pathological significance; dbSNP
P50749	144	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q5T481	52	Natural variant	P	1.0	description:in CMD1DD; unknown pathological significance
Q5T481	83	Natural variant	L	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	177	Natural variant	T	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	194	Natural variant	M	1.0	description:in CMD1DD; unknown pathological significance
Q5T481	196	Natural variant	M	1.0	description:in CMD1DD; unknown pathological significance
Q5T481	259	Natural variant	G	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	634	Natural variant	R	1.0	description:in CMD1DD; dbSNP
Q5T481	634	Natural variant	R	1.0	description:in CMD1DD; impaired mRNA splicing of TTN (Titin) mRNA; dbSNP
Q5T481	635	Natural variant	S	1.0	description:in CMD1DD; causes the formation of anomalous isoforms in TTN (Titin); impaired localization to the nucleus, leading to mislocalization to the cytoplasm
Q5T481	636	Natural variant	R	1.0	description:in CMD1DD; impaired localization to the nucleus, leading to mislocalization to the cytoplasm; dbSNP
Q5T481	636	Natural variant	R	1.0	description:in CMD1DD; also found in patients with left ventricular non-compaction; dbSNP
Q5T481	636	Natural variant	R	1.0	description:in CMD1DD; impaired splicing of target mRNAs, such as TTN, CAMK2D and CACNA1C; decreased localization to the nucleus associated with relocalization to P-body and stress granules; dbSNP
Q5T481	637	Natural variant	S	1.0	description:in CMD1DD; also found in patients with left ventricular non-compaction; dbSNP
Q5T481	638	Natural variant	P	1.0	description:in CMD1DD; impaired localization to the nucleus, leading to mislocalization to the cytoplasm; dbSNP
Q5T481	674	Natural variant	D	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	716	Natural variant	R	1.0	description:in CMD1DD; dbSNP
Q5T481	888	Natural variant	D	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	905	Natural variant	M	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	913	Natural variant	E	1.0	description:in CMD1DD; decreased stability; impaired mRNA splicing of target mRNAs; dbSNP
Q5T481	914	Natural variant	V	1.0	description:in CMD1DD; impaired mRNA splicing of target mRNAs; does not affect nuclear localization
Q5T481	1039	Natural variant	P	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	1057	Natural variant	R	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	1081	Natural variant	P	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q5T481	1206	Natural variant	E	1.0	description:in CMD1DD; unknown pathological significance; dbSNP
Q6PJF5	186	Natural variant	I	1.0	description:in TOC; dbSNP
Q6PJF5	189	Natural variant	P	1.0	description:in TOC; dbSNP
Q9HC23	24	Natural variant	A	1.0	description:in HH4; phenotype consistent with Kallmann syndrome; dbSNP
Q9HC23	32	Natural variant	G	1.0	description:in HH4; phenotype consistent with Kallmann syndrome; dbSNP
Q9HC23	34	Natural variant	C	1.0	description:in HH4; totally abolished intracellular calcium mobilization; dbSNP
Q9HC23	46	Natural variant	C	1.0	description:in HH4; dbSNP
Q9HC23	50	Natural variant	I	1.0	description:in HH4; no effect on intracellular calcium mobilization; dbSNP
Q9HC23	73	Natural variant	R	1.0	description:in HH4; phenotype consistent with Kallmann syndrome; impaired calcium mobilization; dbSNP
Q9HAZ2	271	Natural variant	E	1.0	description:in CMD1LL; unknown pathological significance; dbSNP
Q9HAZ2	816	Natural variant	N	1.0	description:in LVNC8; dbSNP
Q9HAZ2	887	Natural variant	L	1.0	description:in CMD1LL; unknown pathological significance; dbSNP
P04049	237	Natural variant	A	1.0	description:in CMD1NN; shows a mild increase in kinase activity; dbSNP
P04049	256	Natural variant	R	1.0	description:in NS5; dbSNP
P04049	257	Natural variant	S	1.0	description:in NS5 and LPRD2; shows in vitro greater kinase activity and enhanced ERK activation than wild-type; dbSNP
P04049	259	Natural variant	S	1.0	description:in an ovarian serous carcinoma sample; somatic mutation; increased ERK activation; dbSNP
P04049	259	Natural variant	S	1.0	description:in NS5; dbSNP
P04049	260	Natural variant	T	1.0	description:in hypertrophic cardiomyopathy; unknown pathological significance; dbSNP
P04049	260	Natural variant	T	1.0	description:in NS5
P04049	261	Natural variant	P	1.0	description:in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP
P04049	261	Natural variant	P	1.0	description:in NS5; shows greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP
P04049	261	Natural variant	P	1.0	description:in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP
P04049	263	Natural variant	V	1.0	description:in NS5; shows in vitro greater kinase activity and enhanced MAPK1 activation than wild-type; dbSNP
P04049	310	Natural variant	T	1.0	description:in CMD1NN; shows a mild increase in kinase activity; dbSNP
P04049	332	Natural variant	P	1.0	description:in CMD1NN; shows a mild increase in kinase activity; dbSNP
P04049	335	Natural variant	Q	1.0	description:in a lung adenocarcinoma sample; somatic mutation
P04049	626	Natural variant	H	1.0	description:in CMD1NN; shows a mild increase in kinase activity; dbSNP
P04049	641	Natural variant	T	1.0	description:in CMD1NN; shows a mild increase in kinase activity; dbSNP
Q9H1K0	425	Natural variant	G	1.0	description:found in a patient with intractable epileptic encephalopathy, developmental delay and additional multi-organ symptoms; unknown pathological significance; dbSNP
O15357	982	Natural variant	N	1.0	description:associated with susceptibility to NIDDM; dbSNP
O95343	37	Natural variant	G	1.0	description:in SCHZC and HPE2; dbSNP
O95343	69	Natural variant	G	1.0	description:in HPE2; dbSNP
O95343	79	Natural variant	M	1.0	description:in HPE2
O95343	244	Natural variant	G	1.0	description:in HPE2; dbSNP
O95343	250	Natural variant	V	1.0	description:in HPE2; Significantly decreased its ability to activate NR4A3; dbSNP
O95343	254	Natural variant	F	1.0	description:in HPE2
O95343	257	Natural variant	R	1.0	description:in HPE2
O95343	257	Natural variant	R	1.0	description:in HPE2; Significantly decreased interaction with NR4A3; Significantly decreased its ability to activate NR4A3; dbSNP
O95343	257	Natural variant	R	1.0	description:in HPE2
O95343	258	Natural variant	R	1.0	description:in HPE2
O95343	262	Natural variant	R	1.0	description:in HPE2
O95343	269	Natural variant	R	1.0	description:in HPE2
O95343	269	Natural variant	R	1.0	description:in HPE2
O95343	269	Natural variant	R	1.0	description:in HPE2
O95343	297	Natural variant	P	1.0	description:in HPE2; dbSNP
O43541	287	Natural variant	E	1.0	description:in CRS7; unknown pathological significance; dbSNP
O43541	306	Natural variant	T	1.0	description:in CRS7; associated with disease susceptibility
O43541	323	Natural variant	P	1.0	description:in CRS7; associated with disease susceptibility; dbSNP
O43541	325	Natural variant	A	1.0	description:found in a patient with congenital mitral valve prolapse; dbSNP
Q16637	2	Natural variant	A	1.0	description:in SMA2 and SMA3; dbSNP
Q16637	30	Natural variant	D	1.0	description:in SMA2; dbSNP
Q16637	245	Natural variant	P	1.0	description:in SMA3; dbSNP
Q16637	262	Natural variant	S	1.0	description:in SMA3; dbSNP
Q16637	262	Natural variant	S	1.0	description:in SMA3; slightly reduces SMN binding to RPP20/POP7; dbSNP
Q16637	272	Natural variant	Y	1.0	description:in SMA1; abolishes SMN1 binding to RPP20/POP7 and severely impairs binding to SNRPB, GEMIN8 and homooligomerization; dbSNP
Q16637	274	Natural variant	T	1.0	description:in SMA2 and SMA3; Impairs SMN1 binding to RPP20/POP7, GEMIN8 and homooligomerization; dbSNP
Q16637	275	Natural variant	G	1.0	description:in SMA3; impairs homooligomerization.; dbSNP
Q16637	279	Natural variant	G	1.0	description:in SMA2 and SMA3; dbSNP
Q16637	279	Natural variant	G	1.0	description:in SMA1; slightly reduces SMN binding to RPP20/POP7. Impairs homooligomerization and axon localization; dbSNP
Q5T4T6	647	Natural variant	N	1.0	description:does not affect localization to centromeres; dbSNP
Q5T4T6	672	Natural variant	P	1.0	description:does not affect localization to centromeres; dbSNP
P09651	277	Natural variant	Q	1.0	description:in ALS20; unknown pathological significance
P09651	314	Natural variant	D	1.0	description:in ALS20; dbSNP
P09651	314	Natural variant	D	1.0	description:in IBMPFD3; reduces binding to UBQLN2; dbSNP
P09651	319	Natural variant	N	1.0	description:in ALS20; dbSNP
P09651	340	Natural variant	P	1.0	description:in ALS20; increases subcellular localization of HNRNPA1 in cytoplasmic inclusions with stress granules
Q96KN7	1057	Natural variant	H	1.0	description:found in a patient associated with LCA6; dbSNP
Q5TD94	87	Natural variant	P	1.0	description:in CILD11; dbSNP
P55017	60	Natural variant	T	1.0	description:in GTLMNS; dbSNP
P55017	62	Natural variant	D	1.0	description:in GTLMNS; dbSNP
P55017	62	Natural variant	D	1.0	description:in GTLMNS
P55017	68	Natural variant	E	1.0	description:in GTLMNS; dbSNP
P55017	69	Natural variant	H	1.0	description:in GTLMNS; dbSNP
P55017	83	Natural variant	R	1.0	description:in GTLMNS; dbSNP
P55017	83	Natural variant	R	1.0	description:in GTLMNS; dbSNP
P55017	90	Natural variant	H	1.0	description:in GTLMNS; dbSNP
P55017	121	Natural variant	E	1.0	description:in GTLMNS; 27% residual Na(+) uptake activity; increased MAPK1/3 (ERK1/2) phosphorylation in response to IL18; no effect on localization at the plasma membrane; dbSNP
Q08357	382	Natural variant	R	1.0	description:in IBGC1; dbSNP
Q08357	434	Natural variant	S	1.0	description:in IBGC1; dbSNP
P04279	79	Natural variant	S	1.0	description:less common genetic variant; dbSNP
Q9UIU6	23	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q9UIU6	446	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9UIU6	780	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q8NHU3	62	Natural variant	I	1.0	description:in CDLSMD; unknown pathological significance; no effect on enzymatic activity; does not localize to plasma membrane; accumulates in the endoplasmic reticulum
P35712	766	Natural variant	S	1.0	description:in TOLCAS; unknown pathological significance
Q06945	59	Natural variant	I	1.0	description:in CSS10; loss of DNA-binding transcription factor activity; dbSNP
Q07837	510	Natural variant	Q	1.0	description:in CSNU; dbSNP
Q9ULL8	146	Natural variant	R	1.0	description:found in a patient with Rett syndrome-like phenotype; unknown pathological significance; dbSNP
Q9ULL8	1089	Natural variant	S	1.0	description:in SDSX; dbSNP
P78362	243	Natural variant	G	1.0	description:in a glioblastoma multiforme sample; somatic mutation
Q9NUY8	518	Natural variant	R	1.0	description:in PCH11; unknown pathological significance
Q3LI58	15	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q8N743	373	Natural variant	E	1.0	description:in allele KIR3DL3*027, allele KIR3DL3*029 and allele KIR3DL3*031; dbSNP
P35498	17	Natural variant	F	1.0	description:in DRVT
P35498	27	Natural variant	R	1.0	description:in GEFS+2; dbSNP
P35498	45	Natural variant	D	1.0	description:found in a patient with an unclassified form of epilepsy; also found in a patient with epilepsy-aphasia and febrile seizures plus; unknown pathological significance; dbSNP
P35498	58	Natural variant	G	1.0	description:in DRVT
P35498	61	Natural variant	L	1.0	description:in DRVT
P35498	63	Natural variant	F	1.0	description:in DRVT; dbSNP
P35498	68	Natural variant	I	1.0	description:in DRVT; borderline phenotype; dbSNP
P35498	74	Natural variant	S	1.0	description:in GEFS+2; dbSNP
P35498	525	Natural variant	S	1.0	description:in DRVT
P35498	542	Natural variant	R	1.0	description:found in a patient with intractable epilepsy and in a patient with generalized epilepsy with febril seizures; also found in patients with autism; unknown pathological significance; dbSNP
P35498	616	Natural variant	E	1.0	description:probable disease-associated variant found in a patient with drug-resistant epilepsy and mild cognitive impairment; dbSNP
P35498	626	Natural variant	S	1.0	description:in DRVT; also found in a patient with cryptogenic generalized epilepsy; dbSNP
P35498	674	Natural variant	D	1.0	description:in DRVT
P35498	1068	Natural variant	E	1.0	description:in DRVT
P35498	1174	Natural variant	T	1.0	description:in FHM3; dbSNP
P35498	1741	Natural variant	C	1.0	description:in DRVT
P35498	1742	Natural variant	D	1.0	description:in GEFS+2; dbSNP
P35498	1749	Natural variant	G	1.0	description:in DRVT; dbSNP
P35498	1756	Natural variant	C	1.0	description:in DRVT; dbSNP
P35498	1957	Natural variant	E	1.0	description:in infantile spasms; dbSNP
P35498	1977	Natural variant	M	1.0	description:found in a patient with febrile seizures and non-specific acute encephalopathy; unknown pathological significance
P35498	1988	Natural variant	R	1.0	description:found in a patient with epilepsy-aphasia and febrile seizures plus; unknown pathological significance; dbSNP
Q8IWL2	19	Natural variant	V	1.0	description:in allele 6A and allele 6A(5); dbSNP
Q8IWL2	50	Natural variant	L	1.0	description:in allele 6A(2); dbSNP
Q8IWL1	9	Natural variant	T	1.0	description:in allele 1A(0); dbSNP
Q8IWL1	91	Natural variant	A	1.0	description:in allele 1A; dbSNP
Q9UQD0	58	Natural variant	D	1.0	description:in DEE13; unknown pathological significance; no effect on channel activity
Q9UQD0	479	Natural variant	E	1.0	description:in DEE13; unknown pathological significance
Q9UQD0	662	Natural variant	R	1.0	description:in DEE13; unknown pathological significance; dbSNP
Q9NRH2	611	Natural variant	G	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP
Q9NRH2	765	Natural variant	I	1.0	description:in a breast pleomorphic lobular carcinoma sample; somatic mutation
O43776	11	Natural variant	R	1.0	description:in NEDMILG; unknown pathological significance; decreased protein levels in patient cells; dbSNP
O43776	17	Natural variant	T	1.0	description:in NEDMILG; decreased protein levels in patient cells; decreased asparagine-tRNA ligase activity in patient cells; dbSNP
O95359	798	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
O95359	1347	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q96J66	19	Natural variant	R	1.0	description:no effect on glycosylation; no effect on transport activity; no effect on plasma membrane localization; dbSNP
Q04671	10	Natural variant	R	1.0	description:in OCA2; dbSNP
Q04671	27	Natural variant	G	1.0	description:in OCA2; dbSNP
Q04671	86	Natural variant	S	1.0	description:in OCA2; dbSNP
Q04671	112	Natural variant	C	1.0	description:in OCA2; dbSNP
Q14160	454	Natural variant	P	1.0	description:in NTD; protein interactions not affected by the mutation; shows reduced protein localization to the cell membrane; dbSNP
Q14160	1535	Natural variant	R	1.0	description:in NTD; protein interactions not affected by the mutation; shows reduced protein localization to the cell membrane; dbSNP
Q9Y2K2	1161	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q8IZX4	47	Natural variant	G	1.0	description:in a lung small cell carcinoma sample; somatic mutation
Q8IZX4	1824	Natural variant	H	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q13546	324	Natural variant	D	1.0	description:in AIEFL; prevents cleavage by CASP8; increased kinase activity; increased inflammatory response
Q13546	324	Natural variant	D	1.0	description:in AIEFL; prevents cleavage by CASP8; changed inflammatory response; dbSNP
Q13546	324	Natural variant	D	1.0	description:in AIEFL; prevents cleavage by CASP8; increased kinase activity; increased inflammatory response
Q13546	324	Natural variant	D	1.0	description:in AIEFL; prevents cleavage by CASP8; changed inflammatory response
Q8NEQ6	52	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q8NEQ6	100	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q06124	560	Natural variant	L	1.0	description:in NS1; unknown pathological significance; dbSNP
Q9BQ52	211	Natural variant	R	1.0	description:in HPC2; dbSNP
Q9BQ52	217	Natural variant	S	1.0	description:in HPC2; risk factor for disease development; does not affect the enzymatic activity; dbSNP
Q9BQ52	806	Natural variant	G	1.0	description:in HPC2; dbSNP
P57059	411	Natural variant	S	1.0	description:in DEE30; no change in subcellular location
P57059	469	Natural variant	G	1.0	description:in a metastatic melanoma sample; somatic mutation
P57059	636	Natural variant	G	1.0	description:in DEE30; no change in subcellular location; dbSNP
P35711	362	Natural variant	Q	1.0	description:in a patient with amyotrophic lateral sclerosis; dbSNP
P78324	486	Natural variant	A	1.0	description:requires 2 nucleotide substitutions
Q96GP6	499	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
O75631	273	Natural variant	P	1.0	description:found in patients with renal adysplasia; unknown pathological significance; normal targeting to the cell surface; dbSNP
A2VEC9	2799	Natural variant	R	1.0	description:found in patient with Joubert syndrome; unknown pathological significance; dbSNP
P57054	25	Natural variant	M	1.0	description:in DEE55; reduced GPI-anchor biosynthetic process; may affect expression of isoform A; dbSNP
Q9H3S1	713	Natural variant	R	1.0	description:no effect on localization to cell membrane; dbSNP
Q96Q15	3583	Natural variant	K	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation
P35716	116	Natural variant	Y	1.0	description:in CSS9; decreases transcriptional activity; dbSNP
Q13501	212	Natural variant	R	1.0	description:in FTDALS3; dbSNP
Q13501	219	Natural variant	G	1.0	description:in FTDALS3
Q13501	226	Natural variant	S	1.0	description:in FTDALS3; dbSNP
Q13501	228	Natural variant	P	1.0	description:in FTDALS3; dbSNP
Q13501	232	Natural variant	P	1.0	description:in FTDALS3; dbSNP
Q13501	238	Natural variant	K	1.0	description:confirmed at protein level; dbSNP
Q13501	238	Natural variant	K	1.0	description:in FTDALS3
Q13501	258	Natural variant	D	1.0	description:in FTDALS3; dbSNP
Q13501	318	Natural variant	S	1.0	description:in FTDALS3
Q13501	321	Natural variant	R	1.0	description:in FTDALS3; likely benign variant; dbSNP
Q13501	329	Natural variant	D	1.0	description:in FTDALS3; dbSNP
Q13501	348	Natural variant	P	1.0	description:in FTDALS3; dbSNP
Q13501	370	Natural variant	S	1.0	description:in FTDALS3; dbSNP
Q13501	381	Natural variant	A	1.0	description:in FTDALS3; dbSNP
P36956	527	Natural variant	R	1.0	description:in IFAP2 and HMD; loss of sterol-regulated protein processing; loss of localization to the nucleus; decreased DNA-binding transcription factor activity RNA polymerase II-specific; dbSNP
P36956	527	Natural variant	R	1.0	description:in HMD; dbSNP
P36956	528	Natural variant	N	1.0	description:in IFAP2; loss of sterol-regulated protein processing; loss of localization to the nucleus; decreased DNA-binding transcription factor activity RNA polymerase II-specific
P36956	530	Natural variant	L	1.0	description:in IFAP2; loss of sterol-regulated protein processing; loss of localization to the nucleus; decreased DNA-binding transcription factor activity RNA polymerase II-specific; dbSNP
Q8NEY8	173	Natural variant	V	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q13127	160	Natural variant	R	1.0	description:in WT6; inhibits transcriptional repression activity
Q13127	412	Natural variant	H	1.0	description:in WT6
Q13950	53	Natural variant	Q	1.0	description:in CLCD
Q13950	84	Natural variant	A	1.0	description:in CLCD; the patient also shows brachydactyly of hands and feet
Q13950	225	Natural variant	R	1.0	description:in CLCD
Q13950	225	Natural variant	R	1.0	description:in CLCD; interferes with nuclear localization; abolishes DNA binding; dbSNP
Q13950	225	Natural variant	R	1.0	description:in CLCD; interferes with nuclear localization; has severely impaired DNA binding and transactivation; dbSNP
Q13950	228	Natural variant	R	1.0	description:in CLCD
Q13950	233	Natural variant	K	1.0	description:in CLCD
Q13950	287	Natural variant	D	1.0	description:in CLCD
Q13950	362	Natural variant	A	1.0	description:in CLCD
Q13950	420	Natural variant	T	1.0	description:in CLCD
Q13950	420	Natural variant	T	1.0	description:in CLCD
Q13285	123	Natural variant	G	1.0	description:in SPGF8 and POF7; activity levels similar to wild-type; dbSNP
Q13285	129	Natural variant	P	1.0	description:in SPGF8 and POF7; loss of activity; dbSNP
Q13285	131	Natural variant	P	1.0	description:in SPGF8; impairs transactivational activity; dbSNP
Q13285	191	Natural variant	R	1.0	description:in SPGF8; impairs transactivational activity; dbSNP
Q13285	212	Natural variant	G	1.0	description:in SPGF8; impairs transactivational activity; dbSNP
P49335	334	Natural variant	K	1.0	description:in DFNX2; dbSNP
P28069	24	Natural variant	P	1.0	description:in CPHD1; dbSNP
P28069	76	Natural variant	P	1.0	description:in CPHD1; reduces transactivation capacity on the GH1 gene; increases the functional binding on the GH1 promoter; increases the interaction with ELK1, LHX3 and PITX1
Q96FL8	10	Natural variant	V	1.0	description:does not affect plasma membrane expression. Does not affect TEA and metformin transport
Q96FL8	474	Natural variant	N	1.0	description:does not affect plasma membrane localization. Decreases TEA transport. Km value for TEA is increased. Does not affect metformin transport
Q9H2X9	975	Natural variant	R	1.0	description:in EIG14; rare variant associated with disease susceptibility; results in reduced chloride transport; decreased localization at the cell surface; unable to induce cortical dendritic spines formation; dbSNP
Q9P283	42	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
O15524	22	Natural variant	R	1.0	description:in AISIMD; loss of inhibition of cytokine-induced STAT phosphorylation, including IFNG-induced STAT1 phosphorylation, IL2-induced STAT5 phosphorylation and IL4-induced STAT6 phosphorylation
Q9HAT2	3	Natural variant	A	1.0	description:rare variant found in a patient with Crohn disease; probably not involved in disease susceptibility; the mutant enzyme has normal activity and is normally secreted; dbSNP
Q15831	314	Natural variant	P	1.0	description:in colorectal cancer; no effect heterotrimeric complex assembly with STRADA and CAB39
Q15831	315	Natural variant	P	1.0	description:in PJS; pathogenicity uncertain; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP
Q15831	324	Natural variant	P	1.0	description:in gastric carcinoma; no effect heterotrimeric complex assembly with STRADA and CAB39; dbSNP
Q15831	354	Natural variant	F	1.0	description:in colorectal cancer; somatic mutation; dbSNP
Q15831	367	Natural variant	T	1.0	description:in colorectal cancer; somatic mutation; dbSNP
O60313	8	Natural variant	A	1.0	description:in OPA1; unknown pathological significance; dbSNP
O60313	80	Natural variant	Y	1.0	description:in OPA1; dbSNP
O60313	95	Natural variant	T	1.0	description:in OPA1; dbSNP
O60313	102	Natural variant	Y	1.0	description:in OPA1; dbSNP
Q9C0D0	479	Natural variant	N	1.0	description:in DEE70; severely impaired interaction with actin; dbSNP
Q08209	447	Natural variant	A	1.0	description:in IECEE1; unknown pathological significance; dbSNP
Q08209	470	Natural variant	F	1.0	description:in ACCIID; dbSNP
Q08209	473	Natural variant	A	1.0	description:in ACCIID; dbSNP
Q9H3S7	829	Natural variant	P	1.0	description:in NEDBASS; unknown pathological significance; dbSNP
Q9H3S7	894	Natural variant	H	1.0	description:in NEDBASS; unknown pathological significance; dbSNP
Q9H3S7	916	Natural variant	Q	1.0	description:in NEDBASS; unknown pathological significance; dbSNP
Q9H3S7	1017	Natural variant	Q	1.0	description:in NEDBASS; when associated in cis with R-583; unknown pathological significance; dbSNP
O76082	549	Natural variant	P	1.0	description:reduces carnitine transport but the mutant retains more than 20% of wild-type activity; dbSNP
Q9H3D4	6	Natural variant	S	1.0	description:in ADULT syndrome; dbSNP
Q9H3D4	6	Natural variant	S	1.0	description:in ADULT syndrome; dbSNP
Q9H3D4	6	Natural variant	S	1.0	description:in ADULT syndrome; dbSNP
Q9H3D4	6	Natural variant	S	1.0	description:in ADULT syndrome; dbSNP
Q9H3D4	6	Natural variant	S	1.0	description:in ADULT syndrome; dbSNP
Q9H3D4	6	Natural variant	S	1.0	description:in ADULT syndrome; dbSNP
Q9H3D4	184	Natural variant	S	1.0	description:in head and neck cancer
Q9H3D4	187	Natural variant	A	1.0	description:in lung carcinoma; somatic mutation
Q9H3D4	351	Natural variant	D	1.0	description:in EEC3; dbSNP
Q9H3D4	351	Natural variant	D	1.0	description:in EEC3
Q9H3D4	352	Natural variant	R	1.0	description:in OFC8; dbSNP
O15534	696	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
O15534	985	Natural variant	N	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
O15534	1060	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P00747	147	Natural variant	L	1.0	description:in PLGD; dbSNP
P00747	374	Natural variant	V	1.0	description:in PLGD; Nagoya-1; dbSNP
Q8IWN7	19	Natural variant	P	1.0	description:in RP88; unknown pathological significance; dbSNP
Q8IWN7	152	Natural variant	R	1.0	description:in RP88; unknown pathological significance; dbSNP
Q8IWN7	950	Natural variant	R	1.0	description:in OCMD; unknown pathological significance; dbSNP
Q8IWN7	960	Natural variant	W	1.0	description:in OCMD; dbSNP
Q8IWN7	1199	Natural variant	S	1.0	description:in OCMD; unknown pathological significance; dbSNP
Q8IWN7	1200	Natural variant	G	1.0	description:in OCMD; unknown pathological significance; dbSNP
Q8IWN7	1285	Natural variant	A	1.0	description:in allele RP1L1-3
Q8IWN7	1313	Natural variant	E	1.0	description:in allele RP1L1-2
Q8IWN7	1313	Natural variant	E	1.0	description:in allele RP1L1-3
Q8IWN7	1313	Natural variant	E	1.0	description:in allele RP1L1-4
Q8IWN7	1313	Natural variant	E	1.0	description:in allele RP1L1-5
Q8IWN7	1313	Natural variant	E	1.0	description:in allele RP1L1-6
Q8IWN7	1324	Natural variant	E	1.0	description:in allele RP1L1-3; dbSNP
Q8IWN7	1335	Natural variant	G	1.0	description:in allele RP1L1-2 and allele RP1L1-3; dbSNP
O43435	310	Natural variant	G	1.0	description:in DGS; dbSNP
O43435	337	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q8N554	275	Natural variant	R	1.0	description:may increase breast cancer risk
Q12889	662	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation
P37231	12	Natural variant	P	1.0	description:significant independent determinant of CIMT; may protect from early atherosclerosis in subject at risk for diabetes; associated with BMI; dbSNP
P37231	113	Natural variant	P	1.0	description:in obesity; dbSNP
Q16650	178	Natural variant	Q	1.0	description:in IDDAS; unknown pathological significance; does not affect nuclear localization; no effect on transcriptional repression of FEZF2; does not affect homodimerization; does not affect interaction with FOXP2; dbSNP
Q16650	418	Natural variant	Q	1.0	description:in IDDAS; unknown pathological significance; does not affect nuclear localization; no effect on transcriptional repression of FEZF2; does not affect homodimerization; decreased interaction with FOXP2; loss of interaction with BCL11A; dbSNP
Q16650	542	Natural variant	P	1.0	description:in IDDAS; unknown pathological significance; does not affect nuclear localization; no effect on transcriptional repression of FEZF2; does not affect homodimerization; does not affect interaction with FOXP2; does not affect interaction with BCL11A
Q8WZ04	16	Natural variant	L	1.0	description:in DFNB63; unknown pathological significance; dbSNP
O00295	149	Natural variant	V	1.0	description:found in a renal cell carcinoma sample; somatic mutation
Q7Z4N2	1438	Natural variant	R	1.0	description:in a patient with night blindness started in the third decade; associated in cis with T-962
Q92765	324	Natural variant	R	1.0	description:in OS1; associated with disease susceptibility; has diminished ability to antagonize Wnt signaling, in vitro; dbSNP
Q9H4B6	185	Natural variant	A	1.0	description:in a colon cancer cell line
P51168	616	Natural variant	P	1.0	description:in LIDLS1; dbSNP
P51168	616	Natural variant	P	1.0	description:in LIDLS1
P51168	617	Natural variant	P	1.0	description:in LIDLS1; dbSNP
P51168	618	Natural variant	P	1.0	description:in LIDLS1; dbSNP
P51168	620	Natural variant	Y	1.0	description:in LIDLS1; constitutive channel activation; dbSNP
P38935	974	Natural variant	D	1.0	description:in HMN6; unknown pathological significance; dbSNP
Q6ZMD2	507	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P54219	84	Natural variant	F	1.0	description:found in patients with bipolar disorder; increases the vesicular uptake of noradrenaline and dopamine; dbSNP
P54219	101	Natural variant	A	1.0	description:found in a patient with bipolar disorder; decreases the vesicular uptake of noradrenaline, dopamine and serotonin; dbSNP
Q8NBP7	23	Natural variant	L	1.0	description:this variant seems to have a modifier effect on LDLR mutation and familial hypercholesterolemia
P55347	265	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P62854	115	Natural variant	M	1.0	description:in DBA10
Q15022	535	Natural variant	R	1.0	description:in IMMAS; unknown pathological significance
P14679	19	Natural variant	H	1.0	description:in OCA1A; dbSNP
P14679	21	Natural variant	P	1.0	description:in OCA1A; dbSNP
P14679	294	Natural variant	E	1.0	description:in OCA1A; dbSNP
P14679	294	Natural variant	E	1.0	description:in OCA1A and OCA1B; dbSNP
P14679	298	Natural variant	R	1.0	description:in OCA1A; dbSNP
P14679	299	Natural variant	R	1.0	description:in OCA1A; dbSNP
P14679	299	Natural variant	R	1.0	description:in OCA1A; dbSNP
P16473	310	Natural variant	R	1.0	description:in CHNG1
P16473	390	Natural variant	C	1.0	description:in CHNG1; persistent hypothyroidism and defective thyroid development; abolishes high affinity hormone binding
P16473	715	Natural variant	N	1.0	description:in papillary cancer
P16473	723	Natural variant	K	1.0	description:in papillary cancer
P16473	727	Natural variant	D	1.0	description:may be a predisposing factor in toxic multinodular goiter pathogenesis; activation of the cAMP cascade does not differ from the wild-type; dbSNP
Q8IYT8	627	Natural variant	G	1.0	description:in a metastatic melanoma sample; somatic mutation
Q8IYT8	662	Natural variant	A	1.0	description:in a metastatic melanoma sample; somatic mutation
Q9UBW7	61	Natural variant	V	1.0	description:likely benign variant; found in a patient with congenital anomalies of the kidney and urinary tract; no effect on localization to the nucleus
Q9UBW7	126	Natural variant	E	1.0	description:likely benign variant; found in a patient with congenital anomalies of the kidney and urinary tract; no effect on localization to the nucleus; no effect on transcriptional repression activity
Q9UBW7	997	Natural variant	D	1.0	description:likely benign variant; found in a patient with congenital anomalies of the kidney and urinary tract; no effect on localization to the nucleus
Q9UBW7	1031	Natural variant	E	1.0	description:likely benign variant; found in a patient with congenital anomalies of the kidney and urinary tract; no effect on localization to the nucleus; no effect on transcriptional repression activity
P08247	277	Natural variant	D	1.0	description:in XLID96; unknown pathological significance
P08247	293	Natural variant	G	1.0	description:in XLID96; unknown pathological significance; dbSNP
Q9UKZ4	342	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q9H6R7	454	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q9BYP7	854	Natural variant	S	1.0	description:in a lung squamous cell carcinoma sample; somatic mutation
Q9BYP7	1634	Natural variant	S	1.0	description:in a renal clear cell carcinoma sample; somatic mutation
Q9NQZ6	198	Natural variant	R	1.0	description:in WRWF; causes a decrease in synapse number and density; dbSNP
Q9NQZ6	200	Natural variant	A	1.0	description:in WRWF; dbSNP
Q9NQZ6	200	Natural variant	A	1.0	description:in WRWF
Q9NQZ6	201	Natural variant	P	1.0	description:in WRWF
Q9NQZ6	201	Natural variant	P	1.0	description:in WRWF; causes a decrease in synapse number and density; dbSNP
Q9NQZ6	203	Natural variant	C	1.0	description:in WRWFFR
Q9NQZ6	206	Natural variant	C	1.0	description:in WRWFFR; dbSNP
Q9NQZ6	213	Natural variant	R	1.0	description:in WRWF; increased cytoplasmic subcellular localization; partial loss of function; rescues partially interneurons differentiation when expressed in a zebrafish heterologous system; dbSNP
Q9NQZ6	217	Natural variant	K	1.0	description:in WRWF; dbSNP
Q9H4Q4	352	Natural variant	A	1.0	description:in HSAN8; reduced protein amount; results in protein aggregation
Q96GQ5	43	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
P37088	181	Natural variant	R	1.0	description:significant increase of amiloride-sensitive sodium currents; dbSNP
Q15208	18	Natural variant	E	1.0	description:in a metastatic melanoma sample; somatic mutation
Q9UPQ9	1357	Natural variant	V	1.0	description:in GDSBA; unknown pathological significance
P19429	2	Natural variant	A	1.0	description:in CMD2A; dbSNP
P19429	36	Natural variant	K	1.0	description:in CMD1FF; dbSNP
Q9ULW0	464	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation
Q562E7	856	Natural variant	P	1.0	description:in CAMRQ2; dbSNP
P18887	431	Natural variant	K	1.0	description:in SCAR26; may result in aberrant splicing; dbSNP
Q9Y2I8	119	Natural variant	S	1.0	description:in NOCGUS
Q9GZT5	213	Natural variant	G	1.0	description:in STHAG4 and OODD; unknown pathological significance; dbSNP
Q9GZT5	217	Natural variant	D	1.0	description:in STHAG4; unknown pathological significance; dbSNP
Q9GZT5	306	Natural variant	N	1.0	description:in STHAG4; unknown pathological significance; dbSNP
Q9GZT5	348	Natural variant	R	1.0	description:found in a patient with dental anomalies; unknown pathological significance; dbSNP
Q9GZT5	356	Natural variant	G	1.0	description:in OODD; unknown pathological significance
Q9GZT5	357	Natural variant	T	1.0	description:in STHAG4; unknown pathological significance; dbSNP
Q9GZT5	360	Natural variant	R	1.0	description:probable disease-associated variant found in patients with an unclassified form of ectodermal dysplasia
Q9BWH6	525	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q96T21	540	Natural variant	R	1.0	description:in THMA; dbSNP
Q9UHD8	106	Natural variant	R	1.0	description:in HNA; dbSNP
Q9UHD8	111	Natural variant	S	1.0	description:in HNA; dbSNP
P01241	3	Natural variant	T	1.0	description:found in patients with isolated growth hormone deficiency; dbSNP
P01241	16	Natural variant	L	1.0	description:in IGHD1B; suppresses secretion
P01241	79	Natural variant	C	1.0	description:in short stature; idiopathic autosomal; affects binding affinity of GH for GHR and the potency of GH to activate the JAK2/STAT5 signaling pathway; dbSNP
Q13586	72	Natural variant	H	1.0	description:in TAM1; myoblasts with the mutation have significantly increased clustering of STIM1, regardless of calcium levels, indicating that calcium sensing in the sarcoplasmic reticulum is impaired; dbSNP
Q13586	80	Natural variant	N	1.0	description:in TAM1; myoblasts with the mutation have significantly increased clustering of STIM1, regardless of calcium levels, indicating that calcium sensing in the sarcoplasmic reticulum is impaired; dbSNP
Q13586	81	Natural variant	G	1.0	description:in TAM1; increases store-operated Ca(2+) influx
Q13586	84	Natural variant	D	1.0	description:in TAM1; myoblasts with the mutation have significantly increased clustering of STIM1, regardless of calcium levels, indicating that calcium sensing in the sarcoplasmic reticulum is impaired; dbSNP
Q13586	96	Natural variant	L	1.0	description:in TAM1; myoblasts with the mutation have significantly increased clustering of STIM1, regardless of calcium levels, indicating that calcium sensing in the sarcoplasmic reticulum is impaired
Q92502	188	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q92502	242	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q9NVV9	6	Natural variant	S	1.0	description:in DYT6
Q9NVV9	6	Natural variant	S	1.0	description:in DYT6; dbSNP
Q9NVV9	7	Natural variant	A	1.0	description:in DYT6
Q9NVV9	8	Natural variant	Y	1.0	description:in DYT6
Q9NVV9	9	Natural variant	G	1.0	description:in DYT6; dbSNP
Q9NVV9	12	Natural variant	N	1.0	description:in DYT6
Q9NVV9	13	Natural variant	R	1.0	description:in DYT6
Q9NVV9	16	Natural variant	K	1.0	description:in DYT6; lower activity than wild-type
Q9NVV9	17	Natural variant	D	1.0	description:in DYT6; dbSNP
Q9NVV9	89	Natural variant	K	1.0	description:in DYT6; dbSNP
Q9NVV9	132	Natural variant	F	1.0	description:in DYT6; dbSNP
P02810	20	Natural variant	D	1.0	description:in allele PRH1-PIF, allele PRH1-PA and allele PRH1-DB; dbSNP
P02810	42	Natural variant	I	1.0	description:in allele PRH1-PA and allele PRH1-DB; dbSNP
P02810	66	Natural variant	D	1.0	description:in allele PRH2-1; dbSNP
P02810	97	Natural variant	Q	1.0	description:in allele PRH1-DB
P02810	119	Natural variant	R	1.0	description:in allele PRH1-PA; interferes with proteolytic cleavage at Arg-122; dbSNP
P02810	163	Natural variant	Q	1.0	description:in allele PRH2-3; dbSNP
O14994	470	Natural variant	S	1.0	description:in patients affected by schizophrenia; dbSNP
Q99593	237	Natural variant	R	1.0	description:in HOS; extensive upper limb malformations; affects transcriptional regulation of MYH6; dbSNP
Q99593	237	Natural variant	R	1.0	description:in HOS; extensive upper limb malformations; strongly reduced affinity for DNA; dbSNP
Q8TAF3	628	Natural variant	E	1.0	description:found in a patient with spastic paraplegia; unknown pathological significance
Q01804	398	Natural variant	G	1.0	description:could be associated with cerebellar ataxia and hypogonadotropic hypogonadism; dbSNP
Q15198	23	Natural variant	H	1.0	description:in CRC; somatic mutation; dbSNP
Q9H4A3	1199	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
Q9H4A3	1799	Natural variant	Q	1.0	description:in breast cancer samples; infiltrating ductal carcinoma; somatic mutation
Q9H4A3	2190	Natural variant	S	1.0	description:in a breast pleomorphic lobular carcinoma sample; somatic mutation
Q9H4A3	2362	Natural variant	F	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q96KR1	319	Natural variant	L	1.0	description:found in a patient with spastic paraplegia; unknown pathological significance; dbSNP
Q4FZB7	513	Natural variant	A	1.0	description:in MRD51; unknown pathological significance; dbSNP
Q4FZB7	540	Natural variant	R	1.0	description:in MRD51; unknown pathological significance; dbSNP
Q86TC9	20	Natural variant	Y	1.0	description:in CMH22 and CMD1KK; perturbs MYPN nuclear shuttling and leads to disruption of intercalated disks; dbSNP
Q86TC9	153	Natural variant	K	1.0	description:in CMH22; dbSNP
Q86TC9	213	Natural variant	I	1.0	description:in CMD1KK; dbSNP
Q86TC9	217	Natural variant	A	1.0	description:in CMH22; dbSNP
Q86TC9	410	Natural variant	V	1.0	description:in CMH22; dbSNP
Q86TC9	611	Natural variant	A	1.0	description:in CMD1KK; dbSNP
Q86TC9	841	Natural variant	P	1.0	description:in CMH22; dbSNP
P32243	133	Natural variant	P	1.0	description:in MCOPS5; dbSNP
P32243	134	Natural variant	P	1.0	description:in MCOPS5; dbSNP
P32243	134	Natural variant	P	1.0	description:in CPHD6; unknown pathological significance; loss of transcriptional activity, when tested on bicoid binding sites; decreases transactivation mediated by the wild-type protein, when tested on bicoid binding sites; no effect on DNA-binding; dbSNP
P32243	225	Natural variant	N	1.0	description:in CPHD6; acts as a dominant inhibitor of the HESX1 gene; dbSNP
Q70E73	891	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q70E73	1228	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P47712	442	Natural variant	H	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q16821	554	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q16821	905	Natural variant	D	1.0	description:can be associated with insulin resistance; dbSNP
Q16821	931	Natural variant	A	1.0	description:in NIDDM; dbSNP
Q9ULT0	672	Natural variant	S	1.0	description:in GIDID1; dbSNP
Q9ULT0	678	Natural variant	S	1.0	description:in GIDID1
Q6PI48	45	Natural variant	S	1.0	description:in LBSL; dbSNP
Q6PI48	613	Natural variant	L	1.0	description:in LBSL; dbSNP
Q6PI48	626	Natural variant	L	1.0	description:in LBSL; dbSNP
Q6PI48	626	Natural variant	L	1.0	description:in LBSL; dbSNP
Q6PI48	629	Natural variant	Y	1.0	description:in LBSL; dbSNP
P21675	575	Natural variant	P	1.0	description:in MRXS33; dbSNP
P21675	651	Natural variant	E	1.0	description:in a metastatic melanoma sample; somatic mutation
P21675	1316	Natural variant	I	1.0	description:in MRXS33; dbSNP
Q9UHD2	533	Natural variant	A	1.0	description:no effect on IFNB induction
Q7Z7G0	663	Natural variant	D	1.0	description:found in a patient with isolated coloboma; unknown pathological significance
Q5VWI1	437	Natural variant	K	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P20333	196	Natural variant	M	1.0	description:seems to be associated with hyperandrogenism, polycystic ovary syndrome (PCOS) and systemic lupus erythematosus; dbSNP
Q9UM01	5	Natural variant	T	1.0	description:in LPI; dbSNP
P17600	79	Natural variant	S	1.0	description:in XLID50; results in reduced synaptic vesicle mobility, increased clustering of synaptic vesicles at presynatptic terminals and increased frequency of miniature excitatory postsynaptic currents; dbSNP
P17600	550	Natural variant	A	1.0	description:in XLID50; unknown pathological significance; no effect on phosphorylation by CaMK2 and MAPK1; has no effect on axon elongation when tested in SYN1-knockout mouse neurons; slightly reduced protein targeting to presynapse; dbSNP
P17600	567	Natural variant	T	1.0	description:no effect on phosphorylation by CaMK2 and MAPK1; has no effect on axon elongation when tested in SYN1-knockout mouse neurons; slightly reduced protein targeting to presynapse; dbSNP
Q07011	250	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
O75554	113	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
P57082	248	Natural variant	G	1.0	description:in ICPPS; dbSNP
P57082	531	Natural variant	Q	1.0	description:in ICPPS; dbSNP
P31483	334	Natural variant	M	1.0	description:in ALS26; unknown pathological significance; dbSNP
P31483	355	Natural variant	G	1.0	description:in ALS26; unknown pathological significance; dbSNP
P31483	360	Natural variant	V	1.0	description:in ALS26; unknown pathological significance; dbSNP
P31483	362	Natural variant	P	1.0	description:in ALS26; accelerated formation of TIA1 amyloid-like fibrils; impaired stress granule disassembly; accumulation of insoluble TARDBP/TDP43-positive stress granules; dbSNP
P31483	381	Natural variant	A	1.0	description:in ALS26; unknown pathological significance; dbSNP
P31483	384	Natural variant	E	1.0	description:in WDM; results in a mild increase of stress granule numbers compared to controls; impaired stress granule disassembly; dbSNP
Q9HCS4	147	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
Q9NZC2	223	Natural variant	T	1.0	description:affects protein maturation; dbSNP
O14836	202	Natural variant	R	1.0	description:in CVID2; dbSNP
P40238	594	Natural variant	L	1.0	description:in CAMT; dbSNP
P22735	42	Natural variant	S	1.0	description:in ARCI1; skin phenotype consistent with lamellar ichthyosis; dbSNP
P22735	53	Natural variant	C	1.0	description:in ARCI1
P22735	94	Natural variant	G	1.0	description:in ARCI1; dbSNP
P22735	102	Natural variant	D	1.0	description:in ARCI1; skin phenotype consistent with lamellar ichthyosis; dbSNP
P22735	126	Natural variant	R	1.0	description:in ARCI1; dbSNP
P22735	126	Natural variant	R	1.0	description:in ARCI1; dbSNP
P17643	24	Natural variant	A	1.0	description:in OCA3; dbSNP
Q8N2C7	189	Natural variant	V	1.0	description:in IHPRF2; dbSNP
Q8N2C7	1700	Natural variant	P	1.0	description:in IHPRF2; dbSNP
P22314	41	Natural variant	M	1.0	description:in VEXAS; somatic mutation; the underlying nucleotide substitution affects normal alternative translation initiation and leads to aberrant initiation from M-67 to produce a shorter protein with strongly reduced enzymatic activity
P22314	41	Natural variant	M	1.0	description:in VEXAS; somatic mutation; the underlying nucleotide substitution affects normal alternative translation initiation and leads to aberrant initiation from M-67 to produce a shorter protein with strongly reduced enzymatic activity
P22314	41	Natural variant	M	1.0	description:in VEXAS; somatic mutation; does not affect ubiquitin activating enzyme activity; does not affect subcellular localization; the underlying nucleotide substitution affects normal alternative translation initiation and leads to aberrant initiation from M-67 to produce a shorter protein with strongly reduced enzymatic activity
Q6ZMN7	784	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q5THJ4	4210	Natural variant	A	1.0	description:in SCAR4; altered mitochondrial morphology in patient cells; dbSNP
Q5THJ4	4228	Natural variant	R	1.0	description:in SCAR4; dbSNP
Q8N823	252	Natural variant	P	1.0	description:requires 2 nucleotide substitutions; dbSNP
Q9BRI3	54	Natural variant	H	1.0	description:in TNZD; decreased protein abundance; increased protein aggregation; no dominant negative effect; dbSNP
P48788	174	Natural variant	R	1.0	description:in DA2B1; dbSNP
Q7Z5H5	220	Natural variant	D	1.0	description:in allele VN1R4*2 and allele VN1R4*3; dbSNP
Q92734	149	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
Q92734	285	Natural variant	P	1.0	description:in HMSNO; does not affect interaction with PDCD6; dbSNP
Q9H3S3	31	Natural variant	D	1.0	description:in patients with sporadic hearing loss
Q5TCY1	806	Natural variant	S	1.0	description:in a lung large cell carcinoma sample; somatic mutation
Q5TCY1	855	Natural variant	P	1.0	description:in a metastatic melanoma sample; somatic mutation; dbSNP
Q5MCW4	87	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q15526	56	Natural variant	A	1.0	description:in MC4DN1; benign variant; dbSNP
Q9H6P5	234	Natural variant	T	1.0	description:in SULEHS; dbSNP
P07101	19	Natural variant	S	1.0	description:found in a patient with ARSEGS; unknown pathological significance; dbSNP
Q7Z3I7	512	Natural variant	C	1.0	description:in a colorectal cancer sample; somatic mutation
Q9ULJ6	287	Natural variant	A	1.0	description:in NEDDFSA; unknown pathological significance
Q9ULJ6	296	Natural variant	T	1.0	description:in NEDDFSA
Q9ULJ6	296	Natural variant	T	1.0	description:in NEDDFSA; dbSNP
Q9ULJ6	298	Natural variant	T	1.0	description:in NEDDFSA
Q9ULJ6	300	Natural variant	T	1.0	description:in NEDDFSA; leads to altered positioning of pyramidal neurons; decreased transcription coactivator activity; does not affect nuclear localization; dbSNP
Q9ULJ6	551	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
P51508	179	Natural variant	S	1.0	description:found in a family with intellectual disability; unknown pathological significance; dbSNP
P06753	4	Natural variant	A	1.0	description:in CFTD; dbSNP
P06753	9	Natural variant	M	1.0	description:in NEM1; decrease in the sensitivity of contraction to activating calcium; dbSNP
P18206	954	Natural variant	L	1.0	description:in CMD1W
O43379	1078	Natural variant	V	1.0	description:in MCPH2; uncertain pathological significance; dbSNP
Q9BRR0	200	Natural variant	K	1.0	description:requires 2 nucleotide substitutions; dbSNP
Q5T2D3	288	Natural variant	G	1.0	description:found in a family with an early age of onset of diabetes; unknown pathological significance; reduced the stability and catalytic activity
Q9Y5E8	719	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q9Y5E8	758	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q8TEQ8	344	Natural variant	M	1.0	description:in HPMRS2; decrease in mannose-ethanolamine phosphotransferase activity; decreased protein expression; unknown pathological significance; dbSNP
Q9Y2R2	620	Natural variant	R	1.0	description:in IDDM, RA, SLE and VTLG; also found in patients with Graves disease, Hashimoto thyroiditis and Addison disease; associated with reduced risk of Crohn disease but not of ulcerative colitis; affects CSK kinase binding; alters B cell receptor signaling and memory B cell proliferation; dbSNP
Q9Y252	102	Natural variant	R	1.0	description:found in an esophageal cancer sample; esophageal squamous cell carcinoma; somatic mutation; dbSNP
Q9Y252	242	Natural variant	A	1.0	description:found in an esophageal cancer sample; esophageal squamous cell carcinoma; somatic mutation; dbSNP
Q9Y252	244	Natural variant	G	1.0	description:found in an esophageal cancer sample; esophageal squamous cell carcinoma; somatic mutation; dbSNP
Q5TGL8	203	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q7LG56	33	Natural variant	P	1.0	description:found in a patient with combined respiratory complex deficiencies, muscle weakness and hearing loss; unknown pathological significance; dbSNP
Q7Z333	496	Natural variant	P	1.0	description:in SCAN2; dbSNP
Q7Z333	603	Natural variant	N	1.0	description:in SCAN2; atypical; associated with K-653; dbSNP
Q7Z333	653	Natural variant	Q	1.0	description:in SCAN2; atypical; associated with D-603; dbSNP
Q7Z333	1294	Natural variant	R	1.0	description:in SCAN2; dbSNP
Q7Z333	1554	Natural variant	C	1.0	description:in ALS4; likely benign variant; dbSNP
Q7Z333	2547	Natural variant	I	1.0	description:in ALS4; dbSNP
Q14563	688	Natural variant	T	1.0	description:in HH16; phenotype consistent with Kallmann syndrome; digenic; found in a patient also carrying mutation Asp-217 in KAL1; dbSNP
Q14563	730	Natural variant	R	1.0	description:in HH16; phenotype consistent with Kallmann syndrome; dbSNP
Q14563	733	Natural variant	R	1.0	description:in HH16; phenotype consistent with Kallmann syndrome; dbSNP
Q9NS62	460	Natural variant	R	1.0	description:in ANIB12; unknown pathological significance; decreased function in endothelial cell-matrix adhesion; decreased interaction with TLN1; dbSNP
Q9NS62	466	Natural variant	E	1.0	description:in ANIB12; unknown pathological significance; loss of function in endothelial cell-matrix adhesion; decreased interaction with TLN1; dbSNP
Q9NS62	600	Natural variant	G	1.0	description:in ANIB12; unknown pathological significance; loss of function in endothelial cell-matrix adhesion; decreased interaction with TLN1; dbSNP
Q9NS62	639	Natural variant	P	1.0	description:in ANIB12; decreased function in endothelial cell-matrix adhesion; decreased interaction with TLN1; dbSNP
Q9NS62	653	Natural variant	T	1.0	description:in ANIB12; unknown pathological significance; loss of function in endothelial cell-matrix adhesion; decreased interaction with TLN1; dbSNP
Q9NS62	775	Natural variant	S	1.0	description:in ANIB12; unknown pathological significance; loss of function in endothelial cell-matrix adhesion; decreased interaction with TLN1; dbSNP
P53814	637	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P53814	763	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
P49768	35	Natural variant	R	1.0	description:in AD3; unknown pathological significance; decreased protease activity with APP; dbSNP
P49768	311	Natural variant	K	1.0	description:probable disease-associated variant found in patients with late-onset Alzheimer disease; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP
P49768	315	Natural variant	Y	1.0	description:found in a renal cell carcinoma sample; somatic mutation
P49768	333	Natural variant	D	1.0	description:in CMD1U; results in slightly decreased protease activity with APP and slightly decreased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP
P49768	352	Natural variant	R	1.0	description:in AD3; unknown pathological significance
P49768	354	Natural variant	T	1.0	description:in AD3; unknown pathological significance; results in decreased protease activity with APP and decreased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP
P49768	358	Natural variant	R	1.0	description:in AD3; unknown pathological significance; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP
P49768	365	Natural variant	S	1.0	description:in AD3; unknown pathological significance; dbSNP
P49768	377	Natural variant	R	1.0	description:in AD3; unknown pathological significance
P49768	378	Natural variant	G	1.0	description:in AD3; decreased protease activity with APP; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio
P49768	378	Natural variant	G	1.0	description:in AD3; abolishes protease activity with APP; dbSNP
P49768	381	Natural variant	L	1.0	description:in AD3; dbSNP
P49768	381	Natural variant	L	1.0	description:in AD3; results in altered amyloid-beta production and increased amyloid-beta 42/amyloid-beta 40 ratio; dbSNP
P60484	348	Natural variant	T	1.0	description:in endometrial hyperplasia; reduced phosphatase activity towards PtdIns(3,4,5)P3; mildly reduced tumor suppressor activity; reduced ability to inactivate AKT/PKB
P60484	369	Natural variant	V	1.0	description:retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 phosphatase activity; retains ability to bind phospholipid membranes
P60484	401	Natural variant	T	1.0	description:retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 phosphatase activity; retains ability to bind phospholipid membranes
Q15678	360	Natural variant	H	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q01973	776	Natural variant	S	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation
Q63HN8	118	Natural variant	C	1.0	description:rare variant detected in a patient with Moyamoya disease in Caucasian population
Q63HN8	133	Natural variant	L	1.0	description:rare variant detected in a patient with Moyamoya disease in Caucasian population
Q63HN8	209	Natural variant	I	1.0	description:rare variant detected in a patient with Moyamoya disease in Caucasian population
P21912	3	Natural variant	A	1.0	description:found in a patient with a Cowden-like phenotype; unknown pathological significance; associated with increased manganese superoxide dismutase expression and normal levels of reactive oxygen species; associated with a 1.2-fold increase in AKT expression and 1.3-fold change in MAPK expression; dbSNP
P21912	29	Natural variant	A	1.0	description:in PCC
P55000	15	Natural variant	W	1.0	description:in MDM; no expression of the protein; dbSNP
Q9BVQ7	172	Natural variant	P	1.0	description:in NEDHLS
Q9BVQ7	176	Natural variant	G	1.0	description:in DFNB119
P18583	1637	Natural variant	T	1.0	description:in ZTTKS; unknown pathological significance; de novo mutation associated in cis with Y-1843
P18583	1843	Natural variant	S	1.0	description:in ZTTKS; unknown pathological significance; de novo mutation associated in cis with S-1637
P41225	248	Natural variant	A	1.0	description:in PHPX; reduced transcriptional activity and impaired nuclear localization
P41225	248	Natural variant	A	1.0	description:in MRXGH
P56715	373	Natural variant	T	1.0	description:in RP1; unknown pathological significance; dbSNP
P56715	663	Natural variant	K	1.0	description:in RP1; unknown pathological significance; dbSNP
P56715	669	Natural variant	A	1.0	description:in RP1; dbSNP
P56715	900	Natural variant	K	1.0	description:in RP1
P56715	984	Natural variant	D	1.0	description:in RP1; dbSNP
P56715	985	Natural variant	N	1.0	description:associated with susceptibility to hypertriglyceridemia; dbSNP
P56715	1370	Natural variant	K	1.0	description:in RP1; unknown pathological significance; dbSNP
P56715	1652	Natural variant	R	1.0	description:in RP1; unknown pathological significance; dbSNP
P56715	1808	Natural variant	L	1.0	description:in RP1; unknown pathological significance; dbSNP
Q96RN1	639	Natural variant	I	1.0	description:not a cause of male infertility; dbSNP
Q96RN1	812	Natural variant	E	1.0	description:in SPGF3; there is a reduced interactions with CFTR and complete failure to activate CFTR-dependent anion transport; dbSNP
Q96RN1	954	Natural variant	R	1.0	description:in SPGF3; there is a reduced interactions with CFTR and complete failure to activate CFTR-dependent anion transport; dbSNP
Q7LBE3	622	Natural variant	V	1.0	description:decreased plasma membrane expression which partially accounts for decreased whole cell currents; transport is reduced to about 50%; dbSNP
Q8NF91	8387	Natural variant	V	1.0	description:in EDMD4; unknown pathological significance; dbSNP
Q9BYT1	9	Natural variant	R	1.0	description:in POROK8; dbSNP
Q9NQC3	429	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation
O60783	108	Natural variant	R	1.0	description:in COXPD38; dbSNP
O60939	28	Natural variant	R	1.0	description:in ATFB14; the mutant results in reduced sodium currents and altered channel gating when coexpressed with SCN5A in a heterologous expression system; dbSNP
O60939	28	Natural variant	R	1.0	description:in ATFB14; the mutant results in reduced sodium currents and altered channel gating when coexpressed with SCN5A in a heterologous expression system; dbSNP
O60939	211	Natural variant	D	1.0	description:found in a patient with Brugada syndrome; unknown pathological significance; induces a reduction in sodium current density most likely by decreasing SCN5A protein cell surface expression; dbSNP
Q9Y345	89	Natural variant	A	1.0	description:no effect on subcellular location; no effect on glycine transport; dbSNP
Q9Y345	184	Natural variant	Q	1.0	description:no effect on glycine transport
P56693	174	Natural variant	Q	1.0	description:in PCWH; without Hirschsprung disease; reduced DNA binding capacity; dbSNP
P56693	175	Natural variant	P	1.0	description:in PCWH; reduced DNA binding capacity
P56693	175	Natural variant	P	1.0	description:in PCWH; reduced DNA binding capacity
P56693	175	Natural variant	P	1.0	description:in PCWH; reduced DNA binding capacity
P56693	321	Natural variant	G	1.0	description:in PCWH
Q9H0J4	569	Natural variant	V	1.0	description:in SPGF35; unknown pathological significance
Q9NVW2	356	Natural variant	Y	1.0	description:in TOKAS; dbSNP
Q9Y2W3	90	Natural variant	I	1.0	description:in IDDNPF; no effect on protein abundance; no effect on glucose transport activity; dbSNP
Q96DX4	41	Natural variant	G	1.0	description:in SEMDFA; dbSNP
O94885	507	Natural variant	S	1.0	description:in DUH1; dbSNP
O94885	509	Natural variant	E	1.0	description:in DUH1; increased interaction with GNAS; increased interaction with IQGAP1; increased protein levels; increased protein stability; dbSNP
O94885	513	Natural variant	S	1.0	description:in DUH1; unknown pathological significance; dbSNP
O94885	515	Natural variant	L	1.0	description:in DUH1; affects the regulation of cell mobility resulting in increased melanocyte migration; increased interaction with GNAS; increased interaction with IQGAP1; increased protein levels; increased protein stability; dbSNP
O94885	519	Natural variant	S	1.0	description:in DUH1; dbSNP
O94885	551	Natural variant	Y	1.0	description:in DUH1; affects the regulation of cell mobility resulting in increased melanocyte migration; increased interaction with GNAS; increased interaction with IQGAP1; increased protein levels; increased protein stability; dbSNP
O94885	551	Natural variant	Y	1.0	description:in DUH1; dbSNP
O94885	617	Natural variant	E	1.0	description:in CAPOK; affects the regulation of cell mobility; patient fibroblasts migrate better than control fibroblasts; dbSNP
Q9BYB0	970	Natural variant	A	1.0	description:found in a patient with neuropsychiatric disorders; unknown pathological significance; dbSNP
Q9BYB0	1173	Natural variant	A	1.0	description:found in a patient with neuropsychiatric disorders; unknown pathological significance; dbSNP
Q9BYB0	1263	Natural variant	P	1.0	description:found in a patient with neuropsychiatric disorders; unknown pathological significance; dbSNP
Q9BYB0	1406	Natural variant	L	1.0	description:found in a patient with neuropsychiatric disorders; unknown pathological significance; dbSNP
Q9BYB0	1443	Natural variant	M	1.0	description:found in a patient with neuropsychiatric disorders; unknown pathological significance; dbSNP
Q9BYB0	1452	Natural variant	A	1.0	description:in PHMDS
Q9BYB0	1557	Natural variant	G	1.0	description:found in a patient with neuropsychiatric disorders; unknown pathological significance; dbSNP
Q9BYB0	1654	Natural variant	P	1.0	description:found in patients with neuropsychiatric disorders; unknown pathological significance; dbSNP
Q92508	718	Natural variant	G	1.0	description:in DHS1; dbSNP
Q53EL6	120	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q8N490	7	Natural variant	A	1.0	description:in DYT8; dbSNP
Q8N490	9	Natural variant	A	1.0	description:in DYT8; dbSNP
Q7Z3G6	605	Natural variant	V	1.0	description:found in a patient with myoclonic epilepsy; unknown pathological significance; results in decreased protein activity; less active in stimulating calcium release compared to wild-type; dbSNP
P21817	1352	Natural variant	A	1.0	description:may be associated with susceptibility to malignant hyperthermia; dbSNP
P21817	1393	Natural variant	K	1.0	description:in MHS1; unknown pathological significance; dbSNP
P21817	1787	Natural variant	P	1.0	description:may be associated with susceptibility to malignant hyperthermia; dbSNP
P21817	2060	Natural variant	G	1.0	description:may be associated with susceptibility to malignant hyperthermia; dbSNP
P21817	2400	Natural variant	D	1.0	description:in MHS1; dbSNP
P21817	2404	Natural variant	E	1.0	description:in MHS1; dbSNP
P21817	2730	Natural variant	D	1.0	description:in MHS1; dbSNP
P21817	2880	Natural variant	E	1.0	description:in MHS1; dbSNP
P21817	3290	Natural variant	E	1.0	description:in MHS1; dbSNP
P21817	3501	Natural variant	D	1.0	description:in MHS1; dbSNP
P21817	4501	Natural variant	P	1.0	description:may be associated with susceptibility to malignant hyperthermia; dbSNP
Q9NY46	1160	Natural variant	E	1.0	description:in FFEVF4; affects voltage-dependent sodium channel activity; increased level of persistent sodium current compared to wild-type channels and increased current activation in response to depolarizing voltage ramps; dbSNP
Q9NY72	6	Natural variant	R	1.0	description:in ATFB16; affects steady-state channel inactivation; dbSNP
Q9NY72	10	Natural variant	L	1.0	description:in BRGDA7 and ATFB16; unknown pathological significance; results in a decrease in peak sodium current density; dbSNP
Q9NY72	195	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q7Z6J9	307	Natural variant	A	1.0	description:in PCH2A and PCH4; dbSNP
O95255	4	Natural variant	P	1.0	description:found in patient with putative diagnosis of PXE; uncertain pathological significance; loss-of-function mutation; localization comparable to wild-type; dbSNP
O95255	9	Natural variant	A	1.0	description:found in patient with putative diagnosis of PXE; uncertain pathological significance; loss-of-function mutation; localization comparable to wild-type; dbSNP
O95255	21	Natural variant	P	1.0	description:found in patient with putative diagnosis of PXE; uncertain pathological significance; loss-of-function mutation; localization comparable to wild-type; dbSNP
O95255	881	Natural variant	R	1.0	description:in PXE; dbSNP
Q15459	511	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q6P3W7	863	Natural variant	Q	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q9Y5Y9	554	Natural variant	L	1.0	description:in FEPS2; increases the excitability of small DRG neurons; dbSNP
Q9Y5B9	432	Natural variant	L	1.0	description:in NEDDFAC; unknown pathological significance
O75914	67	Natural variant	R	1.0	description:in XLID30; dbSNP
C9JE40	189	Natural variant	L	1.0	description:in OOMD4; dbSNP
Q9NST1	453	Natural variant	S	1.0	description:associated with lower hepatic fat content in African Americans; dbSNP
P46777	285	Natural variant	A	1.0	description:in DBA6
Q6P5W5	251	Natural variant	R	1.0	description:in AEZ; unknown pathological significance; dbSNP
Q6P5W5	309	Natural variant	C	1.0	description:in AEZ; unknown pathological significance; dbSNP
Q99250	12	Natural variant	D	1.0	description:probable disease-associated variant found in a patient with autism spectrum disorder; decreased voltage-gated sodium channel activity; faster channel inactivation; loss of function
Q99250	467	Natural variant	A	1.0	description:probable disease-associated variant found in patients with GEFS+; dbSNP
Q99250	575	Natural variant	A	1.0	description:there is no significant effects on the voltage-dependence of the channel; dbSNP
Q99250	649	Natural variant	D	1.0	description:found in a patient with Dravet syndrome; unknown pathological significance
Q99250	674	Natural variant	T	1.0	description:probable disease-associated variant found in a patient with autism spectrum disorder
Q99250	1128	Natural variant	M	1.0	description:found in a patient with acute encephalitis with refractory and repetitive partial seizures; unknown pathological significance; dbSNP
Q99250	1744	Natural variant	G	1.0	description:probable disease-associated variant found in a patient with autism spectrum disorder
Q99572	25	Natural variant	N	1.0	description:in a colorectal cancer sample; somatic mutation
P35913	854	Natural variant	L	1.0	description:in RP40; autosomal recessive
P05165	712	Natural variant	C	1.0	description:in PA-1; loss of biotinylation
Q96BD5	429	Natural variant	G	1.0	description:in IDDBCS; unknown pathological significance
O00337	34	Natural variant	E	1.0	description:in allele A
Q8TBB6	464	Natural variant	C	1.0	description:in RP68; dbSNP
Q8TBB6	695	Natural variant	R	1.0	description:in RP68; uncertain pathological significance; dbSNP
Q8TBB6	708	Natural variant	F	1.0	description:in RP68; dbSNP
Q9P2R6	471	Natural variant	V	1.0	description:in NEDBEH; unknown pathological significance; dbSNP
Q9P2R6	1156	Natural variant	G	1.0	description:in NEDBEH; unknown pathological significance; dbSNP
Q9P2R6	1262	Natural variant	P	1.0	description:in NEDBEH; unknown pathological significance; dbSNP
Q9P2R6	1431	Natural variant	H	1.0	description:in NEDBEH; unknown pathological significance; dbSNP
Q96D71	113	Natural variant	A	1.0	description:in NBIA7; primary fibroblasts from patients, who are compound heterozygous with L-78, show much higher intracellular iron content than fibroblasts from control individuals and abnormally elevated levels of transferrin receptor 1/TFRC at the cell surface; dbSNP
Q8N9C0	7	Natural variant	R	1.0	description:found in a renal cell carcinoma sample; somatic mutation; dbSNP
Q8NFM7	735	Natural variant	A	1.0	description:in HH18; rare variant associated with susceptibility to disease; the patient carries a second mutation in the HH-associated gene KISS1R; results in decreased expression at the cell surface; dbSNP
Q13253	35	Natural variant	P	1.0	description:in BDB2; dbSNP
Q13253	35	Natural variant	P	1.0	description:in SYM1A and TCC; dbSNP
Q13253	35	Natural variant	P	1.0	description:in SYM1A and BDB2; dbSNP
Q13253	36	Natural variant	A	1.0	description:in BDB2
Q13253	48	Natural variant	E	1.0	description:in BDB2
Q13253	83	Natural variant	P	1.0	description:found in a family with radioulnar synostosis; unknown pathological significance
Q13253	104	Natural variant	L	1.0	description:found in a case of radioulnar synostosis; unknown pathological significance
P54845	50	Natural variant	S	1.0	description:in RP27; decreases phosphorylation; no effect on subcellular localization; increased transcriptional coactivator activity
P54845	50	Natural variant	S	1.0	description:in RP27; decreases phosphorylation; no effect on subcellular localization; increased transcriptional coactivator activity
P54845	50	Natural variant	S	1.0	description:in RP27; decreases phosphorylation; no effect on subcellular localization; increased transactivational activity; increased transcriptional coactivator activity; dbSNP
P54845	51	Natural variant	P	1.0	description:in RP27; decreases phosphorylation; no effect on subcellular localization; increased transcriptional coactivator activity
P54845	51	Natural variant	P	1.0	description:in RP27; decreases phosphorylation; no effect on subcellular localization; increased transcriptional coactivator activity; dbSNP
P54845	51	Natural variant	P	1.0	description:in RP27; autosomal dominant; decreases phosphorylation; no effect on subcellular localization; increased transcriptional coactivator activity
P54845	67	Natural variant	P	1.0	description:in RP27; no effect on phosphorylation; no effect on subcellular localization; no effect on transcriptional coactivator activity; dbSNP
P54845	76	Natural variant	A	1.0	description:in RDCP; unknown pathological significance; alters phosphorylation; no effect on subcellular localization; no effect on transcriptional coactivator activity; dbSNP
P54845	96	Natural variant	M	1.0	description:in RP27; increased transactivational activity; dbSNP
P54845	122	Natural variant	G	1.0	description:in RP27; unknown pathological significance; alters phosphorylation; no effect on subcellular localization; no effect on transcriptional coactivator activity; dbSNP
O43526	637	Natural variant	L	1.0	description:in BFNS1; dbSNP
O43526	777	Natural variant	P	1.0	description:found in a patient with continuous spikes and waves during sleep; unknown pathological significance; dbSNP
Q8TDZ2	758	Natural variant	A	1.0	description:requires 2 nucleotide substitutions; dbSNP
Q9UKN7	2205	Natural variant	T	1.0	description:associated with moderately severe sensorineural hearing loss (DFNB3) in a Smith-Magenis syndrome patient; dbSNP
Q9UM47	43	Natural variant	C	1.0	description:in CADASIL1
Q9HC29	113	Natural variant	D	1.0	description:in IBD1; unknown pathological significance; dbSNP
Q16236	79	Natural variant	E	1.0	description:in IMDDHH; dbSNP
Q16236	80	Natural variant	T	1.0	description:in IMDDHH; increased protein abundance; increased positive regulation of transcription of target genes; changed cell redox homeostasis; dbSNP
Q16236	81	Natural variant	G	1.0	description:in IMDDHH; dbSNP
O94953	1095	Natural variant	P	1.0	description:in MRD65; unknown pathological significance
Q13562	242	Natural variant	V	1.0	description:found in one consanguineous family with non-syndromic autosomal recessive retinitis pigmentosa; unknown pathological significance; dbSNP
Q14957	679	Natural variant	R	1.0	description:found in a patient with schizophrenia; unknown pathological significance; dbSNP
Q14957	989	Natural variant	S	1.0	description:found in a patient with schizophrenia; unknown pathological significance; dbSNP
Q14957	995	Natural variant	S	1.0	description:found in a patient with schizophrenia; unknown pathological significance
O75469	27	Natural variant	P	1.0	description:in allele PXR*2; dbSNP
O75469	36	Natural variant	G	1.0	description:in allele PXR*3; dbSNP
P11686	167	Natural variant	R	1.0	description:in SMDP2; dbSNP
P11686	186	Natural variant	N	1.0	description:influences susceptibility to RDS in premature infants; dbSNP
P11686	188	Natural variant	L	1.0	description:in SMDP2; dbSNP
Q02241	916	Natural variant	P	1.0	description:in CDAN3A; results in loss of function; does not rescue defective cytokinesis when expressed in KIF3-deficient cells
P51970	140	Natural variant	N	1.0	description:in a breast cancer sample; somatic mutation
P04070	14	Natural variant	W	1.0	description:in patients with PROC deficiency
P04070	189	Natural variant	R	1.0	description:in patients with PROC deficiency; La Jolla-3; dbSNP
P04070	194	Natural variant	R	1.0	description:in patients with PROC deficiency; dbSNP
P04070	210	Natural variant	P	1.0	description:in THPH3; dbSNP
P04070	211	Natural variant	R	1.0	description:in patients with PROC deficiency; dbSNP
P04070	211	Natural variant	R	1.0	description:in THPH3; London-1/Tochigi; dbSNP
P12272	169	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q92729	830	Natural variant	H	1.0	description:in a colorectal cancer sample; somatic mutation
Q92729	835	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q92729	856	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P05111	60	Natural variant	R	1.0	description:found in a patient with early-onset epithelial ovarian tumor; unknown pathological significance; alters the ratio of secreted activins and ihibins
P05111	257	Natural variant	A	1.0	description:may play a role in premature ovarian failure; dbSNP
Q13233	189	Natural variant	L	1.0	description:in SRXY6; increases phosphorylation of the downstream target MAPK3/MAPK1 compared to wild-type and enhances binding of RHOA to the mutant MAP3K1 complex; dbSNP
Q13233	189	Natural variant	L	1.0	description:in SRXY6; increases phosphorylation of the downstream targets MAPK14 and MAPK3/MAPK1 compared to wild-type and enhances binding of RHOA to the mutant MAP3K1 complex; dbSNP
Q13233	211	Natural variant	V	1.0	description:in SRXY6
Q13233	616	Natural variant	G	1.0	description:in SRXY6; dbSNP
P61244	9	Natural variant	V	1.0	description:in PCC; does not repress MYC transcriptional activity; dbSNP
P61244	23	Natural variant	D	1.0	description:in PCC; unknown pathological significance; does not affect MYC transcriptional activity
P61244	25	Natural variant	R	1.0	description:in PCC; does not repress MYC transcriptional activity
P61244	114	Natural variant	N	1.0	description:does not affect MYC transcriptional activity; dbSNP
P61244	142	Natural variant	S	1.0	description:does not affect MYC transcriptional activity; dbSNP
P20700	436	Natural variant	A	1.0	description:found in a family with amyotrophic lateral sclerosis carrying a probable causative mutation in MATR3; unknown pathological significance; dbSNP
Q8TD19	870	Natural variant	P	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation
Q9HC10	1323	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9HC10	1939	Natural variant	R	1.0	description:in AUNB1; dbSNP
A1E959	269	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
Q8TCI5	80	Natural variant	R	1.0	description:found in patients with severe ciliopathies and left-right asymmetry defects; inhibits AURKA activity; dbSNP
P51810	5	Natural variant	R	1.0	description:in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum; lacks G protein-activation abilities; dbSNP
P51810	35	Natural variant	G	1.0	description:in OA1; results in altered glycosylation pattern and subcellular localization consistent with protein retention in the endoplasmic reticulum; dbSNP
P51810	39	Natural variant	L	1.0	description:in OA1; dbSNP
Q99081	483	Natural variant	L	1.0	description:in CRS3; dbSNP
Q9UJY1	67	Natural variant	G	1.0	description:in a glioblastoma multiforme sample; somatic mutation
Q9UJY1	90	Natural variant	P	1.0	description:in HMN2A; no effect on cytoskeleton architecture; no effect on cytoplasmic location; no effect on interaction with BAG3; dbSNP
Q9UJY1	138	Natural variant	N	1.0	description:in HMN2A; no effect on cytoskeleton architecture; no effect on cytoplasmic location; no effect on interaction with BAG3; dbSNP
Q9UJY1	141	Natural variant	K	1.0	description:in HMN2A; strengthen interaction with HSPB1; dbSNP
Q9UJY1	141	Natural variant	K	1.0	description:in HMN2A; no effect on cytoskeleton architecture; no effect on cytoplasmic location; increased interaction with BAG3; dbSNP
Q9UJY1	141	Natural variant	K	1.0	description:in HMN2A; strengthen interaction with HSPB1; no effect on cytoskeleton architecture; no effect on cytoplasmic location; increased interaction with BAG3; dbSNP
P15382	7	Natural variant	T	1.0	description:in JLNS2; impairs glycosylation at N-5; dbSNP
P15382	8	Natural variant	A	1.0	description:in LQT5; unknown pathological significance; dbSNP
P15382	10	Natural variant	T	1.0	description:in LQT5; unknown pathological significance; dbSNP
P15382	28	Natural variant	S	1.0	description:in LQT5; unknown pathological significance; dbSNP
P15382	32	Natural variant	R	1.0	description:in LQT5; unknown pathological significance; dbSNP
P15382	36	Natural variant	R	1.0	description:in LQT5; unknown pathological significance; dbSNP
P15382	125	Natural variant	T	1.0	description:in LQT5; unknown pathological significance; dbSNP
P15382	127	Natural variant	P	1.0	description:in LQT5; moderately reduces I(KS) current density; no change of the voltage dependence of channel activation; markedly reduces interaction with KCNQ1 C-terminus; no effect on plasma membrane localization; loss of cAMP-mediated up-regulation of the I(KS) current; no effect on interaction with AKAP9; impairs phosphorylation at S-27 during cAMP-dependent stimulation; dbSNP
Q2KJY2	1904	Natural variant	D	1.0	description:found in a patient with spinocerebellar ataxia; unknown pathological significance; dbSNP
Q03426	376	Natural variant	G	1.0	description:in POROK3; dbSNP
Q03426	376	Natural variant	G	1.0	description:in HIDS; dbSNP
Q03426	377	Natural variant	V	1.0	description:in HIDS; most frequent mutation; dbSNP
Q92887	921	Natural variant	G	1.0	description:altered transporter activity; dbSNP
O60934	679	Natural variant	Y	1.0	description:found in a renal cell carcinoma sample; somatic mutation
Q8NEV4	1347	Natural variant	D	1.0	description:in a renal clear cell carcinoma sample; somatic mutation
Q96PY6	294	Natural variant	A	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q96G74	352	Natural variant	L	1.0	description:in MCAND; in mice embryo the mutation is lethal; reduced cleavage activity towards 'K-48'-chains but not 'K-63'-chains; no effect on nuclear location; no effect on phosphorylation; dbSNP
Q96G74	494	Natural variant	G	1.0	description:in MCAND; decreased mRNA and protein levels; no effect on cleavage activity towards 'K-48'-chains but not 'K-63'-chains; in mice embryo the mutation is lethal; no effect on phosphorylation
Q9H427	260	Natural variant	T	1.0	description:in allele TASK-5A and allele TASK-5C; dbSNP
Q9H427	261	Natural variant	P	1.0	description:in allele TASK-5A; dbSNP
Q9H427	323	Natural variant	L	1.0	description:in allele TASK-5A and allele TASK-5C; dbSNP
P28300	79	Natural variant	A	1.0	description:in AAT10; unknown pathological significance; dbSNP
P28300	154	Natural variant	L	1.0	description:in AAT10; unknown pathological significance; dbSNP
O60663	223	Natural variant	R	1.0	description:in NPS; dbSNP
O60663	236	Natural variant	A	1.0	description:in NPS; dbSNP
O60663	241	Natural variant	S	1.0	description:in NPS
O60663	246	Natural variant	R	1.0	description:in FSGS10; dbSNP
O60663	246	Natural variant	R	1.0	description:in FSGS10; decreased transcriptional activity; dbSNP
Q96T17	32	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q16644	28	Natural variant	P	1.0	description:in a glioblastoma multiforme sample; somatic mutation; dbSNP
O15021	2467	Natural variant	E	1.0	description:in a lung squamous cell carcinoma sample; somatic mutation
Q29980	383	Natural variant	T	1.0	description:in allele MICB*001, allele MICB*002, allele MICB*005, allele MICB*006, allele MICB*007, allele MICB*008, allele MICB*012, allele MICB*013, allele MICB*014, allele MICB*015, allele MICB*016, allele MICB*018, allele MICB*019, allele MICB*020 and allele MICB*022; dbSNP
Q9Y5N6	232	Natural variant	Y	1.0	description:in MGORS3; dbSNP
Q92620	324	Natural variant	R	1.0	description:in RP84; dbSNP
Q92620	332	Natural variant	G	1.0	description:in RP84; unknown pathological significance; dbSNP
P18031	387	Natural variant	P	1.0	description:associated with low glucose tolerance; dbSNP
P49736	44	Natural variant	R	1.0	description:in DFNA70; increases the apoptotic process; no effect on cell proliferation and cell cycle phase; dbSNP
Q9Y6K9	406	Natural variant	D	1.0	description:in EDAID1; dbSNP
Q9Y6K9	407	Natural variant	M	1.0	description:in IP; impairs binding to ubiquitin; dbSNP
Q9Y6K9	413	Natural variant	H	1.0	description:in IP
Q9Y6K9	417	Natural variant	C	1.0	description:in EDAID1; dbSNP
Q9Y6K9	417	Natural variant	C	1.0	description:in EDAID1; loss of sumoylation; dbSNP
Q9Y6K9	417	Natural variant	C	1.0	description:in IMD33; dbSNP
Q8TEM1	786	Natural variant	R	1.0	description:confirmed at protein level; dbSNP
O94827	820	Natural variant	G	1.0	description:in CMTRIC; in vitro assay suggests a defect in activating the NF-kappa-B signaling pathway; dbSNP
P35568	608	Natural variant	T	1.0	description:may contribute to insulin resistance by impairing metabolic signaling through PI3K-dependent pathways; dbSNP
P35568	723	Natural variant	G	1.0	description:in NIDDM; dbSNP
P35568	1043	Natural variant	S	1.0	description:in NIDDM
P35568	1095	Natural variant	C	1.0	description:in NIDDM
Q92985	95	Natural variant	F	1.0	description:abolished IFNB induction upon Sendai virus infection
Q92985	117	Natural variant	D	1.0	description:abolished IFNB induction upon Sendai virus infection
Q92985	133	Natural variant	G	1.0	description:no effect on IFNB induction upon Sendai virus infection
Q92985	214	Natural variant	G	1.0	description:requires 2 nucleotide substitutions; no effect on IFNB induction upon Sendai virus infection
Q92985	254	Natural variant	T	1.0	description:no effect IFNB induction upon Sendai virus infection
O15232	70	Natural variant	R	1.0	description:in EDM5; dbSNP
Q71F56	251	Natural variant	E	1.0	description:in MRFACD; unknown pathological significance; dbSNP
Q71F56	2023	Natural variant	D	1.0	description:in a patient with dextro-looped transposition of the great arteries; unknown pathological significance; dbSNP
Q6P0Q8	275	Natural variant	K	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation
P53985	204	Natural variant	K	1.0	description:in SDLT; dbSNP
P53985	472	Natural variant	G	1.0	description:in SDLT; dbSNP
P15260	14	Natural variant	V	1.0	description:may influence susceptibility to autoimmune and inflammatory diseases such as systemic lupus erythematosus, atopic asthma and atopic dermatitis complicated by eczema herpeticum; no significant effect on interferon-gamma-mediated signaling pathway; dbSNP
P15260	335	Natural variant	H	1.0	description:associated with susceptibility to Helicobacter pylori infection; no significant effect on interferon-gamma-mediated signaling pathway; dbSNP
P15260	352	Natural variant	I	1.0	description:no significant effect on interferon-gamma-mediated signaling pathway; dbSNP
P15260	397	Natural variant	Y	1.0	description:associated with susceptibility to atopic dermatitis complicated by eczema herpeticum; does not affect completely interferon-gamma-mediated signaling pathway; dbSNP
P15260	467	Natural variant	L	1.0	description:associated with susceptibility to Helicobacter pylori infection; may influence susceptibility to allergic diseases such as bronchial asthma and allergic rhinitis; could be detected on the cell surface; no significant effect on interferon-gamma-mediated signaling pathway; dbSNP
P15260	485	Natural variant	S	1.0	description:in IMD27A; dbSNP
Q9Y6D9	29	Natural variant	S	1.0	description:in a lymphoid cancer cell line; somatic mutation
O00255	476	Natural variant	W	1.0	description:in MEN1
O00255	532	Natural variant	R	1.0	description:in MEN1
O00255	545	Natural variant	P	1.0	description:in MEN1; dbSNP
O00255	549	Natural variant	P	1.0	description:in MEN1; dbSNP
O00255	557	Natural variant	T	1.0	description:in adrenal adenoma; somatic; dbSNP
O00255	560	Natural variant	S	1.0	description:in MEN1; dbSNP
O00255	560	Natural variant	S	1.0	description:in MEN1
P21439	647	Natural variant	E	1.0	description:in GBD1; dbSNP
Q86W28	1045	Natural variant	Q	1.0	description:in a colorectal cancer sample; somatic mutation
Q5VST9	4810	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q86U86	160	Natural variant	E	1.0	description:found in a malignant melanoma cell line
Q86U86	340	Natural variant	G	1.0	description:found in a malignant melanoma cell line; dbSNP
Q86U86	895	Natural variant	T	1.0	description:found in a lung cancer cell line
Q86U86	922	Natural variant	E	1.0	description:found in a breast cancer cell line
Q86U86	925	Natural variant	K	1.0	description:found in a colon cancer cell line
Q86U86	1120	Natural variant	R	1.0	description:found in hematopoietic and lymphoid cancer cell lines; dbSNP
Q86U86	1503	Natural variant	G	1.0	description:found in a stomach cancer cell line
Q86U86	1560	Natural variant	Q	1.0	description:found in an endometrial cancer cell line
P04792	7	Natural variant	P	1.0	description:in HMN2B; induces hyperphosphorylation of neurofilaments; no effect on cytoplasmic location; no effect on dimerization; dbSNP
P04792	34	Natural variant	G	1.0	description:in HMN2B; increased aggregation; increased homooligomerization; changed function in chaperone-mediated protein folding; dbSNP
P04792	39	Natural variant	P	1.0	description:in HMN2B and CMT2F; increased aggregation; increased homooligomerization; decreased phosphorylation by MAPKAPK2; changed function in chaperone-mediated protein folding; dbSNP
P04792	41	Natural variant	E	1.0	description:in HMN2B; increased aggregation; increased homooligomerization; changed function in chaperone-mediated protein folding; dbSNP
P04792	53	Natural variant	G	1.0	description:in HMN2B; no effect on dimerization; no effect on cytoplasmic location; no effect on dimerization; dbSNP
P04792	84	Natural variant	G	1.0	description:in HMN2B; decreased homooligomerization; decreased heterooligomerization with HSPB6; no effect on phosphorylation by MAPKAPK2; decreased function in chaperone-mediated protein folding; dbSNP
P04792	151	Natural variant	T	1.0	description:in HMN2B; no effect on homodimerization; no effect on client proteins binding; no effect on function in chaperone-mediated protein folding; dbSNP
P04792	156	Natural variant	S	1.0	description:no effect on oligomerization; no effect on client proteins binding; no effect on function in chaperone-mediated protein folding; dbSNP
P04792	164	Natural variant	T	1.0	description:in CMT2F; dbSNP
P04792	180	Natural variant	T	1.0	description:in HMN2B; unknown pathological significance; dbSNP
P04792	182	Natural variant	P	1.0	description:in HMN2B; decreased protein abundance; no effect on oligomerization; increased client proteins binding; no effect on function in chaperone-mediated protein folding; alters CDK5-mediated phosphorylation of neurofilament proteins; indirectly impairs their anterograde axonal transport; dbSNP
P04792	187	Natural variant	S	1.0	description:in HMN2B; formation of large cytoplasmic aggregates; no effect on dimerization; dbSNP
P04792	188	Natural variant	R	1.0	description:in CMT2F; unknown pathological significance; dbSNP
P04792	190	Natural variant	Q	1.0	description:found in a patient with sporadic amyotrophic lateral sclerosis; unknown pathological significance; dbSNP
P35680	61	Natural variant	V	1.0	description:in RCAD; dbSNP
P35680	76	Natural variant	G	1.0	description:in RCAD; unknown pathological significance; dbSNP
P35680	235	Natural variant	R	1.0	description:in RCAD
P35680	241	Natural variant	A	1.0	description:in RCAD; dbSNP
P35680	260	Natural variant	E	1.0	description:in RCAD; insignificant differences in transactivation ability between wild-type and mutated HNF1B; dbSNP
P35680	276	Natural variant	R	1.0	description:in RCAD; no impact on interaction with PCBD1; reduced coactivation by PCBD1
P35680	276	Natural variant	R	1.0	description:in RCAD
P35680	285	Natural variant	G	1.0	description:in RCAD
P35680	295	Natural variant	R	1.0	description:in RCAD
P35680	295	Natural variant	R	1.0	description:in RCAD; dbSNP
P35680	295	Natural variant	R	1.0	description:in RCAD
P35680	370	Natural variant	G	1.0	description:in RCAD; dbSNP
P35680	465	Natural variant	S	1.0	description:in NIDDM; 22% reduction in activity; dbSNP
P35680	492	Natural variant	G	1.0	description:in diabetes; early onset association; unknown pathological significance; dbSNP
Q9H5V7	16	Natural variant	Q	1.0	description:in THC7; unknown pathological significance
P02533	116	Natural variant	K	1.0	description:in EBS1C; dbSNP
P78504	31	Natural variant	A	1.0	description:in ALGS1
P78504	1104	Natural variant	H	1.0	description:found in patient with tetralogy of Fallot and pulmonary stenosis; unknown pathological significance; dbSNP
P78504	1213	Natural variant	R	1.0	description:in biliary atresia; extrahepatic; dbSNP
Q7RTS7	482	Natural variant	D	1.0	description:in HYPT3; dbSNP
P50851	2038	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation
Q86YC3	10	Natural variant	L	1.0	description:in SENEBAC; unknown pathological significance
Q96RQ3	46	Natural variant	G	1.0	description:in MCC1D; dbSNP
Q29983	291	Natural variant	S	1.0	description:in allele MICA*054; dbSNP
Q29983	294	Natural variant	P	1.0	description:in allele MICA*011, allele MICA*030 and allele MICA*047; dbSNP
Q29983	356	Natural variant	T	1.0	description:in allele MICA*049; dbSNP
Q29983	373	Natural variant	D	1.0	description:in allele MICA*004, allele MICA*006, allele MICA*010, allele MICA*011, allele MICA*016, allele MICA*019, allele MICA*048 and allele MICA*049; dbSNP
Q29983	377	Natural variant	T	1.0	description:in allele MICA*011; dbSNP
Q29983	383	Natural variant	A	1.0	description:in allele MICA*018; dbSNP
P57740	101	Natural variant	M	1.0	description:in GAMOS7; decreased function in nephrogenesis; unable to fully rescue morpholino-induced nephrogenesis defects in Xenopus; decreased protein amount detected by Western blot in patient cells; affects exon 4 splicing resulting in decreased levels of wild-type mature transcript; impairs assembly of nuclear pore complex; dbSNP
Q14654	380	Natural variant	P	1.0	description:in NIDDM
Q8TE12	369	Natural variant	I	1.0	description:found in autosomal recessive sensorineural hearing loss; unknown pathological significance
Q9NPC6	48	Natural variant	S	1.0	description:in CMH16; dbSNP
P15172	262	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P15172	309	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P52952	7	Natural variant	L	1.0	description:in ASD7; somatic mutation
P52952	15	Natural variant	K	1.0	description:in ASD7; dbSNP
P52952	19	Natural variant	N	1.0	description:in ASD7; somatic mutation
P52952	21	Natural variant	E	1.0	description:in TOF and ASD7; dbSNP
P52952	22	Natural variant	Q	1.0	description:in ASD7 and TOF; dbSNP
P52952	25	Natural variant	R	1.0	description:in ASD7, TOF, CHNG5, HLHS2 and CTHM; unknown pathological significance; exhibits significant functional impairment with reduction of transactivation properties and dominant-negative effect; the mutant protein activity on the DIO2, TG and TPO promoters is significantly impaired; dbSNP
P52952	45	Natural variant	S	1.0	description:in ASD7; somatic mutation; dbSNP
P52952	51	Natural variant	F	1.0	description:in ASD7; somatic mutation; dbSNP
P52952	59	Natural variant	P	1.0	description:in VSD3; significantly reduced activation of NPPA gene compared to wild-type; dbSNP
P52952	63	Natural variant	A	1.0	description:in ASD7; dbSNP
P52952	69	Natural variant	L	1.0	description:in ASD7; somatic mutation
P52952	77	Natural variant	P	1.0	description:in ASD7; somatic mutation
P52952	114	Natural variant	C	1.0	description:in ASD7; somatic mutation
P52952	114	Natural variant	C	1.0	description:in ASD7; somatic mutation
P52952	118	Natural variant	K	1.0	description:in ASD7; somatic mutation
P52952	119	Natural variant	A	1.0	description:in CHNG5; exhibits a significant functional impairment with reduction of transactivation properties and dominant-negative effect which was associated with reduced DNA binding; dbSNP
P52952	124	Natural variant	K	1.0	description:in ASD7; somatic mutation
P52952	126	Natural variant	E	1.0	description:in ASD7; somatic mutation
P52952	127	Natural variant	A	1.0	description:in ASD7; dbSNP
P52952	133	Natural variant	P	1.0	description:in ASD7; somatic mutation; dbSNP
P52952	135	Natural variant	A	1.0	description:in ASD7; somatic mutation
P52952	205	Natural variant	V	1.0	description:in ASD7; somatic mutation
P52952	216	Natural variant	R	1.0	description:in TOF and ASD7; dbSNP
P52952	219	Natural variant	A	1.0	description:in ASD7 and TOF; somatic mutation; dbSNP
P52952	226	Natural variant	D	1.0	description:in ASD7; somatic mutation; dbSNP
P52952	236	Natural variant	P	1.0	description:found in patients with isolated congenital asplenia; unknown pathological significance; does not affect DNA binding; impairs transactivation activity; dbSNP
P52952	248	Natural variant	Y	1.0	description:in ASD7; somatic mutation
P52952	275	Natural variant	P	1.0	description:in ASD7; dbSNP
P52952	279	Natural variant	S	1.0	description:in ASD7; somatic mutation; dbSNP
P52952	279	Natural variant	S	1.0	description:in ASD7; somatic mutation
P52952	281	Natural variant	A	1.0	description:in ASD7; somatic mutation
P52952	283	Natural variant	P	1.0	description:in VSD3; dbSNP
P52952	286	Natural variant	A	1.0	description:in ASD7; somatic mutation
P52952	291	Natural variant	N	1.0	description:in CTMH; dbSNP
P52952	294	Natural variant	N	1.0	description:in ASD7; somatic mutation
P52952	299	Natural variant	D	1.0	description:in ASD7; somatic mutation; dbSNP
P52952	305	Natural variant	S	1.0	description:in ASD7; somatic mutation
P52952	320	Natural variant	G	1.0	description:in ASD7; somatic mutation
P52952	322	Natural variant	R	1.0	description:in ASD7; somatic mutation
P52952	323	Natural variant	A	1.0	description:in ASD7 and TOF
Q9NZP6	37	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9NZP6	114	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q15154	159	Natural variant	N	1.0	description:phosphorylated; dbSNP
Q14739	119	Natural variant	P	1.0	description:in PHA; dbSNP
O75197	29	Natural variant	A	1.0	description:in primary osteoporosis
O75197	1517	Natural variant	Y	1.0	description:in EVR1; decreases protein abundance; dbSNP
O75197	1529	Natural variant	R	1.0	description:in PCLD4; found in a family affected by polycystic liver disease; unknown pathological significance
O75197	1537	Natural variant	A	1.0	description:could be associated with idiopathic osteoporosis; does not result in a significant alteration of Wnt signal transduction; dbSNP
O75197	1541	Natural variant	T	1.0	description:in PCLD4; unknown pathological significance; the patient carried additional PKHD1 variant; dbSNP
O75197	1551	Natural variant	D	1.0	description:in PCLD4; unknown pathological significance; the mutation results in significantly reduced WNT3A-induced signaling pathway; dbSNP
P42679	503	Natural variant	R	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
Q99698	1397	Natural variant	F	1.0	description:in CHS
O95382	925	Natural variant	S	1.0	description:in a breast pleomorphic lobular carcinoma sample; somatic mutation
O95382	968	Natural variant	T	1.0	description:in an ovarian endometrioid cancer sample; somatic mutation
Q8N119	31	Natural variant	R	1.0	description:in HTX7; found associated with K-215; dbSNP
P21757	36	Natural variant	P	1.0	description:found in a family with prostate cancer; dbSNP
P21757	41	Natural variant	S	1.0	description:found in patients with prostate cancer; dbSNP
P26717	2	Natural variant	N	1.0	description:in allele NKG2-C*02; dbSNP
P26717	102	Natural variant	F	1.0	description:in allele NKG2-C*02; dbSNP
Q0D2K0	73	Natural variant	S	1.0	description:in ARCI6; dbSNP
Q0D2K0	80	Natural variant	G	1.0	description:in ARCI6; dbSNP
Q9P032	3	Natural variant	A	1.0	description:in MC1DN15; results in altered complex I assembly; dbSNP
O95169	62	Natural variant	Y	1.0	description:in MC1DN32; dbSNP
O95169	76	Natural variant	P	1.0	description:in MC1DN32; dbSNP
O00476	68	Natural variant	N	1.0	description:found in a patient with gout; does not affect isoform 2 localization at the cell membrane; results in reduced urate efflux; dbSNP
Q12840	986	Natural variant	P	1.0	description:in ALS25; unknown pathological significance; dbSNP
Q12840	1007	Natural variant	R	1.0	description:in ALS25; dbSNP
Q14896	5	Natural variant	G	1.0	description:in CMH4; dbSNP
Q00653	865	Natural variant	D	1.0	description:in CVID10; unknown pathological significance; de novo mutation; dbSNP
Q00653	867	Natural variant	A	1.0	description:in CVID10; unknown pathological significance; de novo mutation; dbSNP
P02545	10	Natural variant	T	1.0	description:in an atypical progeroid patient; diagnosed as Seip syndrome; unknown pathological significance; dbSNP
P02545	24	Natural variant	T	1.0	description:in EDMD3
P02545	386	Natural variant	R	1.0	description:in EDMD2; dramatically aberrant localization with decreased nuclear rim staining and formation of intranuclear foci; distribution of endogenous LMNA, LMNB1 and LMNB2 are altered in cells expressing this mutant; causes an increased loss of endogenous EMD from the nuclear envelope; interacts with itself and with wild-type LMNA and LMNB1; no decrease in the stability compared with wild-type; dbSNP
P02545	388	Natural variant	R	1.0	description:in CMD1A; no effect on nuclear morphology but restricts lamin A to the cytoplasm; dbSNP
P02545	399	Natural variant	R	1.0	description:in FPLD2 and CMD1A; no effect on nuclear morphology and lamin A localization; dbSNP
P02545	401	Natural variant	R	1.0	description:in EDMD2; abnormal nuclear localization in a honeycomb expression pattern in about 22% of cultured skin fibroblasts from heterozygous patients; enhances the interaction with SYNE2; no effect on nuclear localization; no effect on protein level; dbSNP
P02545	411	Natural variant	G	1.0	description:probable disease-associated variant found in patients with metabolic syndromes; no effect on nuclear lamin A localization; no effect on the interaction with SYNE2; dbSNP
P02545	413	Natural variant	G	1.0	description:found in patients with skeletal and cardiac muscular dystrophies; no effect on nuclear lamin A localization; no effect on the interaction with SYNE2; dbSNP
P02545	415	Natural variant	V	1.0	description:rare variant; found in patients with atrial fibrillation; unknown pathological significance; no effect on nuclear lamin A localization; enhances the interaction with SYNE2; causes nuclear deformations in heat shock experiments; dbSNP
P02545	419	Natural variant	R	1.0	description:found in patients with lipodystrophy; no effect on nuclear lamin A localization; no effect on the interaction with SYNE2; dbSNP
P02545	421	Natural variant	L	1.0	description:probable disease-associated variant found in patient with severe metabolic syndrome; no effect on nuclear lamin A localization; no effect on the interaction with SYNE2; dbSNP
P02545	427	Natural variant	R	1.0	description:found in patients with skeletal and cardiac muscular dystrophies; unknown pathological significance; no effect on nuclear lamin A localization; no effect on the interaction with SYNE2
P02545	435	Natural variant	R	1.0	description:in CMD1A; dbSNP
P02545	439	Natural variant	R	1.0	description:in FPLD2; increase in nuclear blebbing and formation of honeycomb-like structures in the nuclei with no accumulation of prelamin A in skin fibroblasts; causes oligomerization of the C-terminal globular domain of lamins A and C under no-reducing conditions and increases binding affinity for DNA; increases sensitivity to oxidative stress; no significant differences in stability and structure compared with the wild-type; dbSNP
P02545	446	Natural variant	D	1.0	description:in EDMD2; dbSNP
P02545	449	Natural variant	G	1.0	description:in EDMD2; dbSNP
P02545	453	Natural variant	R	1.0	description:in MDCL; dbSNP
P02545	453	Natural variant	R	1.0	description:in EDMD2; abnormal nuclear localization; forms nuclear foci in about 8% of cultured skin fibroblasts from heterozygous patients; interacts with itself and with wild-type LMNA and LMNB1; no effect on protein level; dbSNP
P02545	454	Natural variant	L	1.0	description:in EDMD2; dbSNP
P02545	455	Natural variant	R	1.0	description:in MDCL; dbSNP
P02545	456	Natural variant	N	1.0	description:in MDCL; dbSNP
P02545	456	Natural variant	N	1.0	description:in EDMD2; mislocalized in the nucleus; does not alter nuclear size or shape; dbSNP
P02545	456	Natural variant	N	1.0	description:in EDMD2; dbSNP
P02545	461	Natural variant	D	1.0	description:in EDMD2; dbSNP
P02545	465	Natural variant	G	1.0	description:in FPLD2; dbSNP
P02545	467	Natural variant	W	1.0	description:in EDMD2; dbSNP
P02545	469	Natural variant	I	1.0	description:in EDMD2; dbSNP
P02545	471	Natural variant	R	1.0	description:in HGPS; dbSNP
P02545	471	Natural variant	R	1.0	description:in CMD1A; no effect on nuclear morphology and lamin A localization; dbSNP
P02545	573	Natural variant	S	1.0	description:in CMD1A, FPLD2 and MADA; dbSNP
P02545	578	Natural variant	E	1.0	description:in an atypical progeroid patient; diagnosed as Werner syndrome; dbSNP
P02545	582	Natural variant	R	1.0	description:in FPLD2; dbSNP
P02545	602	Natural variant	G	1.0	description:in EDMD2; dbSNP
P02545	608	Natural variant	G	1.0	description:in HGPS; reduced binding to SUN1; may affect splicing by activating a cryptic splice donor site; dbSNP
P02545	624	Natural variant	R	1.0	description:in EDMD2; dbSNP
P02545	631	Natural variant	G	1.0	description:probable disease-associated variant found in a patient with metabolic syndrome; dbSNP
P02545	644	Natural variant	R	1.0	description:in HGPS and EDMD2; unknown pathological significance; partially inhibits tail cleavage; dbSNP
Q12866	958	Natural variant	P	1.0	description:found in a patient with Leber congenital amaurosis; dbSNP
Q13585	532	Natural variant	T	1.0	description:higher fasting circulating triglyceride levels; dbSNP
Q13585	606	Natural variant	I	1.0	description:higher fasting circulating triglyceride levels; dbSNP
Q96E22	91	Natural variant	G	1.0	description:probable disease-associated variant found in a patient with Parkinson's disease; 40 % reduction in prenyltransferase activity
P35240	579	Natural variant	K	1.0	description:in NF2
P52701	20	Natural variant	A	1.0	description:in HNPCC5, CRC and ENDMC; unknown pathological significance; normal mismatch repair activity; dbSNP
P52701	25	Natural variant	A	1.0	description:in HNPCC5; unknown pathological significance; normal mismatch repair activity; dbSNP
P52701	54	Natural variant	G	1.0	description:in CRC; unknown pathological significance; dbSNP
P52701	285	Natural variant	S	1.0	description:in CRC; unknown pathological significance; dbSNP
P52701	295	Natural variant	K	1.0	description:in multiple colorectal adenoma; dbSNP
P52701	326	Natural variant	A	1.0	description:in HNPCC5; unknown pathological significance; normal mismatch repair activity; dbSNP
P52701	340	Natural variant	F	1.0	description:in CRC, breast cancer and leukemia; unknown pathological significance; dbSNP
P59047	23	Natural variant	V	1.0	description:found in a patient with features of Silver-Russell syndrome and multi-locus imprinting disturbance; unknown pathological significance; dbSNP
P59047	52	Natural variant	M	1.0	description:found in patients with Beckwith-Wiedemann syndrome and multi-locus imprinting disturbance; when associated in cis with Q-76; unknown pathological significance; dbSNP
P59047	143	Natural variant	R	1.0	description:found in patients with female infertility; when associated in cis with C-462; unknown pathological significance; dbSNP
Q9H093	503	Natural variant	K	1.0	description:in an ovarian Endometrioid carcinoma sample; somatic mutation; dbSNP
Q9H093	541	Natural variant	G	1.0	description:in a breast pleomorphic lobular carcinoma sample; somatic mutation
Q8TB37	56	Natural variant	G	1.0	description:rare variant found in a patient with mitochondrial complex I deficiency; unknown pathological significance; found in association with a nucleotide transition causing exon skipping; does not affect protein stability, processing and import in the mitochondrion; can restore complex I activity when overexpressed in patient fibroblasts; dbSNP
P01889	2	Natural variant	L	1.0	description:in allele B*13
P01889	4	Natural variant	M	1.0	description:in allele B*13
P01889	9	Natural variant	V	1.0	description:in allele B*13
P01889	14	Natural variant	S	1.0	description:in allele B*13
P01889	15	Natural variant	A	1.0	description:in allele B*13
P01889	17	Natural variant	L	1.0	description:in allele B*13
P01889	299	Natural variant	E	1.0	description:in allele B*73
P01889	306	Natural variant	V	1.0	description:in allele B*15
P01889	349	Natural variant	C	1.0	description:in allele B*14
Q04637	201	Natural variant	R	1.0	description:found in a patient with Rett syndrome-like phenotype; unknown pathological significance; dbSNP
Q04637	502	Natural variant	A	1.0	description:in PARK18; dbSNP
Q04637	686	Natural variant	G	1.0	description:found in patients with Parkinson disease; unknown pathological significance; dbSNP
Q04637	696	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q04637	1164	Natural variant	S	1.0	description:found in a patient with Parkinson disease; unknown pathological significance; dbSNP
Q04637	1197	Natural variant	R	1.0	description:found in a patient with Parkinson disease; unknown pathological significance; dbSNP
Q04637	1205	Natural variant	R	1.0	description:in PARK18; dbSNP
P04264	74	Natural variant	K	1.0	description:in NEPPK; dbSNP
P04264	155	Natural variant	V	1.0	description:in EHK; dbSNP
P04264	155	Natural variant	V	1.0	description:in EHK; dbSNP
P04264	161	Natural variant	L	1.0	description:in EHK; dbSNP
Q8N201	77	Natural variant	R	1.0	description:in NDCAGF; unknown pathological significance; dbSNP
O75112	117	Natural variant	L	1.0	description:in dilated cardiomyopathy with left ventricular non-compaction; dbSNP
O75112	136	Natural variant	P	1.0	description:in dilated cardiomyopathy with left ventricular non-compaction
O75112	147	Natural variant	S	1.0	description:in MFM4; dbSNP
O75112	147	Natural variant	S	1.0	description:in MFM4; dbSNP
O75112	165	Natural variant	R	1.0	description:in MFM4; dbSNP
O75112	165	Natural variant	R	1.0	description:in MFM4; dbSNP
O75112	189	Natural variant	S	1.0	description:in CMD1C; dbSNP
O75112	206	Natural variant	T	1.0	description:in CMD1C; dbSNP
O75112	232	Natural variant	L	1.0	description:in dilated cardiomyopathy with left ventricular non-compaction; dbSNP
O75112	251	Natural variant	K	1.0	description:in dilated cardiomyopathy with left ventricular non-compaction
O75112	262	Natural variant	E	1.0	description:in MFM4; dbSNP
O75112	268	Natural variant	S	1.0	description:in MFM4; dbSNP
O75112	280	Natural variant	Q	1.0	description:in MFM4; dbSNP
O75112	315	Natural variant	P	1.0	description:in MFM-ZASP; dbSNP
O75112	345	Natural variant	I	1.0	description:in CMD1C; dbSNP
O75112	383	Natural variant	S	1.0	description:in MFM4; dbSNP
Q496Y0	122	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P43364	57	Natural variant	S	1.0	description:found in a family with intellectual disability; unknown pathological significance; dbSNP
Q14943	2	Natural variant	L	1.0	description:in allele KIR3DS1*010; dbSNP
Q14943	13	Natural variant	L	1.0	description:in allele KIR3DS1*014; dbSNP
P32245	11	Natural variant	T	1.0	description:in obesity; partial activity; dbSNP
P32245	30	Natural variant	S	1.0	description:in obesity; dbSNP
P32245	36	Natural variant	S	1.0	description:in obesity; shows the same affinity as the wild-type but significant impairment of cAMP-induced activity in response to melanotan II compared with the wild-type receptor
P32245	37	Natural variant	D	1.0	description:in obesity; dbSNP
Q9Y250	29	Natural variant	S	1.0	description:found in an esophageal cancer sample; esophageal squamous cell carcinoma; somatic mutation; dbSNP
Q9Y250	119	Natural variant	K	1.0	description:found in an esophageal cancer sample; esophageal squamous cell carcinoma; somatic mutation; dbSNP
Q9UHC1	499	Natural variant	N	1.0	description:in HNPCC7; dbSNP
Q9UHC1	624	Natural variant	E	1.0	description:in HNPCC7; dbSNP
Q9UHC1	647	Natural variant	R	1.0	description:in HNPCC7; dbSNP
Q9UHC1	817	Natural variant	S	1.0	description:in HNPCC7; dbSNP
Q9UHC1	981	Natural variant	G	1.0	description:in HNPCC7; dbSNP
Q9UHC1	1007	Natural variant	N	1.0	description:in HNPCC7; dbSNP
Q9UHC1	1451	Natural variant	E	1.0	description:in HNPCC7; dbSNP
O75081	306	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P11137	277	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
P11137	705	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q99972	25	Natural variant	C	1.0	description:in GLC1A; dbSNP
Q99972	48	Natural variant	Q	1.0	description:in GLC1A and GLC3A; the GLC3A patient also carries mutation H-368 in CYP1B1 suggesting digenic inheritance; dbSNP
Q99972	53	Natural variant	V	1.0	description:in GLC1A; dbSNP
Q99972	57	Natural variant	N	1.0	description:loss of higher molecular weight isoform; dbSNP
Q9UBF9	33	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UBF9	39	Natural variant	S	1.0	description:in SBM
Q9UBF9	55	Natural variant	S	1.0	description:in MFM3 and MFM3
Q9UBF9	57	Natural variant	T	1.0	description:in MFM3; does not abolish interaction with ACTN1; dbSNP
Q9UBF9	60	Natural variant	S	1.0	description:in MFM3
Q9UBF9	60	Natural variant	S	1.0	description:in MFM3
Q9UBF9	95	Natural variant	S	1.0	description:in MFM3
Q14686	1060	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q14686	1191	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q9HAN9	147	Natural variant	A	1.0	description:in LCA9
Q9HAN9	273	Natural variant	N	1.0	description:in LCA9; results in significantly reduced enzymatic activity; dbSNP
Q13224	15	Natural variant	V	1.0	description:in DEE27; unknown pathological significance; dbSNP
Q13224	1014	Natural variant	Q	1.0	description:found in a patient with schizophrenia; unknown pathological significance
Q13224	1415	Natural variant	S	1.0	description:found in a patient with autism spectrum disorder; unknown pathological significance; dbSNP
Q13224	1439	Natural variant	P	1.0	description:found in a patient with Landau-Kleffner syndrome; unknown pathological significance; dbSNP
Q13224	1452	Natural variant	S	1.0	description:found in a patient with schizophrenia; unknown pathological significance; dbSNP
Q9UPP1	969	Natural variant	S	1.0	description:found in patients with autism spectrum disorders; unknown pathological significance
Q9UJU2	113	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P42702	1068	Natural variant	F	1.0	description:in a colorectal cancer sample; somatic mutation
A0A1B0GTW7	31	Natural variant	S	1.0	description:in HTX12; unknown pathological significance
P10253	46	Natural variant	S	1.0	description:in GSD2; dbSNP
P08235	7	Natural variant	H	1.0	description:in a colorectal cancer sample; somatic mutation
P08235	180	Natural variant	V	1.0	description:decreased mineralocorticoid receptor activity; dbSNP
P08235	241	Natural variant	V	1.0	description:variant of uncertain significance; changed mineralocorticoid receptor activity; changed response curve to aldosterone stimulation
Q9NR56	338	Natural variant	P	1.0	description:in DM1; unknown pathological significance
P20794	272	Natural variant	R	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation
P01106	39	Natural variant	E	1.0	description:in a Burkitt lymphoma sample; dbSNP
P01106	57	Natural variant	P	1.0	description:in a Burkitt lymphoma sample; dbSNP
P01106	59	Natural variant	P	1.0	description:in a Burkitt lymphoma sample; dbSNP
P01106	86	Natural variant	N	1.0	description:in a Burkitt lymphoma sample; dbSNP
Q8IY84	333	Natural variant	P	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP
Q8IY84	411	Natural variant	P	1.0	description:in a lung large cell carcinoma sample; somatic mutation
P24928	1603	Natural variant	R	1.0	description:in NEDHIB; moderate; unknown pathological significance; no effect on cell viability
O43567	311	Natural variant	L	1.0	description:in DEE73; gain-of-function variant; increased ER stress-induced apoptosis
O43567	312	Natural variant	L	1.0	description:in DEE73
Q5T011	1458	Natural variant	F	1.0	description:found in patients with intellectual disability; unknown pathological significance
Q7Z570	324	Natural variant	N	1.0	description:in a colorectal cancer sample; somatic mutation
Q8N511	7	Natural variant	A	1.0	description:in CDG2P; dbSNP
Q8N511	14	Natural variant	A	1.0	description:in CDG2P; dbSNP
Q86Y38	115	Natural variant	A	1.0	description:in PXE; acts as a modifier of disease severity; results in higher serum xylosyltransferase activity; dbSNP
P37275	78	Natural variant	N	1.0	description:in FECD6; no effect on protein expression; no effect on nuclear localization; dbSNP
P37275	525	Natural variant	G	1.0	description:found in a patient with FECD6
P37275	640	Natural variant	Q	1.0	description:in FECD6; down-regulation of several collagen genes expression; dbSNP
P37275	649	Natural variant	P	1.0	description:in FECD6; no effect on protein expression; no effect on nuclear localization; dbSNP
P37275	696	Natural variant	N	1.0	description:in FECD6; no effect on protein expression; no effect on nuclear localization; dbSNP
P37275	810	Natural variant	Q	1.0	description:in FECD6; no effect on protein expression; no effect on nuclear localization; dbSNP
P37275	840	Natural variant	Q	1.0	description:in FECD6; no effect on protein expression; no effect on nuclear localization; dbSNP
Q9H5J0	424	Natural variant	H	1.0	description:in a breast cancer sample; somatic mutation
Q9H5J0	455	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q9BX66	195	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
Q9BX66	237	Natural variant	T	1.0	description:has a protective role in both obesity and diabetes; dbSNP
Q8TAA9	83	Natural variant	S	1.0	description:in NTD; unknown pathological significance; dbSNP
Q8N2B8	127	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
Q5VUA4	812	Natural variant	N	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q5VUA4	1274	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q9UHF0	80	Natural variant	R	1.0	description:in HH10; phenotype consistent with normosmic idiopathic hypogonadotropic hypogonadism; the patient also carries a mutation in HS6ST1; dbSNP
Q9UHF0	90	Natural variant	M	1.0	description:in HH10; has markedly reduced activity; dbSNP
Q9NSU2	240	Natural variant	R	1.0	description:in SLE; dbSNP
Q9NSU2	247	Natural variant	A	1.0	description:in SLE; associated in cis with S-282; dbSNP
Q9NSU2	290	Natural variant	P	1.0	description:in SLE; increases ubiquitination levels; no effect on exonuclease activity; dbSNP
Q9NSU2	303	Natural variant	T	1.0	description:in AGS1; decreases ubiquitination levels; decreases colocalization with UBQLN1; no effect on exonuclease activity; dbSNP
Q9NSU2	305	Natural variant	Y	1.0	description:in SLE; decreases ubiquitination levels; decreases colocalization with UBQLN1; no effect on exonuclease activity; dbSNP
Q9NSU2	306	Natural variant	G	1.0	description:in SLE; dbSNP
Q15661	3	Natural variant	N	1.0	description:in allele alpha; dbSNP
Q495M9	458	Natural variant	D	1.0	description:in USH1G; atypical form with mild retinitis pigmentosa and normal vestibular function; also found in patients with autosomal recessive non-syndromic deafness; strongly reduced affinity for USH1C; dbSNP
Q9C0A1	1913	Natural variant	R	1.0	description:in MARSIS; dbSNP
Q05066	3	Natural variant	S	1.0	description:in SRXY1
Q05066	18	Natural variant	S	1.0	description:in SRXY1; partial; also in two patients with a Turner syndrome phenotype; dbSNP
Q05066	60	Natural variant	V	1.0	description:in SRXY1; dbSNP
Q05066	60	Natural variant	V	1.0	description:in SRXY1; dbSNP
Q05066	62	Natural variant	R	1.0	description:in SRXY1
Q05066	64	Natural variant	M	1.0	description:in SRXY1; alters interaction with DNA and DNA bending; dbSNP
Q05066	64	Natural variant	M	1.0	description:in SRXY1
Q05066	67	Natural variant	F	1.0	description:in SRXY1
Q05066	127	Natural variant	Y	1.0	description:in SRXY1; dbSNP
Q05066	127	Natural variant	Y	1.0	description:in SRXY1; dbSNP
Q05066	131	Natural variant	P	1.0	description:in SRXY1
Q05066	133	Natural variant	R	1.0	description:in SRXY1; dbSNP
Q9NRR5	90	Natural variant	D	1.0	description:in ALS; impaired proteasome efficiency leading to accumulation of CTNNB1; dbSNP
Q13148	267	Natural variant	N	1.0	description:in ALS10; also in a patient with frontotemporal dementia; dbSNP
Q13148	287	Natural variant	G	1.0	description:in ALS10; loss of ability to negatively regulate the expression of CDK6; dbSNP
Q13148	290	Natural variant	G	1.0	description:in ALS10; dbSNP
Q13148	294	Natural variant	G	1.0	description:in ALS10; dbSNP
Q13148	294	Natural variant	G	1.0	description:in ALS10; a patient with bulbar signs and dementia; dbSNP
Q13148	295	Natural variant	G	1.0	description:in ALS10; dbSNP
Q13148	295	Natural variant	G	1.0	description:in ALS10; also in patients with frontotemporal lobar degeneration with motor neuron disease; dbSNP
Q13148	298	Natural variant	G	1.0	description:in ALS10; dbSNP
Q13148	315	Natural variant	A	1.0	description:in ALS10; triggers mitochondrial DNA release into the cytosol, which is then detected by CGAS, leading to activation of the cGAS-STING pathway and autoinflammation; slight reduction in interaction with PPIA/CYPA; dbSNP
Q13148	321	Natural variant	A	1.0	description:in ALS10; loss of ability to negatively regulate the expression of CDK6
Q13148	331	Natural variant	Q	1.0	description:in ALS10; triggers mitochondrial DNA release into the cytosol, which is then detected by CGAS, leading to activation of the cGAS-STING pathway and autoinflammation; impedes the development of normal limb and tail buds and increases the number of apoptotic nuclei when expressed in chick embryos; does not affect the interaction with ATXN2; dbSNP
Q13148	332	Natural variant	S	1.0	description:in ALS10; dbSNP
Q13148	335	Natural variant	G	1.0	description:in ALS10; dbSNP
Q13148	337	Natural variant	M	1.0	description:in ALS10; impedes the development of normal limb and tail buds and increases the number of apoptotic nuclei when expressed in chick embryos; loss of ability to negatively regulate the expression of CDK6; dbSNP
Q13148	343	Natural variant	Q	1.0	description:in ALS10; dbSNP
Q13148	348	Natural variant	G	1.0	description:in ALS10; dbSNP
Q13148	348	Natural variant	G	1.0	description:in ALS10; loss of interaction with PPIA/CYPA
Q13148	357	Natural variant	G	1.0	description:in ALS10
Q13148	361	Natural variant	R	1.0	description:in ALS10; significant reduction in interaction with PPIA/CYPA; dbSNP
Q13148	361	Natural variant	R	1.0	description:in ALS10
Q13148	379	Natural variant	S	1.0	description:in ALS10; dbSNP
Q13148	379	Natural variant	S	1.0	description:in ALS10; dbSNP
Q13148	382	Natural variant	A	1.0	description:in ALS10; dbSNP
Q13148	390	Natural variant	N	1.0	description:in ALS10; dbSNP
Q13148	390	Natural variant	N	1.0	description:in ALS10; dbSNP
Q13148	393	Natural variant	S	1.0	description:in ALS10; dbSNP
Q14669	5	Natural variant	P	1.0	description:in CLABARS; unknown pathological significance; dbSNP
O75385	290	Natural variant	V	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP
O75385	784	Natural variant	S	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q9H2K8	392	Natural variant	S	1.0	description:in a lung small cell carcinoma sample; somatic mutation
Q9Y458	16	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation
Q9Y458	51	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
Q9Y458	307	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q8NFU7	2056	Natural variant	K	1.0	description:found in a consanguineous family with intellectual disability; unknown pathological significance
Q96QT4	830	Natural variant	M	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
Q96QT4	1482	Natural variant	T	1.0	description:mutant channels are functional but show increased susceptibility to inhibition by intracellular magnesium concentrations compared to wild-type channels; dbSNP
P30518	247	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9P253	913	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
Q9BTA9	475	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
Q9Y2X9	527	Natural variant	I	1.0	description:in a breast cancer sample; somatic mutation
P19532	117	Natural variant	R	1.0	description:in MRXSPF
P19532	119	Natural variant	Q	1.0	description:in MRXSPF
P19532	184	Natural variant	E	1.0	description:in MRXSPF
P19532	186	Natural variant	P	1.0	description:in MRXSPF
P19532	187	Natural variant	T	1.0	description:in MRXSPF
P19532	187	Natural variant	T	1.0	description:in MRXSPF
P19532	187	Natural variant	T	1.0	description:in MRXSPF
P19532	187	Natural variant	T	1.0	description:in MRXSPF
P19532	189	Natural variant	Y	1.0	description:in MRXSPF
P19532	190	Natural variant	H	1.0	description:in MRXSPF
P19532	191	Natural variant	L	1.0	description:in MRXSPF
P19532	201	Natural variant	Q	1.0	description:in MRXSPF
Q96HA7	487	Natural variant	E	1.0	description:in SEMDSP; unknown pathological significance; dbSNP
Q96HA7	494	Natural variant	E	1.0	description:in SEMDSP; unknown pathological significance; dbSNP
O75445	1953	Natural variant	A	1.0	description:in USH2A; unknown pathological significance; dbSNP
O75445	5143	Natural variant	R	1.0	description:in USH2A; likely benign variant; dbSNP
O75445	5143	Natural variant	R	1.0	description:in RP39; benign variant; dbSNP
O75445	5145	Natural variant	V	1.0	description:in RP39; unknown pathological significance; dbSNP
O75445	5188	Natural variant	S	1.0	description:in RP39; benign variant; dbSNP
P40337	25	Natural variant	P	1.0	description:in pheochromocytoma; likely benign variant; dbSNP
P40337	38	Natural variant	S	1.0	description:in VHLD; type II
P40337	52	Natural variant	E	1.0	description:in VHLD; type I; dbSNP
P40337	63	Natural variant	L	1.0	description:in pheochromocytoma; dbSNP
P40337	64	Natural variant	R	1.0	description:in pheochromocytoma; dbSNP
P40337	65	Natural variant	S	1.0	description:in pheochromocytoma; dbSNP
P40337	65	Natural variant	S	1.0	description:in VHLD; type I; dbSNP
P40337	65	Natural variant	S	1.0	description:in VHLD; type I; dbSNP
Q01831	334	Natural variant	P	1.0	description:in XP-C; severe; does not affect interaction with KAT2A and transcription coactivator activity in absence of DNA damage; dbSNP
Q9UNY5	123	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
Q8WZ42	279	Natural variant	R	1.0	description:in MFM9; disrupts NBR1-binding; dbSNP
Q8WZ42	740	Natural variant	R	1.0	description:in CMH9; dbSNP
Q8WZ42	743	Natural variant	A	1.0	description:in CMD1G; affects interaction with TCAP/telethonin; dbSNP
Q8WZ42	799	Natural variant	T	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
Q8WZ42	937	Natural variant	E	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
Q8WZ42	3799	Natural variant	S	1.0	description:in CMD1G
Q8WZ42	32996	Natural variant	R	1.0	description:in CMD1G; dbSNP
Q8WZ42	33242	Natural variant	R	1.0	description:in a gastric adenocarcinoma sample; somatic mutation; dbSNP
Q8WZ42	33904	Natural variant	L	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
Q92994	542	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q07283	1400	Natural variant	R	1.0	description:found in a renal cell carcinoma sample; somatic mutation
Q86YW5	6	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
O60784	307	Natural variant	G	1.0	description:in IMD85; decreases interaction with TOLLIP and UBC
Q6IQ55	635	Natural variant	D	1.0	description:in a lung small cell carcinoma sample; somatic mutation
Q6IQ55	842	Natural variant	E	1.0	description:found in a patient with SCA11; unknown pathological significance; dbSNP
Q6IQ55	1110	Natural variant	R	1.0	description:found in a patient with SCA11; unknown pathological significance; dbSNP
Q7LBC6	336	Natural variant	D	1.0	description:in DIJOS; unknown pathological significance; dbSNP
P08559	10	Natural variant	R	1.0	description:in PDHAD; affects mitochondrial import of precursor protein; dbSNP
Q8IYB4	226	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P56645	639	Natural variant	V	1.0	description:associated with delayed sleep phase syndrome (DSPS); dbSNP
P56645	1028	Natural variant	M	1.0	description:only found in PER3.4 allele; dbSNP
P01213	22	Natural variant	C	1.0	description:in SCA23; dbSNP
P01213	138	Natural variant	R	1.0	description:in SCA23; PDYN, dynorphin A and dynorphin B are located in Purkinje cells as observed in control cerebellum, but cerebellar tissue with the mutation has decreased levels of SLC1A6 and CALB1, both of which are markers of Purkinje cells; SLC1A6 accumulates and aggregates in patient cerebellar tissue; dbSNP
Q9GZU2	594	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P53350	12	Natural variant	R	1.0	description:in a lung squamous cell carcinoma sample; somatic mutation
O94823	540	Natural variant	I	1.0	description:found in a family with Parkinson disease; unknown pathological significance; dbSNP
O94823	558	Natural variant	A	1.0	description:found in a patient with early-onset Parkinson disease; unknown pathological significance; dbSNP
O94823	648	Natural variant	G	1.0	description:found in patients with early-onset Parkinson disease; unknown pathological significance; impaired ATPase flippase activity; dbSNP
O94823	671	Natural variant	G	1.0	description:found in patients with early-onset Parkinson disease; unknown pathological significance; impaired ATPase flippase activity; dbSNP
O94823	1421	Natural variant	L	1.0	description:found in patients with Parkinson disease; unknown pathological significance; dbSNP
P0C0L4	418	Natural variant	V	1.0	description:in allotype C4A4
Q96H96	29	Natural variant	F	1.0	description:in MSA1; associated with disease susceptibility
Q96H96	49	Natural variant	P	1.0	description:in MSA1; associated with disease susceptibility
Q96H96	57	Natural variant	S	1.0	description:in MSA1; associated with disease susceptibility
P17813	8	Natural variant	L	1.0	description:in HHT1; dbSNP
P17813	11	Natural variant	A	1.0	description:in HHT1
Q9Y3I1	481	Natural variant	R	1.0	description:found in two patients with Kufor-Rakeb syndrome also carrying R-877 in ATP13A2; dbSNP
P28472	11	Natural variant	G	1.0	description:in ECA5, the mutant protein is hyperglycosylated and has reduced mean current densities compared to wild-type; dbSNP
P28472	15	Natural variant	A	1.0	description:in ECA5, the mutant protein is hyperglycosylated and has reduced mean current densities compared to wild-type; dbSNP
P30968	10	Natural variant	N	1.0	description:in HH7; is able to bind GnRH but with a reduced affinity in vitro; dbSNP
P30968	18	Natural variant	N	1.0	description:in HH7; dbSNP
P23416	396	Natural variant	P	1.0	description:in MRXSP; unknown pathological significance
P23416	400	Natural variant	P	1.0	description:in MRXSP; unknown pathological significance
P31271	125	Natural variant	A	1.0	description:in HFG
P31271	129	Natural variant	A	1.0	description:in HFG
Q7Z6Z7	660	Natural variant	G	1.0	description:in MRXST; dbSNP
Q7Z6Z7	669	Natural variant	H	1.0	description:in MRXST; dbSNP
Q7Z6Z7	1328	Natural variant	M	1.0	description:in MRXST; dbSNP
Q7Z6Z7	2981	Natural variant	R	1.0	description:in MRXST; dbSNP
Q7Z6Z7	3070	Natural variant	R	1.0	description:in MRXST; dbSNP
P09429	190	Natural variant	D	1.0	description:in gastric-carcinoma cell line
Q5VV43	311	Natural variant	A	1.0	description:may be associated with susceptibility to dyslexia; dbSNP
P05787	53	Natural variant	G	1.0	description:in CIRRH; dbSNP
P05787	54	Natural variant	Y	1.0	description:in CIRRH
P05787	62	Natural variant	G	1.0	description:in CIRRH; dbSNP
O14654	20	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
O14654	215	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
O14654	557	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q16566	469	Natural variant	I	1.0	description:in a lung large cell carcinoma sample; somatic mutation; dbSNP
Q13064	145	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
A0A0C5B5G6	14	Natural variant	K	1.0	description:specific to the Northeast Asian population; associated with increased susceptibility of sedentary males to type 2 diabetes; increased plasma levels of MOTS-c peptide
Q8NCE2	462	Natural variant	Y	1.0	description:in CNM1; may act as a disease modifier; mutation found in a patient also carrying mutation Lys-368 in DNM2; reduced enzymatic activity; dbSNP
P29371	449	Natural variant	A	1.0	description:may contribute to hypogonadotropic hypogonadism in patients carrying disease-causing mutations in SPRY4 or KAL1; dbSNP
Q9C000	54	Natural variant	A	1.0	description:in MSPC; increased NLRP1-inflammasome complex assembly; altered protein folding; dbSNP
Q9C000	66	Natural variant	A	1.0	description:in MSPC; increased NLRP1-inflammasome complex assembly; altered protein folding; dbSNP
Q9C000	77	Natural variant	M	1.0	description:in MSPC; destabilization of the N-terminal fragment; dbSNP
Q9C000	155	Natural variant	L	1.0	description:in VAMAS1; risk factor; dbSNP
P37287	19	Natural variant	R	1.0	description:in PNH1; dbSNP
P27986	326	Natural variant	M	1.0	description:does not affect insulin-stimulated lipid kinase activity; dbSNP
P35241	578	Natural variant	D	1.0	description:in DFNB24; dbSNP
Q8TDN2	126	Natural variant	L	1.0	description:in RCD3B; dbSNP
O43318	410	Natural variant	R	1.0	description:found in a consanguineous family with intellectual disability; unknown pathological significance; dbSNP
O43318	512	Natural variant	P	1.0	description:in FMD2; does not affect interaction with TAB2; does not affect homodimerization; increases autophosphorylation; increases MAPK signaling; increases NF-kappa-B signaling; dbSNP
O75444	54	Natural variant	S	1.0	description:in AYGRP; dbSNP
O75444	58	Natural variant	T	1.0	description:in AYGRP; dbSNP
O75444	58	Natural variant	T	1.0	description:in AYGRP; dbSNP
O75444	59	Natural variant	P	1.0	description:in AYGRP; dbSNP
O75444	59	Natural variant	P	1.0	description:in AYGRP; dbSNP
O75444	62	Natural variant	T	1.0	description:in AYGRP; dbSNP
O75444	69	Natural variant	P	1.0	description:in AYGRP; dbSNP
Q96PU8	336	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P43487	16	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q12809	141	Natural variant	P	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	149	Natural variant	G	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	164	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	176	Natural variant	R	1.0	description:in LQT2; dbSNP
Q12809	218	Natural variant	M	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	238	Natural variant	G	1.0	description:in LQT2; dbSNP
Q12809	242	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	251	Natural variant	P	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	259	Natural variant	D	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	277	Natural variant	A	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	291	Natural variant	M	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	301	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	306	Natural variant	G	1.0	description:in LQT2; dbSNP
Q12809	312	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	314	Natural variant	G	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	320	Natural variant	S	1.0	description:in LQT2; dbSNP
Q12809	323	Natural variant	D	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	885	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	887	Natural variant	R	1.0	description:in LQT2; dbSNP
Q12809	894	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	894	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	903	Natural variant	G	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	906	Natural variant	S	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	913	Natural variant	A	1.0	description:in LQT2; dbSNP
Q12809	917	Natural variant	P	1.0	description:in LQT2; dbSNP
Q12809	920	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	920	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	922	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	922	Natural variant	R	1.0	description:in LQT2; dbSNP
Q12809	924	Natural variant	G	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	924	Natural variant	G	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	925	Natural variant	G	1.0	description:in LQT2; dbSNP
Q12809	937	Natural variant	S	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	948	Natural variant	R	1.0	description:in LQT2; dbSNP
Q12809	968	Natural variant	P	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	983	Natural variant	T	1.0	description:in LQT2; dbSNP
Q12809	996	Natural variant	N	1.0	description:in LQT2; dbSNP
Q12809	1005	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1007	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1033	Natural variant	R	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1036	Natural variant	G	1.0	description:in LQT2; dbSNP
Q12809	1038	Natural variant	V	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1049	Natural variant	L	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1066	Natural variant	L	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1078	Natural variant	Y	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1093	Natural variant	P	1.0	description:in LQT2; unknown pathological significance; dbSNP
Q12809	1115	Natural variant	M	1.0	description:in LQT2; dbSNP
Q12809	1153	Natural variant	H	1.0	description:in LQT2; unknown pathological significance; dbSNP
P46019	1070	Natural variant	R	1.0	description:in GSD9A; dbSNP
Q9UHY1	432	Natural variant	P	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP
O43933	1237	Natural variant	A	1.0	description:in PBD-CG1; dbSNP
Q8IY17	1359	Natural variant	R	1.0	description:in BNHS; dbSNP
Q8IY17	1362	Natural variant	R	1.0	description:found in a patient with Gordon-Holmes syndrome; unknown pathological significance; dbSNP
Q9NP85	3	Natural variant	R	1.0	description:in NPHS2
Q9NP85	18	Natural variant	R	1.0	description:in NPHS2
Q9NP85	26	Natural variant	R	1.0	description:in NPHS2
Q9NP85	28	Natural variant	K	1.0	description:in NPHS2; dbSNP
Q9NP85	29	Natural variant	A	1.0	description:in NPHS2; dbSNP
Q9NP85	30	Natural variant	E	1.0	description:in NPHS2; dbSNP
Q9NP85	30	Natural variant	E	1.0	description:in NPHS2
Q9NP85	39	Natural variant	Q	1.0	description:in NPHS2
Q9NP85	89	Natural variant	P	1.0	description:in NPHS2
Q9NP85	92	Natural variant	G	1.0	description:in NPHS2; dbSNP
Q9NP85	97	Natural variant	G	1.0	description:in NPHS2; unknown pathological significance; dbSNP
Q9NP85	333	Natural variant	E	1.0	description:in NPHS2; unknown pathological significance; dbSNP
Q9NP85	341	Natural variant	P	1.0	description:in NPHS2; dbSNP
Q9NP85	370	Natural variant	V	1.0	description:in NPHS2
Q12756	11	Natural variant	R	1.0	description:in SPG30
Q12756	11	Natural variant	R	1.0	description:in SPG30
Q12756	13	Natural variant	R	1.0	description:in KAND
Q12756	13	Natural variant	R	1.0	description:in KAND; complete loss of motility, when tested in vitro; dbSNP
Q12756	30	Natural variant	M	1.0	description:in SPG30; unknown pathological significance
Q12756	202	Natural variant	A	1.0	description:in NESCAVS; affects subcellular location; reduces accumulation in distal regions of the neurites; dbSNP
Q12756	203	Natural variant	R	1.0	description:in KAND
Q12756	206	Natural variant	A	1.0	description:in KAND; unknown pathological significance; dbSNP
Q12756	210	Natural variant	M	1.0	description:in KAND; unknown pathological significance
Q12756	211	Natural variant	N	1.0	description:in KAND; unknown pathological significance
Q12756	214	Natural variant	S	1.0	description:in KAND
Q12756	215	Natural variant	S	1.0	description:in NESCAVS; affects subcellular location; reduces accumulation in distal regions of the neurites; dbSNP
Q12756	216	Natural variant	R	1.0	description:in NESCAVS; disrupts microtubule motility; dbSNP
Q12756	216	Natural variant	R	1.0	description:in NESCAVS; dbSNP
Q12756	216	Natural variant	R	1.0	description:in NESCAVS; reduces accumulation in distal regions of the neurites; dbSNP
Q12756	217	Natural variant	S	1.0	description:in KAND; affects subcellular location; contrary to wild-type, does not accumulate in the distal tips of differentiated SH-SY5Y cells, but localizes closer to the cell body in transfected cells
Q12756	220	Natural variant	V	1.0	description:no effect on microtubule motility; dbSNP
Q12756	229	Natural variant	R	1.0	description:in KAND; unknown pathological significance; dbSNP
Q12756	247	Natural variant	V	1.0	description:in KAND
Q12756	248	Natural variant	D	1.0	description:in KAND; affects subcellular location and motility; contrary to wild-type, does not accumulate in the distal tips of differentiated SH-SY5Y cells, but localizes closer to the cell body in transfected cells; retains its ability to move processively along microtubules, but shows a strongly reduced velocity
Q12756	248	Natural variant	D	1.0	description:in KAND; affects subcellular location; contrary to wild-type, does not accumulate in the distal tips of differentiated SH-SY5Y cells, but localizes closer to the cell body in transfected cells
Q12756	249	Natural variant	L	1.0	description:in NESCAVS; dbSNP
Q12756	251	Natural variant	G	1.0	description:in KAND; affects subcellular location; contrary to wild-type, does not accumulate in the distal tips of differentiated SH-SY5Y cells, but localizes closer to the cell body in transfected cells; complete loss of motility, when tested in vitro
Q12756	252	Natural variant	S	1.0	description:in SPG30
Q12756	253	Natural variant	E	1.0	description:in NESCAVS; reduces accumulation in distal regions of the neurites; disrupts microtubule motility; dbSNP
Q12756	254	Natural variant	R	1.0	description:in KAND; affects subcellular location; contrary to wild-type, does not accumulate in the distal tips of differentiated SH-SY5Y cells, but localizes closer to the cell body in transfected cells
Q12756	254	Natural variant	R	1.0	description:in NESCAVS; affects subcellular location; contrary to wild-type, does not accumulate in the distal tips of differentiated SH-SY5Y cells, but localizes closer to the cell body in transfected cells
Q12756	254	Natural variant	R	1.0	description:in NESCAVS; affects subcellular location, binding to microtubules and motility; contrary to wild-type, does not accumulate in the distal tips of differentiated SH-SY5Y cells, but localizes closer to the cell body in transfected cells; retains its ability to move processively along microtubules, but shows reduced velocity and processivity; increased interaction with microtubules
Q12756	255	Natural variant	A	1.0	description:in SPG30; reduces accumulation in distal regions of the neurites; no effect on microtubule motility; dbSNP
Q12756	258	Natural variant	T	1.0	description:in SPG30
Q12756	267	Natural variant	E	1.0	description:in KAND
Q12756	272	Natural variant	N	1.0	description:in KAND; unknown pathological significance; dbSNP
Q12756	274	Natural variant	S	1.0	description:in KAND; retains its ability to move processively along microtubules, but shows reduced velocity and processivity; decreased interaction with microtubules; dbSNP
Q12756	275	Natural variant	L	1.0	description:in KAND
Q12756	278	Natural variant	L	1.0	description:in KAND; strong decrease in localization at the distal tip of neurites and accumulation in the neuronal cell body, when assayed in differentiated SH-SY5Y cells
Q12756	279	Natural variant	G	1.0	description:in KAND
Q12756	279	Natural variant	G	1.0	description:in KAND
Q12756	280	Natural variant	K	1.0	description:in KAND
Q5JUK3	741	Natural variant	I	1.0	description:in DEE14; dbSNP
Q5JUK3	1088	Natural variant	R	1.0	description:in DEE14; unknown pathological significance; dbSNP
Q15773	80	Natural variant	F	1.0	description:in a colorectal cancer sample; somatic mutation
Q9ULH7	390	Natural variant	D	1.0	description:found in a renal cell carcinoma sample; somatic mutation
P49959	572	Natural variant	R	1.0	description:in cancer; dbSNP
O75364	13	Natural variant	S	1.0	description:in CTRCT11; dbSNP
P22460	42	Natural variant	L	1.0	description:found in a patient with pulmonary arterial hypertension; unknown pathological significance
P22460	114	Natural variant	T	1.0	description:found in a patient with pulmonary arterial hypertension; unknown pathological significance
P22460	300	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q99748	96	Natural variant	A	1.0	description:may contribute to Hirschsprung disease in patients carrying a RET mutation; dbSNP
P08100	4	Natural variant	T	1.0	description:in RP4
P08100	342	Natural variant	T	1.0	description:in RP4; dbSNP
P08100	345	Natural variant	V	1.0	description:in RP4; dbSNP
P08100	345	Natural variant	V	1.0	description:in RP4; dbSNP
P08100	347	Natural variant	P	1.0	description:in RP4
P08100	347	Natural variant	P	1.0	description:in RP4; common variant; dbSNP
P08100	347	Natural variant	P	1.0	description:in RP4; dbSNP
P08100	347	Natural variant	P	1.0	description:in RP4; dbSNP
P08100	347	Natural variant	P	1.0	description:in RP4; dbSNP
Q9NQX0	462	Natural variant	Q	1.0	description:in PDA3; dbSNP
Q9UK17	450	Natural variant	L	1.0	description:in BRGDA9; unknown pathological significance; gain of function mutation; dbSNP
Q9UK17	530	Natural variant	S	1.0	description:in BRGDA9; unknown pathological significance; does not affect the electrophysiological properties of the channel
Q9UK17	600	Natural variant	G	1.0	description:in BRGDA9; unknown pathological significance; gain of function mutation; dbSNP
P60410	64	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
P60410	159	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P32004	9	Natural variant	W	1.0	description:in HSAS
P32004	1194	Natural variant	S	1.0	description:in HSAS and MASA; dbSNP
P32004	1224	Natural variant	S	1.0	description:in HSAS
P50281	17	Natural variant	T	1.0	description:in WNCHRS; results in increased MMP14 proteosomal degradation and reduced protein localization to cell membrane; dbSNP
P34130	7	Natural variant	C	1.0	description:in GLC1O; unknown pathological significance
P34130	84	Natural variant	E	1.0	description:in GLC1O; unknown pathological significance; dbSNP
P34130	90	Natural variant	R	1.0	description:in GLC1O; unknown pathological significance; dbSNP
Q86VP3	209	Natural variant	E	1.0	description:in DEE66; increased interaction with SIRT1; increased interaction with HDAC1; increased interaction with TRPV1; dbSNP
O14813	72	Natural variant	A	1.0	description:in CFEOM2; dbSNP
O14813	256	Natural variant	P	1.0	description:may be involved in congenital central hypoventilation syndrome; dbSNP
P09619	987	Natural variant	R	1.0	description:in IBGC4; decreased protein abundance; no effect on receptor activity; decreased PDGF signaling pathway; dbSNP
P09619	1071	Natural variant	E	1.0	description:in IBGC4; no effect on protein abundance; no effect on receptor activity; decreased PDGF signaling pathway
Q8NFJ6	357	Natural variant	R	1.0	description:in HH3; dbSNP
Q96MT3	472	Natural variant	Y	1.0	description:in EPM1B; dbSNP
Q96MT3	682	Natural variant	R	1.0	description:may be associated with NTD; dbSNP
Q96MT3	739	Natural variant	S	1.0	description:may be associated with NTD; dbSNP
Q96MT3	771	Natural variant	D	1.0	description:may be associated with NTD; dbSNP
Q96MT3	799	Natural variant	S	1.0	description:may be associated with NTD
P40692	338	Natural variant	N	1.0	description:in HNPCC2; dbSNP
P40692	379	Natural variant	Y	1.0	description:in HNPCC2; dbSNP
P40692	384	Natural variant	V	1.0	description:can be associated with HNPCC in some populations; dbSNP
P40692	385	Natural variant	R	1.0	description:in HNPCC2; unknown pathological significance; dbSNP
P40692	385	Natural variant	R	1.0	description:in HNPCC2; unknown pathological significance; dbSNP
P40692	389	Natural variant	R	1.0	description:in HNPCC2; unknown pathological significance; no effect on nuclear localization; normal interaction with PMS2 and EXO1; dbSNP
P40692	403	Natural variant	P	1.0	description:no decrease in mismatch repair activity; no effect on nuclear localization; dbSNP
P40692	406	Natural variant	S	1.0	description:no decrease in mismatch repair activity; no effect on nuclear localization; dbSNP
P40692	423	Natural variant	R	1.0	description:no effect on protein expression; dbSNP
P40692	441	Natural variant	A	1.0	description:in HNPCC2; dbSNP
P40692	443	Natural variant	K	1.0	description:in HNPCC2; unknown pathological significance; no decrease in mismatch repair activity; no effect on nuclear localization; dbSNP
P40692	460	Natural variant	E	1.0	description:in HNPCC2; unknown pathological significance; dbSNP
P40692	472	Natural variant	R	1.0	description:in CRC; unknown pathological significance; dbSNP
P40692	474	Natural variant	R	1.0	description:in HNPCC2; unknown pathological significance; dbSNP
P40692	474	Natural variant	R	1.0	description:associated with HNPCC2; no effect on MLH1 splicing; dbSNP
P40692	485	Natural variant	D	1.0	description:in HNPCC2; dbSNP
P40692	485	Natural variant	D	1.0	description:in HNPCC2; unknown pathological significance; dbSNP
P40692	492	Natural variant	A	1.0	description:in HNPCC2; also found in sporadic colorectal cancer; dbSNP
P42345	8	Natural variant	A	1.0	description:in a lung large cell carcinoma sample; somatic mutation
P42345	1832	Natural variant	A	1.0	description:in SKS; dbSNP
P42345	2476	Natural variant	P	1.0	description:in a glioblastoma multiforme sample; somatic mutation
Q07444	19	Natural variant	W	1.0	description:in allele NKG2-E*01 and allele NKG2-E*03; requires 2 nucleotide substitutions; dbSNP
Q07444	19	Natural variant	W	1.0	description:in allele NKG2-E*02; dbSNP
O15399	922	Natural variant	A	1.0	description:found in patients with schizophrenia; unknown pathological significance; dbSNP
O15399	926	Natural variant	A	1.0	description:found in a patient with autism spectrum disorder; unknown pathological significance
O14745	153	Natural variant	R	1.0	description:in NPHLOP2; the mutant expressed in cultured renal cells increases the generation of cAMP by PTH and inhibits phosphate transport; dbSNP
Q9BW27	645	Natural variant	R	1.0	description:in NPHS17; loss of function in nephrogenesis; unable to rescue morpholino-induced nephrogenesis defects in Xenopus; decreased interaction with NUP160; dbSNP
O60733	484	Natural variant	D	1.0	description:in NBIA2A
O60260	82	Natural variant	A	1.0	description:in PARK2; dbSNP
O60260	92	Natural variant	A	1.0	description:in PARK2; dbSNP
P10916	13	Natural variant	A	1.0	description:in CMH10; with mid-left ventricular chamber thickening; decrease calcium binding affinity; large increase in its calcium binding affinity upon phosphorylation; dbSNP
P28360	67	Natural variant	M	1.0	description:in STHAG1; dbSNP
P28360	84	Natural variant	E	1.0	description:in OFC5; cleft palate only; dbSNP
P28360	97	Natural variant	G	1.0	description:in OFC5; cleft palate only
P28360	120	Natural variant	V	1.0	description:in OFC5; cleft palate only; dbSNP
P28360	122	Natural variant	G	1.0	description:in OFC5; bilateral cleft palate; dbSNP
P28360	157	Natural variant	R	1.0	description:in OFC5; unilateral cleft palate; dbSNP
Q9H1R3	87	Natural variant	A	1.0	description:in CMH; dbSNP
Q9H1R3	95	Natural variant	A	1.0	description:in CMH; dbSNP
Q9H1R3	117	Natural variant	A	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP
P43699	339	Natural variant	A	1.0	description:in NMTC1; loss of transcription regulatory region DNA binding; decreased transcription factor activity, sequence-specific DNA binding; tested for the thyroglobulin gene; associated with dominant impairment of thyroid-specific genes transcription and increased thyroid cells proliferation; dbSNP
O60393	44	Natural variant	R	1.0	description:no effect on transactivation activity; not statistically significant decrease of nuclear location; dbSNP
O60393	91	Natural variant	G	1.0	description:in POF5; unknown pathological significance; decreased transactivation activity; decreased nuclear location; intranuclear and cytosolic aggregates; dbSNP
O60393	111	Natural variant	G	1.0	description:in POF5; unknown pathological significance; loss of transactivation activity; intranuclear and cytosolic aggregates; not statistically significant decrease of nuclear location; dbSNP
O60393	117	Natural variant	R	1.0	description:in POF5; unknown pathological significance; decreased transactivation activity; dbSNP
O60393	152	Natural variant	G	1.0	description:in POF5; unknown pathological significance; decreased nuclear location; intranuclear and cytosolic aggregates; dbSNP
O60393	371	Natural variant	K	1.0	description:in POF5; unknown pathological significance; decreased transactivation activity; dbSNP
O60393	452	Natural variant	D	1.0	description:in POF5; likely benign variant; decreased nuclear location; intranuclear and cytosolic aggregates; dbSNP
O60393	619	Natural variant	P	1.0	description:no effect on transactivation activity; dbSNP
Q8TCU5	111	Natural variant	R	1.0	description:found in a patient with autism spectrum disorder; unknown pathological significance
Q8TCU5	1028	Natural variant	I	1.0	description:found in a patient with schizophrenia; unknown pathological significance; dbSNP
O95644	315	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9BZ23	134	Natural variant	E	1.0	description:in NBIA1; no effect on enzyme activity or its mitochondrial localization; dbSNP
P05186	17	Natural variant	S	1.0	description:in HOPS
P07225	15	Natural variant	L	1.0	description:in THPH5; reduced mutant protein levels and secretion
P07225	18	Natural variant	V	1.0	description:in THPH5; expresses very low/undetectable PROS1 levels compared to wild-type; has impaired secretion; intracellular degradation of unsecreted material is found
P15918	612	Natural variant	H	1.0	description:found in a patient with an atypical form of combined immunodeficiency; unknown pathological significance; dbSNP
P00797	16	Natural variant	L	1.0	description:in ADTKD4; affects ER translocation and processing of nascent preprorenin, resulting in abolished prorenin and renin biosynthesis and secretion; dbSNP
Q9UK53	335	Natural variant	A	1.0	description:in HNSCC
P51812	729	Natural variant	R	1.0	description:in CLS; dbSNP
Q504Q3	1201	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P08F94	17	Natural variant	A	1.0	description:in PKD4; dbSNP
P08F94	19	Natural variant	R	1.0	description:in a colorectal cancer sample and PKD4; somatic mutation; unknown pathological significance; dbSNP
P08F94	3957	Natural variant	R	1.0	description:in PKD4; dbSNP
P08F94	4037	Natural variant	L	1.0	description:found in a patient affected by polycystic liver disease; unknown pathological significance; dbSNP
Q5T1V6	77	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q92796	40	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q92838	69	Natural variant	R	1.0	description:in XHED; dbSNP
Q92838	118	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation
Q92838	125	Natural variant	S	1.0	description:in XHED; unknown pathological significance
Q92838	132	Natural variant	Q	1.0	description:in XHED; unknown pathological significance
Q92838	153	Natural variant	R	1.0	description:in XHED; abolishes proteolytic processing; dbSNP
Q92838	153	Natural variant	R	1.0	description:in XHED; unknown pathological significance; dbSNP
Q92838	155	Natural variant	R	1.0	description:in XHED; abolishes proteolytic processing; dbSNP
Q92838	156	Natural variant	R	1.0	description:in XHED; abolishes proteolytic processing; dbSNP
Q92838	156	Natural variant	R	1.0	description:in XHED
Q92838	156	Natural variant	R	1.0	description:in XHED; abolishes proteolytic processing; dbSNP
Q92838	156	Natural variant	R	1.0	description:in XHED
Q92838	158	Natural variant	K	1.0	description:in XHED; abolishes proteolytic processing; dbSNP
Q92838	189	Natural variant	G	1.0	description:in XHED
Q92838	198	Natural variant	G	1.0	description:in XHED
Q92838	207	Natural variant	G	1.0	description:in XHED
Q92838	207	Natural variant	G	1.0	description:in XHED
Q92838	209	Natural variant	P	1.0	description:in XHED; dbSNP
Q92838	211	Natural variant	T	1.0	description:in XHED
Q92838	218	Natural variant	G	1.0	description:in XHED
Q92838	221	Natural variant	G	1.0	description:in XHED; unknown pathological significance
Q92838	224	Natural variant	G	1.0	description:in XHED; dbSNP
Q92838	252	Natural variant	H	1.0	description:in XHED; loss of interaction with EDAR for isoform 1; decreased interaction with EDA2R for isoform 3; changed downstream signaling; dbSNP
Q92838	252	Natural variant	H	1.0	description:in XHED
P06028	22	Natural variant	T	1.0	description:in M(v) antigen; dbSNP
P06028	48	Natural variant	T	1.0	description:in S antigen and Mit antigen; dbSNP
P11161	268	Natural variant	I	1.0	description:in CHN1; loss of large and small myelinated nerve fibers; dbSNP
P00740	17	Natural variant	I	1.0	description:in HEMB; severe; UK 22
P00740	20	Natural variant	L	1.0	description:in HEMB; unknown pathological significance; decreased protein abundance; decreased function in blood coagulation
P00740	28	Natural variant	C	1.0	description:in HEMB; moderate; HB130; dbSNP
P00740	28	Natural variant	C	1.0	description:in HEMB; decreased protein abundance; decreased function in blood coagulation
P00740	30	Natural variant	V	1.0	description:in HEMB
P00740	37	Natural variant	A	1.0	description:in WARFS; reduced affinity of the glutamate carboxylase for the factor IX precursor; 4.4-fold decreased in the EC(50) for warfarin; dbSNP
P00740	37	Natural variant	A	1.0	description:in WARFS; 2.5-fold decreased in the EC(50) for warfarin; dbSNP
O60883	349	Natural variant	K	1.0	description:found in siblings with a novel form of progressive myoclonus epilepsy; unknown pathological significance; no effect on expression levels, cell surface location, signaling activity or ubiquitination; dbSNP
P04439	3	Natural variant	V	1.0	description:in allele A*34
P04439	5	Natural variant	A	1.0	description:in allele A*80
P04439	10	Natural variant	L	1.0	description:in allele A*02
P04439	14	Natural variant	S	1.0	description:in allele A*29
P04439	23	Natural variant	W	1.0	description:in allele A*74
P04439	334	Natural variant	R	1.0	description:allele A*80
P04439	335	Natural variant	K	1.0	description:in allele A*23
P04439	338	Natural variant	D	1.0	description:allele A*80
P04439	345	Natural variant	T	1.0	description:in allele A*02
P04439	358	Natural variant	V	1.0	description:in allele A*25
Q8NFD5	571	Natural variant	P	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
Q8NFD5	854	Natural variant	S	1.0	description:found in a patient with short stature; unknown pathological significance
Q8NFD5	897	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q8NFD5	1496	Natural variant	P	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
Q8NFD5	1519	Natural variant	G	1.0	description:probable disease-associated variant found in a patient with short stature; de novo mutation
P17405	36	Natural variant	V	1.0	description:does not affect enzymatic activity; dbSNP
P17405	51	Natural variant	D	1.0	description:in NPDB; unknown pathological significance; dbSNP
P17405	186	Natural variant	P	1.0	description:in NPDA; reduces enzyme activity; intermediate form with clinical features of both Niemann-Pick disease types A and B; dbSNP
Q9NZM4	64	Natural variant	E	1.0	description:in CSS12; unknown pathological significance
Q9NZM4	1423	Natural variant	E	1.0	description:in CSS12; unknown pathological significance
Q9HCU4	2812	Natural variant	R	1.0	description:found in a patient with congenital hydrocephalus; unknown pathological significance; dbSNP
A8MXD5	38	Natural variant	P	1.0	description:in DFNB25; dbSNP
A8MXD5	64	Natural variant	G	1.0	description:in DFNB25; dbSNP
P78363	54	Natural variant	C	1.0	description:in STGD1; dbSNP
P78363	55	Natural variant	H	1.0	description:in CORD3; unknown pathological significance
P78363	58	Natural variant	N	1.0	description:in STGD1; dbSNP
P78363	60	Natural variant	A	1.0	description:in STGD1
P78363	60	Natural variant	A	1.0	description:in STGD1; dbSNP
P78363	60	Natural variant	A	1.0	description:in STGD1; dbSNP
P78363	897	Natural variant	T	1.0	description:in STGD1; dbSNP
P78363	1183	Natural variant	G	1.0	description:in CORD3; unknown pathological significance; dbSNP
P78363	1300	Natural variant	R	1.0	description:in STGD1; unknown pathological significance; dbSNP
P78363	1484	Natural variant	P	1.0	description:in STGD1; unknown pathological significance
P78363	1486	Natural variant	P	1.0	description:in STGD1; dbSNP
P78363	1488	Natural variant	C	1.0	description:in STGD1; dbSNP
P78363	1488	Natural variant	C	1.0	description:in STGD1 and FFM; also found in a patient with chorioretinal atrophy; reduced retinal-stimulated ATP hydrolysis; does not affect secondary structure; oss of structural flexibility; significantly decreases all-trans-retinal binding; dbSNP
P78363	1488	Natural variant	C	1.0	description:in STGD1; dbSNP
P78363	1490	Natural variant	C	1.0	description:in STGD1 and CORD3; reduced retinal-stimulated ATP hydrolysis; dbSNP
P78363	1503	Natural variant	P	1.0	description:in STGD1; unknown pathological significance
P78363	1508	Natural variant	G	1.0	description:in FFM
P78363	1511	Natural variant	P	1.0	description:in STGD1; unknown pathological significance; dbSNP
P78363	1512	Natural variant	P	1.0	description:in STGD1; unknown pathological significance; dbSNP
P78363	1513	Natural variant	Q	1.0	description:in STGD1; dbSNP
P78363	1517	Natural variant	R	1.0	description:in ARMD2; dbSNP
P78363	2255	Natural variant	S	1.0	description:benign variant; dbSNP
P78363	2263	Natural variant	R	1.0	description:in STGD1; dbSNP
Q9NQW6	431	Natural variant	R	1.0	description:in FSGS8; results in decreased interaction with CD2AP; dbSNP
Q9NQW6	618	Natural variant	G	1.0	description:in FSGS8; dbSNP
Q9H3R5	2	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P12111	2047	Natural variant	G	1.0	description:in BTHLM1
P12111	2056	Natural variant	G	1.0	description:in BTHLM1
P12111	2080	Natural variant	G	1.0	description:in BTHLM1; dbSNP
P12111	3082	Natural variant	P	1.0	description:in DYT27; dbSNP
Q9BQT9	874	Natural variant	H	1.0	description:in a colorectal cancer sample; somatic mutation
Q5SYB0	572	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q8WTS1	7	Natural variant	E	1.0	description:in CDS; dbSNP
O15013	227	Natural variant	N	1.0	description:found in a patient with hereditary motor and sensory neuropathy; unknown pathological significance; dbSNP
Q9BYV9	788	Natural variant	E	1.0	description:in IMD60; unknown pathological significance; severely decreased localization in the nucleus; the mutant aggregates in the cytoplasm; dbSNP
Q9C0K0	32	Natural variant	E	1.0	description:in a patient with amyotrophic lateral sclerosis
Q9C0K0	229	Natural variant	P	1.0	description:in a patient with amyotrophic lateral sclerosis; dbSNP
Q9C0K0	331	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
Q9C0J9	362	Natural variant	Y	1.0	description:associated with short sleep phenotype; abolishes inhibition of CLOCK-BMAL1 and NPAS2/BMAL1 transactivation activities; dbSNP
Q9C0J9	384	Natural variant	P	1.0	description:associated with short sleep phenotype; heterogeneous phenotype; increases inhibition of CLOCK-BMAL1 and NPAS2/BMAL1 transactivation activities; dbSNP
Q9C0J9	384	Natural variant	P	1.0	description:associated with short sleep phenotype; abolishes inhibition of CLOCK-BMAL1 and NPAS2/BMAL1 transactivation activities; dbSNP
Q6ZUT6	189	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q99967	179	Natural variant	S	1.0	description:in ASD8; demonstrates only about 75% of the repressive activity of wild-type
P54756	582	Natural variant	G	1.0	description:in a lung adenocarcinoma sample; somatic mutation; dbSNP
P02675	44	Natural variant	R	1.0	description:in Christchurch-2, Seattle-1 and Ijmuiden; dbSNP
P02675	45	Natural variant	G	1.0	description:in Ise
P02675	74	Natural variant	R	1.0	description:in Nijmegen; dbSNP
P02675	95	Natural variant	C	1.0	description:in CAFBN; hypofibrinogenemia; heterozygous; decreased fibrinogen complex assembly; no effect on fibrinogen complex secretion
P02675	98	Natural variant	A	1.0	description:in DYSFIBRIN; fibrinogen Naples and Milano-2; associated with defective thrombin binding and thrombophilia; dbSNP
P21217	20	Natural variant	L	1.0	description:in Le(-); dbSNP
P23771	366	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
Q14332	142	Natural variant	P	1.0	description:found in a patient with features of Robinow syndrome; unknown pathological significance; dbSNP
Q969Y2	3	Natural variant	R	1.0	description:in COXPD23; unknown pathological significance; dbSNP
Q6MZN7	112	Natural variant	V	1.0	description:associated with low viral load in HIV patients; dbSNP
Q8IV16	14	Natural variant	F	1.0	description:it may act as a disease modifier preserving from severe HLPP1D when associated with R-68 or F-89; results in increased GPIHBP1 expression at the cell surface; does not affect interaction with LPL when associated in cis with R-68 in one individual; dbSNP
Q8IV16	56	Natural variant	G	1.0	description:no discernible effect on interaction with LPL, chylomicrons or APOA5; dbSNP
Q8IV16	144	Natural variant	S	1.0	description:in HLPP1D; dbSNP
Q8IV16	175	Natural variant	G	1.0	description:in HLPP1D; affects protein expression at the cell surface; reduces interaction with LPL; dbSNP
O00165	130	Natural variant	L	1.0	description:in SCN3; dbSNP
O00165	141	Natural variant	F	1.0	description:in SCN3; mild form; dbSNP
O00165	172	Natural variant	V	1.0	description:in SCN3; likely benign variant; dbSNP
Q96MG2	108	Natural variant	P	1.0	description:affecting excitation/contraction coupling in muscle fibers; the sensitivity of CACNA1S voltage sensor is shifted to higher depolarizing voltages in cells carrying this variant; dbSNP
Q96MG2	150	Natural variant	G	1.0	description:affecting excitation/contraction coupling in muscle fibers; the sensitivity of CACNA1S voltage sensor is shifted to higher depolarizing voltages in cells carrying this variant; dbSNP
P06213	762	Natural variant	R	1.0	description:in IRAN type A; dbSNP
P06213	1378	Natural variant	R	1.0	description:in IRAN type A; dbSNP
Q96L96	433	Natural variant	Q	1.0	description:in a lung large cell carcinoma sample; somatic mutation
Q96L96	1364	Natural variant	G	1.0	description:in a metastatic melanoma sample; somatic mutation
Q5IJ48	1249	Natural variant	R	1.0	description:in RP; unknown pathological significance; reduces protein stability and expression
Q5IJ48	1249	Natural variant	R	1.0	description:in FSGS9; dbSNP
Q86TM3	141	Natural variant	N	1.0	description:found in a renal cell carcinoma case; somatic mutation
Q14126	812	Natural variant	G	1.0	description:in ARVD10; dbSNP
B1AK53	719	Natural variant	S	1.0	description:in DFNB36; irregular microvillar organization; dbSNP
B1AK53	744	Natural variant	D	1.0	description:in DFNB36; irregular microvillar organization; dbSNP
B1AK53	774	Natural variant	R	1.0	description:in DFNB36; sporadic case with mild phenotype; unknown pathological significance; dbSNP
B1AK53	848	Natural variant	K	1.0	description:in DFNB36; severe phenotype; severe impairment of microvillar elongation; espin is less efficiently targeted to the microvilli and accumulates in the nucleus; dbSNP
Q9HB96	184	Natural variant	P	1.0	description:in FANCE; uncertain pathological significance
P35555	20	Natural variant	Y	1.0	description:in MFS; dbSNP
P35555	39	Natural variant	A	1.0	description:probable disease-associated variant found in a patient with Marfan-like syndrome
P35555	55	Natural variant	G	1.0	description:in MFS
P35555	2708	Natural variant	N	1.0	description:in MFS; dbSNP
P35555	2726	Natural variant	R	1.0	description:probable disease-associated variant found in a patient with Marfan-like syndrome; defects in protein processing; dbSNP
P35555	2741	Natural variant	I	1.0	description:in MFLS; dbSNP
Q68DX3	727	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P35367	385	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P04080	4	Natural variant	G	1.0	description:in EPM1; dbSNP
P58107	1094	Natural variant	S	1.0	description:de novo variant found in a patient with childhood apraxia of speech; unknown pathological significance
Q8TBJ5	188	Natural variant	G	1.0	description:in a patient with amyotrophic lateral sclerosis; dbSNP
Q5H9T9	262	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
Q5H9T9	764	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation
Q5H9T9	775	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P51841	10	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P07305	1	Natural variant	M	1.0	description:in RNA edited version
B7U540	354	Natural variant	T	1.0	description:in TTPP2; small decrease in current density; dbSNP
B7U540	360	Natural variant	K	1.0	description:in TTPP2; abolishes potassium inward and outward currents density
B7U540	366	Natural variant	K	1.0	description:in TTPP2; hypermorphic; longer time required for half-maximal current degradation; dbSNP
B7U540	388	Natural variant	E	1.0	description:in TTPP2; reduces potassium inward and outward currents density
Q676U5	300	Natural variant	T	1.0	description:in IBD10; has no effect on the stability of the protein under normal conditions; enhances the cleavage and the degradation mediated by activated CASP3; results in reduced autophagy and defective clearance of intestinal pathogens; impairs interaction with TMEM59; slows TMEM59 intracellular trafficking; increases production of type IIFNs; dbSNP
Q07812	11	Natural variant	G	1.0	description:in a plasmacytoma cell line; dbSNP
P05997	228	Natural variant	G	1.0	description:in EDSCL2
P05997	963	Natural variant	G	1.0	description:in EDSCL2; dbSNP
Q07864	1255	Natural variant	L	1.0	description:found in a colorectal sample; somatic mutation
Q07864	1925	Natural variant	I	1.0	description:found in a colorectal sample; somatic mutation
Q99607	95	Natural variant	A	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	147	Natural variant	A	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	177	Natural variant	R	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	187	Natural variant	T	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	345	Natural variant	S	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	368	Natural variant	P	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	382	Natural variant	V	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	408	Natural variant	V	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	411	Natural variant	V	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	500	Natural variant	A	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	512	Natural variant	P	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
Q99607	604	Natural variant	R	1.0	description:no effect on transcriptional activity shown in IFNB1 promoter-driven luciferase assay; dbSNP
P54760	516	Natural variant	G	1.0	description:in CMAVM2; unknown pathological significance; dbSNP
Q9ULV1	33	Natural variant	P	1.0	description:in EVR1; benign variant; dbSNP
Q9ULV1	36	Natural variant	G	1.0	description:in EVR1; dbSNP
Q9ULV1	40	Natural variant	E	1.0	description:in EVR1; dbSNP
Q9ULV1	157	Natural variant	M	1.0	description:in EVR1; loss of function; dbSNP
Q9ULV1	181	Natural variant	C	1.0	description:in EVR1; increased signaling activity; dbSNP
Q9ULV1	525	Natural variant	G	1.0	description:in EVR1
P14136	385	Natural variant	S	1.0	description:in ALXDRD; dbSNP
P14136	416	Natural variant	R	1.0	description:in ALXDRD; dbSNP
P27539	68	Natural variant	R	1.0	description:found in a patient with atrioventricular canal-cleft mitral valve; unknown pathological significance; dbSNP
P84243	8	Natural variant	A	1.0	description:in BRYLIB2; unknown pathological significance; no effect on protein abundance
P84243	9	Natural variant	R	1.0	description:in BRYLIB2
P84243	9	Natural variant	R	1.0	description:in BRYLIB1
P84243	9	Natural variant	R	1.0	description:in BRYLIB1
P84243	10	Natural variant	K	1.0	description:in BRYLIB2; unknown pathological significance; no effect on protein abundance
P84243	11	Natural variant	S	1.0	description:in BRYLIB2; unknown pathological significance
P84243	14	Natural variant	G	1.0	description:in BRYLIB2; unknown pathological significance
P84243	16	Natural variant	A	1.0	description:in BRYLIB1; unknown pathological significance
P84243	18	Natural variant	R	1.0	description:in BRYLIB1
P84243	23	Natural variant	T	1.0	description:in BRYLIB1; unknown pathological significance
P84243	23	Natural variant	T	1.0	description:in BRYLIB2; unknown pathological significance; no effect on protein abundance
P84243	28	Natural variant	K	1.0	description:in GLM; glioblastoma multiforme samples and diffuse intrinsic pontine glioma; somatic mutation; more prevalent in pediatric than adult malignancies; results in reduced allosteric activation of PRC2 causing a global decrease of H3K27me3 levels; has no effect on H3K4me3 or H3K36me3 levels; dbSNP
P84243	30	Natural variant	A	1.0	description:in BRYLIB2; unknown pathological significance
P84243	30	Natural variant	A	1.0	description:in BRYLIB1; unknown pathological significance
P84243	32	Natural variant	S	1.0	description:in BRYLIB1; unknown pathological significance
P84243	35	Natural variant	G	1.0	description:in GLM; glioblastoma multiforme samples; somatic mutation; also found in osteosarcoma samples; results in global decrease of H3K36me2 and H3K36me3 levels; has no effect on H3K27me3 levels; dbSNP
P84243	35	Natural variant	G	1.0	description:in GLM and BRYLIB2; glioblastoma multiforme samples; somatic mutation; affects regulation of gene expression and results in up-regulation of MYCN; results in global decrease of H3K36me2 and H3K36me3 levels; has no effect on H3K27me3 levels
P84243	35	Natural variant	G	1.0	description:probable disease-associated variant found in giant cell tumors of bone; somatic mutation
P84243	37	Natural variant	K	1.0	description:in BRYLIB1
P84243	37	Natural variant	K	1.0	description:probable disease-associated variant found in chondroblastoma and clear cell chondrosarcoma; somatic mutation; also found in a subset of human papillomavirus-negative head and neck squamous cell carcinomas; results in global decrease of H3K36me2 and H3K36me3 levels and increased H3K27me3 levels
P84243	40	Natural variant	H	1.0	description:in BRYLIB2; unknown pathological significance
P84243	40	Natural variant	H	1.0	description:in BRYLIB1; unknown pathological significance
P84243	41	Natural variant	R	1.0	description:in BRYLIB1; unknown pathological significance; increased protein abundance
Q6XYB7	171	Natural variant	A	1.0	description:found in a patient with atrial septal defects; unknown pathological significance; dbSNP
Q04844	13	Natural variant	G	1.0	description:in CMS4B; impaired association with alpha CHRNA1 subunit of AChR; dbSNP
Q04844	431	Natural variant	A	1.0	description:in CMS4B; causes an increase in distributions of rates for channel opening and closing increasing the range of activation kinetics; dbSNP
P01160	150	Natural variant	R	1.0	description:in ATRST2; dbSNP
Q9UBG3	480	Natural variant	G	1.0	description:in ESCR; dbSNP
P48165	118	Natural variant	A	1.0	description:in CTRCT1; unknown pathological significance; dbSNP
P48165	247	Natural variant	I	1.0	description:likely benign variant; does not affect gap junctions formation and gap junctional currents; dbSNP
Q53GD3	6	Natural variant	R	1.0	description:no effect on thiamine pyrophosphate transporter activity; dbSNP
Q9Y5Y3	7	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q14CZ7	22	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q99502	41	Natural variant	E	1.0	description:found in a patient with congenital cataract; dbSNP
Q99502	95	Natural variant	P	1.0	description:in BOR1
Q99502	140	Natural variant	G	1.0	description:in BOR1
Q99502	242	Natural variant	S	1.0	description:in BOS1; dbSNP
P30793	15	Natural variant	G	1.0	description:in HGCH-3
P30793	23	Natural variant	P	1.0	description:in DRD; dbSNP
O60229	1897	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
P35475	18	Natural variant	L	1.0	description:in MPS1S; dbSNP
O43186	41	Natural variant	R	1.0	description:in RP; dbSNP
O43186	41	Natural variant	R	1.0	description:in CORD2; exhibits reduced DNA binding, transcriptional synergy and interaction with NRL; dbSNP
O43186	42	Natural variant	E	1.0	description:in LCA7; unknown pathological significance; dbSNP
O43186	115	Natural variant	R	1.0	description:in RP; unknown pathological significance; dbSNP
O43186	141	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
O43186	242	Natural variant	V	1.0	description:in CORD2; dbSNP
Q5T442	125	Natural variant	R	1.0	description:associated with lymphedema in a small family
Q5T442	149	Natural variant	G	1.0	description:associated with lymphedema in a small family; dbSNP
Q5T442	260	Natural variant	R	1.0	description:in LMPHM3; dbSNP
Q5T442	316	Natural variant	P	1.0	description:associated with lymphedema in a small family; dbSNP
Q96CG8	44	Natural variant	Q	1.0	description:found in patients with Barrett esophagus; dbSNP
Q08345	496	Natural variant	S	1.0	description:in a lung squamous cell carcinoma sample; somatic mutation
O60610	678	Natural variant	P	1.0	description:in DFNA1; dbSNP
Q9Y238	351	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q9GZV9	157	Natural variant	F	1.0	description:in HFTC2; dbSNP
Q9GZV9	176	Natural variant	R	1.0	description:in ADHR; partially resistant to cleavage by furin; dbSNP
Q9GZV9	179	Natural variant	R	1.0	description:in ADHR; C-terminal processing is abolished; reduced proteolysis by PHEX; resistant to cleavage by furin; dbSNP
Q9GZV9	179	Natural variant	R	1.0	description:in ADHR; C-terminal processing is abolished; dbSNP
P35637	191	Natural variant	G	1.0	description:in ALS6; dbSNP
P35637	216	Natural variant	R	1.0	description:in ALS6 and ETM4; dbSNP
P35637	225	Natural variant	G	1.0	description:in ALS6; dbSNP
P35637	230	Natural variant	G	1.0	description:in ALS6; dbSNP
P35637	234	Natural variant	R	1.0	description:in ALS6; dbSNP
P35637	244	Natural variant	R	1.0	description:in ALS6; dbSNP
P35637	254	Natural variant	M	1.0	description:found in a patient with frontotemporal lobar degeneration; dbSNP
P35637	431	Natural variant	P	1.0	description:in ETM4; dbSNP
P35637	507	Natural variant	G	1.0	description:in ALS6; dbSNP
P35637	514	Natural variant	R	1.0	description:in ALS6; dbSNP
P35637	514	Natural variant	R	1.0	description:in ALS6
P35637	515	Natural variant	G	1.0	description:in ALS6; dbSNP
P35637	517	Natural variant	H	1.0	description:does not affect protein nuclear localization; dbSNP
P35637	518	Natural variant	R	1.0	description:in ALS6; dbSNP
P35637	521	Natural variant	R	1.0	description:in ALS6; results in aberrant trafficking and cytoplasmic retention of the protein; dbSNP
P35637	521	Natural variant	R	1.0	description:in ALS6; results in aberrant trafficking and cytoplasmic retention of the protein; dbSNP
P35637	521	Natural variant	R	1.0	description:in ALS6; results in aberrant trafficking and cytoplasmic retention of the protein; dbSNP
P35637	522	Natural variant	R	1.0	description:in ALS6; dbSNP
P35637	524	Natural variant	R	1.0	description:in ALS6; dbSNP
P35637	524	Natural variant	R	1.0	description:in ALS6; dbSNP
P35637	525	Natural variant	P	1.0	description:in ALS6; dbSNP
P35637	526	Natural variant	Y	1.0	description:in ALS6; unknown pathological significance
P34059	15	Natural variant	L	1.0	description:in MPS4A; dbSNP
P34059	16	Natural variant	V	1.0	description:in MPS4A; reduced enzymatic activity; dbSNP
P34059	23	Natural variant	G	1.0	description:in MPS4A
O60318	409	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P39905	21	Natural variant	P	1.0	description:in HSCR3; unknown pathological significance; dbSNP
P39905	93	Natural variant	R	1.0	description:may be a risk factor for Hirschsprung disease; dbSNP
Q9UBX0	6	Natural variant	Q	1.0	description:in CPHD5; dbSNP
Q9UBX0	26	Natural variant	I	1.0	description:in CPHD5; the mutated protein is associated with impaired transcriptional repression but not DNA binding; dbSNP
P14653	27	Natural variant	A	1.0	description:in allele HOXB1*B
P14653	207	Natural variant	R	1.0	description:in HCFP3; decreased transactivation activity at low DNA concentrations; increased transactivation activity at high DNA concentrations compared to wild-type; dbSNP
Q49A92	161	Natural variant	K	1.0	description:in a colorectal cancer sample; somatic mutation
P43897	312	Natural variant	R	1.0	description:in COXPD3; dbSNP
P08709	13	Natural variant	L	1.0	description:in FA7D; Morioka; dbSNP
P43694	6	Natural variant	A	1.0	description:in VSD1; dbSNP
P43694	9	Natural variant	A	1.0	description:in TOF; slightly diminished DNA-binding affinity; decreased transcriptional activity; no effect on subcellular location; no effect on interaction with TBX5; dbSNP
P43694	39	Natural variant	V	1.0	description:probable disease-associated variant found in patients with dilated cardiomyopathy; results in significantly reduced transactivation activity; dbSNP
P43694	43	Natural variant	R	1.0	description:in VSD1; significantly reduced activation of the NPPA promoter with the mutant protein compared to wild-type; dbSNP
P43694	46	Natural variant	S	1.0	description:in VSD1
P43694	51	Natural variant	L	1.0	description:in TOF; slightly diminished DNA-binding affinity; decreased transcriptional activity; no effect on subcellular location; no effect on interaction with TBX5
P43694	52	Natural variant	S	1.0	description:in ASD2; dbSNP
P43694	93	Natural variant	G	1.0	description:in ASD2; unknown pathological significance; dbSNP
P43694	118	Natural variant	A	1.0	description:in TOF
P43694	163	Natural variant	P	1.0	description:in AVSD4; also in a patient with VSD1 and a patient with TOF; dbSNP
P43694	310	Natural variant	M	1.0	description:in ASD2; dbSNP
P43694	316	Natural variant	Q	1.0	description:in ASD2; unknown pathological significance; dbSNP
P43694	346	Natural variant	A	1.0	description:in AVSD4; dbSNP
P43694	359	Natural variant	E	1.0	description:in VSD1; dbSNP
P43694	403	Natural variant	L	1.0	description:in ASD2; dbSNP
P43694	407	Natural variant	P	1.0	description:in VSD1 and TOF; unknown pathological significance; dbSNP
P43694	429	Natural variant	S	1.0	description:in VSD1
P43694	442	Natural variant	A	1.0	description:in VSD1; dbSNP
P47871	428	Natural variant	R	1.0	description:no effect on glucagon-elicited cAMP production
P47871	438	Natural variant	S	1.0	description:no effect on glucagon-elicited cAMP production
P47871	458	Natural variant	D	1.0	description:no effect on glucagon-elicited cAMP production
P47871	461	Natural variant	A	1.0	description:no effect on glucagon-elicited cAMP production
P47871	476	Natural variant	P	1.0	description:no effect on glucagon-elicited cAMP production
Q02577	9	Natural variant	A	1.0	description:found in a patient with features of hypogonadotropic hypogonadism and Kabuki syndrome also carrying a KMT2D variant; unknown pathological significance; reduced transactivation activity on KISS1 promoter; requires 2 nucleotide substitutions
Q02577	31	Natural variant	V	1.0	description:in HH27; the patient also carries KISS1 and PROKR2 variants; unknown pathological significance
P22830	55	Natural variant	G	1.0	description:in EPP1; dbSNP
P22830	62	Natural variant	P	1.0	description:in EPP1; dbSNP
Q02221	39	Natural variant	S	1.0	description:in MC4DN18; reduced complex IV assembly; decreased COX6A2 protein stability; dbSNP
Q02221	43	Natural variant	C	1.0	description:in MC4DN18; reduced complex IV assembly; decreased COX6A2 protein stability; dbSNP
Q8WYN3	474	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q13206	566	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q96HY7	305	Natural variant	Q	1.0	description:in AAKAD; unknown pathological significance; dbSNP
P05305	198	Natural variant	K	1.0	description:associated with HDL cholesterol levels is some populations and in a sex-specific manner; dbSNP
P32249	338	Natural variant	A	1.0	description:in an acute myeloid leukemia sample; somatic mutation; dbSNP
P21917	284	Natural variant	S	1.0	description:in allele D4.7
P11166	468	Natural variant	R	1.0	description:in GLUT1DS1; dbSNP
P11166	485	Natural variant	P	1.0	description:in GLUT1DS1; creates a dileucine internalization motif that promotes recruitment of clathrin and mislocalization of the protein to endocytic compartments
Q99217	4	Natural variant	W	1.0	description:in AI1E; dbSNP
Q99217	37	Natural variant	T	1.0	description:in AI1E; dbSNP
Q99217	56	Natural variant	P	1.0	description:in AI1E; dbSNP
Q8NFD2	764	Natural variant	E	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation
Q01484	1458	Natural variant	E	1.0	description:in LQT4; unknown pathological significance; abnormal calcium ion homeostasis, when tested in a heterologous system; dbSNP
Q01484	3740	Natural variant	L	1.0	description:in LQT4; loss of function; dbSNP
Q01484	3744	Natural variant	T	1.0	description:in LQT4; loss of function; dbSNP
Q01484	3906	Natural variant	R	1.0	description:in LQT4; loss of function; dbSNP
Q01484	3931	Natural variant	E	1.0	description:in LQT4; loss of function; dbSNP
P13497	12	Natural variant	G	1.0	description:in OI13; the mutation leads to severely reduced post-translational N-glycosylation of the protein and impairs protein secretion; leads to both reduced secretion and subsequent reduced processing of the substrates CHRD and COL1A1; dbSNP
P13497	45	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q8NFC6	246	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
P33076	120	Natural variant	K	1.0	description:in BLS2
Q15003	243	Natural variant	P	1.0	description:in MCPH23; impairs mitotic chromosome compaction; dbSNP
Q9UBY8	263	Natural variant	W	1.0	description:in CLN8; dbSNP
Q9UBY8	269	Natural variant	E	1.0	description:in CLN8; dbSNP
Q9NVF7	345	Natural variant	P	1.0	description:found in a renal cell carcinoma case; somatic mutation
Q9NVF7	348	Natural variant	R	1.0	description:in DEE100
Q9NVF7	348	Natural variant	R	1.0	description:in DEE100
P56524	244	Natural variant	T	1.0	description:in NEDCHF; decreased interaction with YWHAB
P56524	247	Natural variant	E	1.0	description:in NEDCHF; decreased interaction with YWHAB
P56524	248	Natural variant	P	1.0	description:in NEDCHF
P56524	248	Natural variant	P	1.0	description:in NEDCHF
Q9H772	13	Natural variant	A	1.0	description:in STHAG9; dbSNP
P15516	41	Natural variant	R	1.0	description:in histatin-3-2; loss of the proteolytic cleavage site; dbSNP
O95342	676	Natural variant	D	1.0	description:in fluvastatin-induced cholestasis; does not affect transport capacity for taurocholate
O95342	677	Natural variant	M	1.0	description:does not affect taurocholate transport activity; does not affect protein expression; does not affect cell surface protein expression; dbSNP
O95342	696	Natural variant	R	1.0	description:in PFIC2; unknown pathological significance; dbSNP
Q6NS38	9	Natural variant	A	1.0	description:found in a patient with endometrial cancer; slightly decreased PCNA-binding
Q6NS38	10	Natural variant	Q	1.0	description:increased PCNA-binding; dbSNP
Q9NXL2	67	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
Q01954	532	Natural variant	L	1.0	description:in POF16; unknown pathological significance; affects nuclear localization; the mutant exhibits a punctate localization in the nucleus; dbSNP
P61769	11	Natural variant	A	1.0	description:in IMD43; lower levels of B2M, MHC class I and FCGRT proteins; dbSNP
Q58F21	928	Natural variant	G	1.0	description:in SPGF21; no effect on protein expression; unknown pathological significance; dbSNP
O76090	567	Natural variant	L	1.0	description:in a sporadic case of age-related macular degeneration; unknown pathological significance; dbSNP
Q01668	1	Natural variant	M	1.0	description:in a NIDDM patient
Q9NWW5	6	Natural variant	R	1.0	description:in CLN4A; dbSNP
Q9NWW5	17	Natural variant	G	1.0	description:in CLN6; unknown pathological significance; dbSNP
P35638	115	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
O14521	12	Natural variant	G	1.0	description:may increase susceptibility for developing pheochromocytoma, paraganglioma, intestinal carcinoid tumor and breast, renal and uterus carcinoma; associated with increased manganese superoxide dismutase expression; associated with increased reactive oxygen species; associated with 1.9-fold increase in both AKT and MAPK expression; dbSNP
O14521	50	Natural variant	H	1.0	description:may increase susceptibility for developing paraganglioma, breast and thyroid carcinoma; may be involved in somatic Merkel cell carcinoma; associated with increased manganese superoxide dismutase expression; associated with increased reactive oxygen species; associated with a 2.0-fold increase in AKT expression and a 1.7-fold increase in MAPK expression; dbSNP
P01133	1070	Natural variant	P	1.0	description:in HOMG4; affects basolateral sorting of pro-EGF preventing the hormone to stimulate EGFR; lack of TRPM6 activation; dbSNP
O43281	361	Natural variant	M	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q16676	356	Natural variant	A	1.0	description:decreased activation of transcription from PGF and C3 promoters; dbSNP
Q16676	364	Natural variant	I	1.0	description:increased activation of transcription from the C3 promoter but no effect on the PGF promoter; dbSNP
O60741	47	Natural variant	G	1.0	description:in DEE24; likely benign variant; dbSNP
O60741	85	Natural variant	E	1.0	description:in GEFSP10; unknown pathological significance
O60741	100	Natural variant	S	1.0	description:in DEE24; dominant-negative mutation resulting in gain of channel function; dbSNP
O60741	680	Natural variant	S	1.0	description:in GEFSP10; unknown pathological significance
O60741	715	Natural variant	R	1.0	description:in GEFSP10; unknown pathological significance; dbSNP
O60741	851	Natural variant	P	1.0	description:found in a patient with sinus bradychardia; unknown pathological significance; affects channel properties as it results in a negative shift in the threshold voltage of activation and slower activation kinetics compared to the wild-type
Q6UWZ7	348	Natural variant	A	1.0	description:not associated with susceptibility to breast cancer; dbSNP
Q6UWZ7	361	Natural variant	R	1.0	description:in BC; results in reduced DSB repair efficiency; primarily localizes to the cytoplasm and has reduced nuclear localization; does not affect interaction with BRCA1; results in highly reduced interaction with UIMC1/RAP80; dbSNP
Q6UWZ7	373	Natural variant	D	1.0	description:not associated with susceptibility to breast cancer; dbSNP
Q9NR80	100	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
Q5SZL2	58	Natural variant	S	1.0	description:in LIS10
Q5SZL2	65	Natural variant	D	1.0	description:in LIS10
Q5SZL2	68	Natural variant	I	1.0	description:in LIS10; unknown pathological significance
Q5SZL2	69	Natural variant	G	1.0	description:in LIS10; unknown pathological significance
Q5SZL2	345	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q9UHG0	424	Natural variant	Q	1.0	description:in DFNB66; results in ciliary abnormalities including increased ciliary length; dbSNP
Q96DT5	34	Natural variant	E	1.0	description:requires 2 nucleotide substitutions; dbSNP
Q8WUF8	228	Natural variant	E	1.0	description:found in patients with CHARGES; unknown pathological significance; dbSNP
Q05932	499	Natural variant	S	1.0	description:expression reduced by 2.11-fold; Vmax with methotrexate as substrate is significantly reduced resulting in significantly decreased intrinsic clearance of methotrexate; apparent Vmax for glutamic acid is reduced 5-fold; reaction velocity at 100 nmol/L of pemetrexed is significantly reduced and folic acid dose-response curve is shifted to the right which corresponds to 4.28-fold increase in the EC(50) for folic acid; IC(50) of methotrexate is 1.64-fold higher and accumulation of a lower ratio of long-chain methotrexate polyglutamates to short-chain polyglutamates is detected; all results are for isoform 2 variant in comparison to the wild-type of it; dbSNP
O15353	169	Natural variant	E	1.0	description:in TLIND; unknown pathological significance
O15353	242	Natural variant	P	1.0	description:does not affect transcriptional activity as shown by a transcriptional reporter assay; dbSNP
O15353	430	Natural variant	P	1.0	description:does not affect transcriptional activity as shown by a transcriptional reporter assay; dbSNP
Q6QNK2	18	Natural variant	Y	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	18	Natural variant	Y	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	827	Natural variant	T	1.0	description:does not affect subcellular location; increases G-protein coupled receptor activity; dbSNP
Q6QNK2	831	Natural variant	A	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	836	Natural variant	A	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	836	Natural variant	A	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	851	Natural variant	M	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	868	Natural variant	R	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	869	Natural variant	V	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	870	Natural variant	D	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
Q6QNK2	874	Natural variant	V	1.0	description:does not affect subcellular location; does not change G-protein coupled receptor activity; dbSNP
O60241	1465	Natural variant	R	1.0	description:probable disease-associated variant found in a patient with progressive spastic paraparesis and other neurological symptoms; enhances receptor surface expression; increases the constitutive signaling activity; does not affect interaction with GNAZ; promotes enhanced interaction with GNAI1; decreases interaction with SH3GL2; dbSNP
Q12955	1569	Natural variant	S	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
Q12955	3720	Natural variant	T	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
Q12955	4255	Natural variant	T	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
Q01814	293	Natural variant	G	1.0	description:may exacerbate the severity of non-syndromic sensorineural hearing loss in patients with clinically relevant CDH23 variants; delayed calcium export
Q9H324	25	Natural variant	A	1.0	description:in WMS1; shows consistent and significantly diminished protein secretion
Q9BXS0	382	Natural variant	G	1.0	description:in CFEOM5; causes loss of stability; causes incorrect folding; dbSNP
Q68CJ9	166	Natural variant	P	1.0	description:in HYTG2; unknown pathological significance; no effect on transactivation activity in APOA4, APOC2 or FGF21 promoter-driven luciferase assays; dbSNP
Q68CJ9	180	Natural variant	V	1.0	description:in HYTG2; unknown pathological significance; no effect on transactivation activity in APOA4, APOC2 or FGF21 promoter-driven luciferase assays; dbSNP
Q68CJ9	182	Natural variant	D	1.0	description:in HYTG2; unknown pathological significance; no effect on transactivation activity in APOA4, APOC2 or FGF21 promoter-driven luciferase assays; dbSNP
P07333	693	Natural variant	P	1.0	description:in a lung squamous cell carcinoma sample; somatic mutation
Q16678	28	Natural variant	S	1.0	description:in GLC3A; dbSNP
Q16678	48	Natural variant	R	1.0	description:in allele CYP1B1*2, allele CYP1B1*5, allele CYP1B1*6 and allele CYP1B1*7; dbSNP
O95972	5	Natural variant	S	1.0	description:no or minor deleterious effect observed; dbSNP
Q8N4F0	20	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
P04920	186	Natural variant	A	1.0	description:found in a patient with autosomal recessive osteopetrosis; unknown pathological significance; reduced chloride
P51587	25	Natural variant	G	1.0	description:in BC; abolishes interaction with PALB2; dbSNP
P51587	31	Natural variant	W	1.0	description:in BC; abolishes interaction with PALB2; dbSNP
P51587	31	Natural variant	W	1.0	description:in BC; abolishes interaction with PALB2; dbSNP
P51587	32	Natural variant	F	1.0	description:in BC; dbSNP
P51587	42	Natural variant	Y	1.0	description:in BC and ovarian cancer; unknown pathological significance; dbSNP
P51587	53	Natural variant	K	1.0	description:in BC; dbSNP
P51587	60	Natural variant	N	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	64	Natural variant	T	1.0	description:in BC; dbSNP
P51587	75	Natural variant	A	1.0	description:in ovarian cancer and renal cancer; unknown pathological significance; dbSNP
P51587	81	Natural variant	F	1.0	description:in BC; dbSNP
P51587	118	Natural variant	R	1.0	description:in one patient with esophageal carcinoma; dbSNP
P51587	192	Natural variant	M	1.0	description:in one patient with pancreatic cancer; dbSNP
P51587	201	Natural variant	P	1.0	description:in BC; dbSNP
P51587	211	Natural variant	V	1.0	description:in BC
P51587	222	Natural variant	P	1.0	description:in BC; dbSNP
P51587	225	Natural variant	T	1.0	description:in one patient with BC; normal RNA expression and splicing; dbSNP
P51587	315	Natural variant	C	1.0	description:in one patient with esophageal carcinoma; dbSNP
P51587	326	Natural variant	S	1.0	description:in BC; dbSNP
P51587	327	Natural variant	K	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	355	Natural variant	V	1.0	description:in lung cancer
P51587	405	Natural variant	G	1.0	description:in BC; unknown pathological significance
P51587	431	Natural variant	T	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	448	Natural variant	R	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	462	Natural variant	E	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	505	Natural variant	I	1.0	description:in BC; dbSNP
P51587	554	Natural variant	C	1.0	description:in BC and pancreas cancer; dbSNP
P51587	613	Natural variant	L	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	630	Natural variant	T	1.0	description:in ovarian cancer; dbSNP
P51587	728	Natural variant	D	1.0	description:in BC; dbSNP
P51587	729	Natural variant	I	1.0	description:in BC; dbSNP
P51587	935	Natural variant	D	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	1036	Natural variant	E	1.0	description:in BC; unknown pathological significance
P51587	1106	Natural variant	S	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	1172	Natural variant	S	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	1179	Natural variant	S	1.0	description:in BC; dbSNP
P51587	1302	Natural variant	T	1.0	description:in BC
P51587	1445	Natural variant	K	1.0	description:in BC; unknown pathological significance
P51587	1522	Natural variant	L	1.0	description:in one patient with BC; dbSNP
P51587	1524	Natural variant	F	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	1529	Natural variant	G	1.0	description:in bladder cancer; dbSNP
P51587	1580	Natural variant	C	1.0	description:in BC; somatic mutation; dbSNP
P51587	1679	Natural variant	T	1.0	description:in BC
P51587	1690	Natural variant	K	1.0	description:in BC; dbSNP
P51587	1730	Natural variant	N	1.0	description:in BC; dbSNP
P51587	1771	Natural variant	G	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	1804	Natural variant	V	1.0	description:in BC; dbSNP
P51587	1887	Natural variant	T	1.0	description:in BC; dbSNP
P51587	1901	Natural variant	E	1.0	description:in BC
P51587	1929	Natural variant	I	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	1988	Natural variant	V	1.0	description:in one patient with esophageal carcinoma; somatic mutation; dbSNP
P51587	2031	Natural variant	T	1.0	description:in BC; unknown pathological significance
P51587	2044	Natural variant	G	1.0	description:in one patient with BC; dbSNP
P51587	2072	Natural variant	S	1.0	description:in BC; dbSNP
P51587	2089	Natural variant	E	1.0	description:in BC
P51587	2094	Natural variant	Y	1.0	description:in BC; dbSNP
P51587	2096	Natural variant	P	1.0	description:in BC
P51587	2118	Natural variant	V	1.0	description:in BC; unknown pathological significance
P51587	2128	Natural variant	K	1.0	description:in BC; dbSNP
P51587	2135	Natural variant	N	1.0	description:in BC; dbSNP
P51587	2222	Natural variant	Y	1.0	description:in BC; dbSNP
P51587	2274	Natural variant	G	1.0	description:in BC; dbSNP
P51587	2275	Natural variant	E	1.0	description:in BC; unknown pathological significance
P51587	2293	Natural variant	F	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	2336	Natural variant	R	1.0	description:in FANCD1; affects protein splicing and expression; decreases homologous recombination-mediated DNA repair; dbSNP
P51587	2353	Natural variant	G	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	2415	Natural variant	H	1.0	description:in BC
P51587	2421	Natural variant	Q	1.0	description:in BC
P51587	2440	Natural variant	H	1.0	description:benign variant; no effect on homology-directed repair activity; dbSNP
P51587	2456	Natural variant	Q	1.0	description:in BC; dbSNP
P51587	2466	Natural variant	V	1.0	description:in BC; benign variant; no effect on homology-directed repair activity; dbSNP
P51587	2488	Natural variant	R	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	2490	Natural variant	I	1.0	description:benign variant; no effect on homologous recombination-mediated DNA repair; no effect on interaction with SEM1; dbSNP
P51587	2502	Natural variant	R	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	2502	Natural variant	R	1.0	description:in ovarian cancer; unknown pathological significance; dbSNP
P51587	2510	Natural variant	L	1.0	description:in FANCD1; hypersensitive to DNA damage; disrupts interaction with SEM1; decreased homology-directed repair activity; dbSNP
P51587	2515	Natural variant	T	1.0	description:in BC; unknown pathological significance; dbSNP
P51587	3196	Natural variant	K	1.0	description:in BC; dbSNP
P51587	3300	Natural variant	P	1.0	description:in one patient with esophageal carcinoma; dbSNP
P51587	3357	Natural variant	T	1.0	description:in BC; dbSNP
Q92793	789	Natural variant	A	1.0	description:in RSTS1; dbSNP
Q92793	910	Natural variant	T	1.0	description:in RSTS1; incomplete; dbSNP
Q92793	1872	Natural variant	M	1.0	description:in MKHK1; dbSNP
Q14031	591	Natural variant	G	1.0	description:in DFNX6; dbSNP
Q14031	1130	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
P41181	254	Natural variant	R	1.0	description:in ANDI; results in the loss of arginine vasopressin-mediated phosphorylation at S-256
P41181	254	Natural variant	R	1.0	description:in ANDI; exerts a dominant-negative effect on wild-type-AQP2 in that it interferes with its trafficking to the apical membrane; is a loss of function instead of a gain of function mutation on dominant nephrogenic diabetes insipidus
P41181	258	Natural variant	E	1.0	description:in ANDI; retained in the Golgi compartment; dbSNP
P41181	262	Natural variant	P	1.0	description:in ANDI; mutant protein folds properly and is functional but is retained in intracellular vesicles; able to assemble into tetramers with wild-type AQP2 that properly localize to the apical membrane; dbSNP
Q9HBZ2	46	Natural variant	R	1.0	description:decreased transcription factor activity due to impaired localization to the nucleus; dbSNP
P20933	12	Natural variant	V	1.0	description:in AGU; uncertain pathological significance; dbSNP
P50747	42	Natural variant	E	1.0	description:in HLCS deficiency; benign variant; conserves enzymatic wild-type activity; dbSNP
Q96RK4	457	Natural variant	S	1.0	description:in BBS4
Q96RK4	472	Natural variant	M	1.0	description:in BBS4; dbSNP
Q96RK4	488	Natural variant	T	1.0	description:in a patient with Bardet-Biedl syndrome homozygous for a mutation in BBS12; uncertain pathological role; dbSNP
Q96RK4	503	Natural variant	P	1.0	description:in BBS4; dbSNP
P56945	407	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
I3L3R5	229	Natural variant	E	1.0	description:found in patients with Moyamoya disease; unknown pathological significance
I3L3R5	242	Natural variant	E	1.0	description:found in patients with Moyamoya disease; unknown pathological significance; dbSNP
Q92851	14	Natural variant	K	1.0	description:found in a colon cancer sample; somatic mutation
Q92851	410	Natural variant	V	1.0	description:does not interfere with apoptosis in a dominant negative manner; dbSNP
Q92851	414	Natural variant	A	1.0	description:in NHL; somatic mutation; dbSNP
P08123	109	Natural variant	G	1.0	description:in OIEDS2; decreased N-terminal propeptide processing; dbSNP
P08123	193	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	196	Natural variant	G	1.0	description:in OIEDS2
P08123	202	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	211	Natural variant	G	1.0	description:in OI1; dbSNP
P08123	234	Natural variant	R	1.0	description:in OI2; dbSNP
P08123	247	Natural variant	G	1.0	description:in OI1
P08123	253	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	256	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	283	Natural variant	G	1.0	description:in OI2
P08123	319	Natural variant	G	1.0	description:in OI1; dbSNP
P08123	325	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	328	Natural variant	G	1.0	description:in OI1, OI3 and OI4; dbSNP
P08123	331	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	334	Natural variant	G	1.0	description:in OI2
P08123	337	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	337	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	345	Natural variant	V	1.0	description:in OI3
P08123	349	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	358	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	397	Natural variant	G	1.0	description:in OI2
P08123	409	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	433	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	454	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	457	Natural variant	G	1.0	description:in OI2; requires 2 nucleotide substitutions
P08123	460	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	511	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	517	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	526	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	547	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	562	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	562	Natural variant	G	1.0	description:in OI2
P08123	586	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	592	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	601	Natural variant	G	1.0	description:in OI; dbSNP
P08123	625	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	634	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	637	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	640	Natural variant	G	1.0	description:in OI2
P08123	670	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	676	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	676	Natural variant	G	1.0	description:in OI3 and OI4; dbSNP
P08123	708	Natural variant	R	1.0	description:found in a patient with a variant form of Marfan syndrome; unknown pathological significance; dbSNP
P08123	715	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	730	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	733	Natural variant	G	1.0	description:in OI1; dbSNP
P08123	736	Natural variant	G	1.0	description:in OI1; mild; dbSNP
P08123	739	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	748	Natural variant	G	1.0	description:in OI2
P08123	751	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	754	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	754	Natural variant	G	1.0	description:in OI2
P08123	766	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	778	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	784	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	787	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	790	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	796	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	798	Natural variant	P	1.0	description:in OI2
P08123	811	Natural variant	G	1.0	description:in OI4
P08123	820	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	835	Natural variant	G	1.0	description:in OI3
P08123	835	Natural variant	G	1.0	description:in OI1; dbSNP
P08123	856	Natural variant	G	1.0	description:in OI3
P08123	856	Natural variant	G	1.0	description:in OI2
P08123	877	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	892	Natural variant	G	1.0	description:in OI3 and OI4; dbSNP
P08123	895	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	949	Natural variant	G	1.0	description:in OI3; moderate; dbSNP
P08123	955	Natural variant	G	1.0	description:in OI2
P08123	955	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	973	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	982	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	989	Natural variant	P	1.0	description:in OI4
P08123	991	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	997	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	1003	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	1012	Natural variant	G	1.0	description:in OI3 and OI4; moderate; dbSNP
P08123	1027	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	1066	Natural variant	G	1.0	description:in OI2; dbSNP
P08123	1078	Natural variant	G	1.0	description:in OI2
P08123	1087	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	1096	Natural variant	G	1.0	description:in OI3; dbSNP
P08123	1102	Natural variant	G	1.0	description:in OI4; dbSNP
P08123	1119	Natural variant	A	1.0	description:found in a patient with mild osteogenesis imperfecta associated with increased bone mineral density; results in defective type I procollagen processing; incorporation of the immature procollagen into the matrix leads to increased bone matrix mineralization and altered collagen fibril structure
O75462	340	Natural variant	R	1.0	description:in CISS1; dbSNP
Q13642	246	Natural variant	K	1.0	description:in XMPMA; unknown pathological significance
Q13642	276	Natural variant	C	1.0	description:in EDMD6; drastically reduced protein levels in muscle
Q13642	280	Natural variant	V	1.0	description:in XMPMA; dbSNP
Q14517	4422	Natural variant	T	1.0	description:found in a patient with spinocerebellar ataxia; unknown pathological significance; dbSNP
Q9H334	107	Natural variant	I	1.0	description:likely benign variant; does not affect nuclear localization; no loss of transcriptional repression activity; no loss of ability to self-associate; no loss of interaction with FOXP2
Q9H334	215	Natural variant	P	1.0	description:does not affect nuclear localization; no loss of transcriptional repression activity; no loss of ability to self-associate; no loss of interaction with FOXP2; dbSNP
Q9H334	570	Natural variant	N	1.0	description:does not affect nuclear localization; no loss of transcriptional repression activity; no loss of ability to self-associate; no loss of interaction with FOXP2; dbSNP
Q9H334	597	Natural variant	N	1.0	description:in MRLIAF; unknown pathological significance; does not affect nuclear localization; no loss of transcriptional repression activity; no loss of ability to self-associate; no loss of interaction with FOXP2
Q9H2P0	1094	Natural variant	G	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
P84996	201	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
P84996	201	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
P84996	374	Natural variant	P	1.0	description:in GNASHYP; dbSNP
P84996	375	Natural variant	P	1.0	description:in GNASHYP
P84996	397	Natural variant	L	1.0	description:in GNASHYP
P30038	16	Natural variant	P	1.0	description:in allele ALDH4A1*4; dbSNP
Q5TGY3	47	Natural variant	P	1.0	description:in XIGIS; unknown pathological significance
Q5TGY3	487	Natural variant	R	1.0	description:in XIGIS; unknown pathological significance
Q5TGY3	537	Natural variant	G	1.0	description:in XIGIS
Q5TGY3	548	Natural variant	G	1.0	description:in XIGIS; unknown pathological significance
Q5TGY3	549	Natural variant	R	1.0	description:in XIGIS; unknown pathological significance
Q5TGY3	607	Natural variant	D	1.0	description:in XIGIS; unknown pathological significance; does not affect nuclear localization
Q5TGY3	792	Natural variant	G	1.0	description:in XIGIS; unknown pathological significance; does not affect nuclear localization
Q5TGY3	1348	Natural variant	S	1.0	description:in XIGIS
Q5TGY3	1457	Natural variant	D	1.0	description:in XIGIS
Q5TGY3	1478	Natural variant	P	1.0	description:in XIGIS; unknown pathological significance
P01008	17	Natural variant	Y	1.0	description:in AT3D; type-I
P01008	23	Natural variant	L	1.0	description:in AT3D; type-I; does not undergo post-translational glycosylation; dbSNP
P01008	30	Natural variant	V	1.0	description:in Dublin; dbSNP
P01008	32	Natural variant	C	1.0	description:in AT3D; type-I
P01008	39	Natural variant	I	1.0	description:in AT3D; type-II; Rouen-3; lack of heparin-binding properties; dbSNP
P01008	52	Natural variant	M	1.0	description:previously Whitechapel; dbSNP
P01008	53	Natural variant	C	1.0	description:in AT3D
P01008	56	Natural variant	R	1.0	description:in AT3D; type-II; Rouen-4; lack of heparin-binding properties; dbSNP
Q9NP61	290	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q66PJ3	102	Natural variant	K	1.0	description:in RNA edited version
Q12830	1924	Natural variant	A	1.0	description:in NEDDFL; dbSNP
Q9H165	47	Natural variant	T	1.0	description:in IDPFH; de novo mutation; loss of function in transactivation of transcription; reduces the interaction between isoform 2 and isoform 3; disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3; does not affect the interaction of isoform 2 with TBR1; dbSNP
Q9H165	47	Natural variant	T	1.0	description:in IDPFH, de novo mutation, loss of function in transactivation of transcription, reduces the interaction between isoform 2 and isoform 3, disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3; dbSNP
Q9H165	47	Natural variant	T	1.0	description:in IDPFH, de novo mutation, loss of function transactivation of transcription, reduces the interaction between isoform 2 and isoform 3, disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3, does not affect the interaction of isoform 2 with TBR1; dbSNP
Q9H165	48	Natural variant	C	1.0	description:in IDPFH; de novo mutation; loss of function in transactivation of transcription; reduces the interaction between isoform 2 and isoform 3; disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3; does not affect the interaction of isoform 2 with TBR1; dbSNP
Q9H165	48	Natural variant	C	1.0	description:in IDPFH, de novo mutation, loss of function in transactivation of transcription, reduces the interaction between isoform 2 and isoform 3, disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3; dbSNP
Q9H165	48	Natural variant	C	1.0	description:in IDPFH, de novo mutation, loss of function in transactivation of transcription, reduces the interaction between isoform 2 and isoform 3, disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3, does not affect the interaction of isoform 2 with TBR1; dbSNP
Q9H165	66	Natural variant	H	1.0	description:in IDPFH; de novo mutation; loss of function in transactivation of transcription; reduces the interaction between isoform 2 and isoform 3; disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3; does not affect the interaction of isoform 2 with TBR1; dbSNP
Q9H165	66	Natural variant	H	1.0	description:in IDPFH, de novo mutation, loss of function in transactivation of transcription, reduces the interaction between isoform 2 and isoform 3, disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3; dbSNP
Q9H165	66	Natural variant	H	1.0	description:in IDPFH, de novo mutation, loss of function in transactivation of transcription, reduces the interaction between isoform 2 and isoform 3, disrupts the nuclear paraspeckle distribution of isoform 2 and isoform 3, does not affect the interaction of isoform 2 with TBR1; dbSNP
Q9H165	142	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q92560	315	Natural variant	E	1.0	description:found in a malignant pleural mesothelioma sample; dbSNP
Q92560	718	Natural variant	R	1.0	description:in KURIS; unknown pathological significance; able to rescue impaired H2AK119ub deubiquitination when expressed in BAP1-deficient cells; does not affect localization to the nucleus
Q13948	490	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q6UXH8	327	Natural variant	G	1.0	description:in HKLLS1; dbSNP
P09884	79	Natural variant	I	1.0	description:in VEODS; no effect on protein abundance; decreased DNA replication; dbSNP
P09884	110	Natural variant	G	1.0	description:in VEODS; decreased protein abundance; may alter splicing; dbSNP
Q9H9B1	43	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q15485	80	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation
P56159	371	Natural variant	L	1.0	description:may be involved in congenital central hypoventilation syndrome; dbSNP
Q9HCJ1	490	Natural variant	E	1.0	description:in CCAL2; sporadic; dbSNP
Q9NQ11	12	Natural variant	T	1.0	description:in KRS; no effect on stability; no effect on location; decreased ATPase activity; dbSNP
P98194	201	Natural variant	P	1.0	description:in HHD; has normal catalytic cycle
P46100	1538	Natural variant	V	1.0	description:in ATRX; unknown pathological significance
P82251	10	Natural variant	R	1.0	description:in CSNU
P12830	777	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P12830	832	Natural variant	V	1.0	description:in HDGC; dbSNP
P12830	838	Natural variant	S	1.0	description:in an ovarian carcinoma sample; somatic mutation; loss of heterozygosity; dbSNP
P35212	319	Natural variant	P	1.0	description:in allele CX37*2; dbSNP
Q99895	18	Natural variant	G	1.0	description:found in a patient with chronic pancreatitis; unknown pathological significance; catalytic activity comparable to that of wild type; the mutant undergoes proteolytic degradation during trypsin-mediated activation; dbSNP
Q8IY37	93	Natural variant	R	1.0	description:in NEDBAVC; unknown pathological significance; dbSNP
Q8IY37	167	Natural variant	E	1.0	description:in NEDBAVC; unknown pathological significance; requires 2 nucleotide substitutions
O75140	452	Natural variant	A	1.0	description:in FFEVF1; inhibits slightly DEPDC5 signaling; stimulates slightly kinase activity of mTORC1; does not change association with the GATOR complex; does not change RRAGA/RRAGC and RRAGB/RRAGC heterodimer formation; dbSNP
O75140	485	Natural variant	R	1.0	description:in FFEVF1; does not inhibit DEPDC5 signaling; stimulates slightly kinase activity of mTORC1; does not change association with the GATOR complex; does not change RRAGA/RRAGC and RRAGB/RRAGC heterodimer formation; dbSNP
O75140	542	Natural variant	Q	1.0	description:in FFEVF1; unknown pathological significance; dbSNP
O75140	1065	Natural variant	K	1.0	description:in FFEVF1; unknown pathological significance; dbSNP
O75140	1073	Natural variant	S	1.0	description:in FFEVF1; inhibits slightly DEPDC5 signaling; does not change kinase activity of mTORC1; does not change association with the GATOR complex; does not change RRAGA/RRAGC and RRAGB/RRAGC heterodimer formation; dbSNP
O75140	1081	Natural variant	T	1.0	description:in FFEVF1; unknown pathological significance; dbSNP
O75140	1104	Natural variant	S	1.0	description:in FFEVF1; unknown pathological significance; dbSNP
O75140	1154	Natural variant	S	1.0	description:in FFEVF1; unknown pathological significance; dbSNP
O75140	1162	Natural variant	S	1.0	description:in FFEVF1; does not inhibit DEPDC5 signaling; does not change kinase activity of mTORC1; does not change association with the GATOR complex; does not change RRAGA/RRAGC and RRAGB/RRAGC heterodimer formation; dbSNP
Q92997	216	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
P54098	3	Natural variant	R	1.0	description:in PEOB1; dbSNP
P54098	511	Natural variant	S	1.0	description:in PEOA1; dbSNP
P54098	517	Natural variant	G	1.0	description:in SANDO; dbSNP
P30084	2	Natural variant	A	1.0	description:in ECHS1D; dbSNP
P14770	7	Natural variant	L	1.0	description:in BSS; dbSNP
Q09472	827	Natural variant	L	1.0	description:in a breast cancer sample
Q09472	1013	Natural variant	E	1.0	description:in a breast cancer sample; dbSNP
Q09472	2007	Natural variant	Q	1.0	description:found in a patient with spinocerebellar ataxia; unknown pathological significance; dbSNP
Q09472	2221	Natural variant	P	1.0	description:in a colorectal cancer sample; dbSNP
O95477	1172	Natural variant	E	1.0	description:associated with premature coronary heart disease; dbSNP
O95477	1289	Natural variant	D	1.0	description:in TGD; dbSNP
O95477	1477	Natural variant	C	1.0	description:in TGD; loss of interaction with APOE; unable to generate APOE-containing high density lipoproteins; moderately decreased protein abundance; moderately decreased ATPase activity; moderately decreased phospholipid translocase activity; dbSNP
Q9Y653	38	Natural variant	R	1.0	description:in BFPP; abolishes interaction with COL3A1; dbSNP
Q9Y653	38	Natural variant	R	1.0	description:in BFPP; abolishes interaction with COL3A1; reduces cell surface localization; dbSNP
O95180	456	Natural variant	C	1.0	description:in ECA6; results in increased T-current amplitude and lower threshold for spikes generation; results in increased neuronal excitability
O95180	499	Natural variant	G	1.0	description:in ECA6; dbSNP
O95180	516	Natural variant	H	1.0	description:found in a patient with drug-resistant focal epilepsy; unknown pathological significance; dbSNP
O95180	618	Natural variant	P	1.0	description:in EIG6; dbSNP
O95180	648	Natural variant	P	1.0	description:in ECA6; creates a dileucine internalization motif that promotes recruitment of clathrin; dbSNP
O95180	744	Natural variant	R	1.0	description:in ECA6; dbSNP
O95180	748	Natural variant	A	1.0	description:in ECA6; dbSNP
O95180	755	Natural variant	G	1.0	description:in EIG6; dbSNP
O95180	773	Natural variant	G	1.0	description:in ECA6; dbSNP
O95180	1951	Natural variant	V	1.0	description:probable disease-associated variant responsible for primary aldosteronism found in a patient with aldosterone-producing adenoma; changed Ca(2+) channel activity; dbSNP
O95180	1970	Natural variant	S	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
O95180	2083	Natural variant	P	1.0	description:in HALD4; changed calcium channel activity; dbSNP
P29400	54	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	114	Natural variant	G	1.0	description:in ATS1
P29400	123	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	129	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	129	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	174	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	177	Natural variant	G	1.0	description:in ATS1; presenting with dot-and-fleck retinopathy; dbSNP
P29400	177	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	192	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	204	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	216	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	219	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	230	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	239	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	264	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	289	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	292	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	292	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	295	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	298	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	319	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	325	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	325	Natural variant	G	1.0	description:in ATS1; juvenile and adult types; dbSNP
P29400	331	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	365	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	371	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	374	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	383	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	400	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	406	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	409	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	412	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	415	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	420	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	420	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	423	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	466	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	472	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	491	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	494	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	497	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	521	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	521	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	524	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	545	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	545	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	558	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	561	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	567	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	573	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	579	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	579	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	603	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	609	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	609	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	621	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	624	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	629	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	632	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	633	Natural variant	E	1.0	description:in ATS1; dbSNP
P29400	635	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	638	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	638	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	638	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	653	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	669	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	681	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	684	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	687	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	722	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	739	Natural variant	P	1.0	description:in ATS1; juvenile type; dbSNP
P29400	740	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	743	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	772	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	796	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	802	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	808	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	811	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	822	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	852	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	852	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	866	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	869	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	872	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	878	Natural variant	G	1.0	description:in ATS1
P29400	898	Natural variant	M	1.0	description:in ATS1; mild phenotype; dbSNP
P29400	902	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	911	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	941	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	942	Natural variant	S	1.0	description:in ATS1
P29400	947	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	953	Natural variant	G	1.0	description:in ATS1; found on the same allele as variant Glu-1211; dbSNP
P29400	1006	Natural variant	G	1.0	description:in ATS1
P29400	1006	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1015	Natural variant	G	1.0	description:in ATS1
P29400	1015	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1030	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1036	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1039	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	1045	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1066	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1066	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1086	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1104	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1107	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1143	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	1143	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	1158	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1161	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1167	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1170	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1182	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	1196	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1205	Natural variant	G	1.0	description:in ATS1; juvenile type; dbSNP
P29400	1211	Natural variant	G	1.0	description:in ATS1; found on the same allele as variant Val-953; dbSNP
P29400	1211	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1220	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1229	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	1241	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1244	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1252	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	1261	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1270	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1333	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1357	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1379	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	1410	Natural variant	R	1.0	description:in ATS1; adult and juvenile types; dbSNP
P29400	1421	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	1422	Natural variant	R	1.0	description:in ATS1; juvenile type; dbSNP
P29400	1427	Natural variant	G	1.0	description:in ATS1; adult type; dbSNP
P29400	1442	Natural variant	G	1.0	description:in ATS1; dbSNP
P29400	1451	Natural variant	G	1.0	description:in ATS1; dbSNP
P20908	25	Natural variant	L	1.0	description:in EDSCL1; not or less efficiently secreted into the extracellular matrix
P20908	25	Natural variant	L	1.0	description:in EDSCL1; not or less efficiently secreted into the extracellular matrix
P20908	514	Natural variant	G	1.0	description:in FMDMF; dbSNP
P20908	530	Natural variant	G	1.0	description:in EDSCL1; dbSNP
P20908	611	Natural variant	R	1.0	description:in FMDMF; unknown pathological significance
P20908	908	Natural variant	P	1.0	description:found in a renal cell carcinoma case; somatic mutation; dbSNP
P20908	1164	Natural variant	P	1.0	description:in FMDMF; unknown pathological significance
P20908	1400	Natural variant	P	1.0	description:in FMDMF; unknown pathological significance
P20908	1486	Natural variant	G	1.0	description:in EDSCL1
P20908	1489	Natural variant	G	1.0	description:in EDSCL1
P43146	1217	Natural variant	M	1.0	description:in MRMV1; unknown pathological significance; dbSNP
P43146	1250	Natural variant	A	1.0	description:in MRMV1; unknown pathological significance; dbSNP
P43146	1375	Natural variant	P	1.0	description:in a colorectal carcinoma; dbSNP
Q9Y6C2	22	Natural variant	A	1.0	description:found in a patient with connective tissue disorder and peripheral neuropathy; unknown pathological significance; decreased secretion; accumulates in the endoplasmic reticulum; dbSNP
Q96RJ6	36	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q6P4F2	4	Natural variant	M	1.0	description:in MEOAL; unknown pathological significance; expressed at low levels in fibroblasts and muscles from a homozygous patient; dbSNP
Q13480	387	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
Q9UN86	434	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q68CZ1	937	Natural variant	R	1.0	description:in a patient with Leber congenital amaurosis; dbSNP
P23945	680	Natural variant	N	1.0	description:associated with longer menstrual cycles; dbSNP
Q14353	8	Natural variant	P	1.0	description:no effect on activity; dbSNP
Q9Y6D6	316	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q8WWL7	597	Natural variant	K	1.0	description:in a colorectal cancer sample; somatic mutation
Q8IZC6	697	Natural variant	G	1.0	description:in STLS; dbSNP
P12259	775	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
Q96A65	220	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
Q6ZUT3	296	Natural variant	G	1.0	description:in NYS1; dbSNP
Q6ZUT3	301	Natural variant	Y	1.0	description:in NYS1; dbSNP
Q6ZUT3	306	Natural variant	Q	1.0	description:in NYS1
Q6ZUT3	340	Natural variant	S	1.0	description:in NYS1
Q9BWX5	16	Natural variant	Y	1.0	description:in CHTD5; decreased transcriptional activity; dbSNP
Q9BWX5	132	Natural variant	R	1.0	description:in CHTD5; unknown pathological significance
Q9BWX5	138	Natural variant	Y	1.0	description:in CHTD5; decreased transcriptional activity
Q14CM0	553	Natural variant	C	1.0	description:in XLID104; dbSNP
P50440	23	Natural variant	R	1.0	description:in CCDS3; unknown pathological significance; reduces glycine amidinotransferase activity; dbSNP
P18505	421	Natural variant	H	1.0	description:found in 1.1% of population and in some schizophrenic patients; dbSNP
O75129	229	Natural variant	A	1.0	description:found in a clear cell renal carcinoma case; somatic mutation
O75129	298	Natural variant	D	1.0	description:found in a patient with global developmental delay; unknown pathological significance
O60759	329	Natural variant	P	1.0	description:found in a renal cell carcinoma case; somatic mutation
Q5TCH4	11	Natural variant	R	1.0	description:in allele CYP4A22*2 and CYP4A22*3; dbSNP
Q8TDB6	209	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
O75923	155	Natural variant	G	1.0	description:in LGMDR2; dbSNP
O75923	2000	Natural variant	R	1.0	description:in MMD1; dbSNP
Q96LB3	86	Natural variant	G	1.0	description:in SPGF58; affects subcellular location, instead of being homogenously distributed along the sperm flagellum, concentrates in the proximal part of the flagellum; also affects splicing
A4D126	53	Natural variant	A	1.0	description:in MDDGC7
A4D126	54	Natural variant	G	1.0	description:in MDDGC7; decreased alpha-dystroglycan glycosylation; dbSNP
Q5SW96	202	Natural variant	S	1.0	description:in FHCL4; Lebanon; requires 2 nucleotide substitutions; dbSNP
Q9H2A9	77	Natural variant	R	1.0	description:in PSS3; results in decreased enzyme activity; the mutant protein shows reduced glycosylation; dbSNP
D6RIA3	595	Natural variant	G	1.0	description:found in patients with obliterative portal venopathy; unknown pathological significance; dbSNP
D6RIA3	1415	Natural variant	F	1.0	description:found in a patient with obliterative portal venopathy; unknown pathological significance; dbSNP
D6RIA3	1632	Natural variant	T	1.0	description:found in patients with obliterative portal venopathy; unknown pathological significance
P10645	382	Natural variant	G	1.0	description:may be associated with a reduced risk for hypertension especially in men; reduces activity 4.7 fold; no effect on plasmin-mediated proteolytic processing; increase in ability to inhibit nicotine-evoked catecholamine secretion in vitro; displays alterations in baroreceptor function; dbSNP
P10645	388	Natural variant	P	1.0	description:increases activity 2.3 fold; decrease in plasmin-mediated proteolytic processing; decrease in ability to inhibit nicotine-evoked catecholamine secretion in vitro; dbSNP
P10645	392	Natural variant	R	1.0	description:no effect on plasmin-mediated proteolytic processing; decrease in ability to inhibit nicotine-evoked catecholamine secretion in vitro; dbSNP
Q96S66	25	Natural variant	D	1.0	description:in RP32; reduces ion channel activity; no impact on interaction with CALR; no impact on ER localization; dbSNP
P50570	627	Natural variant	P	1.0	description:in CNM1
P50570	627	Natural variant	P	1.0	description:in CNM1; dbSNP
Q9BZG8	6	Natural variant	M	1.0	description:in DEDSSH; normal diphthamide modification of elongation factor 2; dbSNP
Q9BZG8	7	Natural variant	A	1.0	description:in breast and ovarian cancer; dbSNP
Q9BZG8	34	Natural variant	A	1.0	description:in breast and ovarian cancer
Q9BZG8	389	Natural variant	S	1.0	description:in breast and ovarian cancer
Q9UMD9	265	Natural variant	S	1.0	description:in JEB4
Q9UMD9	627	Natural variant	G	1.0	description:in JEB4
Q9UMD9	633	Natural variant	G	1.0	description:in JEB4; dbSNP
Q9UMD9	939	Natural variant	T	1.0	description:in ERED; dbSNP
Q9UMD9	1303	Natural variant	R	1.0	description:in JEB4; dbSNP
O15528	497	Natural variant	P	1.0	description:in VDDR1A; dbSNP
Q16828	182	Natural variant	S	1.0	description:in HH19; rare variant associated with susceptibility to disease; the patient carries a second mutation in the HH-associated gene FGFR1; dbSNP
Q16828	189	Natural variant	N	1.0	description:in HH19; dbSNP
Q9UJJ9	5	Natural variant	L	1.0	description:rare variant; found in individuals suffering from stuttering; unknown pathological significance
Q9UJJ9	25	Natural variant	A	1.0	description:rare variant; found in individuals suffering from stuttering; unknown pathological significance; dbSNP
Q9UJJ9	230	Natural variant	L	1.0	description:rare variant; found in individuals suffering from stuttering; unknown pathological significance; dbSNP
Q9UJJ9	286	Natural variant	T	1.0	description:does not affect localization to Golgi apparatus; dbSNP
A0M8Q6	34	Natural variant	N	1.0	description:in IMGTALLELEIGLC7*01
O00763	193	Natural variant	R	1.0	description:in a pancreatic ductal adenocarcinoma sample; somatic mutation
Q6H8Q1	274	Natural variant	K	1.0	description:in a pancreatic ductal adenocarcinoma sample; somatic mutation
Q86TB3	942	Natural variant	E	1.0	description:in an ovarian undifferentiated carcinoma sample; somatic mutation
Q86TB3	1476	Natural variant	K	1.0	description:in a melanoma metastatic sample; somatic mutation
P25054	99	Natural variant	R	1.0	description:in FAP1; unknown pathological significance; dbSNP
P25054	784	Natural variant	S	1.0	description:in FAP1
P25054	817	Natural variant	G	1.0	description:in gastric cancer
P25054	880	Natural variant	I	1.0	description:in colorectal carcinoma and gastric cancer; from a patient with MMRCS; dbSNP
P25054	890	Natural variant	V	1.0	description:in colorectal carcinoma; from a patient with MMRCS; dbSNP
P25054	906	Natural variant	S	1.0	description:in colorectal tumor
P25054	911	Natural variant	E	1.0	description:in FAP1 and colorectal tumor
P25054	942	Natural variant	N	1.0	description:in gastric cancer
P25054	1027	Natural variant	Y	1.0	description:in colorectal tumor; dbSNP
P25054	1057	Natural variant	E	1.0	description:found in a family whose members exhibit gastrointestinal cancers and multiple pigmented cutaneous lesions; unknown pathological significance
P25054	1120	Natural variant	G	1.0	description:in gastric cancer; dbSNP
P25054	1171	Natural variant	R	1.0	description:in gastric cancer; dbSNP
P25054	1176	Natural variant	P	1.0	description:in FAP1
P25054	1184	Natural variant	A	1.0	description:in FAP1
P25054	1197	Natural variant	F	1.0	description:in gastric cancer
P25054	1254	Natural variant	I	1.0	description:in a colorectal cancer sample; somatic mutation
P25054	1259	Natural variant	I	1.0	description:in gastric cancer
P25054	1292	Natural variant	T	1.0	description:in FAP1; unknown pathological significance; dbSNP
P25054	1296	Natural variant	A	1.0	description:in MDB; sporadic; dbSNP
P25054	1307	Natural variant	I	1.0	description:may be associated with increased risk of colon and breast cancer; dbSNP
P25054	1312	Natural variant	G	1.0	description:in gastric cancer
P25054	1313	Natural variant	T	1.0	description:in FAP1 and colorectal tumor; dbSNP
P25054	1317	Natural variant	E	1.0	description:may contribute to colorectal tumor development; dbSNP
P25054	1326	Natural variant	V	1.0	description:in gastric cancer
P25054	1348	Natural variant	R	1.0	description:in FAP1
P25054	1395	Natural variant	S	1.0	description:in hepatoblastoma; dbSNP
P25054	1422	Natural variant	D	1.0	description:in colorectal tumor
P25054	1472	Natural variant	V	1.0	description:in MDB; sporadic; dbSNP
P25054	1495	Natural variant	S	1.0	description:in MDB; sporadic
P25054	1508	Natural variant	A	1.0	description:in colorectal carcinoma from a patient with MMRCS
P25054	2621	Natural variant	S	1.0	description:in FAP1; unknown pathological significance; dbSNP
P25054	2839	Natural variant	L	1.0	description:in FAP1; dbSNP
P02649	21	Natural variant	E	1.0	description:in ApoE5; associated with hyperlipoproteinemia and atherosclerosis; increased binding to LDL receptor; dbSNP
P02649	31	Natural variant	E	1.0	description:in HLPP3; ApoE4 Philadelphia, ApoE5 French-Canadian and ApoE5-type; only ApoE4 Philadelphia is associated with HLPP3; dbSNP
P08686	479	Natural variant	R	1.0	description:in AH3; dbSNP
P08686	482	Natural variant	P	1.0	description:in AH3; reduced enzyme activity to 70% of normal; dbSNP
P08686	483	Natural variant	R	1.0	description:in AH3; moderate; 1-2% of activity; dbSNP
P08686	483	Natural variant	R	1.0	description:in AH3; dbSNP
P08686	483	Natural variant	R	1.0	description:in AH3; salt wasting form; dbSNP
P08686	493	Natural variant	N	1.0	description:in allele CYP21A2*6; dbSNP
Q9NYF0	45	Natural variant	R	1.0	description:in NTD; uncertain pathological significance; does not affect interaction with DVL2; does not affect subcellular location; increases RHOA activation but decreases the ability to activate JNK; dbSNP
Q9NYF0	356	Natural variant	N	1.0	description:in NTD; does not affect interaction with DVL2; does not affect subcellular location; results in reduced RHOA and JNK activation
Q9NYF0	682	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9NYF0	702	Natural variant	V	1.0	description:found in a patient with closed spina bifida; sporadic case; unknown pathological significance; dbSNP
Q9NYF0	808	Natural variant	T	1.0	description:found in a patient with encephalocele; sporadic case; unknown pathological significance
Q14562	168	Natural variant	R	1.0	description:found in a patient with a neurodevelopmental disorder; unknown pathological significance
O75190	89	Natural variant	F	1.0	description:in LGMDD1; the mutation results in inefficient inhibition of protein aggregation by isoform B; dbSNP
O75190	93	Natural variant	F	1.0	description:in LGMDD1; the mutation results in inefficient inhibition of protein aggregation by isoform B; dbSNP
O75190	96	Natural variant	P	1.0	description:found in a family with autosomal-dominantly inherited distal-onset myopathy; significant loss of its ability to suppress aggregation of polyglutamine-containing proteins
O75190	96	Natural variant	P	1.0	description:in LGMDD1; dbSNP
Q5JWR5	1155	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
O75487	412	Natural variant	R	1.0	description:found in a patient with features of Robinow syndrome; unknown pathological significance; dbSNP
O14976	962	Natural variant	G	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation; dbSNP
P10912	544	Natural variant	I	1.0	description:benign variant; associated with lower plasma HDL cholesterol levels in hypercholesterolemia patients that carry a pathogenic variant in LDLR; dbSNP
Q9BYR4	64	Natural variant	C	1.0	description:in allele KAP3-v1
Q9HCE0	1511	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q9HCE0	1865	Natural variant	C	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P00748	328	Natural variant	T	1.0	description:in HAE3; dbSNP
P00748	328	Natural variant	T	1.0	description:in HAE3; dbSNP
Q8WUU5	102	Natural variant	S	1.0	description:in CMD2B; dbSNP
Q9C091	116	Natural variant	T	1.0	description:in DFNA80; unknown pathological significance
Q9C091	241	Natural variant	R	1.0	description:able to rescue renal hypoplasia in zebrafish morphants; dbSNP
Q9C091	273	Natural variant	G	1.0	description:in RHDA3
Q9C091	283	Natural variant	N	1.0	description:in DFNA80; unknown pathological significance
Q9C091	328	Natural variant	R	1.0	description:in RHDA3; dbSNP
Q8WUI4	43	Natural variant	V	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
O14558	20	Natural variant	P	1.0	description:decreases phosphorylation at Ser-16; abolishes cardioprotective effects; dbSNP
Q14571	2498	Natural variant	G	1.0	description:in ANHD; loss of function mutation; dbSNP
Q9UQ05	797	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UPQ3	854	Natural variant	P	1.0	description:in a family with an autistic patient; dbSNP
Q6UXC1	1174	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q14055	326	Natural variant	Q	1.0	description:in IDD; requires 2 nucleotide substitutions; dbSNP
P02458	207	Natural variant	G	1.0	description:in SEDSTN; dbSNP
P02458	240	Natural variant	G	1.0	description:in STL1; dbSNP
P02458	267	Natural variant	G	1.0	description:in STL1O; dbSNP
P02458	270	Natural variant	G	1.0	description:in STL1
P02458	275	Natural variant	R	1.0	description:in CZECHD; dbSNP
P02458	282	Natural variant	G	1.0	description:in STL1
P02458	303	Natural variant	G	1.0	description:in KD; abnormal allele expressed in the cartilage; dbSNP
P02458	318	Natural variant	G	1.0	description:in DRRD; dbSNP
P02458	354	Natural variant	G	1.0	description:in spondylometaphyseal dysplasia; congenital type; dbSNP
P02458	375	Natural variant	G	1.0	description:in SEDC
P02458	447	Natural variant	G	1.0	description:in SEDC
P02458	453	Natural variant	G	1.0	description:in STL1; dbSNP
P02458	453	Natural variant	G	1.0	description:in ACG2; dbSNP
P02458	453	Natural variant	G	1.0	description:in ACG2
P02458	492	Natural variant	G	1.0	description:in SEMDSTWK; dbSNP
P02458	501	Natural variant	G	1.0	description:in STL1
P02458	504	Natural variant	G	1.0	description:in SEMDSTWK; dbSNP
P02458	510	Natural variant	G	1.0	description:in ACG2
P02458	513	Natural variant	G	1.0	description:in ACG2; dbSNP
P02458	516	Natural variant	G	1.0	description:in ACG2; dbSNP
P02458	547	Natural variant	D	1.0	description:in ACG2
P02458	565	Natural variant	R	1.0	description:in STL1; dbSNP
P02458	667	Natural variant	L	1.0	description:in DRRD; dbSNP
P02458	717	Natural variant	G	1.0	description:in ANFH1; dbSNP
P02458	717	Natural variant	G	1.0	description:in ACG2
P02458	719	Natural variant	R	1.0	description:in OSCDP; also in mild spondyloepiphyseal dysplasia and precocious osteoarthritis; dbSNP
P02458	771	Natural variant	G	1.0	description:in ACG2
P02458	771	Natural variant	G	1.0	description:in ACG2
P02458	774	Natural variant	G	1.0	description:in SEDC and hypochondrogenesis; lethal; dbSNP
P02458	780	Natural variant	G	1.0	description:in ACG2
P02458	795	Natural variant	G	1.0	description:in ACG2
P02458	804	Natural variant	G	1.0	description:in hypochondrogenesis
P02458	855	Natural variant	G	1.0	description:in SEDC; dbSNP
P02458	891	Natural variant	G	1.0	description:in ACG2 and SEDC; dbSNP
P02458	894	Natural variant	G	1.0	description:in ACG2
P02458	897	Natural variant	G	1.0	description:in SEMDSTWK
P02458	904	Natural variant	R	1.0	description:in EDMMD and STL1; dbSNP
P02458	909	Natural variant	G	1.0	description:in SEMDSTWK; dbSNP
P02458	948	Natural variant	G	1.0	description:in ACG2
P02458	969	Natural variant	G	1.0	description:in ACG2; dbSNP
P02458	981	Natural variant	G	1.0	description:in ACG2
P02458	989	Natural variant	R	1.0	description:in SEDC; dbSNP
P02458	992	Natural variant	R	1.0	description:in SEMDSTWK; dbSNP
P02458	1005	Natural variant	G	1.0	description:in hypochondrogenesis; dbSNP
P02458	1017	Natural variant	G	1.0	description:in ACG2
P02458	1053	Natural variant	G	1.0	description:in hypochondrogenesis; lethal; dbSNP
P02458	1065	Natural variant	G	1.0	description:in ACG2
P02458	1110	Natural variant	G	1.0	description:in ACG2; dbSNP
P02458	1113	Natural variant	G	1.0	description:in hypochondrogenesis
P02458	1119	Natural variant	G	1.0	description:in ACG2
P02458	1143	Natural variant	G	1.0	description:in ACG2
P02458	1158	Natural variant	G	1.0	description:in STL1
P02458	1170	Natural variant	G	1.0	description:in ANFH1 and LCPD; dbSNP
P02458	1173	Natural variant	G	1.0	description:in SEDC; dbSNP
P02458	1176	Natural variant	G	1.0	description:in SEDC
P02458	1176	Natural variant	G	1.0	description:mutation found in a patient with features of multiple epiphyseal dysplasia; features overlap with SEDC
P02458	1179	Natural variant	G	1.0	description:mutation found in a patient with features of multiple epiphyseal dysplasia; features overlap with SEDC
P02458	1184	Natural variant	I	1.0	description:in SEDC
P02458	1188	Natural variant	G	1.0	description:in ACG2
P02458	1197	Natural variant	G	1.0	description:in SEDC; dbSNP
P12107	565	Natural variant	G	1.0	description:in STL2
P12107	625	Natural variant	G	1.0	description:in STL2; dbSNP
P12107	676	Natural variant	G	1.0	description:in STL2; overlapping phenotype with Marshall syndrome; dbSNP
P12107	796	Natural variant	G	1.0	description:in FBCG1
P12107	1027	Natural variant	G	1.0	description:in STL2
P12107	1042	Natural variant	G	1.0	description:in FBCG1
P12107	1326	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
P12107	1328	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P12107	1328	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation
P12107	1513	Natural variant	G	1.0	description:in STL2; dbSNP
P12107	1516	Natural variant	G	1.0	description:in STL2; overlapping phenotype with Marshall syndrome; dbSNP
P39060	184	Natural variant	E	1.0	description:in GLCC; unknown pathological significance; dbSNP
Q99928	352	Natural variant	T	1.0	description:found in a patient with MRT52; unknown pathological significance; dbSNP
O00458	39	Natural variant	Q	1.0	description:found in a renal cell carcinoma sample; somatic mutation
Q14653	146	Natural variant	N	1.0	description:decreased IFNB induction upon Sendai virus infection
P48551	318	Natural variant	Y	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
P48551	324	Natural variant	S	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
P48551	346	Natural variant	P	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
P48551	362	Natural variant	P	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
P48551	385	Natural variant	P	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
P48551	450	Natural variant	S	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
Q27J81	13	Natural variant	A	1.0	description:in FSGS5; dbSNP
Q99612	116	Natural variant	S	1.0	description:found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation; dbSNP
Q99612	123	Natural variant	A	1.0	description:found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation; dbSNP
Q99612	155	Natural variant	S	1.0	description:found in gastric cancer samples; somatic mutation; dbSNP
Q99612	169	Natural variant	L	1.0	description:found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation; dbSNP
Q99612	172	Natural variant	P	1.0	description:found in gastric cancer samples; somatic mutation
Q99612	180	Natural variant	S	1.0	description:found in gastric cancer samples; somatic mutation; dbSNP
Q99612	198	Natural variant	R	1.0	description:found in gastric cancer samples; somatic mutation
Q8NAX2	312	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P06850	30	Natural variant	P	1.0	description:found in patients with autosomal dominant nocturnal frontal lobe epilepsy; unknown pathological significance; results in decreased protein levels; decreased protein secretion; dbSNP
Q9C098	108	Natural variant	P	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation
Q8IZD9	1674	Natural variant	M	1.0	description:in NEDIDHA; unknown pathological significance; dbSNP
P14138	224	Natural variant	A	1.0	description:in HSCR4; risk factor associated with disease susceptibility; dbSNP
P24530	17	Natural variant	L	1.0	description:no effect on cell membrane location; dbSNP
P24530	17	Natural variant	L	1.0	description:probable disease-associated variant found in patients with Waardenburg syndrome 2; loss of cell membrane location; new cytoplasmic location
P24530	57	Natural variant	G	1.0	description:associated with increased susceptibility for Hirschsprung disease; sex-dependent gene dosage effect; dbSNP
Q8TE73	2881	Natural variant	A	1.0	description:in CILD3; dbSNP
Q8N7M0	49	Natural variant	E	1.0	description:may act as disease modifier for Duchenne muscular dystrophy being associated with earlier loss of ambulation; dbSNP
Q9BX63	47	Natural variant	P	1.0	description:in BC; early onset; loss of ATPase and helicase activities; dbSNP
Q9BX63	1034	Natural variant	P	1.0	description:in a patient with ovarian cancer; unknown pathological significance; dbSNP
Q5T1H1	1232	Natural variant	I	1.0	description:in RP25; dbSNP
Q5T1H1	1682	Natural variant	D	1.0	description:in RP25; dbSNP
P02765	256	Natural variant	S	1.0	description:in allele AHSG*1; dbSNP
P02765	276	Natural variant	D	1.0	description:in allele AHSG*5; dbSNP
P02765	317	Natural variant	R	1.0	description:in allele AHSG*3; dbSNP
P02765	317	Natural variant	R	1.0	description:in APMR1; unknown pathological significance; dbSNP
Q8WYB5	483	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
Q9NP60	606	Natural variant	F	1.0	description:in a breast cancer sample; somatic mutation
Q2M1P5	641	Natural variant	R	1.0	description:in BBS; the patient also carries homozygous mutation R-390 in BBS1; may affect splicing; hypomorphic variant in vitro; dbSNP
Q2M1P5	987	Natural variant	E	1.0	description:in ACLS; atypical phenotype; unknown pathological significance; dbSNP
Q2M1P5	994	Natural variant	Q	1.0	description:in BBS; the patient is a compound heterozygote for a truncating mutation and mutation R-390 in BBS1; hypomorphic variant in vitro; dbSNP
Q9NR82	429	Natural variant	S	1.0	description:in MRD46; no effect on protein abundance; no effect on potassium ion transmembrane transport; changed voltage-gated potassium channel activity; changed gating properties; dbSNP
Q9H6U6	567	Natural variant	P	1.0	description:in HEMARS; no protein detected in patient cells that also carry R-577, suggesting the mutant is unstable
Q9H6U6	577	Natural variant	G	1.0	description:in HEMARS; no protein detected in patient cells that also carry L-567, suggesting the mutant is unstable
Q07021	186	Natural variant	C	1.0	description:in COXPD33; unknown pathological significance; dbSNP
Q07021	188	Natural variant	Y	1.0	description:in COXPD33; unknown pathological significance; dbSNP
Q07021	204	Natural variant	F	1.0	description:in COXPD33; unknown pathological significance; dbSNP
Q96D53	98	Natural variant	L	1.0	description:in NPHS9
Q6Y7W6	56	Natural variant	N	1.0	description:may be associated with PARK11; dbSNP
Q6Y7W6	112	Natural variant	T	1.0	description:in PARK11; dbSNP
Q6Y7W6	256	Natural variant	E	1.0	description:in PARK11; unknown pathological significance
Q6Y7W6	273	Natural variant	S	1.0	description:in PARK11; unknown pathological significance; dbSNP
Q6Y7W6	278	Natural variant	I	1.0	description:in PARK11; dbSNP
Q6Y7W6	335	Natural variant	S	1.0	description:in PARK11; dbSNP
Q6Y7W6	345	Natural variant	A	1.0	description:in PARK11; unknown pathological significance
Q6Y7W6	349	Natural variant	D	1.0	description:in PARK11; unknown pathological significance; dbSNP
Q6Y7W6	377	Natural variant	S	1.0	description:in PARK11; unknown pathological significance
Q6Y7W6	457	Natural variant	N	1.0	description:in PARK11; unknown pathological significance; dbSNP
Q6Y7W6	473	Natural variant	P	1.0	description:in PARK11; unknown pathological significance; dbSNP
Q6Y7W6	979	Natural variant	Q	1.0	description:in PARK11; unknown pathological significance
Q6Y7W6	1070	Natural variant	D	1.0	description:in PARK11; unknown pathological significance
Q6Y7W6	1209	Natural variant	L	1.0	description:in PARK11; unknown pathological significance; dbSNP
Q6Y7W6	1242	Natural variant	V	1.0	description:in PARK11; dbSNP
O14979	378	Natural variant	D	1.0	description:in LGMDD3; dbSNP
O14979	378	Natural variant	D	1.0	description:in LGMDD3; dbSNP
P19013	72	Natural variant	A	1.0	description:in allele K4A1; dbSNP
P19013	82	Natural variant	T	1.0	description:in alleles K4A1 and K4A2
P01130	726	Natural variant	T	1.0	description:in FHCL1; Paris-9; unknown pathological significance; dbSNP
P01130	825	Natural variant	N	1.0	description:in FHCL1; does not affect receptor expression at the cell surface; does not affect LDL binding; results in impaired LDL uptake and internalization; dbSNP
P01130	826	Natural variant	P	1.0	description:in FHCL1; dbSNP
P01130	827	Natural variant	V	1.0	description:in New York-5; dbSNP
P01130	828	Natural variant	Y	1.0	description:in FHCL1; J.D.Bari/Syria; 2-fold decreased affinity for LDLRAP1; dbSNP
P01130	844	Natural variant	G	1.0	description:in Turku; dbSNP
Q8IZD2	284	Natural variant	Y	1.0	description:in ODLURO
Q8IZD2	907	Natural variant	D	1.0	description:in ODLURO
Q8IZD2	1376	Natural variant	P	1.0	description:in ODLURO
Q6ZRV2	557	Natural variant	G	1.0	description:in AI3A; mild form; dbSNP
O15360	8	Natural variant	N	1.0	description:in FANCA; benign variant; dbSNP
P28799	9	Natural variant	A	1.0	description:in UP-FTD; no significant difference in the total mRNA between cases and controls; although the mutant protein is expressed it is not secreted and appears to be trapped within an intracellular compartment; dbSNP
Q9UKT5	8	Natural variant	S	1.0	description:in esophagus cancer samples; dbSNP
Q9UKT5	12	Natural variant	S	1.0	description:in esophagus cancer sample; impairs homodimerization and reduces ubiquitin ligase activity
Q9UKT5	13	Natural variant	P	1.0	description:in esophagus cancer sample
P42263	833	Natural variant	G	1.0	description:in MRXSW; reduced receptor expression possibly due to rapid degradation; dbSNP
P01860	269	Natural variant	T	1.0	description:in variant OMM
P01860	314	Natural variant	S	1.0	description:in variant OMM
P01860	314	Natural variant	S	1.0	description:in variant ZUC
P48449	12	Natural variant	G	1.0	description:in APMR4; unknown pathological significance
P48449	14	Natural variant	Y	1.0	description:in APMR4; unknown pathological significance
Q99814	534	Natural variant	P	1.0	description:in ECYT4; impairs interaction with EGLN1 and VHL
Q99814	535	Natural variant	M	1.0	description:in ECYT4
Q99814	535	Natural variant	M	1.0	description:in ECYT4; impairs interaction with EGLN1; dbSNP
Q99814	537	Natural variant	G	1.0	description:in ECYT4; impairs interaction with EGLN1 and VHL; dbSNP
Q99814	537	Natural variant	G	1.0	description:in ECYT4; gain of function; affects hydroxylation; dbSNP
Q99814	540	Natural variant	F	1.0	description:in ECYT4; affects the interaction with EGLN1 and VHL
Q9UBX5	90	Natural variant	G	1.0	description:in CMT1H; dbSNP
O97980	16	Natural variant	H	1.0	description:in allele HB-1Y; loss of CTL recognition for epitope HB-1. No influence on HLA-B/HLA-B44 binding, nor on the processing by the proteasome; dbSNP
P15884	29	Natural variant	P	1.0	description:probable disease-associated variant found in a family with symmetrical acral keratoderma
P15884	358	Natural variant	G	1.0	description:in PTHS; also expressed in the nucleus with a pattern indistinguishable from the wild-type; does not have a major impact on homodimer formation; affects transcriptional activity in a context-dependent manner
P15884	535	Natural variant	D	1.0	description:in PTHS; loss of function; also expressed in the nucleus with a pattern indistinguishable from the wild-type; does not have a major impact on homodimer formation; affects transcriptional activity in a context-dependent manner
Q96J84	573	Natural variant	S	1.0	description:in NPHS23; unknown pathological significance; affects integrity of podocyte cell-cell junctions and leads to altered cellular permeability; dbSNP
Q9BZL6	848	Natural variant	G	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q9BZL6	870	Natural variant	G	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
O43734	19	Natural variant	D	1.0	description:in PSORS13; there is a reducing binding of this variant to TRAF6; dbSNP
Q14993	361	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q9UPY3	435	Natural variant	P	1.0	description:found in Wilms tumor from a patient with GLOW syndrome; somatic mutation; unknown pathological significance
O43365	42	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
O43365	131	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q00056	37	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q86SU0	453	Natural variant	R	1.0	description:in DFNB42; uncertain pathological significance; no effect on interaction with MARVELD2; no effect on tight junction location; dbSNP
P05114	1	Natural variant	M	1.0	description:in RNA edited version
P55010	418	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
P60568	21	Natural variant	A	1.0	description:in FT-IL2-A and FT-IL2-B
P60568	22	Natural variant	P	1.0	description:in FT-IL2-B
P0DOY3	83	Natural variant	K	1.0	description:in IMGT allele IGLC3*04
P05155	11	Natural variant	L	1.0	description:in HAE; phenotype consistent with hereditary angioedema type 1
P05155	118	Natural variant	T	1.0	description:in HAE; dbSNP
P24394	400	Natural variant	E	1.0	description:associated with cedar pollen sensitization; dbSNP
P24394	503	Natural variant	S	1.0	description:lowered total IgE concentration; dbSNP
P24394	576	Natural variant	Q	1.0	description:associated with atopic dermatitis; lowered total IgE concentration; no effect on IL4-induced signal transduction; dbSNP
P24394	786	Natural variant	S	1.0	description:in 1.8% of the population; dbSNP
Q9UPM8	719	Natural variant	K	1.0	description:found in deaf patients; unknown pathological significance
Q9UPM8	801	Natural variant	E	1.0	description:in STUT1; slightly decreased assembly of the AP-4 complex; dbSNP
Q9UPM8	905	Natural variant	S	1.0	description:in STUT1; unknown pathological significance; dbSNP
Q9Y6D5	209	Natural variant	E	1.0	description:in PVNH2; unknown pathological significance; dbSNP
Q9P2K1	117	Natural variant	S	1.0	description:in JBTS9; unknown pathological significance; dbSNP
Q9P2K1	1045	Natural variant	V	1.0	description:in JBTS9; dbSNP
P13501	24	Natural variant	S	1.0	description:antagonist of the chemokine receptors CCR1 and CCR3; dbSNP
Q9P2D1	41	Natural variant	M	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	55	Natural variant	H	1.0	description:in HH5; phenotype consistent with Kallmann syndrome; dbSNP
Q9P2D1	72	Natural variant	Y	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	86	Natural variant	P	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	99	Natural variant	A	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	238	Natural variant	V	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	254	Natural variant	Q	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	439	Natural variant	P	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	558	Natural variant	P	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	685	Natural variant	A	1.0	description:in HH5
Q9P2D1	699	Natural variant	S	1.0	description:in CHARGES; unknown pathological significance
Q9P2D1	699	Natural variant	S	1.0	description:in CHARGES; unknown pathological significance
Q9P2D1	728	Natural variant	D	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	758	Natural variant	R	1.0	description:in HH5; dbSNP
Q9P2D1	942	Natural variant	T	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	944	Natural variant	R	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	944	Natural variant	R	1.0	description:in HH5; dbSNP
Q9P2D1	947	Natural variant	R	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	1576	Natural variant	F	1.0	description:in CHARGES; unknown pathological significance
Q9P2D1	1592	Natural variant	R	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	1684	Natural variant	G	1.0	description:in CHARGES and HH5; dbSNP
Q9P2D1	1838	Natural variant	M	1.0	description:in HH5; dbSNP
Q9P2D1	1866	Natural variant	D	1.0	description:in CHARGES; unknown pathological significance
Q9P2D1	2259	Natural variant	A	1.0	description:in CHARGES and HH5; unknown pathological significance; dbSNP
Q9P2D1	2286	Natural variant	G	1.0	description:in CHARGES
Q9P2D1	2366	Natural variant	L	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	2398	Natural variant	R	1.0	description:in HH5
Q9P2D1	2418	Natural variant	R	1.0	description:in CHARGES
Q9P2D1	2464	Natural variant	K	1.0	description:in CHARGES; unknown pathological significance
Q9P2D1	2495	Natural variant	R	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	2683	Natural variant	P	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	2702	Natural variant	R	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	2733	Natural variant	A	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	2833	Natural variant	Q	1.0	description:in HH5
Q9P2D1	2880	Natural variant	P	1.0	description:in HH5; phenotype consistent with normosmic idiopathic hypogonadotropic hypogonadism; dbSNP
Q9P2D1	2931	Natural variant	V	1.0	description:in CHARGES; unknown pathological significance; dbSNP
Q9P2D1	2948	Natural variant	K	1.0	description:in HH5; phenotype consistent with Kallmann syndrome; dbSNP
Q03692	18	Natural variant	G	1.0	description:in SMCD; dbSNP
Q03692	18	Natural variant	G	1.0	description:in SMCD; dbSNP
O14810	128	Natural variant	L	1.0	description:in DEE63; unknown pathological significance; dbSNP
Q05397	793	Natural variant	V	1.0	description:in a glioblastoma multiforme sample; somatic mutation
O14497	1658	Natural variant	R	1.0	description:found in a gastric cancer sample; somatic mutation; dbSNP
O14497	1907	Natural variant	I	1.0	description:found in a breast cancer sample; somatic mutation; dbSNP
P62952	2	Natural variant	Y	1.0	description:in RNA edited version; dbSNP
P62952	5	Natural variant	Q	1.0	description:in RNA edited version
P62952	15	Natural variant	K	1.0	description:in RNA edited version; dbSNP
Q9UQN3	104	Natural variant	T	1.0	description:in FTDALS7; cells expressing the mutant protein have large cytoplasmic vacuoles with an accumulation of the mutant protein on the outer membrane termed halos; cells with the mutant protein also have aberrant localization of CD63 and an increase in MAP1LC3A overall indicating a defect in the autophagic pathway; dbSNP
Q9UQN3	148	Natural variant	D	1.0	description:in FTDALS7; dbSNP
Q9UQN3	206	Natural variant	Q	1.0	description:in FTDALS7; cells expressing the mutant protein have large cytoplasmic vacuoles with an accumulation of the mutant protein on the outer membrane termed halos; cells with the mutant protein also have aberrant localization of CD63 and an increase in MAP1LC3A overall indicating a defect in the autophagic pathway; dbSNP
Q14050	35	Natural variant	G	1.0	description:in EDM3; dbSNP
Q14050	103	Natural variant	R	1.0	description:associated with an increased risk for intervertebral disk disease; dbSNP
P82279	27	Natural variant	C	1.0	description:in RP12; dbSNP
P82279	45	Natural variant	C	1.0	description:in RP12; dbSNP
P82279	1381	Natural variant	P	1.0	description:in LCA8
P82279	1383	Natural variant	R	1.0	description:in RP12; dbSNP
P02511	154	Natural variant	G	1.0	description:in CMD1II; dbSNP
P02511	157	Natural variant	R	1.0	description:in CMD1II; dbSNP
P02511	171	Natural variant	A	1.0	description:in CTRCT16; unknown pathological significance; dbSNP
Q8N1I0	1718	Natural variant	P	1.0	description:found in prostate and ovarian cancer cell lines; abolishes ability to interact with CRK and to activate Rap1
Q8N1I0	1755	Natural variant	S	1.0	description:found in colorectal cancer cell line
Q8N1I0	1884	Natural variant	V	1.0	description:found in a prostate cancer cell line; dbSNP
Q15054	194	Natural variant	G	1.0	description:found in a renal cell carcinoma sample; somatic mutation
Q15054	195	Natural variant	M	1.0	description:found in a renal cell carcinoma sample; somatic mutation
Q96ND0	82	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q969F0	10	Natural variant	A	1.0	description:16% of the population; infertile and fertile individuals; dbSNP
Q969F0	34	Natural variant	I	1.0	description:in fertile and infertile individuals
Q6QHK4	140	Natural variant	N	1.0	description:in POF6; one individual with premature ovarian failure
Q6UX39	78	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
O15075	29	Natural variant	G	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
O15075	291	Natural variant	S	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
Q68CQ4	67	Natural variant	Q	1.0	description:decreases degradation of p53/TP53; dbSNP
Q68CQ4	111	Natural variant	G	1.0	description:decreases degradation of p53/TP53; dbSNP
Q13609	19	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q7L5A8	35	Natural variant	D	1.0	description:in SPG35; patients present spastic paraparesis associated with leukodystrophy and dystonia; dbSNP
Q14320	137	Natural variant	A	1.0	description:likely benign variant; it rescues craniofacial patterning defects in zebrafish morphant embryos; dbSNP
Q14320	143	Natural variant	E	1.0	description:likely benign variant; it rescues craniofacial patterning defects in zebrafish morphant embryos; dbSNP
Q9UM73	877	Natural variant	A	1.0	description:in an ovarian serous carcinoma sample; somatic mutation; dbSNP
Q8WXI3	19	Natural variant	D	1.0	description:in GLC1F; uncertain pathological significance; dbSNP
Q8WXI3	32	Natural variant	S	1.0	description:in GLC1F; uncertain pathological significance; dbSNP
Q8WXI3	39	Natural variant	L	1.0	description:in GLC1F; uncertain pathological significance; dbSNP
Q8WXI3	48	Natural variant	T	1.0	description:in GLC1F; uncertain pathological significance; dbSNP
P22748	12	Natural variant	A	1.0	description:in RP17; dbSNP
P22748	14	Natural variant	R	1.0	description:in RP17; abolishes interaction with SLC4A4; impaired SLC4A4 cotransporter activity stimulation; dbSNP
P13942	621	Natural variant	P	1.0	description:in DFNB53; dbSNP
P13942	661	Natural variant	G	1.0	description:in OSMEDB; dbSNP
P13942	808	Natural variant	G	1.0	description:in DFNA13; dbSNP
P13942	888	Natural variant	P	1.0	description:in DFNB53; dbSNP
P13942	1034	Natural variant	R	1.0	description:in DFNA13; dbSNP
P13942	1441	Natural variant	G	1.0	description:in OSMEDA; dbSNP
P02461	183	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	183	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	183	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	192	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	201	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	204	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	204	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	210	Natural variant	G	1.0	description:in EDSVASC
P02461	219	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	225	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	228	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	240	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	243	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	249	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	249	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	252	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	252	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	252	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	255	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	264	Natural variant	G	1.0	description:in EDSVASC
P02461	267	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	297	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	303	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	321	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	327	Natural variant	G	1.0	description:in EDSVASC
P02461	345	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	417	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	420	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P02461	444	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	489	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	501	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	519	Natural variant	G	1.0	description:in EDSVASC
P02461	540	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	549	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	552	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	567	Natural variant	G	1.0	description:in EDSVASC
P02461	582	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	588	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	636	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	657	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	660	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	666	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	699	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	726	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	738	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	738	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	744	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	756	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	762	Natural variant	G	1.0	description:in EDSVASC
P02461	786	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	804	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	828	Natural variant	G	1.0	description:in EDSVASC
P02461	828	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	852	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	879	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	882	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	900	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	903	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	909	Natural variant	G	1.0	description:in EDSVASC
P02461	909	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	918	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	924	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	936	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	936	Natural variant	G	1.0	description:in EDSVASC
P02461	939	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	942	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	957	Natural variant	G	1.0	description:in EDSVASC; severe variant; dbSNP
P02461	960	Natural variant	G	1.0	description:in EDSVASC; severe variant; dbSNP
P02461	966	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	972	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	984	Natural variant	G	1.0	description:in EDSVASC; requires 2 nucleotide substitutions; dbSNP
P02461	996	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	999	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1011	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1014	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1032	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1035	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1044	Natural variant	G	1.0	description:in EDSVASC
P02461	1050	Natural variant	G	1.0	description:in EDSVASC; mild variant; dbSNP
P02461	1050	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1071	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1077	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1089	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1098	Natural variant	G	1.0	description:in EDSVASC
P02461	1098	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1101	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1104	Natural variant	G	1.0	description:in EDSVASC
P02461	1161	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1164	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1164	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1164	Natural variant	G	1.0	description:in spondyloepiphyseal dysplasia
P02461	1167	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1170	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1170	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1173	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1173	Natural variant	G	1.0	description:in EDSVASC; Gottron type acrogeria; dbSNP
P02461	1176	Natural variant	G	1.0	description:in EDSVASC; severe
P02461	1179	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1182	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1185	Natural variant	G	1.0	description:in EDSVASC; severe variant; dbSNP
P02461	1185	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P02461	1188	Natural variant	G	1.0	description:in EDSVASC; severe variant; dbSNP
P02461	1188	Natural variant	G	1.0	description:in EDSVASC; dbSNP
P24468	75	Natural variant	Q	1.0	description:in CHTD4; the mutation results in reduced transcription activation of the EGR1 promoter; does not affect transcription activation of the APOBFT promoter
Q2NKJ3	503	Natural variant	G	1.0	description:in CRMCC1; dbSNP
Q9UQB3	34	Natural variant	G	1.0	description:probable disease-associated variant found in autism; hypomorphic variant affecting dendritic spines development and maintenance; results in reduced interaction with CTNNB1; dbSNP
Q9UQB3	189	Natural variant	P	1.0	description:probable disease-associated variant found in autism; hypomorphic variant affecting Wnt signaling; dbSNP
Q9UQB3	224	Natural variant	P	1.0	description:probable disease-associated variant found in autism; hypomorphic variant affecting Wnt signaling; dbSNP
Q9UQB3	275	Natural variant	G	1.0	description:found in patients with autism; unknown pathological significance; has no effect on Wnt signaling; dbSNP
Q9UQB3	330	Natural variant	R	1.0	description:has no effect on Wnt signaling; dbSNP
Q9UQB3	454	Natural variant	R	1.0	description:probable disease-associated variant found in autism; hypomorphic variant affecting Wnt signaling; dbSNP
Q9UQB3	465	Natural variant	D	1.0	description:has no effect on Wnt signaling; dbSNP
Q9UQB3	482	Natural variant	A	1.0	description:has no effect on Wnt signaling; dbSNP
Q9UQB3	507	Natural variant	Q	1.0	description:probable disease-associated variant found in autism; hypomorphic variant affecting Wnt signaling; dbSNP
Q9UQB3	810	Natural variant	G	1.0	description:has no effect on Wnt signaling; dbSNP
Q9UQB3	1159	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation
P22455	772	Natural variant	S	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation
O95876	54	Natural variant	D	1.0	description:in CHDTHP; impairs protein stability; dbSNP
O95876	55	Natural variant	R	1.0	description:in a patient with Meckel syndrome compound heterozygous for mutations in CC2D2A; dbSNP
Q92908	91	Natural variant	P	1.0	description:probable disease-associated variant found in patients with atrial fibrillation; gain of function; no effect on subcellular localization; dbSNP
Q92908	177	Natural variant	A	1.0	description:probable disease-associated variant found in patients with atrial fibrillation; gain of function; no effect on subcellular localization; dbSNP
Q92908	178	Natural variant	A	1.0	description:in AVSD5; increased transcriptional activity; dbSNP
Q92908	184	Natural variant	S	1.0	description:in ASD9 and TOF; loss of transcriptional activity; dbSNP
Q92908	198	Natural variant	L	1.0	description:in TOF; uncertain pathological significance; does not affect transcriptional activity; dbSNP
Q92908	235	Natural variant	Y	1.0	description:probable disease-associated variant found in patients with atrial fibrillation; significant loss of transcriptional activator activity
Q92908	543	Natural variant	A	1.0	description:probable disease-associated variant found in patients with atrial fibrillation; gain of function; no effect on subcellular localization; dbSNP
Q92908	585	Natural variant	R	1.0	description:probable disease-associated variant found in patients with atrial fibrillation; gain of function; no effect on subcellular localization; dbSNP
O95996	2003	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q13510	22	Natural variant	Q	1.0	description:in FRBRL
Q13510	23	Natural variant	H	1.0	description:in FRBRL
P02452	22	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	146	Natural variant	P	1.0	description:in OI2; rare variant; unknown pathological significance; dbSNP
P02452	188	Natural variant	G	1.0	description:in OIEDS1; decreased N-terminal propeptide processing; dbSNP
P02452	191	Natural variant	G	1.0	description:in OIEDS1; severely decreased cleavage of N-terminal propeptide; affects collagen fibril organization; collagen dermal fibrils in patients have smaller diameters than in age-matched controls; dbSNP
P02452	194	Natural variant	G	1.0	description:in OI1; dbSNP
P02452	197	Natural variant	G	1.0	description:in OI4
P02452	200	Natural variant	G	1.0	description:in OI1; patient diagnosed with OI1/OI4; dbSNP
P02452	203	Natural variant	G	1.0	description:in OIEDS1
P02452	203	Natural variant	G	1.0	description:in OI3 and OIEDS1; small decrease of N-terminal propeptide; affects collagen fibril organization; collagen dermal fibrils in patients have smaller diameters than in age-matched controls; dbSNP
P02452	212	Natural variant	G	1.0	description:in OIEDS1; small decrease of N-terminal propeptide; affects collagen fibril organization; collagen dermal fibrils in patients have smaller diameters than in age-matched controls; dbSNP
P02452	221	Natural variant	G	1.0	description:in OI1; mild form; dbSNP
P02452	224	Natural variant	G	1.0	description:in OI1; mild phenotype; dbSNP
P02452	242	Natural variant	G	1.0	description:in OI; dbSNP
P02452	254	Natural variant	G	1.0	description:in OIEDS1; affects collagen fibril organization; collagen dermal fibrils in patients have smaller diameters than in age-matched controls; dbSNP
P02452	257	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	263	Natural variant	G	1.0	description:in OI1; mild form; dbSNP
P02452	263	Natural variant	G	1.0	description:in OI1; mild form; dbSNP
P02452	266	Natural variant	G	1.0	description:in OI1 and OIEDS1; affects collagen fibril organization; collagen dermal fibrils in patients have smaller diameters than in age-matched controls; dbSNP
P02452	272	Natural variant	G	1.0	description:in OI1; dbSNP
P02452	275	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	287	Natural variant	G	1.0	description:in OI1; dbSNP
P02452	288	Natural variant	E	1.0	description:in OI1; the patient also has mutation Glu-1219; unknown pathological significance; dbSNP
P02452	288	Natural variant	E	1.0	description:in OI2; rare variant; unknown pathological significance
P02452	312	Natural variant	R	1.0	description:in EDSCL1; dbSNP
P02452	320	Natural variant	G	1.0	description:in OI1; dbSNP
P02452	332	Natural variant	G	1.0	description:in OI3; mild to moderate form; dbSNP
P02452	338	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	349	Natural variant	V	1.0	description:in OI1; dbSNP
P02452	350	Natural variant	G	1.0	description:in OI3; dbSNP
P02452	353	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	353	Natural variant	G	1.0	description:in OI2
P02452	353	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	356	Natural variant	G	1.0	description:in OI4; mild form; dbSNP
P02452	368	Natural variant	G	1.0	description:in OI2
P02452	383	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	389	Natural variant	G	1.0	description:in OI; moderate form; dbSNP
P02452	389	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	390	Natural variant	A	1.0	description:in OI2; rare variant; unknown pathological significance; dbSNP
P02452	398	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	398	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	401	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	404	Natural variant	G	1.0	description:in OI; moderate form; dbSNP
P02452	422	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	425	Natural variant	G	1.0	description:in OI2; lethal form; dbSNP
P02452	434	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	455	Natural variant	G	1.0	description:in OI2
P02452	470	Natural variant	G	1.0	description:in OI2
P02452	476	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	509	Natural variant	G	1.0	description:in OI2
P02452	527	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	530	Natural variant	G	1.0	description:in OI2, OI3 and OI4; mild to lethal form; dbSNP
P02452	533	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	548	Natural variant	G	1.0	description:in OI2
P02452	555	Natural variant	P	1.0	description:in OI1; dbSNP
P02452	560	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	560	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	560	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	569	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	574	Natural variant	R	1.0	description:found in a patient with isolated osteopenia and vascular rupture; unknown pathological significance; dbSNP
P02452	581	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	593	Natural variant	G	1.0	description:in OI3 and OI4; dbSNP
P02452	593	Natural variant	G	1.0	description:in OI2 and OI3; moderate to lethal form; dbSNP
P02452	602	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	605	Natural variant	G	1.0	description:in OI2
P02452	614	Natural variant	G	1.0	description:in OI2
P02452	647	Natural variant	G	1.0	description:in OI1; dbSNP
P02452	656	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	683	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	701	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	704	Natural variant	G	1.0	description:in OI3; dbSNP
P02452	719	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	719	Natural variant	G	1.0	description:in OI3; dbSNP
P02452	722	Natural variant	G	1.0	description:in OI1; dbSNP
P02452	728	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	734	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	737	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	740	Natural variant	G	1.0	description:in OI2
P02452	743	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	743	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	764	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	767	Natural variant	G	1.0	description:in OI3; severe; dbSNP
P02452	773	Natural variant	G	1.0	description:in OI2; de novo mutation
P02452	776	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	809	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	815	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	821	Natural variant	G	1.0	description:in OI3; dbSNP
P02452	824	Natural variant	G	1.0	description:in OI2
P02452	833	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	839	Natural variant	G	1.0	description:in OI2; mild to moderate form; dbSNP
P02452	842	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	845	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	848	Natural variant	G	1.0	description:in OI2
P02452	851	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	855	Natural variant	N	1.0	description:in OI2; rare variant; unknown pathological significance
P02452	866	Natural variant	G	1.0	description:in OI3 and OI2; dbSNP
P02452	869	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	875	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	884	Natural variant	G	1.0	description:in OI2 and OI3; extremely severe form; dbSNP
P02452	896	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	896	Natural variant	G	1.0	description:in OI2
P02452	906	Natural variant	G	1.0	description:found in a patient with mild osteogenesis imperfecta; uncertain pathological significance; dbSNP
P02452	926	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	947	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	977	Natural variant	G	1.0	description:in OI2
P02452	980	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1001	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1010	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	1014	Natural variant	R	1.0	description:in CAFYD; dbSNP
P02452	1022	Natural variant	G	1.0	description:in OI3; severe form; dbSNP
P02452	1022	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1025	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1040	Natural variant	G	1.0	description:in OI2 and OI3; moderate to lethal form; dbSNP
P02452	1043	Natural variant	G	1.0	description:in OI2
P02452	1049	Natural variant	G	1.0	description:in OI3; dbSNP
P02452	1052	Natural variant	G	1.0	description:in OI2
P02452	1055	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1058	Natural variant	G	1.0	description:in OI3 and OI4; mild form; dbSNP
P02452	1061	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1061	Natural variant	G	1.0	description:in OI4; dbSNP
P02452	1066	Natural variant	R	1.0	description:in OIEDS1; affects dimer formation, helix stability and organization of collagen fibrils; dbSNP
P02452	1076	Natural variant	G	1.0	description:in OI3; severe form; dbSNP
P02452	1079	Natural variant	G	1.0	description:in OI1 and OI2; mild to moderate form; dbSNP
P02452	1082	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1088	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1088	Natural variant	G	1.0	description:in OI1; de novo mutation; unknown pathological significance
P02452	1091	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1093	Natural variant	R	1.0	description:found in a patient with isolated osteopenia and vascular rupture; unknown pathological significance; dbSNP
P02452	1094	Natural variant	G	1.0	description:in OI2
P02452	1100	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1106	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1124	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1142	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1151	Natural variant	G	1.0	description:in OI3; dbSNP
P02452	1151	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1154	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1157	Natural variant	G	1.0	description:in OI1; dbSNP
P02452	1166	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1172	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1181	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1184	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1187	Natural variant	G	1.0	description:in OI2 and OI3; extremely severe form; dbSNP
P02452	1187	Natural variant	G	1.0	description:in OI2; dbSNP
P02452	1195	Natural variant	G	1.0	description:in OI1; mild form; dbSNP
Q9Y6Y1	1473	Natural variant	S	1.0	description:found in patients with late onset progressive myoclonus epilepsy; unknown pathological significance; dbSNP
A5YKK6	642	Natural variant	Q	1.0	description:in VIBOS; uncertain pathological significance
A5YKK6	1038	Natural variant	T	1.0	description:in VIBOS; uncertain pathological significance
Q9H799	2684	Natural variant	S	1.0	description:in JBTS17
Q9H799	2837	Natural variant	V	1.0	description:in OFD6
Q14203	196	Natural variant	I	1.0	description:no effect of its interaction with TBCB; no loss of localization to microtubules; dbSNP
Q14203	1101	Natural variant	R	1.0	description:in ALS; associated with disease susceptibility; dbSNP
P11532	334	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation
P11532	3421	Natural variant	A	1.0	description:in BMD
Q9NVP1	41	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q01362	237	Natural variant	E	1.0	description:risk factor for atopic dermatitis and asthma; dbSNP
P55075	14	Natural variant	H	1.0	description:in HH6; phenotype consistent with normosmic idiopathic hypogonadotropic hypogonadism; dbSNP
P55075	26	Natural variant	P	1.0	description:in HH6; phenotype consistent with Kallmann syndrome; dbSNP
P55075	218	Natural variant	T	1.0	description:in HH6; phenotype consistent with normosmic idiopathic hypogonadotropic hypogonadism; dbSNP
P37023	111	Natural variant	E	1.0	description:no loss of receptor activity in response to BMP9; mutant protein is capable of targeting the cell surface appropriately; dbSNP
Q9Y4W6	74	Natural variant	E	1.0	description:in OPA12; unknown pathological significance
P10275	2	Natural variant	E	1.0	description:in PAIS; dbSNP
P10275	54	Natural variant	L	1.0	description:in prostate cancer
P10275	57	Natural variant	L	1.0	description:in prostate cancer; dbSNP
P10275	64	Natural variant	Q	1.0	description:in prostate cancer
P10275	114	Natural variant	Q	1.0	description:in prostate cancer
P10275	182	Natural variant	K	1.0	description:in prostate cancer
P10275	196	Natural variant	Q	1.0	description:in AIS
P10275	216	Natural variant	G	1.0	description:20% lower transactivation capacity; dbSNP
P10275	257	Natural variant	L	1.0	description:in AIS
P10275	268	Natural variant	M	1.0	description:in prostate cancer
P10275	271	Natural variant	P	1.0	description:in prostate cancer
P10275	342	Natural variant	P	1.0	description:in prostate cancer; dbSNP
P10275	392	Natural variant	P	1.0	description:in AIS; dbSNP
P10275	392	Natural variant	P	1.0	description:in AIS; dbSNP
P10275	445	Natural variant	Q	1.0	description:in AIS; unknown pathological significance; dbSNP
P10275	492	Natural variant	G	1.0	description:in AIS
P10275	529	Natural variant	D	1.0	description:in prostate cancer
P10275	648	Natural variant	S	1.0	description:in prostate cancer; dbSNP
Q6NZI2	14	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q4KMG0	684	Natural variant	T	1.0	description:in HPE11; benign variant; dbSNP
Q4KMG0	689	Natural variant	P	1.0	description:in HPE11; dbSNP
Q4KMG0	691	Natural variant	V	1.0	description:in HPE11; dbSNP
Q4KMG0	940	Natural variant	S	1.0	description:in HPE11; dbSNP
Q9BR76	411	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q53TN4	226	Natural variant	R	1.0	description:in some patients with hereditary hemochromatosis; dbSNP
P08034	230	Natural variant	R	1.0	description:in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques; dbSNP
P08034	230	Natural variant	R	1.0	description:in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques; dbSNP
P08034	235	Natural variant	F	1.0	description:in CMTX1; the mutation causes abnormal hemichannel opening with excessive permeability of the plasma membrane and decreased cell survival; dbSNP
P08034	238	Natural variant	R	1.0	description:in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques; dbSNP
P08034	239	Natural variant	L	1.0	description:in CMTX1; localized mainly on the cell membrane forming gap junction-like plaques
P08034	264	Natural variant	R	1.0	description:in CMTX1; dbSNP
P08034	280	Natural variant	C	1.0	description:in CMTX1; forms channels normally
O14681	319	Natural variant	T	1.0	description:in some patients with early onset breast cancer; dbSNP
Q8TC76	214	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q8WW38	30	Natural variant	E	1.0	description:in TOF and CTHM; does not affect its ability to interact with GATA4; dbSNP
Q8WW38	402	Natural variant	S	1.0	description:in SRXY9; results in reduced transactivation activity on the AMH promoter; abolished its ability to interact with GATA4; dbSNP
Q8WW38	544	Natural variant	M	1.0	description:in SRXY9 and TOF; reduced its ability to interact with GATA4; dbSNP
Q8WW38	657	Natural variant	S	1.0	description:in TOF; slightly impairs its ability to interact with GATA4; dbSNP
Q86XK2	138	Natural variant	R	1.0	description:in IDDFBA; dbSNP
Q86XK2	905	Natural variant	P	1.0	description:in IDDFBA; dbSNP
Q86XK2	910	Natural variant	D	1.0	description:in IDDFBA; dbSNP
Q14155	790	Natural variant	T	1.0	description:found in a clear cell renal carcinoma case; somatic mutation
O95817	71	Natural variant	R	1.0	description:in CMD1HH; dbSNP
O95817	209	Natural variant	P	1.0	description:in MFM6; interferes with the differentiation of skeletal muscle cells; does not cause functional alterations in cardiomyocyte cells; dbSNP
O95817	218	Natural variant	R	1.0	description:in CMD1HH; interferes with the assembly of Z-disks; increases stress-induced apoptosis; dbSNP
O95817	258	Natural variant	R	1.0	description:no functional consequences; dbSNP
P35520	18	Natural variant	R	1.0	description:associated with 1/3 to 2/3 the enzyme activity of the wild-type; dbSNP
P35520	49	Natural variant	P	1.0	description:in CBSD; decreased expression; no effect on cystathionine beta-synthase activity; increased homotetramer formation; dbSNP
P35520	58	Natural variant	R	1.0	description:in CBSD; linked with V-114; 18% of activity; dbSNP
P35520	65	Natural variant	H	1.0	description:in CBSD; decreased cystathionine beta-synthase activity; inhibited by AdoMet and AdoHcy; decreased homotetramer formation; dbSNP
P25063	57	Natural variant	A	1.0	description:may be associated with an increased risk for multiple sclerosis; homozygous patients express higher levels of CD24 on peripheral blood T-cells than homozygous controls; dbSNP
Q01955	297	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	407	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	532	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	631	Natural variant	G	1.0	description:in ATS2; unknown pathological significance; dbSNP
Q01955	640	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	739	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	853	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	985	Natural variant	G	1.0	description:in BFH; dbSNP
Q01955	1015	Natural variant	G	1.0	description:in BFH; dbSNP
Q01955	1167	Natural variant	G	1.0	description:in ATS3; in isolated microhematuria at heterozygosity; dbSNP
Q01955	1207	Natural variant	G	1.0	description:in ATS2; in isolated microhematuria at heterozygosity; dbSNP
Q01955	1215	Natural variant	R	1.0	description:in ATS2; unknown pathological significance; dbSNP
Q01955	1216	Natural variant	G	1.0	description:in ATS2
Q01955	1277	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	1330	Natural variant	I	1.0	description:in ATS2; unknown pathological significance; dbSNP
Q01955	1334	Natural variant	G	1.0	description:in ATS2; dbSNP
Q01955	1347	Natural variant	D	1.0	description:in ATS2; unknown pathological significance; dbSNP
Q16281	162	Natural variant	D	1.0	description:in ACHM2; dbSNP
Q9P021	3	Natural variant	C	1.0	description:in SSMCF; dbSNP
O75398	186	Natural variant	E	1.0	description:in a primary colorectal cancer; dbSNP
O75398	191	Natural variant	K	1.0	description:in a primary colorectal cancer
O75398	191	Natural variant	K	1.0	description:in a primary colorectal cancer
O75398	356	Natural variant	E	1.0	description:in a primary colorectal cancer; requires 2 nucleotide substitutions
O75398	364	Natural variant	S	1.0	description:in a primary colorectal cancer
O75398	367	Natural variant	Q	1.0	description:in a primary colorectal cancer
O75398	370	Natural variant	V	1.0	description:in a primary colorectal cancer
O75398	397	Natural variant	Y	1.0	description:in a primary colorectal cancer
O75398	442	Natural variant	V	1.0	description:in a primary colorectal cancer
O75398	545	Natural variant	A	1.0	description:in a primary colorectal cancer; dbSNP
O75398	545	Natural variant	A	1.0	description:in a primary colorectal cancer
P08246	25	Natural variant	A	1.0	description:in SCN1; dbSNP
P08246	262	Natural variant	P	1.0	description:found in patients with severe congenital or cyclic neutropenia; dbSNP
Q16394	27	Natural variant	Q	1.0	description:in EXT1; no loss of activity
P06727	367	Natural variant	T	1.0	description:in allele APOA-IV*1A and allele Budapest-1; dbSNP
P06727	380	Natural variant	Q	1.0	description:in allele APOA-IV*2 and allele APOA-IV*0A; associated with E-187 in allele APOA-IV*0A; dbSNP
P06727	381	Natural variant	Q	1.0	description:in allele APOA-IV*0 and allele APOA-IV*5; allele APOA-IV*5 is further defined by a silent nucleotide substitution
Q8IZP9	64	Natural variant	N	1.0	description:found in a family with intellectual disability; unknown pathological significance; dbSNP
Q9HCE6	96	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P13637	220	Natural variant	D	1.0	description:in AHC2; no effect on ATPase activity; dbSNP
O14965	57	Natural variant	I	1.0	description:increased kinase activity; dbSNP
O60566	15	Natural variant	M	1.0	description:in a colorectal cancer cell line; dbSNP
O60566	550	Natural variant	R	1.0	description:in MVA1; heterozygous compound with nonsense mutation; dbSNP
P00915	254	Natural variant	G	1.0	description:in Guam; dbSNP
Q9P2H0	668	Natural variant	G	1.0	description:may be associated with susceptibility to monomelic amyotrophy; dbSNP
Q9NZW4	6	Natural variant	Y	1.0	description:in DTDP2; the mutant protein does not translocate into the endoplasmic reticulum; dbSNP
Q9NZW4	15	Natural variant	A	1.0	description:in DGI2; dominant negative mutation; results in signal peptide retention; the mutant protein is retained within the rough ER membrane; dbSNP
Q9NZW4	17	Natural variant	P	1.0	description:in DGI3; the mutant protein is largely retained in the ER
Q9NZW4	17	Natural variant	P	1.0	description:in DGI2 and DGI3; dominant negative mutation; the mutant protein is retained intracellularly; dbSNP
Q9NZW4	17	Natural variant	P	1.0	description:in DFNA39/DGI1; dominant negative mutation; the mutant protein is retained intracellularly; dbSNP
Q9NZW4	18	Natural variant	V	1.0	description:in DGI2; dominant negative mutation; the mutant protein is retained intracellularly
Q9NZW4	18	Natural variant	V	1.0	description:in DFNA39/DGI1 and DGI3; dbSNP
Q9NZW4	68	Natural variant	R	1.0	description:in DGI2; dbSNP
P21860	1337	Natural variant	A	1.0	description:in FERLK; risk factor for erythroleukemia; results in increased ERBB-mediated signaling; results in a block of erythroid differentiation and increased cell proliferation; dbSNP
A6ND36	630	Natural variant	R	1.0	description:found in patient with Joubert syndrome; unknown pathological significance; dbSNP
Q9UI08	188	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9UI08	247	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation
P19235	487	Natural variant	N	1.0	description:in ECYT1 and erythroleukemia; dbSNP
P30154	8	Natural variant	G	1.0	description:in a lung cancer patient; dbSNP
P30154	15	Natural variant	G	1.0	description:in a colorectal cancer patient
Q16671	142	Natural variant	G	1.0	description:in PMDS2
Q6NTF7	15	Natural variant	N	1.0	description:decreases protein stability
Q99490	339	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
Q99490	651	Natural variant	A	1.0	description:in a glioblastoma cell line
Q99490	767	Natural variant	E	1.0	description:in a glioblastoma cell line
Q99490	816	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q99490	1022	Natural variant	S	1.0	description:in a glioblastoma cell line
Q13023	910	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
Q13023	1702	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q13023	1839	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q96QF7	17	Natural variant	D	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	76	Natural variant	V	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	102	Natural variant	S	1.0	description:in SPGFX4; unknown pathological significance
Q96QF7	182	Natural variant	N	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	189	Natural variant	P	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	218	Natural variant	K	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	218	Natural variant	K	1.0	description:in SPGFX4; unknown pathological significance; requires 2 nucleotide substitutions
Q96QF7	285	Natural variant	S	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	295	Natural variant	S	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	441	Natural variant	R	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
Q96QF7	465	Natural variant	T	1.0	description:in SPGFX4; unknown pathological significance; dbSNP
P23508	486	Natural variant	P	1.0	description:in a colorectal cancer sample; dbSNP
P23508	490	Natural variant	S	1.0	description:in a colorectal cancer sample; dbSNP
P23508	506	Natural variant	R	1.0	description:in colorectal cancer samples; somatic mutation; decreased binding to CCAR2; significant decrease in its ability to induce the relocalization of CCAR2 to the cytoplasm; loss of its ability to repress the beta-catenin pathway; loss of its ability to induce the SIRT1-mediated deacetylation of beta-catenin; dbSNP
P23508	698	Natural variant	A	1.0	description:in colorectal cancer samples; somatic mutation; dbSNP
Q6XLA1	8	Natural variant	P	1.0	description:in some patients with endometrial cancer
P35222	23	Natural variant	S	1.0	description:in hepatocellular carcinoma; no effect; dbSNP
P35222	32	Natural variant	D	1.0	description:in hepatocellular carcinoma; dbSNP
P35222	32	Natural variant	D	1.0	description:in PTR and hepatocellular carcinoma; dbSNP
P35222	32	Natural variant	D	1.0	description:in PTR, hepatoblastoma and hepatocellular carcinoma; dbSNP
P35222	33	Natural variant	S	1.0	description:in PTR, MDB and hepatocellular carcinoma; dbSNP
P35222	33	Natural variant	S	1.0	description:in hepatocellular carcinoma
P35222	33	Natural variant	S	1.0	description:in colorectal cancer and PTR; constitutively active Wnt signaling pathway; enhances transactivation of target genes; dbSNP
P35222	34	Natural variant	G	1.0	description:in PTR; dbSNP
P35222	34	Natural variant	G	1.0	description:in hepatocellular carcinoma; dbSNP
P35222	34	Natural variant	G	1.0	description:in hepatoblastoma; dbSNP
P35222	35	Natural variant	I	1.0	description:in hepatocellular carcinoma
P35222	37	Natural variant	S	1.0	description:in MDB and hepatocellular carcinoma; enhances transactivation of target genes; dbSNP
P35222	37	Natural variant	S	1.0	description:in PTR, hepatoblastoma and ovarian cancer; dbSNP
P35222	37	Natural variant	S	1.0	description:in PTR; dbSNP
P35222	37	Natural variant	S	1.0	description:in hepatocellular carcinoma; dbSNP
P35222	41	Natural variant	T	1.0	description:in hepatoblastoma and hepatocellular carcinoma; also in a desmoid tumor; strongly reduces phosphorylation and degradation; abolishes phosphorylation on Ser-33 and Ser-37 and enhances transactivation of target genes; dbSNP
P35222	41	Natural variant	T	1.0	description:in PTR, hepatocellular carcinoma and ovarian cancer; dbSNP
P35222	45	Natural variant	S	1.0	description:in hepatocellular carcinoma; dbSNP
P35222	45	Natural variant	S	1.0	description:in hepatocellular carcinoma; dbSNP
P35222	45	Natural variant	S	1.0	description:in colorectal cancer
P35222	710	Natural variant	R	1.0	description:in EVR7; unknown pathological significance; dbSNP
P51530	227	Natural variant	K	1.0	description:in PEOA6; the mutant protein has significantly reduced nuclease and helicase activity; consistent with a loss of function mutation; dbSNP
Q13316	117	Natural variant	D	1.0	description:in one individual with tumoral calcinosis; dbSNP
P55265	193	Natural variant	P	1.0	description:in AGS6; dbSNP
P55265	999	Natural variant	K	1.0	description:in AGS6; dbSNP
P55265	1007	Natural variant	G	1.0	description:in AGS6; dbSNP
Q9UQ84	410	Natural variant	L	1.0	description:abrogates exonuclease activity; dbSNP
Q9UQ84	439	Natural variant	T	1.0	description:may be associated with an increased risk of colorectal cancer; dbSNP
Q9UQ84	640	Natural variant	P	1.0	description:reduces interaction with MSH2; abrogates interaction with MSH2; when associated with L-770; dbSNP
Q9UQ84	757	Natural variant	P	1.0	description:may be associated with a reduced risk of colorectal cancer; dbSNP
Q9UQ84	759	Natural variant	G	1.0	description:reduces interaction with MSH2; abrogates interaction with MSH2; when associated with L-770; dbSNP
Q9UQ84	770	Natural variant	P	1.0	description:reduces interaction with MSH2; abrogates interaction with MSH2; when associated with S-640 or E-759; dbSNP
Q96AP0	405	Natural variant	P	1.0	description:in DKCB7; localizes properly on telomeres; decreased interaction with TINF2; dbSNP
Q9NP70	11	Natural variant	M	1.0	description:in ameloblastoma
Q9NP70	439	Natural variant	H	1.0	description:in an ameloblastoma sample; dbSNP
Q96C12	731	Natural variant	P	1.0	description:in AIMAH2; dbSNP
Q96C12	736	Natural variant	Y	1.0	description:in AIMAH2; loss of function in promoting apoptosis
Q96C12	754	Natural variant	L	1.0	description:in AIMAH2; loss of function in promoting apoptosis
Q96C12	808	Natural variant	H	1.0	description:in AIMAH2
Q96C12	826	Natural variant	P	1.0	description:in AIMAH2; unknown pathological significance
Q9H251	3138	Natural variant	R	1.0	description:in PITA5; unknown pathological significance; dbSNP
Q9H251	3175	Natural variant	R	1.0	description:in USH1D; dbSNP
Q9H251	3296	Natural variant	D	1.0	description:in PITA5; unknown pathological significance; dbSNP
Q9UNH5	493	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation
Q9Y5P4	132	Natural variant	S	1.0	description:in MRD34; dbSNP
Q9Y5P4	138	Natural variant	S	1.0	description:found in a patient with intellectual disability
Q9BWK5	82	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q6E0U4	13	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
P28715	1078	Natural variant	S	1.0	description:found in a patient diagnosed with multiple sclerosis; unknown pathological significance; dbSNP
P28715	1080	Natural variant	G	1.0	description:requires 2 nucleotide substitutions; dbSNP
P03372	6	Natural variant	H	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P03372	264	Natural variant	M	1.0	description:in a breast cancer sample; somatic mutation
Q9UBZ4	392	Natural variant	N	1.0	description:identified in a patient with mtDNA maintenance disorders; dbSNP
Q68DC2	441	Natural variant	Q	1.0	description:in NPHP16; dbSNP
Q9H8Y5	585	Natural variant	R	1.0	description:found in a patient with infantile-onset inflammatory bowel disease; unknown pathological significance; decreased function in cellular response to hydrogen peroxide; decreased protein abundance; does not affect interaction with VCP; dbSNP
Q5T5A4	28	Natural variant	K	1.0	description:found in patients with an intermediate form of Charcot-Marie-Tooth disease; does not affect subcellular location; reduced protein expression; increased intracellular Ca(2+); dbSNP
P30279	280	Natural variant	T	1.0	description:in MPPH3; dbSNP
P30279	280	Natural variant	T	1.0	description:in MPPH3; dbSNP
P30279	281	Natural variant	P	1.0	description:in MPPH3; dbSNP
P30279	281	Natural variant	P	1.0	description:in MPPH3; dbSNP
P30279	284	Natural variant	V	1.0	description:in MPPH3; dbSNP
Q8N812	26	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
Q96JP9	716	Natural variant	T	1.0	description:found in a patient with Joubert syndrome; unknown pathological significance
P01911	5	Natural variant	K	1.0	description:in allele DRB1*03
P01911	6	Natural variant	L	1.0	description:in allele DRB1*04
P01911	13	Natural variant	T	1.0	description:in allele DRB1*03
P01911	14	Natural variant	A	1.0	description:in allele DRB1*03
P01911	29	Natural variant	S	1.0	description:in allele DRB1*01
P01911	260	Natural variant	Q	1.0	description:in allele DRB1*10
P01911	262	Natural variant	T	1.0	description:in allele DRB1*03
P35523	43	Natural variant	Q	1.0	description:in MCAR; decreased chloride transport; decreased localization to the plasma membrane; dominant negative effect on chloride transport and localization to the plasma membrane; no significant effect on chloride channel activity; no effect on homodimerization; dbSNP
P35523	70	Natural variant	S	1.0	description:in MCAR; unknown pathological significance; no effect on chloride transport; dbSNP
P35523	82	Natural variant	T	1.0	description:in MCAR; unknown pathological significance; no effect on chloride transport; dbSNP
P35523	708	Natural variant	F	1.0	description:in MCAR
P35523	932	Natural variant	P	1.0	description:in MCAR; unknown pathological significance; dbSNP
P35523	947	Natural variant	V	1.0	description:in MCAR; unknown pathological significance
P35523	950	Natural variant	E	1.0	description:in MCAD; unknown pathological significance; dbSNP
Q9Y463	90	Natural variant	H	1.0	description:in AOMS3; expression of glucose-6-phosphatase is significantly higher than wild-type; dbSNP
Q16643	278	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q16643	640	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q92630	198	Natural variant	P	1.0	description:in a glioblastoma multiforme sample; somatic mutation; dbSNP
Q86YF9	24	Natural variant	S	1.0	description:in MVP3; decreased protein stability
P14416	311	Natural variant	S	1.0	description:may be associated with a higher risk for schizophrenia; dbSNP
Q18PE1	469	Natural variant	P	1.0	description:in CMS10; dbSNP
O43918	228	Natural variant	G	1.0	description:in APS1; changes the subcellular localization and in addition disrupts the transactivating capacity of the wild-type AIRE; acts with a dominant negative effect by binding to the wild-type AIRE thus preventing the protein from forming the complexes needed for transactivation; dbSNP
O43918	252	Natural variant	P	1.0	description:in APS1; benign variant; does not affect transcriptional transactivation activity; dbSNP
O43918	484	Natural variant	V	1.0	description:found in a patient with acrofacial vitiligo and gastric parietal cell autoantibodies; unknown pathological significance; dbSNP
O43918	539	Natural variant	P	1.0	description:in APS1; dbSNP
P50995	38	Natural variant	G	1.0	description:in ALS23; unknown pathological significance; changed cytoplasmic localization with decreased association with vesicle-like structures; increased interaction with S100A6; dbSNP
P50995	40	Natural variant	D	1.0	description:in ALS23; forms cytoplasmic aggregates in patient tissues; no effect on nuclear and cytoplasmic localization; loss of interaction with S100A6; dbSNP
P50995	40	Natural variant	D	1.0	description:in IBMWMA
P50995	175	Natural variant	G	1.0	description:in ALS23; unknown pathological significance; dbSNP
P50995	189	Natural variant	G	1.0	description:in ALS23; unknown pathological significance; no effect on aggregation; loss of interaction with S100A6; dbSNP
Q92481	73	Natural variant	P	1.0	description:in CHAR; dbSNP
Q9C0C7	364	Natural variant	L	1.0	description:found in a fetus with encephalocele; unknown pathological significance; reduced induction of autophagy
P03950	12	Natural variant	F	1.0	description:in ALS9
P03950	20	Natural variant	P	1.0	description:in ALS9
P51795	100	Natural variant	R	1.0	description:in DENT1
P03928	55	Natural variant	W	1.0	description:in MC5DM2 and CMHI; dbSNP
O00238	31	Natural variant	R	1.0	description:in AMD3; unknown pathological significance; mouse BMPR1B construct containing this mutation shows reduced GDF5-dependent receptor activation, mouse BMPR1B construct containing this mutation shows no loss of cell membrane localization; dbSNP
O00238	31	Natural variant	R	1.0	description:in a gastric adenocarcinoma sample; somatic mutation; dbSNP
O00238	53	Natural variant	C	1.0	description:in AMD3; mouse BMPR1B construct containing this mutation shows loss of GDF5-dependent receptor activation, chicken BMPR1B construct containing this mutation does not show reduced chondrocyte differentiation, mouse BMPR1B construct containing this mutation shows no loss of cell membrane localization; dbSNP
Q06187	11	Natural variant	L	1.0	description:in XLA; dbSNP
Q06187	12	Natural variant	K	1.0	description:in XLA
Q06187	14	Natural variant	S	1.0	description:in XLA; dbSNP
Q06187	19	Natural variant	K	1.0	description:in XLA
Q06187	25	Natural variant	F	1.0	description:in XLA
Q06187	27	Natural variant	K	1.0	description:in XLA
Q06187	28	Natural variant	R	1.0	description:in XLA; no effect on phosphorylation of GTF2I
Q06187	28	Natural variant	R	1.0	description:in XLA; moderate; dbSNP
Q06187	28	Natural variant	R	1.0	description:in XLA
Q06187	33	Natural variant	T	1.0	description:in XLA; severe; dbSNP
Q06187	39	Natural variant	Y	1.0	description:in XLA
Q06187	40	Natural variant	Y	1.0	description:in XLA; dbSNP
Q06187	40	Natural variant	Y	1.0	description:in XLA
Q06187	61	Natural variant	I	1.0	description:in XLA
Q06187	64	Natural variant	V	1.0	description:in XLA
Q06187	64	Natural variant	V	1.0	description:in XLA
Q06187	184	Natural variant	T	1.0	description:in XLA
Q06187	190	Natural variant	P	1.0	description:in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions
P02746	42	Natural variant	G	1.0	description:in C1QD
P08572	192	Natural variant	V	1.0	description:does not affect COL4A2 and COL4A1 secretion; dbSNP
P08572	701	Natural variant	K	1.0	description:does not affect COL4A2 and COL4A1 secretion; dbSNP
P08572	718	Natural variant	P	1.0	description:does not affect COL4A2 and COL4A1 secretion; dbSNP
P08572	1037	Natural variant	G	1.0	description:in BSVD2; dbSNP
P08572	1109	Natural variant	R	1.0	description:does not affect COL4A2 and COL4A1 secretion; dbSNP
P08572	1123	Natural variant	E	1.0	description:associated with ICH susceptibility; results in a significantly decreased extracellular-to-intracellular ratio of COL4A2 and COL4A1 proteins, indicating interference with the proper secretion of both these proteins; dbSNP
P08572	1150	Natural variant	Q	1.0	description:associated with ICH susceptibility; results in a significantly decreased extracellular-to-intracellular ratio of COL4A2 and COL4A1 proteins, indicating interference with the proper secretion of both these proteins; dbSNP
P08572	1152	Natural variant	G	1.0	description:in BSVD2; incomplete penetrance; dbSNP
P08572	1389	Natural variant	G	1.0	description:probable disease-associated variant found in a family with porencephaly and small-vessel disease in the form of scattered white matter lesions; impairs COL4A2 and COL4A1 secretion; the mutant protein is retained in the endoplasmic reticulum
P35670	456	Natural variant	V	1.0	description:decreased copper transport rates; no effect on ATPase activity; dbSNP
P35670	486	Natural variant	A	1.0	description:in WD; unknown pathological significance; does not affect interaction with COMMD1; dbSNP
P35670	1136	Natural variant	E	1.0	description:in WD; unknown pathological significance
P35670	1431	Natural variant	S	1.0	description:in WD; unknown pathological significance
P35670	1432	Natural variant	S	1.0	description:in WD; unknown pathological significance; dbSNP
P35670	1434	Natural variant	T	1.0	description:in WD; unknown pathological significance; localized at the TGN as the wild-type under conditions of low-copper levels; dbSNP
P25440	30	Natural variant	G	1.0	description:in a glioblastoma multiforme sample; somatic mutation
P25440	558	Natural variant	R	1.0	description:in a gastric adenocarcinoma sample; somatic mutation
P25440	714	Natural variant	P	1.0	description:in a glioblastoma multiforme sample; somatic mutation
P02747	34	Natural variant	G	1.0	description:in C1QD; dbSNP
P30988	447	Natural variant	L	1.0	description:associated with change in bone mineral density; dbSNP
O14646	141	Natural variant	R	1.0	description:in PILBOS; dbSNP
O14646	1708	Natural variant	R	1.0	description:in PILBOS; dbSNP
Q9HCK8	2498	Natural variant	H	1.0	description:in AUTS18
Q9GZX3	15	Natural variant	L	1.0	description:in MCD
Q9GZX3	22	Natural variant	L	1.0	description:in MCD; dbSNP
Q9GZX3	31	Natural variant	P	1.0	description:in MCD; dbSNP
P02462	352	Natural variant	P	1.0	description:in ICH; the mutant protein is retained intracellularly and is not secreted normally; dbSNP
P02462	498	Natural variant	G	1.0	description:in HANAC; dbSNP
P02462	498	Natural variant	G	1.0	description:in HANAC; dbSNP
P02462	510	Natural variant	G	1.0	description:in HANAC and RATOR; dbSNP
P02462	519	Natural variant	G	1.0	description:in HANAC; dbSNP
P02462	525	Natural variant	G	1.0	description:in HANAC; requires 2 nucleotide substitutions; dbSNP
P02462	528	Natural variant	G	1.0	description:in HANAC; dbSNP
P02462	538	Natural variant	R	1.0	description:in ICH; the mutant protein is retained intracellularly and is not secreted normally; dbSNP
P02462	562	Natural variant	G	1.0	description:in BSVD1; dbSNP
P02462	655	Natural variant	G	1.0	description:in SCHZC
P02462	708	Natural variant	G	1.0	description:in BSVD1; dbSNP
P02462	720	Natural variant	G	1.0	description:in BSVD1; diffuse small vessel disease of the brain associated with Axenfeld-Rieger anomaly and leukoencephalopathy; dbSNP
P02462	749	Natural variant	G	1.0	description:in BSVD1; dbSNP
P02462	755	Natural variant	G	1.0	description:in BSVD1; associated with ocular anomalies of variable severity in some patients; dbSNP
P02462	773	Natural variant	G	1.0	description:in BSVD1; dbSNP
P02462	805	Natural variant	G	1.0	description:in BSVD1; dbSNP
P02462	870	Natural variant	G	1.0	description:in SCHZC; dbSNP
P02462	882	Natural variant	G	1.0	description:in BSVD1
P02462	897	Natural variant	G	1.0	description:in SCHZC
P02462	948	Natural variant	G	1.0	description:in SCHZC; dbSNP
P02462	1041	Natural variant	G	1.0	description:in SCHZC
P02462	1082	Natural variant	G	1.0	description:in SCHZC
P02462	1130	Natural variant	G	1.0	description:in BSVD1; dbSNP
P02462	1236	Natural variant	G	1.0	description:in BSVD1; dbSNP
P02462	1266	Natural variant	G	1.0	description:in BSVD1
P02462	1326	Natural variant	G	1.0	description:in SCHZC; dbSNP
P02462	1332	Natural variant	G	1.0	description:in SCHZC; dbSNP
P02462	1423	Natural variant	G	1.0	description:in BSVD1; dbSNP
P14854	20	Natural variant	R	1.0	description:in MC4DN7; severely reduced COX6B1 protein levels in patient muscle
P14854	20	Natural variant	R	1.0	description:in MC4DN7; dbSNP
Q96EP5	381	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q8TD84	1702	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q16570	42	Natural variant	G	1.0	description:antigen Fy(b); dbSNP
P33897	13	Natural variant	N	1.0	description:does not affect fatty acid beta-oxidation; dbSNP
P18850	567	Natural variant	Y	1.0	description:in ACHM7; dbSNP
O15169	345	Natural variant	P	1.0	description:in HCC; dbSNP
O15169	425	Natural variant	G	1.0	description:in HCC; dbSNP
O15169	650	Natural variant	G	1.0	description:in HCC; also found in hepatoblastoma; dbSNP
O75419	155	Natural variant	E	1.0	description:in MGORS7; unknown pathological significance; associated in cis with T-321; dbSNP
O75419	157	Natural variant	R	1.0	description:in MGORS7; decreased protein level; dbSNP
Q9H221	19	Natural variant	D	1.0	description:associated significantly with GBD4; dbSNP
Q9UHB7	254	Natural variant	T	1.0	description:in CHOPS; dbSNP
Q9UHB7	254	Natural variant	T	1.0	description:in CHOPS; dbSNP
Q9UHB7	258	Natural variant	R	1.0	description:in CHOPS; dbSNP
Q9UHB7	757	Natural variant	S	1.0	description:found in a clear cell renal carcinoma case; somatic mutation
O43184	712	Natural variant	G	1.0	description:in a cutaneous metastatic melanoma sample; somatic mutation
O43184	792	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
O43184	893	Natural variant	P	1.0	description:in a cutaneous metastatic melanoma sample; somatic mutation; dbSNP
Q8J025	9	Natural variant	L	1.0	description:in HYPT1; dominant-negative mutant that perturbs the translational processing from the endoplasmic reticulum to the plasma membrane; dbSNP
Q86TH1	50	Natural variant	W	1.0	description:in GPHYSD1; dbSNP
Q86TH1	72	Natural variant	R	1.0	description:in GPHYSD1; dbSNP
P51790	85	Natural variant	Y	1.0	description:in NEDHYBA
Q86V15	38	Natural variant	L	1.0	description:probable disease-associated variant found in a patient with congenital heart defect; severe decrease of positive regulation of transcription from TH promoter
Q9HAW4	439	Natural variant	H	1.0	description:in a breast cancer sample; somatic mutation
Q8IWE4	2	Natural variant	G	1.0	description:in a cancer; unknown pathological significance
P17661	2	Natural variant	S	1.0	description:in MFM1; dbSNP
P17661	7	Natural variant	S	1.0	description:in MFM1; dbSNP
P17661	13	Natural variant	S	1.0	description:in MFM1; some patients manifest a severe cardiac phenotype with right ventricular predominance; dbSNP
P17661	16	Natural variant	R	1.0	description:in MFM1; dbSNP
P17661	46	Natural variant	S	1.0	description:in MFM1; exhibits significantly delayed filament assembly kinetics when bound to NEB; enhanced binding affinity towards NEB; dbSNP
P17661	46	Natural variant	S	1.0	description:in MFM1; dbSNP
P17661	419	Natural variant	P	1.0	description:in MFM1; found in a family with myofibrillar myopathy and arrhythmogenic right ventricular cardiomyopathy; dbSNP
P17661	442	Natural variant	T	1.0	description:in MFM1; reveals a severe disturbance of filament-formation competence and filament-filament interactions; dbSNP
P17661	449	Natural variant	K	1.0	description:in MFM1
P17661	449	Natural variant	K	1.0	description:in MFM1; dbSNP
P17661	451	Natural variant	I	1.0	description:in CMD1I and MFM1; reveals a severe disturbance of filament-formation competence and filament-filament interactions; reduced interaction with CRYAB; dbSNP
P17661	453	Natural variant	T	1.0	description:in MFM1; exhibits significantly delayed filament assembly kinetics when bound to NEB and NEBL; enhanced binding affinity towards NEB and NEBL; dbSNP
P17661	454	Natural variant	R	1.0	description:in MFM1; reveals a severe disturbance of filament-formation competence and filament-filament interactions; increased interaction with CRYAB; dbSNP
P17661	460	Natural variant	S	1.0	description:in MFM1; reveals a severe disturbance of filament-formation competence and filament-filament interactions; dbSNP
Q8N7J2	457	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation
P16157	1592	Natural variant	D	1.0	description:in Duesseldorf; dbSNP
Q96L58	6	Natural variant	R	1.0	description:in EDSSPD2; no effect on Golgi apparatus subcellular localization; dbSNP
Q9NYQ6	2312	Natural variant	R	1.0	description:does not affect protein localization to the cell membrane; dbSNP
Q9NYQ6	2739	Natural variant	N	1.0	description:does not affect protein localization to the cell membrane; dbSNP
Q9NYQ6	2964	Natural variant	S	1.0	description:in NTD; shows reduced protein localization to the cell membrane; dbSNP
Q9NYQ6	2983	Natural variant	P	1.0	description:in NTD; shows reduced protein localization to the cell membrane; dbSNP
Q9NYQ6	3001	Natural variant	T	1.0	description:in LMPHM9; unknown pathological significance
P0DN86	24	Natural variant	P	1.0	description:requires 2 nucleotide substitutions
Q9Y6H1	2	Natural variant	P	1.0	description:may influence risk for Lewy body disorders; dbSNP
Q9Y6H1	4	Natural variant	G	1.0	description:may influence risk for Lewy body disorders; dbSNP
Q9Y6H1	14	Natural variant	P	1.0	description:may influence risk for Lewy body disorders; dbSNP
Q9Y6H1	34	Natural variant	P	1.0	description:may influence risk for Lewy body disorders; dbSNP
Q9Y6H1	37	Natural variant	A	1.0	description:may influence risk for Lewy body disorders; dbSNP
Q9Y6H1	49	Natural variant	A	1.0	description:may influence risk for Lewy body disorders; dbSNP
Q9Y6H1	61	Natural variant	T	1.0	description:in PARK22; does not affect subcellular location; dbSNP
Q9Y6H1	93	Natural variant	A	1.0	description:may influence risk for Lewy body disorders; dbSNP
O75718	13	Natural variant	A	1.0	description:in OI7; severe form; dbSNP
P17302	239	Natural variant	R	1.0	description:in CMDR; dbSNP
P17302	239	Natural variant	R	1.0	description:in congenital heart malformations
P17302	251	Natural variant	S	1.0	description:in congenital heart malformations
P17302	253	Natural variant	A	1.0	description:in congenital heart malformations
P17302	283	Natural variant	P	1.0	description:in congenital heart malformations
P17302	290	Natural variant	T	1.0	description:in congenital heart malformations
P17302	352	Natural variant	E	1.0	description:in heart malformations
P17302	362	Natural variant	R	1.0	description:in HLHS1 and AVSD3; unknown pathological significance; associated with Q-376 in one individual with atrioventricular septal defect; abolishes phosphorylation by PKA and PKC; dbSNP
P17302	364	Natural variant	S	1.0	description:in heart malformations; shows abnormalities in the regulation of cell-cell communication as compared with cells expressing normal GJA1
P17302	365	Natural variant	S	1.0	description:in heart malformations
P17302	376	Natural variant	R	1.0	description:in HLHS1 and AVSD3; unknown pathological significance; associated with Q-362 in one individual with atrioventricular septal defect; abolishes phosphorylation by PKA and PKC; dbSNP
Q96KN9	269	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
Q96KN9	271	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9H0S4	8	Natural variant	D	1.0	description:found in a patient with a neurodevelopmental disorder; unknown pathological significance; dbSNP
Q09013	428	Natural variant	L	1.0	description:in a lung small cell carcinoma sample; somatic mutation
P01009	4	Natural variant	S	1.0	description:in Z-Wrexham
P01009	26	Natural variant	D	1.0	description:in V-Munich; dbSNP
Q07912	99	Natural variant	R	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; increased autophosphorylation at Y-284; increased function in phosphorylation of peptide substrates and WASP; no effect on subcellular localization to perinuclear region; dbSNP
Q07912	638	Natural variant	V	1.0	description:found in patients with childhood-onset epilepsy; unknown pathological significance; loss of interaction with NEDD4 and NEDD4L; increased protein abundance; dbSNP
P20807	4	Natural variant	V	1.0	description:in LGMDR1; dbSNP
P20807	26	Natural variant	P	1.0	description:in LGMDR1; dbSNP
P20807	606	Natural variant	S	1.0	description:in LGMDR1; dbSNP
P20807	638	Natural variant	Q	1.0	description:in LGMDR1
Q9H211	66	Natural variant	A	1.0	description:in MGORS4; dbSNP
Q9H211	117	Natural variant	Q	1.0	description:in MGORS4; dbSNP
Q15517	56	Natural variant	L	1.0	description:in allele 1.31 and allele 1.32; dbSNP
Q15517	143	Natural variant	N	1.0	description:in allele 2.11
Q15517	150	Natural variant	S	1.0	description:in allele 2.21, allele 2.22 and allele 2.23; dbSNP
Q15517	202	Natural variant	S	1.0	description:in allele 1.11, allele 1.21, allele 1.31, allele 1.32, allele 1.51, allele 1.52, allele 2.11, allele 2.21, allele 2.22 and allele 2.23; dbSNP
Q15517	253	Natural variant	V	1.0	description:in allele 1.32
Q15517	401	Natural variant	S	1.0	description:in allele 1.21; dbSNP
Q15517	408	Natural variant	S	1.0	description:in allele 1.51; dbSNP
Q15517	410	Natural variant	S	1.0	description:in allele 2.11, allele 2.21, allele 2.22 and allele 2.23; dbSNP
Q15517	527	Natural variant	D	1.0	description:in allele 2.21, allele 2.22 and allele 2.23; dbSNP
O14618	163	Natural variant	R	1.0	description:found in a patient with congenital cataracts, hearing loss, neurodegeneration, neonatal hypotonia and hypoglycemia, pericardial effusion and neurodevelopmental regression after infection; the patient also carries a mutation in SLC33A1; mutant protein does not interact with SOD1; dbSNP
P53420	116	Natural variant	G	1.0	description:in BFH; dbSNP
P53420	897	Natural variant	G	1.0	description:in BFH; dbSNP
P53420	960	Natural variant	G	1.0	description:in BFH; dbSNP
P53420	999	Natural variant	G	1.0	description:in BFH; dbSNP
P53420	1030	Natural variant	G	1.0	description:in ATS2; dbSNP
P53420	1132	Natural variant	P	1.0	description:in BFH
P53420	1201	Natural variant	G	1.0	description:in ATS2; dbSNP
P13498	156	Natural variant	P	1.0	description:in CGD4; dbSNP
P18858	152	Natural variant	K	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P50402	54	Natural variant	S	1.0	description:in EDMD1; no loss of binding to F-actin, enhanced rate of actin polymerization and loss of binding to BCLAF1
P50402	133	Natural variant	Q	1.0	description:in EDMD1; loss of binding to F-actin
P50402	183	Natural variant	P	1.0	description:in EDMD1; no loss of binding to F-actin and enhanced rate of actin polymerization; dbSNP
P50402	183	Natural variant	P	1.0	description:in EDMD1; dbSNP
Q9NP58	57	Natural variant	A	1.0	description:in MCOPCB7; unknown pathological significance; hypomorphic mutation; dbSNP
P06280	3	Natural variant	L	1.0	description:does not affect enzyme activity; dbSNP
P06280	3	Natural variant	L	1.0	description:does not affect enzyme activity; dbSNP
P06280	20	Natural variant	A	1.0	description:in FD; loss of enzyme activity; dbSNP
P06280	20	Natural variant	A	1.0	description:in FD; atypical; loss of enzyme activity; dbSNP
P06280	21	Natural variant	L	1.0	description:in FD; loss of enzyme activity; dbSNP
P06280	31	Natural variant	A	1.0	description:in FD; dbSNP
P06280	32	Natural variant	L	1.0	description:in FD; dbSNP
Q8WWN8	1428	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P51690	12	Natural variant	R	1.0	description:in CDPX1; no effect on arylsulfatase activity, protein stability and localization to the Golgi apparatus; dbSNP
O43520	45	Natural variant	N	1.0	description:in ICP1; dbSNP
O43520	70	Natural variant	D	1.0	description:in BRIC1; compound heterozygote with Q-600; uncertain pathological significance; may be associated with ICP; reduces interaction with TMEM30A; has no effect on PC flippase activity; dbSNP
P51793	15	Natural variant	D	1.0	description:in MRXSRC; also in patients with complex congenital diaphragmatic hernia; unknown pathological significance; no reduction in outwardly-rectifying currents; does not affect its localization in endoplasmic reticulum membrane; dbSNP
P12644	91	Natural variant	S	1.0	description:in OFC11; also found in renal hypodysplasia patients; dbSNP
P12644	93	Natural variant	E	1.0	description:in MCOPS6; dbSNP
P12644	116	Natural variant	T	1.0	description:in a renal hypodysplasia patient; dbSNP
P12644	287	Natural variant	R	1.0	description:in OFC11; dbSNP
O43683	492	Natural variant	S	1.0	description:in colorectal cancer; dbSNP
O43683	648	Natural variant	P	1.0	description:in colorectal cancer; dbSNP
P02730	40	Natural variant	E	1.0	description:found in patients with hemolytic anemia; unknown pathological significance; Montefiore; dbSNP
Q9UPW5	423	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
P13671	119	Natural variant	A	1.0	description:in allotype C6 A; dbSNP
Q9NR48	724	Natural variant	A	1.0	description:in MRD52; unknown pathological significance; dbSNP
Q9NR48	972	Natural variant	K	1.0	description:in MRD52; unknown pathological significance
Q9NR48	1276	Natural variant	Y	1.0	description:in MRD52; unknown pathological significance; dbSNP
Q9NR48	1775	Natural variant	C	1.0	description:in MRD52; unknown pathological significance; dbSNP
Q9NR48	2853	Natural variant	D	1.0	description:in MRD52; unknown pathological significance
P23560	2	Natural variant	T	1.0	description:found in a patient with congenital central hypoventilation syndrome; unknown pathological significance; dbSNP
P23560	66	Natural variant	V	1.0	description:strongly associated with susceptibility to eating disorders such as anorexia nervosa and bulimia nervosa; associated with poorer episodic memory; may have a protective effect in obsessive-compulsive disorder; impairs localization to secretory granules or synapses; decreases density of dendritic mushroom spines and synapses; dbSNP
P11274	400	Natural variant	S	1.0	description:in a bladder transitional cell carcinoma sample; somatic mutation
P00751	9	Natural variant	L	1.0	description:may be associated with a reduced risk for age-related macular degeneration; dbSNP
P00751	28	Natural variant	W	1.0	description:in allele FA; requires 2 nucleotide substitutions
P00751	28	Natural variant	W	1.0	description:in allele S
P13569	13	Natural variant	S	1.0	description:in CF; dbSNP
P13569	31	Natural variant	R	1.0	description:in CF; dbSNP
P13569	42	Natural variant	S	1.0	description:in CF; dbSNP
P13569	44	Natural variant	D	1.0	description:in CF; unknown pathological significance; dbSNP
P13569	648	Natural variant	D	1.0	description:in CF; decrease in bicarbonate transport; no effect chloride channel activity; dbSNP
P13569	651	Natural variant	D	1.0	description:in CF; dbSNP
P13569	665	Natural variant	T	1.0	description:in CF; no effect on glycan maturation and channel activity; dbSNP
P13569	668	Natural variant	R	1.0	description:in CBAVD; unknown pathological significance; dbSNP
P13569	693	Natural variant	F	1.0	description:in CF; unknown pathological significance; dbSNP
P13569	754	Natural variant	V	1.0	description:in CF; dbSNP
P13569	766	Natural variant	R	1.0	description:in CBAVD; dbSNP
P13569	792	Natural variant	R	1.0	description:in CBAVD; no effect on glycan maturation but decreased channel activity; dbSNP
P13569	800	Natural variant	A	1.0	description:in CBAVD; small decrease in bicarbonate transport; increase in chloride channel activity in vitro; no effect on glycan maturation; dbSNP
P13569	807	Natural variant	I	1.0	description:in CBAVD; dbSNP
P13569	822	Natural variant	E	1.0	description:in CF; dbSNP
P13569	826	Natural variant	E	1.0	description:in thoracic sarcoidosis; no effect on glycan maturation and channel activity; dbSNP
Q8WYQ3	15	Natural variant	R	1.0	description:in IMMD; associated in cis with R-58 in a IMMD family; unknown pathological significance; does not affect mitochondrial structure and organization; dbSNP
Q8WYQ3	34	Natural variant	P	1.0	description:in FTDALS2; dbSNP
Q8WYQ3	58	Natural variant	G	1.0	description:in IMMD; associated in cis with S-15 in a IMMD family; causes mitochondrial fragmentation; dbSNP
Q8WYQ3	59	Natural variant	S	1.0	description:in FTDALS2; results in disorganization of mitochondrial cristae; dbSNP
Q8WYQ3	66	Natural variant	G	1.0	description:in SMAJ; dbSNP
Q14004	103	Natural variant	Q	1.0	description:in RNA edited version
Q9UKV3	1160	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9H161	7	Natural variant	V	1.0	description:in CRS5; low-penetrance mutation associated with disease susceptibility; results in gain-of-function; dbSNP
Q9H161	211	Natural variant	K	1.0	description:in CRS5; low-penetrance mutation associated with disease susceptibility; results in gain-of-function; dbSNP
Q9H161	218	Natural variant	R	1.0	description:in PFM2; dbSNP
Q9H2U9	14	Natural variant	P	1.0	description:in a cutaneous metastatic melanoma sample; somatic mutation; dbSNP
Q9H2U9	31	Natural variant	R	1.0	description:in a cutaneous metastatic melanoma sample; somatic mutation; dbSNP
Q9H2U9	36	Natural variant	P	1.0	description:in a cutaneous metastatic melanoma sample; somatic mutation; dbSNP
Q9H2U9	180	Natural variant	V	1.0	description:in a cutaneous metastatic melanoma sample; somatic mutation
Q9H2U9	703	Natural variant	S	1.0	description:in a cutaneous metastatic melanoma sample; somatic mutation; does not affect cell growth but conferes reduced cell adhesion to collagen IV and laminin-1; increases cell migration capabilities compared to wild-type
Q99728	564	Natural variant	Q	1.0	description:in an ovarian clear cell adenocarcinoma
Q5H9F3	32	Natural variant	P	1.0	description:in SHUVER; unknown pathological significance; dbSNP
Q5H9F3	327	Natural variant	T	1.0	description:found in a patient with Uruguay faciocardiomusculoskeletal syndrome; unknown pathological significance
Q5H9F3	496	Natural variant	S	1.0	description:in SHUVER; unknown pathological significance; dbSNP
Q5H9F3	782	Natural variant	V	1.0	description:in SHUVER; unknown pathological significance; dbSNP
Q5H9F3	820	Natural variant	N	1.0	description:in SHUVER; unknown pathological significance; dbSNP
Q5H9F3	832	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q8IX12	607	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
Q8TDI0	45	Natural variant	V	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q8TDI0	119	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q8TDI0	272	Natural variant	A	1.0	description:in PMNDS; unknown pathological significance
Q8TDI0	667	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
P42771	142	Natural variant	H	1.0	description:in non-small cell lung carcinoma; dbSNP
P42771	144	Natural variant	R	1.0	description:in squamous cell carcinoma; dbSNP
P42771	150	Natural variant	G	1.0	description:in non-small cell lung carcinoma
Q96RK0	104	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q96RK0	492	Natural variant	R	1.0	description:in MRD45; unknown pathological significance; dbSNP
Q96RK0	652	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P01034	25	Natural variant	A	1.0	description:in ARMD11; alters processing and glycosylation; dbSNP
Q86T65	582	Natural variant	P	1.0	description:in NPHS24; unknown pathological significance; affects the regulation of filopodia formation
Q86T65	1028	Natural variant	S	1.0	description:in NPHS24; unknown pathological significance; affects the regulation of filopodia formation
Q8TDJ6	2417	Natural variant	R	1.0	description:in DFNA71
Q9UNE0	148	Natural variant	C	1.0	description:in ECTD10B
Q3B7T1	45	Natural variant	N	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q3B7T1	95	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation
Q86V85	32	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
P01834	41	Natural variant	W	1.0	description:in IGKCD
Q8TAP9	29	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q8TAP9	144	Natural variant	M	1.0	description:in TTD4; dbSNP
Q9Y243	465	Natural variant	R	1.0	description:in MPPH2; disease phenotype overlaps with megalencephaly-capillary malformation syndrome; dbSNP
Q16610	167	Natural variant	F	1.0	description:in LiP; dbSNP
P33261	17	Natural variant	L	1.0	description:in allele CYP2C19*14; dbSNP
P33261	19	Natural variant	I	1.0	description:in allele CYP2C19*15; dbSNP
O00548	18	Natural variant	Q	1.0	description:in NEDBAS; unknown pathological significance
Q9BYE0	186	Natural variant	D	1.0	description:in SCDO4; dbSNP
P05204	7	Natural variant	E	1.0	description:in variant H17
P55795	206	Natural variant	R	1.0	description:in MRXSB; dbSNP
P55795	206	Natural variant	R	1.0	description:in MRXSB; dbSNP
P55795	209	Natural variant	P	1.0	description:in MRXSB; dbSNP
Q13554	489	Natural variant	P	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
Q05469	146	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
P43243	72	Natural variant	A	1.0	description:in ALS21; unknown pathological significance
P43243	85	Natural variant	S	1.0	description:in ALS21; results in increased interaction with TARDBP; dbSNP
P43243	115	Natural variant	F	1.0	description:in ALS21; dbSNP
P43243	147	Natural variant	R	1.0	description:in ALS21; unknown pathological significance
P43243	154	Natural variant	P	1.0	description:in ALS21; unknown pathological significance; dbSNP
P43243	622	Natural variant	T	1.0	description:in ALS21; dbSNP
O15553	42	Natural variant	R	1.0	description:in arFMF; dbSNP
O15553	108	Natural variant	S	1.0	description:in arFMF; dbSNP
O15553	110	Natural variant	L	1.0	description:in arFMF; dbSNP
O15553	148	Natural variant	E	1.0	description:in arFMF and adFMF; likely benign variant; associated with S-369 and Q-408 in cis; associated with I-694 in some patients; dbSNP
O15553	148	Natural variant	E	1.0	description:in arFMF; dbSNP
O15553	163	Natural variant	E	1.0	description:in arFMF; dbSNP
O15553	167	Natural variant	E	1.0	description:in arFMF; dbSNP
O15553	177	Natural variant	T	1.0	description:in arFMF; dbSNP
O15553	196	Natural variant	G	1.0	description:in arFMF; unknown pathological significance; dbSNP
O15553	202	Natural variant	R	1.0	description:benign variant; no effect on PYCARD/ASC inflammasome formation; dbSNP
O15553	230	Natural variant	E	1.0	description:in arFMF; dbSNP
O15553	242	Natural variant	S	1.0	description:in PAAND; results in constitutive inflammasome activation; increased PYCARD/ASC specks formation; increased caspase-1 activation and IL1B production; loss of S-242 phosphorylation; loss of interaction with 14-3-3 proteins; dbSNP
O15553	244	Natural variant	E	1.0	description:in PAAND; results in constitutive inflammasome activation; increased PYCARD/ASC specks formation; increased caspase-1 activation and IL1B and IL18 production; decreased interaction with 14-3-3 proteins; no effect on interaction with PSTPIP1
O15553	247	Natural variant	I	1.0	description:in arFMF; unknown pathological significance; dbSNP
O15553	267	Natural variant	T	1.0	description:in arFMF; dbSNP
O15553	283	Natural variant	P	1.0	description:in arFMF; unknown pathological significance; dbSNP
O15553	304	Natural variant	G	1.0	description:in arFMF; unknown pathological significance; no effect on PYCARD/ASC inflammasome formation; dbSNP
O15553	319	Natural variant	E	1.0	description:in arFMF; dbSNP
O15553	369	Natural variant	P	1.0	description:in arFMF; unknown pathological significance; associated with Q-148 and Q-408 in cis; dbSNP
O15553	761	Natural variant	R	1.0	description:in arFMF; dbSNP
O15553	780	Natural variant	P	1.0	description:in arFMF; dbSNP
O43283	746	Natural variant	P	1.0	description:in a metastatic melanoma sample; somatic mutation
Q4G163	98	Natural variant	E	1.0	description:in SPGF64; unknown pathological significance
Q4G163	149	Natural variant	G	1.0	description:in SPGF64; unknown pathological significance
Q4G163	250	Natural variant	I	1.0	description:in SPGF64; unknown pathological significance
Q4G163	594	Natural variant	E	1.0	description:in SPGF64; unknown pathological significance
Q4G163	664	Natural variant	G	1.0	description:in SPGF64; unknown pathological significance; dbSNP
P98174	205	Natural variant	S	1.0	description:in AAS
P58012	187	Natural variant	G	1.0	description:in POF3; does not affect nuclear localization; reduces transcriptional activation of OSR2; dbSNP
P58012	193	Natural variant	K	1.0	description:in BPES; type II; dbSNP
P58012	215	Natural variant	Y	1.0	description:in BPES; dbSNP
P58012	217	Natural variant	S	1.0	description:in BPES; diffuse nuclear localization; normal transcriptional activation
P58012	217	Natural variant	S	1.0	description:in BPES; diffuse nuclear localization; increased transactivation activity; dbSNP
P58012	234	Natural variant	A	1.0	description:in BPES; significant higher cytoplasmic retention compared to the wild-type protein
P58012	234	Natural variant	A	1.0	description:in BPES; type II
P58012	234	Natural variant	A	1.0	description:in BPES
P58012	258	Natural variant	Y	1.0	description:in POF3; dbSNP
Q9UKT9	277	Natural variant	E	1.0	description:found in a renal cell carcinoma sample; somatic mutation
P51617	690	Natural variant	S	1.0	description:in a lung adenocarcinoma sample; somatic mutation
P10644	74	Natural variant	R	1.0	description:in CNC1; exhibits increased PKA activity which is attributed to decreased binding to cAMP and/or the catalytic subunit; dbSNP
Q63ZY3	181	Natural variant	S	1.0	description:in NPHS16; increased interaction with ARHGDIA; loss of function in regulation of the Rho signaling pathway; no effect on cytoplasmic localization; loss of function in podocytes migration; dbSNP
P11712	19	Natural variant	L	1.0	description:in allele CYP2C9*7; dbSNP
Q9N2K0	81	Natural variant	V	1.0	description:in allele HERV-H19
Q9N2K0	150	Natural variant	F	1.0	description:in allele HERV-H19
Q13144	447	Natural variant	S	1.0	description:in VWM; dbSNP
O95936	667	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q92731	84	Natural variant	G	1.0	description:found in a patient with a 46,XY disorder of sex development; unknown pathological significance; no change in positive regulation of DNA-binding transcription factor activity; dbSNP
Q14697	232	Natural variant	T	1.0	description:likely benign variant; no effect on PKD1 and PKD2 localization to the cell surface
Q9UJY5	484	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
O75603	203	Natural variant	G	1.0	description:shows normal transcriptional activity; dbSNP
O75603	227	Natural variant	I	1.0	description:shows normal transcriptional activity; dbSNP
O75603	251	Natural variant	Q	1.0	description:in HRPT4; found on the same allele as Q-379; gain-of-function mutation; increases transcriptional activity; dbSNP
O75603	282	Natural variant	Y	1.0	description:shows normal transcriptional activity; dbSNP
O75603	315	Natural variant	N	1.0	description:shows normal transcriptional activity; dbSNP
O75603	379	Natural variant	L	1.0	description:in HRPT4; found on the same allele as E-251; gain-of-function mutation; increases transcriptional activity; dbSNP
O75603	382	Natural variant	V	1.0	description:in HRPT4; unknown pathological significance; dbSNP
O75603	394	Natural variant	Y	1.0	description:in HRPT4; gain-of-function mutation; increases transcriptional activity; dbSNP
O75603	502	Natural variant	N	1.0	description:in FIH2; exerts a dominant-negative effect to abolish transactivation capacity; dbSNP
Q9UL51	126	Natural variant	S	1.0	description:in FEB2; affects channel activity resulting in faster kinetics and increased current density at higher temperature compared to wild type
Q9UL51	756	Natural variant	R	1.0	description:in EIG17; unknown pathological significance; does not affect channel activity; dbSNP
P52732	944	Natural variant	R	1.0	description:in MCLMR; dbSNP
Q3LI63	52	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
O75840	137	Natural variant	T	1.0	description:found in two patients with developmental delay/intellectual disability, neuromuscular and psychiatric symptoms; unknown pathological significance; dbSNP
O75840	139	Natural variant	P	1.0	description:found in a patient with developmental delay/intellectual disability, neuromuscular and psychiatric symptoms; unknown pathological significance
P35453	57	Natural variant	A	1.0	description:in SPD1
P07099	49	Natural variant	R	1.0	description:in allele EPHX1*2; dbSNP
Q9HBX8	928	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; no effect Wnt signlaing upon RSPO1-binding
Q99558	852	Natural variant	T	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation
Q9Y4X5	15	Natural variant	E	1.0	description:probable disease-associated variant found in patient with an acute aortic dissection and ascending aortic aneurysm; dbSNP
Q9Y4X5	44	Natural variant	E	1.0	description:probable disease-associated variant found in patient with basilar tip artery aneurysm and distal left internal carotid artery aneurysm; dbSNP
Q9H8V3	833	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
Q6XUX3	29	Natural variant	R	1.0	description:in CAKUT1; unknown pathological significance; dbSNP
Q9NYP3	28	Natural variant	S	1.0	description:no effect on nuclear localization; complements loss of endogenous DONSON by rescuing the spontaneous fork stalling observed after DONSON depletion; dbSNP
Q8NDI1	395	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
Q8TF64	221	Natural variant	T	1.0	description:in DFNB15; dbSNP
Q9NZ52	574	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P10071	169	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P10071	625	Natural variant	R	1.0	description:in GCPS; dbSNP
P10071	707	Natural variant	P	1.0	description:in GCPS; dbSNP
P10071	727	Natural variant	G	1.0	description:in PAPA1 and PAPB; dbSNP
P10071	934	Natural variant	A	1.0	description:in GCPS; the patient was originally classifed as being affected by acrocallosal syndrome due to the absence of corpus callosum; dbSNP
P10071	1304	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
O75496	17	Natural variant	K	1.0	description:in MGORS6; dbSNP
Q17RS7	766	Natural variant	C	1.0	description:found in a renal cell carcinoma case; somatic mutation
Q15349	732	Natural variant	R	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
Q86YT6	943	Natural variant	V	1.0	description:in LVNC7; dbSNP
Q9GZT9	4	Natural variant	D	1.0	description:increased protection from polycythemia at high altitude; when associated with S-127; dbSNP
Q9GZT9	127	Natural variant	C	1.0	description:increased protection from polycythemia at high altitude; when associated with E-4; dbSNP
Q92913	11	Natural variant	R	1.0	description:in DEE90; loss of ability to induce SCN8A long-term inactivation; no effect on pro-excitatory properties; no effect on interaction with SCN8A; dbSNP
Q92913	11	Natural variant	R	1.0	description:in DEE90; loss of ability to induce SCN8A long-term inactivation; no effect on pro-excitatory properties; no effect on interaction with SCN8A; unknown pathological significance
Q92913	14	Natural variant	R	1.0	description:in DEE90; loss of ability to induce SCN8A long-term inactivation; no effect on pro-excitatory properties; no effect on interaction with SCN8A
Q12946	330	Natural variant	R	1.0	description:in ACDMPV; unknown pathological significance; dbSNP
Q3T906	4	Natural variant	K	1.0	description:in MLIIIA; also found in patients with intermediate phenotype between MLII and MLIIIA; no effect on protein abundance; decreased retention in the Golgi; mistargeted to lysosomes and plasma membrane; decreased UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity; dbSNP
Q3T906	15	Natural variant	S	1.0	description:in MLIIIA; unknown pathological significance; no effect on protein abundance; decreased protein cleavage into alpha and beta subunits; decreased retention in the Golgi; mistargeted to lysosomes and plasma membrane; decreased UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity; dbSNP
Q3T906	785	Natural variant	L	1.0	description:found in a patient with mucolipidosis type II or III; unknown pathological significance; no effect on localization to the Golgi; loss of UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity toward some substrates; dbSNP
P04150	23	Natural variant	R	1.0	description:reduces transactivation activity; does not affect transrepression activity; dbSNP
P04150	72	Natural variant	N	1.0	description:variant of uncertain significance; associated in cis with A-321 and S-766 in one individual; doubles transactivation potential
P04150	321	Natural variant	V	1.0	description:variant of uncertain significance; associated in cis with D-72 and S-766 in one individual; doubles transactivation potential
P04150	363	Natural variant	N	1.0	description:enhances transactivation activity; does not affect transrepression activity; may increase sensitivity to exogenously administered glucocorticoids; may contribute to central obesity in men and show lack of association with other risk factors for coronary heart disease and diabetes mellitus; dbSNP
O60243	404	Natural variant	M	1.0	description:in HH15; with anosmia; 30 to 70% reduction in enzymatic activity compared to wild-type
P20823	12	Natural variant	L	1.0	description:in MODY3; abolishes interaction with PCBD1 and DNA
P20823	20	Natural variant	G	1.0	description:in MODY3; abolishes interaction with PCBD1 and DNA
P20823	31	Natural variant	G	1.0	description:in MODY3; no effect on interaction with PCBD1 and DNA
P20823	48	Natural variant	E	1.0	description:in IDDM20
P20823	128	Natural variant	I	1.0	description:in MODY3
P20823	129	Natural variant	P	1.0	description:in MODY3
P20823	131	Natural variant	R	1.0	description:in MODY3
P20823	131	Natural variant	R	1.0	description:in MODY3
P20823	133	Natural variant	V	1.0	description:in MODY3
P20823	142	Natural variant	S	1.0	description:in MODY3; reduces transcription activation by about 80%
P20823	143	Natural variant	H	1.0	description:in MODY3
P20823	158	Natural variant	K	1.0	description:in MODY3
P20823	159	Natural variant	R	1.0	description:in MODY3
P20823	159	Natural variant	R	1.0	description:in MODY3
P20823	161	Natural variant	A	1.0	description:in MODY3
P20823	165	Natural variant	W	1.0	description:in a hepatocellular carcinoma sample; somatic mutation
P20823	191	Natural variant	G	1.0	description:in late-onset NIDDM
P20823	200	Natural variant	R	1.0	description:in MODY3
P20823	203	Natural variant	R	1.0	description:in MODY3
P20823	203	Natural variant	R	1.0	description:in MODY3
P20823	205	Natural variant	K	1.0	description:in MODY3; reduces transcription activation by about 50%
P20823	206	Natural variant	W	1.0	description:in a hepatic adenoma sample; somatic mutation
P20823	206	Natural variant	W	1.0	description:in a hepatic adenoma sample; somatic mutation
P20823	229	Natural variant	R	1.0	description:in MODY3
P20823	237	Natural variant	N	1.0	description:in a hepatic multiple adenoma sample; somatic mutation
P20823	241	Natural variant	C	1.0	description:in IDDM20 and MODY3
P20823	244	Natural variant	R	1.0	description:in a hepatic adenoma sample; somatic mutation
P20823	250	Natural variant	Q	1.0	description:in a hepatocellular carcinoma sample; somatic mutation
P20823	254	Natural variant	L	1.0	description:in late-onset NIDDM; low penetrance; unknown pathological significance
P20823	259	Natural variant	V	1.0	description:in MODY3
P20823	260	Natural variant	T	1.0	description:in MODY3
P20823	263	Natural variant	R	1.0	description:in MODY3
P20823	268	Natural variant	F	1.0	description:in a hepatic adenoma sample; somatic mutation
P20823	271	Natural variant	R	1.0	description:in MODY3
P20823	271	Natural variant	R	1.0	description:in MODY3
P20823	272	Natural variant	R	1.0	description:in NIDDM; loss of function in positive regulation of DNA-templated transcription
P20823	272	Natural variant	R	1.0	description:in IDDM20 and MODY3
P20823	273	Natural variant	K	1.0	description:in a hepatic adenoma sample; somatic mutation
P20823	319	Natural variant	G	1.0	description:strong association with NIDDM susceptibility; unique to the Canadian Oji-Cree population
P20823	415	Natural variant	G	1.0	description:in IDDM20; decreased function in positive regulation of DNA-templated transcription
P20823	432	Natural variant	S	1.0	description:in MODY3
P20823	447	Natural variant	P	1.0	description:in MODY3
P20823	519	Natural variant	P	1.0	description:in MODY3
P20823	537	Natural variant	T	1.0	description:in MODY3; incomplete penetrance
P20823	574	Natural variant	G	1.0	description:in a black African with an atypical form of diabetes; also in an individual with hepatic adenoma and familial early-onset diabetes; dbSNP
P20823	583	Natural variant	R	1.0	description:in IDDM20
P20823	583	Natural variant	R	1.0	description:in late-onset NIDDM; also in an individual with hepatic hyperplasia and familial early-onset diabetes
P20823	594	Natural variant	S	1.0	description:in MODY3
P20823	618	Natural variant	I	1.0	description:in MODY3
P20823	619	Natural variant	E	1.0	description:in MODY3
P20823	620	Natural variant	T	1.0	description:in MODY3; incomplete penetrance
P15814	142	Natural variant	P	1.0	description:in AGM2; dbSNP
Q8IYF1	498	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q8TE67	8	Natural variant	A	1.0	description:in HYPT5; unknown pathological significance
P10412	128	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P02751	2471	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P22466	39	Natural variant	A	1.0	description:in ETL8; decreased affinity for GALR2; but no effect on affinity for GALR1 and GALR3; decreased activity in GALR2-mediated signaling; dominant-negative that inhibits GALR1-mediated signaling; dbSNP
P42262	792	Natural variant	G	1.0	description:in NEDLIB
P42262	807	Natural variant	A	1.0	description:in NEDLIB
P42858	551	Natural variant	G	1.0	description:inhibits proteolytic cleavage at D-550; abolishes post-translational myristoylation; results in increased cleavage at D-511; dbSNP
Q96NX5	443	Natural variant	A	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP
Q9Y5Q3	54	Natural variant	S	1.0	description:in MCTO; dbSNP
Q9Y5Q3	59	Natural variant	P	1.0	description:in MCTO
Q9Y5Q3	62	Natural variant	T	1.0	description:in MCTO; dbSNP
Q9Y5Q3	63	Natural variant	P	1.0	description:in MCTO
Q9Y5Q3	66	Natural variant	S	1.0	description:in MCTO
Q9Y5Q3	69	Natural variant	S	1.0	description:in MCTO; dbSNP
Q9Y5Q3	70	Natural variant	S	1.0	description:in MCTO; dbSNP
Q9Y5Q3	70	Natural variant	S	1.0	description:in MCTO; dbSNP
Q9Y5Q3	71	Natural variant	P	1.0	description:in MCTO; dbSNP
Q9Y5Q3	71	Natural variant	P	1.0	description:in MCTO; dbSNP
P98172	182	Natural variant	S	1.0	description:in CFNS
Q03468	1038	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
Q03468	1042	Natural variant	P	1.0	description:in CSB
Q03468	1119	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q03468	1119	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q9Y261	328	Natural variant	A	1.0	description:in Japanese subjects with maturity-onset diabetes of the young; unknown pathological significance; dbSNP
Q12948	297	Natural variant	P	1.0	description:in ASGD3; no effect on protein abundance; increased protein stability; no effect on nuclear location; no effect on transcription regulatory region DNA binding; decreased sequence-specific DNA binding transcription factor activity; dbSNP
Q12948	368	Natural variant	T	1.0	description:no effect on protein abundance; no effect on protein stability; no effect on nuclear location; no effect on transcription regulatory region DNA binding; no effect on sequence-specific DNA binding transcription factor activity
Q14956	531	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q14687	627	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P00995	12	Natural variant	L	1.0	description:in PCTT; benign variant; dbSNP
P00995	14	Natural variant	L	1.0	description:in PCTT; dbSNP
O95163	1158	Natural variant	P	1.0	description:reduced interaction with ELP2; does not affect interaction with ELP3; does not affect dimerization; dbSNP
Q9NQT5	31	Natural variant	G	1.0	description:in PCH1B; dbSNP
Q6UXB0	291	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
P16591	404	Natural variant	E	1.0	description:in an ovarian Endometrioid carcinoma sample; somatic mutation
Q8NFG4	79	Natural variant	S	1.0	description:in a sporadic colorectal carcinoma; somatic mutation; dbSNP
Q8NFG4	320	Natural variant	R	1.0	description:in a primary colorectal cancer; dbSNP
P02671	26	Natural variant	D	1.0	description:in Lille-1; dbSNP
P02671	31	Natural variant	G	1.0	description:in Rouen-1; dbSNP
P02671	35	Natural variant	R	1.0	description:in DYSFIBRIN; fibrinogen Metz 1/Hershey III; dbSNP
P02671	37	Natural variant	P	1.0	description:in Kyoto-2; dbSNP
P02671	38	Natural variant	R	1.0	description:in Aarhus-1; dbSNP
P02671	38	Natural variant	R	1.0	description:in Munich-1; requires 2 nucleotide substitutions
P02671	38	Natural variant	R	1.0	description:in Detroit-1; dbSNP
P02671	39	Natural variant	V	1.0	description:in Canterbury; dbSNP
P02671	453	Natural variant	S	1.0	description:in Caracas-2; dbSNP
P02671	545	Natural variant	E	1.0	description:in AMYL8; dbSNP
P02671	573	Natural variant	R	1.0	description:in DYSFIBRIN; fibrinogen Dusart/Paris-5; dbSNP
P02671	573	Natural variant	R	1.0	description:in AMYL8; dbSNP
P11487	6	Natural variant	L	1.0	description:in LAMM; probably impairs secretion; dbSNP
P47869	377	Natural variant	N	1.0	description:found in a patient with epilepsy; unknown pathological significance
P04921	8	Natural variant	N	1.0	description:webb (WB) antigen; dbSNP
P04921	14	Natural variant	L	1.0	description:duch (DH(a)) antigen; dbSNP
P04921	23	Natural variant	A	1.0	description:ahonen (AN(a)) antigen; dbSNP
Q96I76	234	Natural variant	N	1.0	description:found in patients with primary congenital glaucoma; unknown pathological significance; slightly increased transactivation activity on CXCR4 promoter; no effect on nuclear localization; dbSNP
Q96I76	475	Natural variant	G	1.0	description:found in a patient with primary congenital glaucoma; unknown pathological significance; slightly increased transactivation activity on CXCR4 promoter; no effect on nuclear localization; dbSNP
P10321	7	Natural variant	R	1.0	description:in allele C*17
P10321	8	Natural variant	A	1.0	description:in allele C*01
P10321	10	Natural variant	L	1.0	description:in allele C*01
P10321	16	Natural variant	G	1.0	description:in allele C*01
P10321	20	Natural variant	T	1.0	description:in allele C*17
P10321	297	Natural variant	S	1.0	description:in allele C*01
P10321	299	Natural variant	E	1.0	description:in alleles C*05
P10321	299	Natural variant	E	1.0	description:in allele C*04
P10321	309	Natural variant	M	1.0	description:in allele C*01
P10321	350	Natural variant	C	1.0	description:in allele C*01
P10321	363	Natural variant	T	1.0	description:in allele C*01
Q9HCM3	1562	Natural variant	H	1.0	description:in RP86; unknown pathological significance; dbSNP
P17181	24	Natural variant	A	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
P17181	515	Natural variant	E	1.0	description:no effect on activation of STAT1 upon IFNA2 or IFNG binding; dbSNP
Q8IZU9	731	Natural variant	V	1.0	description:found in a patient with intellectual disability; unknown pathological significance; dbSNP
Q9UK96	762	Natural variant	V	1.0	description:requires 2 nucleotide substitutions; found in a patient with lymphoma; partial loss of function in controlling the stability of BCL2
Q2V2M9	351	Natural variant	G	1.0	description:in CMH28; unknown pathological significance; dbSNP
Q2V2M9	363	Natural variant	R	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	371	Natural variant	K	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	383	Natural variant	Q	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	419	Natural variant	V	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	440	Natural variant	P	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	459	Natural variant	R	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	462	Natural variant	R	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	462	Natural variant	R	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	462	Natural variant	R	1.0	description:in CMH28; unknown pathological significance; dbSNP
Q2V2M9	466	Natural variant	R	1.0	description:in CMH28; unknown pathological significance; dbSNP
Q2V2M9	469	Natural variant	R	1.0	description:in CMH28; unknown pathological significance; dbSNP
Q2V2M9	479	Natural variant	N	1.0	description:in CMH28; unknown pathological significance; dbSNP
Q2V2M9	527	Natural variant	S	1.0	description:in CMH28
Q2V2M9	528	Natural variant	H	1.0	description:in CMH28
Q2V2M9	542	Natural variant	S	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	640	Natural variant	E	1.0	description:in CMH28; unknown pathological significance; dbSNP
Q2V2M9	653	Natural variant	G	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	657	Natural variant	A	1.0	description:in CMH28; unknown pathological significance; dbSNP
Q2V2M9	770	Natural variant	D	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	865	Natural variant	P	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	871	Natural variant	A	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	1356	Natural variant	N	1.0	description:in CMH28; unknown pathological significance
Q2V2M9	1376	Natural variant	V	1.0	description:in CMH28; unknown pathological significance
Q6KF10	42	Natural variant	G	1.0	description:in KFS1; dbSNP
Q6KF10	57	Natural variant	D	1.0	description:in LCA17; reduced protein expression associated with decrease in growth factor activity; dbSNP
Q6KF10	249	Natural variant	A	1.0	description:in KFS1, MCOP4 and LCA17; reduced protein expression associated with decrease in growth factor activity; dbSNP
Q6KF10	253	Natural variant	Q	1.0	description:in MCOP4; dbSNP
Q6KF10	289	Natural variant	L	1.0	description:in KFS1; dbSNP
Q6KF10	292	Natural variant	E	1.0	description:in LCA17; increased protein expression associated with decrease in growth factor activity; dbSNP
Q6KF10	327	Natural variant	P	1.0	description:in MCOP4; dbSNP
Q6ZMI3	32	Natural variant	A	1.0	description:in LCCS11; abolishes cell surface localization; abolishes interaction with NFASC; dbSNP
Q14CZ8	23	Natural variant	L	1.0	description:in MLC2A
Q14CZ8	288	Natural variant	R	1.0	description:in MLC2B; dbSNP
P23588	203	Natural variant	P	1.0	description:found in a renal cell carcinoma case; somatic mutation
P08514	874	Natural variant	I	1.0	description:alloantigen HPA-3B; dbSNP
P08514	1026	Natural variant	R	1.0	description:in GT1 and BDPLT16; results in low surface expression of the mutant protein; dbSNP
P08514	1026	Natural variant	R	1.0	description:in BDPLT16; results in abnormal membrane ruffling and cytoplasmic protrusions as well as defective proplatelet formation; dbSNP
Q02156	143	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q6DN12	46	Natural variant	R	1.0	description:found in a patient with left-sided obstructive cardiac lesions; unknown pathological significance; dbSNP
Q6DN12	47	Natural variant	R	1.0	description:found in a patient with left-sided obstructive cardiac lesions; unknown pathological significance; dbSNP
Q6DN12	60	Natural variant	A	1.0	description:found in a patient with left-sided obstructive cardiac lesions; unknown pathological significance; dbSNP
P51608	10	Natural variant	E	1.0	description:in RTT; dbSNP
P51608	155	Natural variant	F	1.0	description:in RTT; dbSNP
P51608	155	Natural variant	F	1.0	description:in RTT; dbSNP
P51608	156	Natural variant	D	1.0	description:in RTT; dbSNP
P51608	158	Natural variant	T	1.0	description:in RTT; dbSNP
P51608	158	Natural variant	T	1.0	description:in RTT; dbSNP
P51608	161	Natural variant	G	1.0	description:in RTT; dbSNP
P51608	167	Natural variant	R	1.0	description:in MRXS13; dbSNP
P51608	210	Natural variant	K	1.0	description:in RTT; dbSNP
P51608	225	Natural variant	P	1.0	description:in MRXS13; dbSNP
P51608	225	Natural variant	P	1.0	description:in RTT; dbSNP
P51608	284	Natural variant	K	1.0	description:in MRXS13; dbSNP
P51608	302	Natural variant	P	1.0	description:in RTT; dbSNP
P51608	302	Natural variant	P	1.0	description:in RTT; dbSNP
P51608	302	Natural variant	P	1.0	description:in RTT; dbSNP
P51608	302	Natural variant	P	1.0	description:in RTT; dbSNP
P51608	305	Natural variant	K	1.0	description:probable disease-associated variant found in a patient with drug-resistant epilepsy with intellectual disability, parkinsonism and other neurologic symptoms; dbSNP
P51608	305	Natural variant	K	1.0	description:in RTT; abolishes interaction with TBL1X; dbSNP
P51608	306	Natural variant	R	1.0	description:in RTT; abolishes interaction with TBL1X and TBL1XR1; dbSNP
P51608	306	Natural variant	R	1.0	description:in RTT; dbSNP
P51608	322	Natural variant	P	1.0	description:in RTT; dbSNP
P51608	322	Natural variant	P	1.0	description:in RTT; dbSNP
P51608	322	Natural variant	P	1.0	description:in MRXS13; dbSNP
P51608	344	Natural variant	R	1.0	description:in RTT; dbSNP
P51608	388	Natural variant	P	1.0	description:in RTT; unknown pathological significance; dbSNP
P51608	399	Natural variant	P	1.0	description:in MRXS13; unknown pathological significance; dbSNP
P51608	428	Natural variant	G	1.0	description:in ENS-MECP2; uncertain pathological significance; dbSNP
P51608	453	Natural variant	R	1.0	description:in MRXS13; dbSNP
P11226	24	Natural variant	T	1.0	description:in Chinese
P11226	52	Natural variant	R	1.0	description:in 0.05% of European and African populations; dbSNP
P11226	54	Natural variant	G	1.0	description:associated with low serum mannose-binding protein (MBP) concentrations and recurrent infections; dbSNP
P11226	57	Natural variant	G	1.0	description:associated with low serum mannose-binding protein (MBP) concentrations; associated with protection against tuberculosis caused by Mycobacterium africanum; dbSNP
Q15303	1275	Natural variant	R	1.0	description:in ALS19; reduces autophosphorylation upon NRG1 stimulation; dbSNP
Q9NY74	50	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
O95677	152	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation
O95677	171	Natural variant	G	1.0	description:in DFNA10; dbSNP
O95677	301	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P54803	41	Natural variant	G	1.0	description:in GLD; dbSNP
P17936	7	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation
P48544	387	Natural variant	G	1.0	description:in LQT13; dbSNP
Q9GZY8	29	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UQF2	59	Natural variant	S	1.0	description:in NIDDM; dbSNP
Q969F8	386	Natural variant	R	1.0	description:in CPPB1; reduced rate of decline in inositol phosphate accumulation after kisspeptin stimulation; prolonged phosphorylation of ERK; dbSNP
P08476	280	Natural variant	G	1.0	description:found in a patient with early-onset epithelial ovarian tumor; uncertain pathological significance
P51460	93	Natural variant	P	1.0	description:in CRYPTO; dbSNP
P51460	102	Natural variant	R	1.0	description:in CRYPTO; dbSNP
P51460	110	Natural variant	N	1.0	description:in CRYPTO; dbSNP
Q68CQ1	183	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
P23352	672	Natural variant	H	1.0	description:in HH1; phenotype consistent with Kallmann syndrome; dbSNP
Q6ZMQ8	81	Natural variant	S	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation
Q9UBF1	6	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q96M86	4745	Natural variant	V	1.0	description:in SPGF65; unknown pathological significance; dbSNP
P13765	18	Natural variant	R	1.0	description:in allele DOB*01
Q8NF50	473	Natural variant	K	1.0	description:in HIES2; dbSNP
P48169	516	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q5JWF2	436	Natural variant	A	1.0	description:in GNASHYP; dbSNP
Q5JWF2	437	Natural variant	A	1.0	description:in GNAS hyperfunction
Q5JWF2	459	Natural variant	P	1.0	description:in GNASHYP; dbSNP
P22301	15	Natural variant	G	1.0	description:in a family affected by Crohn disease; decreases secretion thereby reducing the anti-inflammatory effect; dbSNP
Q9H1B7	195	Natural variant	G	1.0	description:in NEDAMSS; unknown pathological significance; dbSNP
P13647	25	Natural variant	P	1.0	description:in EBS2F; dbSNP
P13647	143	Natural variant	V	1.0	description:in EBS2B; dbSNP
P13647	143	Natural variant	V	1.0	description:in EBS2B; dbSNP
P13647	143	Natural variant	V	1.0	description:probable disease-associated variant found in a patient with EBS with an unspecified subtype
P13647	146	Natural variant	N	1.0	description:in EBS2C; unknown pathological significance
P13647	149	Natural variant	L	1.0	description:in EBS2C; unknown pathological significance
P13647	150	Natural variant	L	1.0	description:in EBS2B; unknown pathological significance; dbSNP
P13647	517	Natural variant	G	1.0	description:in EBS2B; dbSNP
Q15058	1221	Natural variant	G	1.0	description:in MCPH20; Decreased expression at the mRNA level and loss of localization at the midbody during cytokinesis and consequently loss of CIT/CRIK recruitment to the midbody, when analyzed in primary fibroblasts from a patient who is a compound heterozygous with variant D-849
P41229	451	Natural variant	S	1.0	description:in MRXSCJ; dbSNP
Q12791	1217	Natural variant	N	1.0	description:found in patient with epilepsy; unknown pathological significance; dbSNP
P08151	210	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
P08151	506	Natural variant	L	1.0	description:in PPD1; unknown pathological significance; dbSNP
P08151	514	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
P08151	817	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q92947	191	Natural variant	M	1.0	description:in GA1; dbSNP
Q92947	195	Natural variant	A	1.0	description:in GA1
P31644	413	Natural variant	S	1.0	description:in DEE79; decreased subcellular localization to the cell membrane resulting in altered protein localization to the synapse and altered gamma-aminobutyric acid signaling pathway; the mutant subunit decreases the trafficking of the partnering GABRB3 subunit to the cell membrane with no effect on other subunits
Q96P66	308	Natural variant	E	1.0	description:in PITA2; dbSNP
Q9NRM0	25	Natural variant	G	1.0	description:no effect on urate transport activity; dbSNP
Q9NRM0	531	Natural variant	V	1.0	description:decreased urate transport; decreased protein expression; no effect on glucose
Q9P2W1	201	Natural variant	E	1.0	description:in ODG3; impairs function as estrogen receptor coactivator
Q96FT9	34	Natural variant	E	1.0	description:in RP81; results in cilia shortening; dbSNP
Q14003	263	Natural variant	G	1.0	description:variant of uncertain significance; changes channel activity; activates more quickly and deactivates more slowly
Q14003	591	Natural variant	S	1.0	description:in SCA13; unknown pathological significance; reduces channel activity; shifts the voltage dependence of activation; dbSNP
Q14003	643	Natural variant	G	1.0	description:in SCA13; unknown pathological significance; no effect on channel activity; dbSNP
Q14003	645	Natural variant	P	1.0	description:in SCA13; unknown pathological significance; no effect on channel activity; dbSNP
Q14003	746	Natural variant	D	1.0	description:in SCA13; unknown pathological significance; no effect on channel activity; dbSNP
Q9NRM7	40	Natural variant	G	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q14114	952	Natural variant	R	1.0	description:associated with susceptibility to myocardial infarction type 1; increases activation of MAPK14 by oxidized low density lipoprotein; dbSNP
Q32MZ4	68	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q5S007	930	Natural variant	Q	1.0	description:in PARK8; unknown pathological significance; dbSNP
Q13496	294	Natural variant	G	1.0	description:in CNMX; mild
P15502	211	Natural variant	P	1.0	description:found as homozygous mutation in a patient with autosomal recessive cutis laxa also carrying a mutation in FBLN5; unknown pathological significance; dbSNP
P41212	214	Natural variant	P	1.0	description:in THC5; abrogates DNA binding; alters subcellular location; decreases transcriptional repression in a dominant-negative fashion; dbSNP
Q8NEG4	418	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q9NTX9	95	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q969H0	117	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q92562	783	Natural variant	D	1.0	description:in BTOP; partial loss of function; dbSNP
P23769	254	Natural variant	P	1.0	description:in IMD21; dbSNP
P23769	398	Natural variant	R	1.0	description:in IMD21; dbSNP
O00358	248	Natural variant	A	1.0	description:in NMTC4; increased cell growth; increased cell migration; associated with increased expression of the WNT5A gene; dbSNP
O00461	312	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
P81172	59	Natural variant	R	1.0	description:in HFE2B; dbSNP
P81172	70	Natural variant	C	1.0	description:in HFE2B; dbSNP
P81172	71	Natural variant	G	1.0	description:in HFE2B; dbSNP
P81172	78	Natural variant	C	1.0	description:in HFE2B; dbSNP
P25963	32	Natural variant	S	1.0	description:in EDAID2; dbSNP
Q96ID5	467	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9BR39	161	Natural variant	T	1.0	description:in CMH17; dbSNP
Q9BR39	165	Natural variant	S	1.0	description:in CMH17; results in vacuolization of intracellular structures and cardiomyocyte hypertrophy; affects intracellular calcium handling and homeostasis. Greatly reduced phosphorylation. Increased myotube diameter. Reduced RYR1 activity and EC gain. Disruption of interaction with TRPC3; dbSNP
Q9BR39	169	Natural variant	E	1.0	description:probable disease-associated variant found in a patient with atrial fibrillation
Q9BR39	505	Natural variant	G	1.0	description:does not affect protein conformation as shown by circular dichroism; dbSNP
Q96S38	554	Natural variant	L	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation
Q96S38	663	Natural variant	G	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation
Q86U70	299	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q99705	32	Natural variant	N	1.0	description:no significant functional differences; dbSNP
Q99705	34	Natural variant	G	1.0	description:no changes in receptor binding or functional signaling; dbSNP
Q8TC57	430	Natural variant	L	1.0	description:in SPGF48; unknown pathological significance
O60500	1096	Natural variant	G	1.0	description:in NPHS1; unknown pathological significance
O60500	1140	Natural variant	R	1.0	description:in NPHS1; does not affect protein expression on the cell surface; dbSNP
P03971	12	Natural variant	V	1.0	description:in PMDS1; dbSNP
P08581	991	Natural variant	P	1.0	description:in gastric cancer; prolonged tyrosine phosphorylation in response to HGF/SF; transforming activity in athymic nude mice; dbSNP
P08581	992	Natural variant	T	1.0	description:found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP
P08581	1003	Natural variant	Y	1.0	description:probable disease-associated variant found in lesional sample from a patient with sporadically occurring, unilateral osteofibrous dysplasia; somatic mutation; complete loss of ligand-induced CBL-mediated ubiquitination, resulting in protein stabilization
Q15746	1213	Natural variant	V	1.0	description:in AAT7; unknown pathological significance; dbSNP
Q15746	1754	Natural variant	A	1.0	description:in AAT7; 4-fold reduced affinity for calmodulin; decreased kinase activity compared to wild-type protein
Q15746	1759	Natural variant	S	1.0	description:in AAT7; 7-fold reduced affinity for calmodulin; 6-fold decreased Vmax; dbSNP
O43823	664	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation
P49747	290	Natural variant	D	1.0	description:in PSACH; dbSNP
P49747	290	Natural variant	D	1.0	description:in PSACH; mild form
P49747	298	Natural variant	S	1.0	description:in EDM1; phenotypic features overlapping with mild PSACH
P49747	299	Natural variant	G	1.0	description:in PSACH
P49747	311	Natural variant	A	1.0	description:in EDM1
P49747	317	Natural variant	D	1.0	description:in EDM1; atypical form
P49747	326	Natural variant	D	1.0	description:in EDM1
P49747	326	Natural variant	D	1.0	description:in PSACH
P49747	328	Natural variant	C	1.0	description:in PSACH; mild form; dbSNP
P49747	342	Natural variant	D	1.0	description:in EDM1; Fairbank type; dbSNP
P49747	348	Natural variant	C	1.0	description:in EDM1
P49747	348	Natural variant	C	1.0	description:in PSACH; dbSNP
P49747	349	Natural variant	D	1.0	description:in PSACH; mild form
P49747	361	Natural variant	D	1.0	description:in EDM1; Fairbank type
P49747	361	Natural variant	D	1.0	description:in EDM1; binds less calcium
P49747	371	Natural variant	C	1.0	description:in EDM1; Fairbank type
P49747	371	Natural variant	C	1.0	description:in EDM1; dbSNP
P49747	372	Natural variant	D	1.0	description:in PSACH
P49747	374	Natural variant	D	1.0	description:in EDM1
P49747	374	Natural variant	D	1.0	description:in PSACH; mild form
P49747	376	Natural variant	D	1.0	description:in EDM1
P49747	378	Natural variant	D	1.0	description:in PSACH
P49747	385	Natural variant	D	1.0	description:in EDM1; atypical form
P49747	385	Natural variant	D	1.0	description:in EDM1; atypical form; dbSNP
P49747	385	Natural variant	D	1.0	description:in EDM1
P49747	387	Natural variant	C	1.0	description:in PSACH; mild form
P49747	387	Natural variant	C	1.0	description:in PSACH
P49747	397	Natural variant	D	1.0	description:in EDM1
P49747	404	Natural variant	G	1.0	description:in EDM1
P49747	408	Natural variant	D	1.0	description:in EDM1
P49747	410	Natural variant	C	1.0	description:in EDM1; phenotype overlapping with mild PSACH
P49747	415	Natural variant	N	1.0	description:in EDM1
P49747	420	Natural variant	D	1.0	description:in EDM1
P49747	427	Natural variant	G	1.0	description:in EDM1
P49747	440	Natural variant	G	1.0	description:in PSACH; mild form
P49747	440	Natural variant	G	1.0	description:in PSACH; dbSNP
P49747	446	Natural variant	D	1.0	description:in PSACH
P49747	448	Natural variant	C	1.0	description:in PSACH
P49747	453	Natural variant	N	1.0	description:in EDM1; Fairbank type; dbSNP
P49747	457	Natural variant	E	1.0	description:in EDM1
P49747	459	Natural variant	S	1.0	description:in PSACH; severe form
P49747	468	Natural variant	C	1.0	description:in PSACH; severe form; dbSNP
P49747	469	Natural variant	D	1.0	description:in PSACH; severe form; MUT3 mutant; most common mutation; binds less calcium and causes misfolding of the protein; greatly reduced interaction with ACAN; reduced interaction with collagen
P49747	472	Natural variant	D	1.0	description:in PSACH; severe form; dbSNP
P49747	473	Natural variant	D	1.0	description:in EDM1
P49747	473	Natural variant	D	1.0	description:in PSACH; severe form; dbSNP
P49747	473	Natural variant	D	1.0	description:in PSACH
P49747	473	Natural variant	D	1.0	description:in PSACH; severe form; dbSNP
P49747	475	Natural variant	D	1.0	description:in PSACH
P49747	482	Natural variant	D	1.0	description:in PSACH
P49747	501	Natural variant	G	1.0	description:in EDM1; dbSNP
P49747	507	Natural variant	D	1.0	description:in PSACH
P35221	54	Natural variant	R	1.0	description:in MDPT2; no effect on VCL-binding; dbSNP
Q8TDD1	20	Natural variant	W	1.0	description:found in a patient with a neurodevelopmental disorder; unknown pathological significance; dbSNP
Q8TDD1	611	Natural variant	R	1.0	description:found in a patient with a neurodevelopmental disorder; unknown pathological significance; dbSNP
P43026	263	Natural variant	L	1.0	description:in BDC; no induction of SMAD protein signal transduction via BMPR1A; less induction of chondrgenesis; no phosphorylation of SMAD1-SMAD5-SMAD8 protein complex; reduction of protein level; abnormal proteolysis product
P43026	380	Natural variant	R	1.0	description:in BDA2; reduces activity; impairs processing; dbSNP
Q14831	891	Natural variant	E	1.0	description:in NEDSHBA; unknown pathological significance; dbSNP
Q6DN90	335	Natural variant	R	1.0	description:in IDDSSBA; loss of function; dbSNP
Q6DN90	357	Natural variant	T	1.0	description:in IDDSSBA; loss of function; dbSNP
Q08881	19	Natural variant	R	1.0	description:in a metastatic melanoma sample; somatic mutation
Q08881	23	Natural variant	P	1.0	description:in a metastatic melanoma sample; somatic mutation
P35900	4	Natural variant	S	1.0	description:in a colorectal cancer sample; somatic mutation
Q86UP2	226	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q86UP2	1316	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation
O14686	543	Natural variant	S	1.0	description:in KABUK1; unknown pathological significance; dbSNP
O14686	647	Natural variant	P	1.0	description:in KABUK1; dbSNP
O14686	1192	Natural variant	V	1.0	description:in KABUK1; unknown pathological significance
O14686	1258	Natural variant	R	1.0	description:in KABUK1; unknown pathological significance; dbSNP
O14686	1718	Natural variant	A	1.0	description:in KABUK1; unknown pathological significance; dbSNP
O14686	2841	Natural variant	P	1.0	description:in KABUK1; unknown pathological significance; dbSNP
O14686	3876	Natural variant	L	1.0	description:in KABUK1; unknown pathological significance
O14686	3897	Natural variant	L	1.0	description:in KABUK1; unknown pathological significance; dbSNP
O14686	4353	Natural variant	P	1.0	description:in KABUK1; unknown pathological significance; dbSNP
O14686	4420	Natural variant	R	1.0	description:in KABUK1; unknown pathological significance; dbSNP
O14686	5351	Natural variant	R	1.0	description:in KABUK1; unknown pathological significance; dbSNP
Q9HBG7	602	Natural variant	M	1.0	description:decreases interaction with SH2D1A and INPP5D 2-fold, reduced T-cell response; dbSNP
Q8WWI1	354	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation
Q8WWI1	785	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation
Q96KG7	1030	Natural variant	Y	1.0	description:probable disease-associated variant found in a patient with MEGF10 myopathy; dbSNP
Q6T4R5	865	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P06396	22	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
P02724	20	Natural variant	S	1.0	description:in N antigen and M(g) antigen; dbSNP
P02724	23	Natural variant	T	1.0	description:in M(g) antigen
P02724	24	Natural variant	G	1.0	description:in N antigen, M(c) antigen and M(g) antigen; dbSNP
P02724	46	Natural variant	D	1.0	description:in Ny(a) antigen
P02724	47	Natural variant	T	1.0	description:in ENEH/Hut antigen
P02724	47	Natural variant	T	1.0	description:in ENEH/Vw antigen
P02724	50	Natural variant	R	1.0	description:in Or antigen
P02724	66	Natural variant	S	1.0	description:in Vr antigen; dbSNP
P02724	73	Natural variant	P	1.0	description:in Os(a) antigen
P02724	76	Natural variant	E	1.0	description:in Ri(a) antigen
P02724	77	Natural variant	T	1.0	description:in Mt(a) antigen; dbSNP
P02724	78	Natural variant	G	1.0	description:in ERIK antigen; dbSNP
P02724	82	Natural variant	Q	1.0	description:in ENAV/MARS antigen
P68431	28	Natural variant	K	1.0	description:in GLM; non-brain stem pediatric glioblastoma and diffuse intrinsic pontine glioma; somatic mutation; results in a global decrease of H3K27me3 levels; dbSNP
P68431	37	Natural variant	K	1.0	description:probable disease-associated variant found in pediatric undifferentiated soft tissue sarcoma samples; somatic mutation; results in global decrease of H3K36me2 and H3K36me3 levels and increased H3K27me3 levels
P68431	37	Natural variant	K	1.0	description:probable disease-associated variant found in pediatric undifferentiated soft tissue sarcoma samples; somatic mutation; also found in a subset of human papillomavirus-negative head and neck squamous cell carcinomas; results in global decrease of H3K36me2 and H3K36me3 levels and increased H3K27me3 levels
Q9NQE9	36	Natural variant	G	1.0	description:2.5-fold increase in affinity for indolepropinoic acyl-adenylate and cytosine; 2-fold decrease in hypoxanthine affinity; nearly no change in affinity for adenine, guanine and uracil; dbSNP
Q16270	95	Natural variant	K	1.0	description:in RNA edited version; dbSNP
Q8N5M9	14	Natural variant	G	1.0	description:in SCN6; dbSNP
Q587J8	201	Natural variant	A	1.0	description:in HYDM2; unknown pathological significance; dbSNP
P55268	1380	Natural variant	N	1.0	description:in PIERSS and NPHS5; with mild ocular abnormalities; associated with F-1393; dbSNP
P55268	1393	Natural variant	L	1.0	description:in PIERSS and NPHS5; with mild ocular abnormalities; associated with K-1380; dbSNP
Q08397	141	Natural variant	R	1.0	description:associated with exfoliation syndrome in the presence of D-153; dbSNP
Q08397	153	Natural variant	G	1.0	description:associated with exfoliation syndrome in the presence of L-141; dbSNP
Q96L34	418	Natural variant	R	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
Q09428	7	Natural variant	G	1.0	description:in HHF1; dbSNP
Q09428	956	Natural variant	S	1.0	description:in HHF1; dbSNP
Q02952	240	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q14117	490	Natural variant	R	1.0	description:in DPYSD
Q9NRM1	216	Natural variant	S	1.0	description:in AI1B and AI1C; decreased phosphorylation by FAM20C; dbSNP
Q3SXY8	390	Natural variant	R	1.0	description:in a nephronophthisis (NPHP) patient
P51681	333	Natural variant	E	1.0	description:in THCCR5-2
P51681	335	Natural variant	A	1.0	description:in MWCCR5-1567, MWCCR5-1568, ZWCCR5-14 and ZWCCR5-112; dbSNP
P51681	339	Natural variant	Y	1.0	description:in TZCCR5-181A and MWCCR5-107; dbSNP
P51681	345	Natural variant	E	1.0	description:in UGCCR5-145C
P49918	158	Natural variant	P	1.0	description:in BWS; unknown pathological significance; dbSNP
P49918	215	Natural variant	A	1.0	description:in BWS; dbSNP
P49918	274	Natural variant	D	1.0	description:in IMAGE; dbSNP
P49918	276	Natural variant	F	1.0	description:in IMAGE; PCNA binding is disrupted; dbSNP
P49918	276	Natural variant	F	1.0	description:in IMAGE; dbSNP
P49918	278	Natural variant	K	1.0	description:in IMAGE; PCNA binding is disrupted; dbSNP
P49918	279	Natural variant	R	1.0	description:in IMAGE; dbSNP
Q9NQW8	107	Natural variant	G	1.0	description:in ACHM3; unknown pathological significance; dbSNP
Q9NQW8	148	Natural variant	K	1.0	description:in ACHM3; dbSNP
Q9NQW8	156	Natural variant	S	1.0	description:in ACHM3; dbSNP
P54646	371	Natural variant	P	1.0	description:in breast cancer samples; infiltrating ductal carcinoma; somatic mutation
P54646	523	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
P62736	39	Natural variant	R	1.0	description:in AAT6; dbSNP
P38398	132	Natural variant	N	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	142	Natural variant	P	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	147	Natural variant	L	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	165	Natural variant	L	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro
P38398	170	Natural variant	R	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	186	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	191	Natural variant	V	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	227	Natural variant	E	1.0	description:in ovarian cancer; unknown pathological significance
P38398	231	Natural variant	T	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	245	Natural variant	D	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	246	Natural variant	L	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	271	Natural variant	V	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	271	Natural variant	V	1.0	description:in BC; dbSNP
P38398	346	Natural variant	P	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	369	Natural variant	D	1.0	description:in BC; dbSNP
P38398	461	Natural variant	F	1.0	description:in BC; dbSNP
P38398	465	Natural variant	Y	1.0	description:in BC; dbSNP
P38398	507	Natural variant	R	1.0	description:found in breast-ovarian cancer patients; unknown pathological significance; dbSNP
P38398	552	Natural variant	G	1.0	description:in BC; dbSNP
P38398	668	Natural variant	L	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	695	Natural variant	D	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	749	Natural variant	D	1.0	description:in BC; dbSNP
P38398	758	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
P38398	778	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
P38398	798	Natural variant	P	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	810	Natural variant	N	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	826	Natural variant	T	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	835	Natural variant	H	1.0	description:in BROVCA1; unknown pathological significance; dbSNP
P38398	841	Natural variant	R	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	841	Natural variant	R	1.0	description:in BROVCA1; unknown pathological significance; dbSNP
P38398	856	Natural variant	Y	1.0	description:in a patient with sporadic breast cancer; unknown pathological significance; dbSNP
P38398	866	Natural variant	R	1.0	description:in BC; unknown pathological significance
P38398	888	Natural variant	H	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	892	Natural variant	L	1.0	description:in BC; dbSNP
P38398	960	Natural variant	G	1.0	description:in BC; dbSNP
P38398	1025	Natural variant	T	1.0	description:in BC; dbSNP
P38398	1047	Natural variant	V	1.0	description:in BC; dbSNP
P38398	1101	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1139	Natural variant	S	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	1140	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1140	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro
P38398	1150	Natural variant	P	1.0	description:in BC; dbSNP
P38398	1187	Natural variant	S	1.0	description:in BC and BROVCA1
P38398	1200	Natural variant	Q	1.0	description:in BC and BROVCA1; dbSNP
P38398	1204	Natural variant	R	1.0	description:in BC
P38398	1207	Natural variant	K	1.0	description:in BC
P38398	1210	Natural variant	E	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	1214	Natural variant	E	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1217	Natural variant	S	1.0	description:in BC and BROVCA1
P38398	1219	Natural variant	E	1.0	description:found in breast-ovarian cancer patients; unknown pathological significance; dbSNP
P38398	1226	Natural variant	F	1.0	description:in BROVCA1
P38398	1236	Natural variant	N	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1243	Natural variant	R	1.0	description:in BROVCA1
P38398	1267	Natural variant	L	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1282	Natural variant	E	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1297	Natural variant	S	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	1297	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro
P38398	1301	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1346	Natural variant	E	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1378	Natural variant	V	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1400	Natural variant	M	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1407	Natural variant	L	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1411	Natural variant	M	1.0	description:in BC and ovarian cancer; unknown pathological significance; decreased interaction with PALB2; dbSNP
P38398	1443	Natural variant	R	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1448	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1486	Natural variant	S	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1495	Natural variant	R	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	1534	Natural variant	V	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro; dbSNP
P38398	1561	Natural variant	T	1.0	description:found in breast cancer; unknown pathological significance; dbSNP
P38398	1589	Natural variant	R	1.0	description:in BC; unknown pathological significance; functionally neutral in vitro
P38398	1606	Natural variant	K	1.0	description:found in breast cancer; unknown pathological significance; dbSNP
P38398	1623	Natural variant	A	1.0	description:could be associated with cancer susceptibility; major splicing aberration identified with this mutant; dbSNP
P38398	1628	Natural variant	M	1.0	description:in some patients with sporadic breast cancer; unknown pathological significance; dbSNP
P38398	1628	Natural variant	M	1.0	description:found in breast and ovarian cancer patients; unknown pathological significance; dbSNP
P38398	1641	Natural variant	A	1.0	description:in ovarian cancer; unknown pathological significance; dbSNP
P38398	1738	Natural variant	G	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	1739	Natural variant	D	1.0	description:in BC; unknown pathological significance; functionally impaired in vitro; dbSNP
P38398	1739	Natural variant	D	1.0	description:in BC; unknown pathological significance; functionally impaired in vitro; dbSNP
P38398	1746	Natural variant	H	1.0	description:in BC; unknown pathological significance; dbSNP
P38398	1749	Natural variant	P	1.0	description:in ovarian cancer; unknown pathological significance; abolishes ACACA binding and strongly reduces BRIP1 binding; dbSNP
P38398	1753	Natural variant	R	1.0	description:in BC; unknown pathological significance; dbSNP
O75531	12	Natural variant	A	1.0	description:in NGPS; shows a dramatic reduction in BANF1 protein levels indicating that the mutation impairs protein stability; dbSNP
Q9BXL6	420	Natural variant	T	1.0	description:in PSORS2; unknown pathological significance; decreases NF-kappaB transcription factor activity; dbSNP
Q6P1J9	91	Natural variant	R	1.0	description:found in a patient with isolated hyperparathyroidism and parathyroid adenomas
Q6P1J9	95	Natural variant	L	1.0	description:in HRPT1; unknown pathological significance; found as somatic mutation in a parathyroid adenoma sample from a patient who also carries a germline frameshift mutation
Q6P1J9	272	Natural variant	N	1.0	description:found in a parathyroid adenoma sample; dbSNP
Q6P1J9	292	Natural variant	R	1.0	description:found in a Wilms tumor sample; somatic mutation
Q6P1J9	379	Natural variant	D	1.0	description:in HRPT2; dbSNP
P12110	271	Natural variant	G	1.0	description:in BTHLM1; dbSNP
P12110	283	Natural variant	G	1.0	description:in UCMD1; dbSNP
P12110	498	Natural variant	R	1.0	description:in UCMD1; dbSNP
P12110	531	Natural variant	G	1.0	description:in UCMD1
Q16280	97	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P50052	21	Natural variant	G	1.0	description:rare variant found in patients with X-linked intellectual disability; unknown pathological significance; dbSNP
P08588	49	Natural variant	S	1.0	description:common variant associated with low mean resting heart rate; associated with decreased mortality risk in patients with congestive heart failure; dbSNP
P08913	266	Natural variant	N	1.0	description:frequency in Caucasians 0.004 and in African-Americans 0.05; 40% increase in agonist-promoted Gi coupling; dbSNP
O75179	1880	Natural variant	S	1.0	description:in CAGS
O75179	2434	Natural variant	R	1.0	description:in CAGS
P15336	352	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q76LX8	7	Natural variant	R	1.0	description:does not affect protein secretion; dbSNP
Q76LX8	234	Natural variant	H	1.0	description:in TTP; dbSNP
Q76LX8	235	Natural variant	D	1.0	description:in TTP; dbSNP
Q76LX8	250	Natural variant	A	1.0	description:in TTP; mild effect on protein secretion; strong reduction of proteolytic activity; dbSNP
Q76LX8	263	Natural variant	S	1.0	description:in TTP; dbSNP
Q76LX8	268	Natural variant	R	1.0	description:in TTP; affects protein secretion; dbSNP
Q08289	99	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q08289	535	Natural variant	S	1.0	description:in BRGDA4; unknown pathological significance; affects channel activity; dbSNP
P41180	11	Natural variant	L	1.0	description:in HHC1; demonstrates reduced intracellular and plasma membrane expression and signaling to the MAPK pathway in response to extracellular calcium relative to wild-type; fails to be inserted in the microsomes and does not undergo proper glycosylation; dbSNP
P41180	13	Natural variant	L	1.0	description:in HHC1; has a dose-response curve shifted to the right relative to that of wild-type; demonstrates reduced intracellular and plasma membrane expression and signaling to the MAPK pathway in response to extracellular calcium relative to wild-type; fails to be inserted in the microsomes and does not undergo proper glycosylation; dbSNP
P41180	14	Natural variant	T	1.0	description:does not demonstrate reduced intracellular and plasma membrane expression and signaling to the MAPK pathway in response to extracellular calcium relative to wild-type; does not fail to be inserted in the microsomes and does undergo proper glycosylation; dbSNP
P41180	21	Natural variant	G	1.0	description:in HHC1; dbSNP
P41180	886	Natural variant	R	1.0	description:in HHC1
P41180	898	Natural variant	R	1.0	description:in EIG8; dbSNP
P41180	972	Natural variant	T	1.0	description:in HHC1; decreased G-protein coupled receptor signaling pathway; dbSNP
P41180	986	Natural variant	A	1.0	description:associated with high serum level of calcium; is also a potential predisposing factor in disorders of bone and mineral metabolism; dbSNP
P41180	988	Natural variant	A	1.0	description:in EIG8; patients present juvenile myoclonus epilepsy
P41180	988	Natural variant	A	1.0	description:in EIG8; patients present juvenile myoclonus epilepsy; dbSNP
P41180	990	Natural variant	R	1.0	description:associated with low serum level of calcium; dbSNP
Q14839	1608	Natural variant	V	1.0	description:in SIHIWES; unknown pathological significance; dbSNP
Q15848	84	Natural variant	G	1.0	description:does not form high molecular weight multimers; dbSNP
Q15848	90	Natural variant	G	1.0	description:does not form high molecular weight multimers; dbSNP
O95500	232	Natural variant	G	1.0	description:in DFNB29; dbSNP
Q13315	848	Natural variant	E	1.0	description:in a lung adenocarcinoma sample; somatic mutation; dbSNP
Q13315	869	Natural variant	A	1.0	description:found in a patient with familial pancreatic cancer; unknown pathological significance
Q13315	1991	Natural variant	E	1.0	description:in a renal clear cell carcinoma sample; somatic mutation; dbSNP
P54259	1054	Natural variant	H	1.0	description:in CHEDDA
P54259	1058	Natural variant	H	1.0	description:in CHEDDA
P54259	1060	Natural variant	H	1.0	description:in CHEDDA; the mutation resulted in a perturbation of the structural and functional integrity of the HX repeat; altered zinc-binding properties of the HX repeat
P54259	1062	Natural variant	H	1.0	description:in CHEDDA
P54259	1062	Natural variant	H	1.0	description:in CHEDDA
P54259	1063	Natural variant	L	1.0	description:in CHEDDA
Q8TDC3	303	Natural variant	R	1.0	description:in a gastric adenocarcinoma sample; somatic mutation; dbSNP
Q8TDC3	391	Natural variant	G	1.0	description:in a metastatic melanoma sample; somatic mutation
Q9P296	323	Natural variant	S	1.0	description:found in a family with familial combined hyperlipemia; unknown pathological significance; associated with increased plasma triglyceride, plasma cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and ASP; dbSNP
Q8N0U7	151	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation
P22681	499	Natural variant	R	1.0	description:found in patients with acute myeloid leukemia; unknown pathological significance
Q96EP1	166	Natural variant	P	1.0	description:in a patient with non small cell lung carcinomas; homozygous; dbSNP
Q96EP1	202	Natural variant	R	1.0	description:in a patient with non small cell lung carcinomas
Q9UNE7	28	Natural variant	E	1.0	description:in SCAR16; reduces protein level; does not reduce ubiquitin ligase activity and autoubiquitination
P10643	220	Natural variant	R	1.0	description:in C7D; dbSNP
P10643	521	Natural variant	R	1.0	description:in C7D; dbSNP
Q9UPZ9	305	Natural variant	K	1.0	description:in EJM10; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system; dbSNP
Q9UPZ9	615	Natural variant	A	1.0	description:in EJM10; unknown pathological significance; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system; dbSNP
Q9UPZ9	632	Natural variant	R	1.0	description:in EJM10; impairs mitosis, cell-cycle exit and radial neuroblast migration, while promoting apoptosis, when tested in a heterologous system
Q99715	2786	Natural variant	G	1.0	description:in BTHLM2; dbSNP
Q8N302	133	Natural variant	E	1.0	description:in KTS; in 5 patients; displays a stronger angiogenic activity; dbSNP
Q96PE1	29	Natural variant	P	1.0	description:found in a family with atypical autism and severe epilepsy; unknown pathological significance
Q8IZF3	674	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P05089	11	Natural variant	I	1.0	description:in ARGIN; 12% of wild-type activity; dbSNP
Q86XL3	8	Natural variant	A	1.0	description:in MCPH16; unknown pathological significance; dbSNP
Q86XL3	27	Natural variant	A	1.0	description:in MCPH16; unknown pathological significance
Q96QS3	33	Natural variant	L	1.0	description:in XLID29; dbSNP
Q96QS3	115	Natural variant	A	1.0	description:in DEE1
Q96QS3	155	Natural variant	A	1.0	description:in DEE1 and PRTS; also found in non-specific intellectual disability families; frequent variant
Q96QS3	286	Natural variant	G	1.0	description:in XLID29; dbSNP
Q96QS3	521	Natural variant	A	1.0	description:in LISX2; severe phenotype; dbSNP
Q6RI45	1596	Natural variant	K	1.0	description:in XLID93; unknown pathological significance; dbSNP
P08236	30	Natural variant	P	1.0	description:in MPS7; dbSNP
Q13936	28	Natural variant	A	1.0	description:in LQT8; unknown pathological significance; increased channel activity
Q13936	39	Natural variant	A	1.0	description:in BRGDA3; unknown pathological significance; affects channel activity
Q13936	456	Natural variant	M	1.0	description:in LQT8; unknown pathological significance; no effect on channel activity
Q13936	477	Natural variant	E	1.0	description:in LQT8; unknown pathological significance
Q13936	490	Natural variant	G	1.0	description:in BRGDA3; unknown pathological significance; affects channel activity
Q13936	834	Natural variant	K	1.0	description:in LQT8; unknown pathological significance
Q13936	850	Natural variant	E	1.0	description:rare variant; found in a case of sudden unexplained death in the young; unknown pathological significance; results in reduced whole-cell calcium currents
Q13936	857	Natural variant	P	1.0	description:in LQT8
Q13936	857	Natural variant	P	1.0	description:in LQT8; leads to increased calcium currents; increased surface membrane expression of the channel
Q13936	858	Natural variant	R	1.0	description:in LQT8; gain-of-function effect on channel activity; slower inactivation
Q13936	860	Natural variant	R	1.0	description:in LQT8; gain-of-function effect on channel activity
Q13936	878	Natural variant	S	1.0	description:found in a clear cell renal carcinoma case; somatic mutation
Q13936	1787	Natural variant	D	1.0	description:in LQT8; unknown pathological significance
Q13936	1800	Natural variant	T	1.0	description:in LQT8; unknown pathological significance
Q13936	1831	Natural variant	G	1.0	description:in LQT8; unknown pathological significance; no effect on channel activity
Q13936	1948	Natural variant	E	1.0	description:in LQT8; unknown pathological significance
Q13936	1953	Natural variant	T	1.0	description:in LQT8; unknown pathological significance
Q13936	1989	Natural variant	R	1.0	description:in LQT8; unknown pathological significance
Q13936	2081	Natural variant	T	1.0	description:in LQT8; unknown pathological significance; dbSNP
Q13936	2091	Natural variant	A	1.0	description:rare variant; found in a case of sudden unexplained death in the young; unknown pathological significance; results in increased whole-cell calcium currents
Q13936	2097	Natural variant	V	1.0	description:in LQT8; unknown pathological significance
Q13936	2122	Natural variant	A	1.0	description:in LQT8; unknown pathological significance; dbSNP
P49715	84	Natural variant	H	1.0	description:in AML; no effect on expression; no effect on DNA-binding or transactivation activity; dbSNP
Q9BYV8	360	Natural variant	R	1.0	description:probable disease-associated variant found in a patient with Joubert syndrome; digenic inheritance; the patient also carries mutation A-1447 in CC2D2A; dbSNP
Q9Y592	684	Natural variant	E	1.0	description:in NPHP18; accumulates in the nucleus
Q9Y592	692	Natural variant	Q	1.0	description:in NPHP18; accumulates in the nucleus; does not interact with CEP164 and IFT20
Q14738	53	Natural variant	P	1.0	description:found in a patient with delayed psychomotor development, no speech and cataracts; no effect on binding to subunit PPP2CA; no effect on binding to subunit PPP2R1A; dbSNP
Q14738	198	Natural variant	E	1.0	description:in MRD35; decreases binding to subunit PPP2CA; decreases binding to subunit PPP2R1A; dbSNP
P51788	22	Natural variant	M	1.0	description:in HALD2; increased voltage-gated chloride currents due to higher channel open probabilities at physiological cell membrane potentials; dbSNP
P51788	24	Natural variant	G	1.0	description:in HALD2; increased voltage-gated chloride currents; increased aldosterone synthase expression; dbSNP
P51788	26	Natural variant	Y	1.0	description:in HALD2; increased voltage-gated chloride currents due to higher channel open probabilitiesat at physiological cell membrane potentials; dbSNP
P51788	48	Natural variant	P	1.0	description:reduces channel activity; dbSNP
P51788	644	Natural variant	R	1.0	description:no effect; dbSNP
P51788	646	Natural variant	R	1.0	description:reduces channel activity; dbSNP
P51788	715	Natural variant	G	1.0	description:in JAE2; unknown pathological significance; dbSNP
P51788	719	Natural variant	S	1.0	description:found in a patient with childhood absence epilepsy; unknown pathological significance; dbSNP
P51788	725	Natural variant	R	1.0	description:slightly faster channel activation; dbSNP
P51788	747	Natural variant	R	1.0	description:slightly faster channel activation; dbSNP
P51788	865	Natural variant	S	1.0	description:in HALD2; increased voltage-gated chloride currents due to higher channel open probabilities at physiological cell membrane potentials; dbSNP
Q12934	348	Natural variant	D	1.0	description:in CTRCT33; dbSNP
O95999	134	Natural variant	S	1.0	description:found in a MALT lymphoma sample; unknown pathological significance
O95999	162	Natural variant	T	1.0	description:found in a testicular teratoma sample; somatic mutation; dbSNP
O95999	168	Natural variant	T	1.0	description:found in a MALT lymphoma sample; unknown pathological significance; dbSNP
O95999	174	Natural variant	L	1.0	description:found in a MALT lymphoma sample; unknown pathological significance
O95999	210	Natural variant	E	1.0	description:found in a follicular lymphoma sample; unknown pathological significance
O95999	213	Natural variant	G	1.0	description:found in a MALT lymphoma sample; unknown pathological significance; dbSNP
O95999	218	Natural variant	S	1.0	description:found in a germ cell tumor and other cancer cell lines; unknown pathological significance
O95999	230	Natural variant	V	1.0	description:found in a MALT lymphoma sample; unknown pathological significance
O96017	17	Natural variant	A	1.0	description:in an osteogenic sarcoma sample; somatic mutation; might influence susceptibility to breast cancer; does not cause protein abrogation in familial colorectal cancer; dbSNP
O96017	59	Natural variant	T	1.0	description:in multiple cancers; dbSNP
O96017	64	Natural variant	E	1.0	description:in prostate cancer; somatic mutation; dbSNP
O96017	85	Natural variant	P	1.0	description:in an osteogenic sarcoma sample; neutral allele among Ashkenazi Jewish women; dbSNP
Q12873	1236	Natural variant	L	1.0	description:in SNIBCPS; dbSNP
Q12873	1342	Natural variant	R	1.0	description:in SNIBCPS; dbSNP
P41002	3	Natural variant	S	1.0	description:in FTDALS5; unknown pathological significance; impaired degradation by the ubiquitin proteasome system (UPS); dbSNP
P41002	543	Natural variant	T	1.0	description:in FTDALS5; unknown pathological significance; dbSNP
P41002	621	Natural variant	S	1.0	description:in FTDALS5; increased 'Lys-48'-linked polyubiquitination of proteins targeted for proteasomal degradation, but no increase in 'Lys-63'-linked polyubiquitinated proteins; accumulation of ubiquitinated proteins including RRM2 and TARDBP/TDP43; impaired autophagosome-lysosome fusion; impaired degradation by the ubiquitin proteasome system (UPS); increased levels of ubiquitinated autophagy receptor SQSTM1/p62; dbSNP
P41002	624	Natural variant	E	1.0	description:in FTDALS5; impaired degradation by the ubiquitin proteasome system (UPS); dbSNP
P41002	772	Natural variant	I	1.0	description:in FTDALS5; unknown pathological significance; impaired degradation by the ubiquitin proteasome system (UPS); dbSNP
Q9ULV3	47	Natural variant	P	1.0	description:probable disease-associated variant found in patients with adult onset primary cervical dystonia
Q9ULV3	264	Natural variant	S	1.0	description:probable disease-associated variant found in a family with adult onset primary cervical dystonia; exonic splicing enhancer mutation resulting in altered CIZ1 splicing pattern; dbSNP
Q9Y215	59	Natural variant	P	1.0	description:in CMS5; abrogates binding to T subunit
P78314	415	Natural variant	R	1.0	description:in CRBM; dbSNP
P78314	415	Natural variant	R	1.0	description:in CRBM; dbSNP
P78314	418	Natural variant	P	1.0	description:in CRBM; dbSNP
P78314	418	Natural variant	P	1.0	description:in CRBM; dbSNP
P78314	418	Natural variant	P	1.0	description:in CRBM; dbSNP
P78314	420	Natural variant	G	1.0	description:in CRBM; dbSNP
P78314	420	Natural variant	G	1.0	description:in CRBM; dbSNP
Q6W2J9	85	Natural variant	P	1.0	description:in MCOPS2; dbSNP
P10415	59	Natural variant	P	1.0	description:in non-Hodgkin lymphoma; somatic mutation
O00555	287	Natural variant	C	1.0	description:in EA2; dbSNP
O00555	405	Natural variant	A	1.0	description:in SCA6; dbSNP
O00555	797	Natural variant	M	1.0	description:in EA2; dbSNP
O00555	896	Natural variant	P	1.0	description:in EA2; dbSNP
O00555	2134	Natural variant	R	1.0	description:in EA2; dbSNP
O76039	368	Natural variant	N	1.0	description:in a colorectal cancer sample; somatic mutation
O76039	374	Natural variant	A	1.0	description:in a metastatic melanoma sample; somatic mutation
O76039	399	Natural variant	N	1.0	description:in DEE2; dbSNP
O76039	574	Natural variant	P	1.0	description:in an ovarian serous carcinoma sample; somatic mutation; dbSNP
O76039	581	Natural variant	H	1.0	description:in DEE2; unknown pathological significance
O76039	647	Natural variant	P	1.0	description:probable disease-associated variant found in a patient with autism spectrum disorder
O76039	718	Natural variant	V	1.0	description:in DEE2; dbSNP
O76039	793	Natural variant	V	1.0	description:in DEE2; unknown pathological significance; dbSNP
O76039	858	Natural variant	R	1.0	description:in DEE2; unknown pathological significance; dbSNP
P49336	424	Natural variant	R	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation
P05067	665	Natural variant	E	1.0	description:in a patient with late onset Alzheimer disease; dbSNP
P05067	678	Natural variant	D	1.0	description:in AD1; dbSNP
P05067	692	Natural variant	A	1.0	description:in AD1; Flemish mutation; increases the solubility of processed amyloid-beta peptides and increases the stability of peptide oligomers; dbSNP
P05067	693	Natural variant	E	1.0	description:in AD1; dbSNP
P05067	693	Natural variant	E	1.0	description:in CAA-APP; Italian type; dbSNP
P05067	693	Natural variant	E	1.0	description:in CAA-APP; Dutch type; dbSNP
P05067	694	Natural variant	D	1.0	description:in CAA-APP; Iowa type; dbSNP
P04075	347	Natural variant	G	1.0	description:in GSD12; likely benign variant; does not affect thermal stability; 4-fold decrease in catalytic efficiency due to reduced enzyme activity; dbSNP
Q9BT22	258	Natural variant	S	1.0	description:in CDG1K; decreased function in protein glycosylation as shown by rescue assays in an ALG1-deficient yeast strain; dbSNP
Q6UB98	307	Natural variant	S	1.0	description:de novo variant found in a patient with childhood apraxia of speech; unknown pathological significance
P54710	41	Natural variant	G	1.0	description:in HOMG2; fails to localize to plasma membrane; dbSNP
Q6ZN30	346	Natural variant	E	1.0	description:in LUTO; unknown pathological significance; dbSNP
Q14781	98	Natural variant	P	1.0	description:in SRXY5; dbSNP
Q14781	443	Natural variant	R	1.0	description:in SRXY5; dbSNP
P25067	304	Natural variant	R	1.0	description:in FECD1; dbSNP
P25067	357	Natural variant	G	1.0	description:in FECD1; unknown pathological significance; dbSNP
P25067	434	Natural variant	R	1.0	description:in FECD1; dbSNP
P25067	455	Natural variant	Q	1.0	description:in FECD1 and PPCD2; dbSNP
P12109	272	Natural variant	G	1.0	description:in BTHLM1; dbSNP
P12109	274	Natural variant	P	1.0	description:in BTHLM1; dbSNP
P12109	275	Natural variant	G	1.0	description:in BTHLM1; dbSNP
P12109	281	Natural variant	G	1.0	description:in UCMD1; dbSNP
P12109	284	Natural variant	G	1.0	description:in UCMD1; fibroblasts with the mutation assembled and secreted normal collagen VI microfibrils; cell adhesion of heterozygous Arg-284 fibroblasts is markedly decreased but can be rescued by the addition of normal collagen VI; dbSNP
P12109	290	Natural variant	G	1.0	description:in BTHLM1 and UCMD1; dbSNP
P12109	305	Natural variant	G	1.0	description:in BTHLM1
P12109	341	Natural variant	G	1.0	description:in BTHLM1; dbSNP
P12109	341	Natural variant	G	1.0	description:in BTHLM1; dbSNP
P12109	571	Natural variant	K	1.0	description:in BTHLM1; dbSNP
P63104	230	Natural variant	S	1.0	description:found in a patient with a neurodevelopmental disorder; unknown pathological significance; gain-of-function mutation in signal transduction; changed regulation of ERK1 and ERK2 cascade; increased interaction with BRAF; increased interaction with RAF1; loss of phosphorylation by CK1 at Thr-232
P51826	231	Natural variant	P	1.0	description:in KINS
P51826	231	Natural variant	P	1.0	description:in KINS
P51826	233	Natural variant	A	1.0	description:in KINS
P51826	233	Natural variant	A	1.0	description:in KINS
P51826	233	Natural variant	A	1.0	description:in KINS
P51826	235	Natural variant	V	1.0	description:in KINS
P58335	381	Natural variant	Y	1.0	description:in HFS; dbSNP
Q8TE60	202	Natural variant	L	1.0	description:in MMCAT; dbSNP
Q13873	138	Natural variant	P	1.0	description:in PPH1; unknown pathological significance; unchanged subcellular localization
Q13873	182	Natural variant	G	1.0	description:in PPH1; dbSNP
Q13873	519	Natural variant	N	1.0	description:in PPH1; dbSNP
Q13873	775	Natural variant	S	1.0	description:unchanged subcellular localization; dbSNP
Q13873	863	Natural variant	S	1.0	description:in PPH1; abnormal subcellular localization; significant increase in apoptosis of endothelial cells; significant decrease in proliferation of endothelial cells; significant decrease in nitric oxide synthesis by endothelial cells; significant increase in endothelin 1 synthesis by endothelial cells; dbSNP
Q13873	899	Natural variant	R	1.0	description:in PPH1; leads to constitutive activation of the MAPK14 pathway; dbSNP
P55291	8	Natural variant	V	1.0	description:in MRD3; uncertain pathological significance; dbSNP
Q08AD1	361	Natural variant	I	1.0	description:in a colorectal cancer sample; somatic mutation
Q8TD31	776	Natural variant	S	1.0	description:in allele HCR*WWCC; associated with psoriasis; dbSNP
P30260	270	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
Q9HCU0	6	Natural variant	L	1.0	description:in a colorectal cancer sample; somatic mutation
P02748	119	Natural variant	C	1.0	description:in C9D; dbSNP
Q93099	3	Natural variant	E	1.0	description:in AKU; dbSNP
Q93099	13	Natural variant	E	1.0	description:in AKU; dbSNP
Q93099	18	Natural variant	D	1.0	description:in AKU
Q93099	25	Natural variant	L	1.0	description:in AKU
Q92826	84	Natural variant	G	1.0	description:in PC; rare variant associated with disease susceptibility; dbSNP
Q92826	88	Natural variant	Y	1.0	description:found in prostate cancer samples; unknown pathological significance
Q92826	144	Natural variant	L	1.0	description:found in prostate cancer samples; unknown pathological significance
Q92826	216	Natural variant	G	1.0	description:found in prostate cancer samples; unknown pathological significance; dbSNP
Q9UPT6	400	Natural variant	G	1.0	description:in NEDBA; unknown pathological significance; dbSNP
Q9UPT6	578	Natural variant	R	1.0	description:in NEDBA; affects axon development when expressed in a heterologous system; dbSNP
Q2LD37	1329	Natural variant	Y	1.0	description:in ALKKUCS; unknown pathological significance; dbSNP
Q2LD37	1573	Natural variant	M	1.0	description:in ALKKUCS; unknown pathological significance; dbSNP
Q2LD37	1958	Natural variant	R	1.0	description:in ALKKUCS; unknown pathological significance; dbSNP
Q2LD37	3050	Natural variant	P	1.0	description:in ALKKUCS; unknown pathological significance
P22459	89	Natural variant	R	1.0	description:in MCIDDS; unknown pathological significance; mildly decreased function in potassium transmembrane transport; dbSNP
Q99732	23	Natural variant	Y	1.0	description:in one EMPD primary tumor; somatic mutation
Q99732	49	Natural variant	T	1.0	description:in CMT1C; dbSNP
Q96T58	990	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q96T58	1488	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation
Q86YV6	78	Natural variant	A	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation; dbSNP
P01185	17	Natural variant	S	1.0	description:in NDI
P01185	19	Natural variant	A	1.0	description:in NDI; probably causes insufficient processing of precursor; dbSNP
P01185	19	Natural variant	A	1.0	description:in NDI; dbSNP
P01185	21	Natural variant	Y	1.0	description:in NDI; dbSNP
P01185	26	Natural variant	P	1.0	description:in NDI; weakly active; dbSNP
Q8NG66	492	Natural variant	E	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
O95970	26	Natural variant	L	1.0	description:in ETL1; probably affects signal sequence processing and secretion
Q9ULD2	75	Natural variant	Q	1.0	description:in HCC; dbSNP
Q9ULD2	186	Natural variant	T	1.0	description:in HNSCC cell lines; dbSNP
Q9ULD2	563	Natural variant	A	1.0	description:in HCC
Q9ULD2	873	Natural variant	N	1.0	description:in HCC; dbSNP
Q6NSW7	16	Natural variant	E	1.0	description:found in ethnically diverse individuals; dbSNP
Q00604	13	Natural variant	L	1.0	description:in ND; dbSNP
Q00604	16	Natural variant	L	1.0	description:in ND
Q00604	18	Natural variant	I	1.0	description:in EVR2; the patient presented significant phenotypic heterogeneity between the two eyes
Q00604	38	Natural variant	R	1.0	description:in ND and EVR2; dbSNP
Q00604	39	Natural variant	C	1.0	description:in ND
Q00604	41	Natural variant	R	1.0	description:in EVR2
Q00604	41	Natural variant	R	1.0	description:in persistent fetal vasculature syndrome
Q00604	42	Natural variant	H	1.0	description:in EVR2; dbSNP
Q00604	43	Natural variant	H	1.0	description:in ND
Q00604	43	Natural variant	H	1.0	description:in ND
Q00604	44	Natural variant	Y	1.0	description:in ND; dbSNP
Q00604	45	Natural variant	V	1.0	description:in ND; dbSNP
Q00604	45	Natural variant	V	1.0	description:in ND
Q00604	54	Natural variant	K	1.0	description:in EVR2
Q00604	55	Natural variant	C	1.0	description:in ND
Q00604	58	Natural variant	K	1.0	description:in ND and EVR2
Q00604	60	Natural variant	V	1.0	description:in ND; reduction of protein amount in the extracellular matrix; dbSNP
Q00604	61	Natural variant	L	1.0	description:in ND; dbSNP
Q00604	61	Natural variant	L	1.0	description:in EVR2
Q00604	61	Natural variant	L	1.0	description:in ND
Q00604	63	Natural variant	A	1.0	description:in ND
Q00604	65	Natural variant	C	1.0	description:in ND
Q00604	65	Natural variant	C	1.0	description:in ND; dbSNP
Q00604	67	Natural variant	G	1.0	description:in ND; dbSNP
Q00604	67	Natural variant	G	1.0	description:in ND
Q00604	69	Natural variant	C	1.0	description:in ND; unknown pathological significance
Q00604	69	Natural variant	C	1.0	description:in ND; unknown pathological significance; dbSNP
Q00604	74	Natural variant	R	1.0	description:in ND; dbSNP
Q00604	75	Natural variant	S	1.0	description:in ND; dbSNP
Q00604	75	Natural variant	S	1.0	description:in ND
Q00604	89	Natural variant	F	1.0	description:in ND; dbSNP
Q00604	90	Natural variant	R	1.0	description:in ND; dbSNP
Q00604	90	Natural variant	R	1.0	description:in ND; dbSNP
Q00604	92	Natural variant	S	1.0	description:in ND
Q00604	95	Natural variant	C	1.0	description:in ND
Q00604	95	Natural variant	C	1.0	description:in ND
Q00604	96	Natural variant	C	1.0	description:in ND; dbSNP
Q00604	96	Natural variant	C	1.0	description:in ND; dbSNP
Q00604	97	Natural variant	R	1.0	description:in ND
Q00604	98	Natural variant	P	1.0	description:in ND
Q00604	101	Natural variant	S	1.0	description:in ND; dbSNP
Q00604	103	Natural variant	L	1.0	description:in EVR2
Q00604	104	Natural variant	K	1.0	description:in ND
Q00604	104	Natural variant	K	1.0	description:in ND
Q00604	105	Natural variant	A	1.0	description:in ND; dbSNP
Q00604	108	Natural variant	L	1.0	description:in retinopathy of prematurity
Q00604	110	Natural variant	C	1.0	description:in ND; dbSNP
Q00604	110	Natural variant	C	1.0	description:in ND
Q00604	112	Natural variant	G	1.0	description:in ND
Q00604	115	Natural variant	R	1.0	description:in EVR2
Q00604	118	Natural variant	A	1.0	description:in ND
Q00604	120	Natural variant	Y	1.0	description:in EVR2
Q00604	121	Natural variant	R	1.0	description:in EVR2
Q00604	121	Natural variant	R	1.0	description:in EVR2; dbSNP
Q00604	121	Natural variant	R	1.0	description:in EVR2 and ND; reduced amount of protein in the extracellular matrix
Q00604	121	Natural variant	R	1.0	description:in ND and EVR2; dbSNP
Q00604	123	Natural variant	I	1.0	description:in ND
Q00604	124	Natural variant	L	1.0	description:in EVR2; dbSNP
Q00604	126	Natural variant	C	1.0	description:in ND
Q00604	128	Natural variant	C	1.0	description:in ND
Q6X4W1	196	Natural variant	R	1.0	description:in HH9; phenotype consistent with Kallmann syndrome; the patient also carries a mutation in FGFR1; dbSNP
Q9H2S1	30	Natural variant	E	1.0	description:in NEDMAB; unknown pathological significance; no effect on channel function
Q13887	301	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation
Q8NEZ4	3698	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation
O00217	18	Natural variant	R	1.0	description:in MC1DN2; unknown pathological significance; dbSNP
P07196	7	Natural variant	E	1.0	description:in a Charcot-Marie-Tooth disease patient; dbSNP
P07196	8	Natural variant	P	1.0	description:in CMT1F; dbSNP
P07196	8	Natural variant	P	1.0	description:in CMT1F; dbSNP
P07196	8	Natural variant	P	1.0	description:in CMT2E and CMT1F; dbSNP
P07196	22	Natural variant	P	1.0	description:in CMT2E; dbSNP
P07196	440	Natural variant	P	1.0	description:in CMT2E; unknown pathological significance; dbSNP
P07196	527	Natural variant	E	1.0	description:in CMT1F; dbSNP
A1L188	55	Natural variant	F	1.0	description:in MC1DN34; unknown pathological significance; dbSNP
O00712	356	Natural variant	S	1.0	description:in MACID; likely benign variant; does not affect GFAP transcriptional activation; dbSNP
P46821	574	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P46821	1400	Natural variant	S	1.0	description:in DFNA83; unknown pathological significance; reduced neurite length in otic sensory neuron-like cells from patient-derived indifferentiated pluripotent stem cells
Q14680	460	Natural variant	T	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP
Q14432	445	Natural variant	T	1.0	description:in HTNB; increased 3',5'-cyclic-AMP phosphodiesterase activity; increased function in cAMP-mediated signaling; dbSNP
Q14432	445	Natural variant	T	1.0	description:in HTNB; increased phosphorylation at S-428 and S-438; increased affinity for 3',5'-cyclic-AMP; no effect on protein reaction kinetics for 3',5'-cyclic-AMP phosphodiesterase activity; increased 3',5'-cyclic-AMP phosphodiesterase activity; no effect on inhibition by 3',5'-cyclic-GMP; changed function in cAMP-mediated signaling; dbSNP
Q14432	445	Natural variant	T	1.0	description:in HTNB; increased 3',5'-cyclic-AMP phosphodiesterase activity; changed function in cAMP-mediated signaling; dbSNP
Q14432	447	Natural variant	A	1.0	description:in HTNB; increased 3',5'-cyclic-AMP phosphodiesterase activity; changed function in cAMP-mediated signaling; dbSNP
Q14432	447	Natural variant	A	1.0	description:in HTNB; increased 3',5'-cyclic-AMP phosphodiesterase activity; changed function in cAMP-mediated signaling; dbSNP
Q14432	449	Natural variant	G	1.0	description:in HTNB; increased 3',5'-cyclic-AMP phosphodiesterase activity; changed function in cAMP-mediated signaling; dbSNP
Q9NR99	862	Natural variant	S	1.0	description:in LNCR
Q9NR99	1028	Natural variant	V	1.0	description:in LNCR; unknown pathological significance
Q9NR99	1491	Natural variant	P	1.0	description:in LNCR; unknown pathological significance; dbSNP
Q13402	946	Natural variant	M	1.0	description:in USH1B; dbSNP
Q13402	955	Natural variant	G	1.0	description:in USH1B; dbSNP
Q13402	968	Natural variant	E	1.0	description:in USH1B; dbSNP
Q6KC79	15	Natural variant	G	1.0	description:in CDLS1; strongly inhibits interaction with SCC4
Q6KC79	29	Natural variant	P	1.0	description:in CDLS1; strongly inhibits interaction with SCC4
Q6KC79	70	Natural variant	N	1.0	description:in CDLS1
Q6KC79	73	Natural variant	S	1.0	description:in CDLS1; unknown pathological significance
Q6KC79	111	Natural variant	S	1.0	description:in CDLS1; no effect on interaction with SCC4
Q6KC79	179	Natural variant	A	1.0	description:in CDLS1; no effect on interaction with SCC4
Q6KC79	179	Natural variant	A	1.0	description:in CDLS1; benign variant; no effect on interaction with SCC4; dbSNP
Q6KC79	192	Natural variant	P	1.0	description:in CDLS1; no effect on interaction with SCC4
Q6KC79	246	Natural variant	D	1.0	description:in CDLS1; no effect on interaction with SCC4; dbSNP
Q6KC79	254	Natural variant	L	1.0	description:in CDLS1; no effect on interaction with SCC4
Q6KC79	351	Natural variant	P	1.0	description:in CDLS1
Q6KC79	357	Natural variant	K	1.0	description:in CDLS1
Q6KC79	868	Natural variant	R	1.0	description:in CDLS1; dbSNP
O43920	96	Natural variant	P	1.0	description:detected in a patient with mitochondrial complex I deficiency; uncertain pathological significance; dbSNP
Q9Y5X4	121	Natural variant	E	1.0	description:in ESCS; dbSNP
Q8WUJ1	7	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q8WUJ1	7	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation
P14923	19	Natural variant	T	1.0	description:in ARVD12; unknown pathological significance; dbSNP
P14923	39	Natural variant	S	1.0	description:in ARVD12; affects the structure and distribution of mechanical and electrical cell junctions
P98161	13	Natural variant	L	1.0	description:in PKD1
P98161	2889	Natural variant	S	1.0	description:in PKD1; dbSNP
P98161	3355	Natural variant	P	1.0	description:in PKD1; dbSNP
P98161	3375	Natural variant	V	1.0	description:in PKD1; dbSNP
P98161	3382	Natural variant	T	1.0	description:in PKD1; dbSNP
P98161	3511	Natural variant	L	1.0	description:in PKD1; unknown pathological significance; dbSNP
P98161	3632	Natural variant	E	1.0	description:in PKD1; dbSNP
P98161	3649	Natural variant	P	1.0	description:in PKD1
P98161	3651	Natural variant	G	1.0	description:in PKD1
P98161	4154	Natural variant	R	1.0	description:in PKD1; dbSNP
P98161	4155	Natural variant	F	1.0	description:in PKD1
P98161	4225	Natural variant	Q	1.0	description:in PKD1
P98161	4255	Natural variant	P	1.0	description:in PKD1
P98161	4276	Natural variant	R	1.0	description:in PKD1; dbSNP
Q6ZWH5	66	Natural variant	A	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP
Q86UW6	283	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q8IUG5	234	Natural variant	G	1.0	description:in a lung small cell carcinoma sample; somatic mutation
Q8IUG5	347	Natural variant	K	1.0	description:in a lung small cell carcinoma sample; somatic mutation
Q8IUG5	379	Natural variant	R	1.0	description:in a lung small cell carcinoma sample; somatic mutation; dbSNP
Q8IUG5	389	Natural variant	W	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q8IUG5	2295	Natural variant	G	1.0	description:in a lung small cell carcinoma sample; somatic mutation
Q8IUG5	2381	Natural variant	R	1.0	description:in a lung adenocarcinoma sample; somatic mutation; dbSNP
Q8IUG5	2554	Natural variant	D	1.0	description:in a lung large cell carcinoma sample; somatic mutation; dbSNP
P25189	216	Natural variant	T	1.0	description:in CMT1B; referred to as 'T216ER'
P25189	221	Natural variant	A	1.0	description:in DSS
P25189	224	Natural variant	D	1.0	description:in CMT1B; also in two asymptomatic individuals from the same family; dbSNP
P25189	227	Natural variant	R	1.0	description:in CMT1B
P25189	236	Natural variant	K	1.0	description:in CMT2I
P25189	236	Natural variant	K	1.0	description:in CMT1B
B2RTY4	1517	Natural variant	R	1.0	description:in CMS24; unknown pathological significance; dbSNP
B2RTY4	1698	Natural variant	D	1.0	description:in CMS24; unknown pathological significance; dbSNP
B2RTY4	2282	Natural variant	G	1.0	description:in CMS24; unknown pathological significance
B2RTY4	2283	Natural variant	R	1.0	description:in CMS24; unknown pathological significance; dbSNP
Q12879	685	Natural variant	V	1.0	description:in FESD; decreased protein abundance; decreased localization to the cell membrane; changed glutamate-gated calcium ion channel activity characterized by decreased glutamate potency; dbSNP
Q12879	694	Natural variant	I	1.0	description:in FESD; decreased protein abundance; decreased localization to the cell membrane; changed glutamate-gated calcium ion channel activity characterized by decreased glutamate potency and decreased open probability
Q12879	884	Natural variant	D	1.0	description:found in a patient with autism; unknown pathological significance; dbSNP
Q12879	889	Natural variant	G	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation
Q12879	904	Natural variant	I	1.0	description:in FESD; dbSNP
Q12879	920	Natural variant	R	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation
Q12879	929	Natural variant	S	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	933	Natural variant	D	1.0	description:in FESD; unknown pathological significance; dbSNP
Q12879	962	Natural variant	E	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	968	Natural variant	A	1.0	description:probable disease-associated variant found in a patient with schizophrenia
Q12879	976	Natural variant	N	1.0	description:in FESD; dbSNP
Q12879	989	Natural variant	N	1.0	description:found in a patient with neonatal onset epileptic encephalopathy; unknown pathological significance; dbSNP
Q12879	998	Natural variant	V	1.0	description:found in a patient with schizophrenia; unknown pathological significance; dbSNP
Q12879	1073	Natural variant	E	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation
Q12879	1074	Natural variant	P	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	1132	Natural variant	P	1.0	description:found in a cutaneous malignant melanoma sample
Q12879	1133	Natural variant	P	1.0	description:found in a cutaneous malignant melanoma sample
Q12879	1153	Natural variant	D	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	1175	Natural variant	E	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	1229	Natural variant	T	1.0	description:found in a patient with schizophrenia; unknown pathological significance; dbSNP
Q12879	1251	Natural variant	D	1.0	description:in FESD
Q12879	1276	Natural variant	A	1.0	description:found in a patient with continuous spike-wave discharges during slow-wave sleep; also found in a patient with drug-resistant focal epilepsy; also found in a cutaneous malignant melanoma sample as somatic mutation; unknown pathological significance; dbSNP
Q12879	1285	Natural variant	R	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	1318	Natural variant	R	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	1366	Natural variant	P	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation
Q12879	1421	Natural variant	D	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation
Q12879	1425	Natural variant	S	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	1426	Natural variant	E	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation; dbSNP
Q12879	1462	Natural variant	S	1.0	description:found in a cutaneous malignant melanoma sample; somatic mutation
Q9UMS0	21	Natural variant	R	1.0	description:in MMDS1; patient's skeletal muscles and fibroblasts show deficiency of mitochondrial respiratory chain complexes; dbSNP
P35658	424	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation
P35658	1378	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P35658	1392	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation
Q96G30	88	Natural variant	N	1.0	description:found in a patient with obesity; unknown pathological significance; dbSNP
P35749	1758	Natural variant	R	1.0	description:in AAT4; dbSNP
P12883	1929	Natural variant	T	1.0	description:in CMH1; unknown pathological significance; dbSNP
O60391	919	Natural variant	E	1.0	description:found in a patient with autism spectrum disorder; unknown pathological significance; dbSNP
O60391	948	Natural variant	A	1.0	description:found in a patient with schizophrenia; unknown pathological significance; dbSNP
Q86SG6	330	Natural variant	L	1.0	description:in NPHP9; a full-length mouse NEK8 construct containing the mutation shows a defect in ciliary localization with no apparent effect on ciliation, mitosis or centriole number; dbSNP
Q9BYU1	283	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
P52945	18	Natural variant	C	1.0	description:risk factor for type 2 diabetes; dbSNP
P52945	59	Natural variant	Q	1.0	description:risk factor for type 2 diabetes; dbSNP
P52945	76	Natural variant	D	1.0	description:risk factor for type 2 diabetes; dbSNP
P52945	243	Natural variant	P	1.0	description:risk factor for type 2 diabetes
P43405	342	Natural variant	P	1.0	description:in IMD82; constitutively active protein tyrosine kinase activity
P43405	353	Natural variant	A	1.0	description:in IMD82; constitutively active protein tyrosine kinase activity
Q15842	422	Natural variant	S	1.0	description:found in Brugada syndrome and other J-wave syndromes; unknown pathological significance; the mutant channel displays an increase in glibenclamide-sensitive potassium currents compared to wild type; dbSNP
Q9BRK4	121	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9BRK4	291	Natural variant	G	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q8NHW3	64	Natural variant	S	1.0	description:in INSDM; may prevent phosphorylation at S-65; may enhance protein stability; dbSNP
O43908	29	Natural variant	I	1.0	description:in allele NKG2-F*02; dbSNP
Q0ZGT2	131	Natural variant	Q	1.0	description:in CMH20; affects interaction with ACTA1 and F-actin; dbSNP
O60832	2	Natural variant	A	1.0	description:in DKCX; dbSNP
P0CJ72	13	Natural variant	T	1.0	description:decreased cytoprotective action; dbSNP
O15550	834	Natural variant	E	1.0	description:in a patient with chronic myelomonocytic leukemia
O15550	922	Natural variant	R	1.0	description:in a patient with chronic myelomonocytic leukemia
Q9GZU5	31	Natural variant	C	1.0	description:in CSNB1A; dbSNP
Q9GZU5	370	Natural variant	G	1.0	description:in CSNB1A; dbSNP
Q8NI22	81	Natural variant	D	1.0	description:in F5F8D2; dbSNP
Q8NI22	129	Natural variant	D	1.0	description:in F5F8D2; interferes with protein folding; dbSNP
Q8NI22	135	Natural variant	Y	1.0	description:in F5F8D2; dbSNP
Q8NI22	136	Natural variant	I	1.0	description:in F5F8D2; interferes with protein folding; dbSNP
D6RGH6	366	Natural variant	G	1.0	description:in CILD42; reduced number of cilia and basal bodies; dbSNP
D6RGH6	381	Natural variant	R	1.0	description:in CILD42; reduced expression; reduced number of cilia and basal bodies; dbSNP
P27448	570	Natural variant	R	1.0	description:in VIPB; dbSNP
Q8TDR0	520	Natural variant	M	1.0	description:in SLSN9; does not localize to the ciliary tip; dbSNP
P60201	116	Natural variant	T	1.0	description:in HLD1
P12829	11	Natural variant	E	1.0	description:in ATFB18; dbSNP
O76041	654	Natural variant	N	1.0	description:higher frequency of homozygotes in a cohort of non-familial cardiomyopathy Japanese patients as compared to healthy controls; dbSNP
Q15726	115	Natural variant	N	1.0	description:in HH13; significantly reduced efficacy as well as potency
Q32MK0	390	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q13952	165	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation
P08069	739	Natural variant	R	1.0	description:in IGF1RES; leads to failure of processing of the IGF1R proreceptor to mature IGF1R; dbSNP
P08069	1337	Natural variant	R	1.0	description:in IGF1RES; unknown pathological significance; significant decrease in IGF1-induced DNA synthesis; significant increase in IGF1-induced AKT1 phosphorylation in patient fibroblasts; dbSNP
P08069	1347	Natural variant	A	1.0	description:in a lung squamous cell carcinoma sample; somatic mutation
Q9P267	144	Natural variant	T	1.0	description:in MRD1; unknown pathological significance; dbSNP
Q9P267	461	Natural variant	R	1.0	description:in MRD1; unknown pathological significance; dbSNP
Q9P267	654	Natural variant	D	1.0	description:in MRD1; unknown pathological significance; dbSNP
Q9P267	655	Natural variant	A	1.0	description:in MRD1; unknown pathological significance; dbSNP
Q9P267	857	Natural variant	A	1.0	description:in MRD1; unknown pathological significance; dbSNP
Q9P267	1048	Natural variant	T	1.0	description:in MRD1; unknown pathological significance; dbSNP
Q13361	21	Natural variant	W	1.0	description:in AAT9; expression of the mutant protein is significantly decreased; dbSNP
Q99743	394	Natural variant	T	1.0	description:associated with non-Hodgkin's lymphoma and breast cancer risk; dbSNP
Q99743	471	Natural variant	S	1.0	description:susceptibility to seasonal affective disorder (SAD) and diurnal preference; dbSNP
Q8N2Q7	756	Natural variant	R	1.0	description:likely benign variant; does not affect dendritic spine formation; does not affect localization to plasma membrane
Q8N2Q7	835	Natural variant	H	1.0	description:in AUTS20; risk factor for disease development; decreased function in dendritic spine formation; decreased protein abundance; does not affect subcellular location
Q7Z2Y5	424	Natural variant	S	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation
Q7Z2Y5	880	Natural variant	I	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation; dbSNP
P07902	9	Natural variant	Q	1.0	description:in GALAC1; dbSNP
P07902	23	Natural variant	T	1.0	description:in GALAC1; dbSNP
P07902	103	Natural variant	Q	1.0	description:in GALAC1; dbSNP
P07902	112	Natural variant	S	1.0	description:in GALAC1; dbSNP
P07902	113	Natural variant	D	1.0	description:in GALAC1; dbSNP
P07902	114	Natural variant	H	1.0	description:in GALAC1; dbSNP
Q06210	111	Natural variant	R	1.0	description:in CMS12; dbSNP
P10070	608	Natural variant	P	1.0	description:in CJS; dbSNP
P10070	932	Natural variant	P	1.0	description:in HPE9; unknown pathological significance; dbSNP
P10070	1352	Natural variant	M	1.0	description:likely benign variant; associated with N-1520 in Culler-Jones syndrome; decreased transcription factor activity when associated with N-1520; dbSNP
P10070	1520	Natural variant	D	1.0	description:likely benign variant; associated with V-1352 in Culler-Jones syndrome; decreased transcription factor activity when associated with V-1352; dbSNP
P10070	1543	Natural variant	R	1.0	description:no effect on transcription factor activity; dbSNP
P10070	1554	Natural variant	P	1.0	description:in HPE9; unknown pathological significance; dbSNP
P41235	136	Natural variant	R	1.0	description:in MODY1; dbSNP
P41235	402	Natural variant	V	1.0	description:in NIDDM; reduced transactivation activity; dbSNP
Q00978	127	Natural variant	Q	1.0	description:does not affect transcriptional activation in response to type I interferon stimulation; does not affect anti-viral immunity; dbSNP
Q14953	237	Natural variant	E	1.0	description:in allele KIR2DS5*007; increases binding to C2 epitopes of HLA-C alleles when associated with G-179 in allele KIR2DS5*007
O43525	468	Natural variant	N	1.0	description:has no statistically significant effect on the current or biophysical properties of the heteromeric channel; dbSNP
O43525	574	Natural variant	P	1.0	description:rare variant; found in a patient with rolandic epilepsy and additional features such as mild developmental delay and abnormal behavior; unknown pathological significance; dbSNP
O43525	780	Natural variant	R	1.0	description:found in patients with benign familial infantile seizures; unknown pathological significance; dbSNP
Q99453	197	Natural variant	G	1.0	description:confers susceptibility to neuroblastoma; dbSNP
Q99453	241	Natural variant	A	1.0	description:in CCHS1
Q15149	2110	Natural variant	R	1.0	description:in EBS5A; dbSNP
Q03252	427	Natural variant	A	1.0	description:in APLD; dbSNP
Q71SY5	335	Natural variant	A	1.0	description:in CMT2B2; dbSNP
Q7Z494	1314	Natural variant	S	1.0	description:in NPHP3; likely benign variant; dbSNP
O75161	469	Natural variant	R	1.0	description:in NPHP4; dbSNP
O75161	541	Natural variant	P	1.0	description:found in a patient with cardiac laterality defects; unknown pathological significance; dbSNP
O75161	627	Natural variant	T	1.0	description:in SLSN4; dbSNP
O75161	848	Natural variant	R	1.0	description:does not affect interaction with RPGRIP1L; does not affect interaction with RPGRIP1; dbSNP
O75161	883	Natural variant	V	1.0	description:found in a patient with cardiac laterality defects; unknown pathological significance; dbSNP
O75161	906	Natural variant	R	1.0	description:found in a patient with cardiac laterality defects; unknown pathological significance; dbSNP
A6NGG8	372	Natural variant	D	1.0	description:in RP54; dbSNP
A6NGG8	612	Natural variant	L	1.0	description:in RP54; dbSNP
A6NGG8	615	Natural variant	V	1.0	description:in RP54; dbSNP
A6NGG8	1176	Natural variant	Q	1.0	description:found in patients with pathologic myopia; unknown pathological significance; dbSNP
P09874	488	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
P31274	87	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation
Q9Y5N1	280	Natural variant	A	1.0	description:in a Shy-Drager syndrome patient; unknown pathological significance; dbSNP
P08887	358	Natural variant	D	1.0	description:significantly associated with circulating levels of IL6 and soluble IL6R; increases cleavage by ADAM17; dbSNP
O15131	48	Natural variant	F	1.0	description:in a breast cancer sample; somatic mutation
Q96PU5	355	Natural variant	P	1.0	description:impaired ability to inhibit SCNN; dbSNP
Q8IUM7	344	Natural variant	P	1.0	description:does not affect the transcription factor activity; dbSNP
Q8IUM7	359	Natural variant	T	1.0	description:does not affect the transcription factor activity; dbSNP
Q8IUM7	472	Natural variant	P	1.0	description:does not affect the transcription factor activity; dbSNP
Q8IUM7	500	Natural variant	Q	1.0	description:does not affect the transcription factor activity; dbSNP
Q8IUM7	587	Natural variant	T	1.0	description:does not affect the transcription factor activity; dbSNP
Q8IUM7	702	Natural variant	N	1.0	description:does not affect the transcription factor activity; dbSNP
Q8IUM7	750	Natural variant	D	1.0	description:does not affect the transcription factor activity; dbSNP
Q8IUM7	777	Natural variant	T	1.0	description:does not affect the transcription factor activity; dbSNP
Q06495	48	Natural variant	A	1.0	description:in NPHLOP1; causes hypophosphatemic urolithiasis; requires 2 nucleotide substitutions; results in lower phosphate current, decreases affinity for phosphate and decreases phosphate uptake compared to wild-type; shows a dominant-negative effect; dbSNP
O95167	62	Natural variant	N	1.0	description:in a breast cancer sample; somatic mutation
O43272	19	Natural variant	Q	1.0	description:moderate reduction of enzymatic activity; dbSNP
O43272	167	Natural variant	A	1.0	description:may be a risk factor for schizophrenia; moderate reduction of enzymatic activity; dbSNP
O43272	185	Natural variant	R	1.0	description:mild decrease of enzymatic activity; dbSNP
O43272	185	Natural variant	R	1.0	description:moderate reduction of enzymatic activity; dbSNP
P01042	379	Natural variant	M	1.0	description:in HAE6
P01042	574	Natural variant	P	1.0	description:in HAE6; unknown pathological significance
Q96RE7	298	Natural variant	R	1.0	description:in NECFM; dbSNP
Q9P0J0	5	Natural variant	K	1.0	description:in a Hurthle cell variant of papillary carcinoma sample; dbSNP
Q99571	6	Natural variant	A	1.0	description:does not change ATP-induced inward current; does not change affinity for ATP; dbSNP
Q15645	26	Natural variant	H	1.0	description:in OOMD9; decreased protein level in patient cells; dbSNP
P0CW18	599	Natural variant	P	1.0	description:in MCOP6; dbSNP
P78386	78	Natural variant	R	1.0	description:in ECTD4; dbSNP
P51787	2	Natural variant	A	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	7	Natural variant	P	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	46	Natural variant	A	1.0	description:in LQT1; unknown pathological significance; hardly any effect on channel activity, shows fast activation; dbSNP
P51787	66	Natural variant	S	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	73	Natural variant	P	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	398	Natural variant	K	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	417	Natural variant	V	1.0	description:in LQT1; associated with M-254 in a patient; dbSNP
P51787	446	Natural variant	D	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	448	Natural variant	P	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	448	Natural variant	P	1.0	description:in LQT1; benign variant; dbSNP
P51787	451	Natural variant	R	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	452	Natural variant	R	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	455	Natural variant	H	1.0	description:in LQT1; loss of channel activity; dbSNP
P51787	460	Natural variant	G	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	477	Natural variant	P	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	573	Natural variant	F	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	583	Natural variant	R	1.0	description:in LQT1; dbSNP
P51787	583	Natural variant	R	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	586	Natural variant	N	1.0	description:in LQT1; decreases outward potassium current; decreases plasma membrane localization; dbSNP
P51787	587	Natural variant	T	1.0	description:in LQT1; dbSNP
P51787	589	Natural variant	G	1.0	description:in LQT1 and JLNS1; affects plasma membrane localization; strongly reduces potassium current; impairs binding to AKAP9 and the targeting protein kinase A (PKA) catalytic subunit and protein phosphatase 1 (PP1); dbSNP
P51787	590	Natural variant	A	1.0	description:in LQT1; reduces IKs density and causes a right-shift of the current?voltage relation of channel activation; reduces cell surface expression; no effect on interaction with AKAP9; does not affect the cAMP-dependent IKs up-regulation; dbSNP
P51787	591	Natural variant	R	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	591	Natural variant	R	1.0	description:in LQT1; dbSNP
P51787	594	Natural variant	R	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	594	Natural variant	R	1.0	description:in LQT1; dbSNP
P51787	596	Natural variant	E	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	596	Natural variant	E	1.0	description:in LQT1; unknown pathological significance
P51787	600	Natural variant	T	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	611	Natural variant	D	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	614	Natural variant	H	1.0	description:in LQT1; unknown pathological significance; dbSNP
P51787	619	Natural variant	L	1.0	description:in LQT1; decreases outward potassium current; decreases plasma membrane localization; dbSNP
P51787	626	Natural variant	G	1.0	description:in LQT1; dbSNP
P51787	635	Natural variant	G	1.0	description:in LQT1; unknown pathological significance; dbSNP
Q8IUG1	34	Natural variant	C	1.0	description:in allele KAP1.8B; dbSNP
Q8IUG1	40	Natural variant	C	1.0	description:in allele KAP1.8A
Q8IUG1	82	Natural variant	G	1.0	description:in allele KAP1.8B
O15118	248	Natural variant	G	1.0	description:in NPC1; dbSNP
P48145	19	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P08473	12	Natural variant	D	1.0	description:in CMT2T; unknown pathological significance
Q9UPR5	29	Natural variant	P	1.0	description:found in a family with atypical autism and severe epilepsy; unknown pathological significance; dbSNP
Q8WY41	78	Natural variant	S	1.0	description:in SPGF12
Q8WY41	173	Natural variant	A	1.0	description:in SPGF12; dbSNP
Q8WY41	276	Natural variant	R	1.0	description:found in a patient affected by oligo-astheno-teratozoospermia also carrying H-246 on the same allele; requires 2 nucleotide substitutions; unknown pathological significance; dbSNP
O95613	2424	Natural variant	R	1.0	description:found in a patient with intellectual disability, no speech, facial and limbs dysmorphisms; dbSNP
Q9UIF7	18	Natural variant	P	1.0	description:in FAP2; also found in multiple polyposis, colorectal and lung cancer cases; unknown pathological significance; decreased function in DNA repair; dbSNP
Q9UIF7	22	Natural variant	V	1.0	description:does not affect function in DNA repair; dbSNP
Q9UIF7	25	Natural variant	G	1.0	description:does not affect function in DNA repair; dbSNP
Q9UIF7	319	Natural variant	S	1.0	description:does not affect DNA glycosylase activity; does not affect function in DNA repair; dbSNP
Q9UIF7	335	Natural variant	Q	1.0	description:does not affect function in DNA repair; dbSNP
Q9UIF7	335	Natural variant	Q	1.0	description:found in a family with non-polyposis colorectal cancer-like syndrome; unknown pathological significance; does not affect function in DNA repair; dbSNP
Q9UIF7	370	Natural variant	A	1.0	description:does not affect DNA glycosylase activity; dbSNP
Q9UIF7	500	Natural variant	G	1.0	description:decreased function in DNA repair; dbSNP
Q9UIF7	512	Natural variant	S	1.0	description:does not affect DNA glycosylase activity; does not affect function in DNA repair; dbSNP
Q9UIF7	513	Natural variant	P	1.0	description:does not affect function in DNA repair; dbSNP
Q9UIF7	520	Natural variant	R	1.0	description:does not affect DNA glycosylase activity; does not affect function in DNA repair; dbSNP
Q9UIF7	526	Natural variant	L	1.0	description:does not affect function in DNA repair; dbSNP
Q9UIF7	531	Natural variant	R	1.0	description:does not affect function in DNA repair; dbSNP
Q9UIF7	536	Natural variant	T	1.0	description:does not affect DNA glycosylase activity; does not affect function in DNA repair; dbSNP
P46934	627	Natural variant	Y	1.0	description:in a breast cancer sample; somatic mutation
P21359	31	Natural variant	H	1.0	description:in NF1; dbSNP
P21359	665	Natural variant	S	1.0	description:in NF1; unknown pathological significance; dbSNP
P21359	844	Natural variant	L	1.0	description:in NF1; dbSNP
P21359	844	Natural variant	L	1.0	description:in NF1; dbSNP
P21359	844	Natural variant	L	1.0	description:in NF1; sporadic; dbSNP
P21359	847	Natural variant	L	1.0	description:in NF1; dbSNP
P21359	848	Natural variant	G	1.0	description:in NF1; dbSNP
P21359	2507	Natural variant	T	1.0	description:in NF1; dbSNP
P41143	27	Natural variant	C	1.0	description:improved maturation and increased expression at the cell surface; dbSNP
O95206	956	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
P54278	423	Natural variant	A	1.0	description:normal DNA mismatch repair activity; dbSNP
P54278	437	Natural variant	P	1.0	description:in MMRCS4; unknown pathological significance; normal DNA mismatch repair activity; dbSNP
P54278	470	Natural variant	P	1.0	description:no effect on protein abundance; no effect on subcellular localization; normal DNA mismatch repair activity; dbSNP
P54278	475	Natural variant	V	1.0	description:no effect on protein levels; dbSNP
P54278	479	Natural variant	H	1.0	description:in MMRCS4 and HNPCC4; unknown pathological significance; normal DNA mismatch repair activity; dbSNP
P54278	485	Natural variant	T	1.0	description:normal DNA mismatch repair activity; dbSNP
P54278	488	Natural variant	A	1.0	description:in MMRCS4; unknown pathological significance; normal DNA mismatch repair activity; dbSNP
P54278	504	Natural variant	E	1.0	description:in MMRCS4; unknown pathological significance; normal DNA mismatch repair activity; dbSNP
P54278	511	Natural variant	T	1.0	description:normal DNA mismatch repair activity; dbSNP
P54278	511	Natural variant	T	1.0	description:normal DNA mismatch repair activity; dbSNP
P54278	541	Natural variant	K	1.0	description:normal DNA mismatch repair activity; dbSNP
P54278	563	Natural variant	R	1.0	description:normal DNA mismatch repair activity; dbSNP
P54278	571	Natural variant	L	1.0	description:normal DNA mismatch repair activity; dbSNP
P54278	585	Natural variant	L	1.0	description:in MMRCS4 and HNPCC4; unknown pathological significance; normal DNA mismatch repair activity; dbSNP
P54278	597	Natural variant	T	1.0	description:normal DNA mismatch repair activity; significantly reduced interaction with MLH1; dbSNP
Q8NC56	13	Natural variant	L	1.0	description:in CTRCT46; dbSNP
P04180	17	Natural variant	L	1.0	description:in LCATD
Q9HBW1	579	Natural variant	T	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UNW1	41	Natural variant	S	1.0	description:in NMTC2; somatic mutation; dbSNP
P35548	148	Natural variant	P	1.0	description:in CRS2; gain of function; dbSNP
P35548	148	Natural variant	P	1.0	description:in CRS2; dbSNP
Q9HB07	4	Natural variant	R	1.0	description:loss of mitochondrial location
P12036	796	Natural variant	K	1.0	description:in ALS
P23760	99	Natural variant	G	1.0	description:in WS1; dbSNP
P23760	391	Natural variant	Q	1.0	description:in WS1
P14859	88	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q16512	873	Natural variant	F	1.0	description:in a breast infiltrating ductal carcinoma sample; somatic mutation
Q16512	921	Natural variant	A	1.0	description:in a colorectal adenocarcinoma sample; somatic mutation
O14901	62	Natural variant	Q	1.0	description:high frequency in individuals with diabetes mellitus type 2; increased repression activity; increased binding to SIN3A; impairs activation of insulin promoter; dbSNP
O14901	220	Natural variant	T	1.0	description:in MODY7; absent in one family member with diabetes; increased repression activity; no alteration in binding affinity to SIN3A; dbSNP
O14901	347	Natural variant	A	1.0	description:in MODY7; increased repression activity; no alteration in binding affinity to SIN3A; dbSNP
O60333	34	Natural variant	S	1.0	description:in a medulloblastoma sample; somatic mutation; loss of ability to induce apoptosis; dbSNP
O60333	873	Natural variant	T	1.0	description:confers susceptibility to neuroblastoma; found as germline mutation in a neuroblastoma patient; loss of ability to induce apoptosis; dbSNP
O60333	1527	Natural variant	S	1.0	description:confers susceptibility to pheochromocytoma; found as germline mutation in a pheochromocytoma family; loss of ability to induce apoptosis; dbSNP
Q9UHB6	25	Natural variant	L	1.0	description:associated with lower plasma levels of low-density lipoprotein cholesterol; reduces protein stability; dbSNP
Q86YR7	1039	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
O43612	16	Natural variant	L	1.0	description:in NRCLP1; early-onset; impaired trafficking and processing; dbSNP
Q9NQU5	3	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q969Z4	422	Natural variant	R	1.0	description:in AI3C; unknown pathological significance; dbSNP
Q12792	349	Natural variant	T	1.0	description:found in a patient with isolated coloboma, increases interaction with ACTG1
O14795	209	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation
Q9BSI4	280	Natural variant	K	1.0	description:in DKCA3; dbSNP
Q9BSI4	282	Natural variant	R	1.0	description:in DKCA3 and DKCA5; dbSNP
Q9BSI4	282	Natural variant	R	1.0	description:in DKCA3; dbSNP
P53804	1038	Natural variant	S	1.0	description:in an extended family with high risk of late-onset Alzheimer Disease; dbSNP
P53804	1289	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
Q9C0G0	802	Natural variant	G	1.0	description:in SIMHA; unknown pathological significance
Q9C0G0	939	Natural variant	V	1.0	description:in SIMHA
Q9C0G0	962	Natural variant	R	1.0	description:in SIMHA; unknown pathological significance
Q9C0G0	1214	Natural variant	K	1.0	description:in SIMHA; unknown pathological significance
Q14191	1367	Natural variant	C	1.0	description:associated with a higher risk of myocardial infarction; dbSNP
O60315	99	Natural variant	N	1.0	description:in MOWS
O60315	953	Natural variant	R	1.0	description:in MOWS
O60315	983	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation
O60315	1119	Natural variant	Q	1.0	description:in MOWS; dbSNP
Q9H6B1	386	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9H6B1	387	Natural variant	H	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UIJ5	306	Natural variant	S	1.0	description:in a hepatocellular carcinoma sample; somatic mutation
Q9UIJ5	356	Natural variant	M	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q68DE3	1472	Natural variant	Q	1.0	description:rare variant; may be a risk factor for epithelial thyroid carcinoma; results in increased epithelial-mesenchimal transition when coexpressed with 1470-Q--Q-1472 del
O75695	6	Natural variant	S	1.0	description:in RP2; loss of membrane association; enhances interaction with ARL3; dbSNP
Q8IYH5	456	Natural variant	P	1.0	description:in a colorectal cancer sample; somatic mutation
Q5T1R4	484	Natural variant	V	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9NTW7	593	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q9NTW7	609	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
Q15025	263	Natural variant	R	1.0	description:in patients with gastrointestinal diffuse large cell lymphoma; dbSNP
Q15025	286	Natural variant	T	1.0	description:in patients with gastrointestinal diffuse large cell lymphoma; somatic mutation; dbSNP
P04435	30	Natural variant	K	1.0	description:in IMGTALLELETRBV7-9*02
P47985	14	Natural variant	V	1.0	description:in MC3DN10; loss of localization to mitochondrial inner membrane; the mutant protein is distributed over the entire cytosol and in the nucleus; dbSNP
Q9BYV6	392	Natural variant	P	1.0	description:rare variant; found in a patient with hypertrophic cardiomyopathy; unknown pathological significance; dbSNP
Q9BYV6	452	Natural variant	K	1.0	description:rare variant; found in a patient with hypertrophic cardiomyopathy; unknown pathological significance; dbSNP
Q9BYV6	506	Natural variant	T	1.0	description:rare variant; found in a patient with hypertrophic cardiomyopathy; unknown pathological significance; dbSNP
Q9H582	53	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q9H582	242	Natural variant	T	1.0	description:in MYP21; unknown pathological significance; dbSNP
Q9H582	274	Natural variant	E	1.0	description:in MYP21; unknown pathological significance; dbSNP
Q9H582	305	Natural variant	E	1.0	description:in MYP21; unknown pathological significance; dbSNP
Q9H582	369	Natural variant	K	1.0	description:variant of uncertain significance
Q9H582	401	Natural variant	T	1.0	description:in MYP21; unknown pathological significance
Q9H582	587	Natural variant	I	1.0	description:in MYP21; dbSNP
Q9H582	672	Natural variant	S	1.0	description:in MYP21; dbSNP
Q9H582	680	Natural variant	R	1.0	description:in MYP21
Q9H582	683	Natural variant	R	1.0	description:in MYP21; unknown pathological significance; dbSNP
Q9H582	699	Natural variant	C	1.0	description:in MYP21
Q9H582	851	Natural variant	D	1.0	description:in MYP21; unknown pathological significance
Q9H582	956	Natural variant	T	1.0	description:in MYP21; unknown pathological significance; dbSNP
Q9H1D0	18	Natural variant	A	1.0	description:likely benign variant; no effect on localization at the plasma membrane; no change in calcium ion import across plasma membrane; dbSNP
O15391	103	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q5T9L3	531	Natural variant	I	1.0	description:in ZKS; results in decreased secretion of WNT3A and WNT5A; decreased activation of WNT signaling
Q5T9L3	536	Natural variant	R	1.0	description:in ZKS; results in decreased secretion of WNT3A and WNT5A; decreased activation of WNT signaling
Q96J92	562	Natural variant	E	1.0	description:in PHA2B; impaired interaction with KLHL3; dbSNP
Q96J92	564	Natural variant	D	1.0	description:in PHA2B; impaired interaction with KLHL3; dbSNP
Q96J92	565	Natural variant	Q	1.0	description:in PHA2B; impaired interaction with KLHL3; dbSNP
Q96J92	992	Natural variant	P	1.0	description:in a metastatic melanoma sample; somatic mutation
Q96J92	1185	Natural variant	R	1.0	description:in PHA2B; dbSNP
O75362	323	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
O60481	17	Natural variant	G	1.0	description:unknown pathological significance; no effect on its transcriptional activator activity or subcellular localization; dbSNP
O60481	46	Natural variant	A	1.0	description:in VACTERLX
O60481	53	Natural variant	A	1.0	description:unknown pathological significance; no effect on its transcriptional activator activity or subcellular localization
O60481	109	Natural variant	S	1.0	description:in CHTD1; does not affect its transcriptional activator activity; decrease in nuclear localization; dbSNP
O60481	217	Natural variant	P	1.0	description:in HTX1 and CHTD1; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3; decrease in nuclear localization; dbSNP
O60481	447	Natural variant	A	1.0	description:in CHTD1; Increase in transcriptional activator activity; decrease in nuclear localization
Q8WYQ9	290	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q8TF50	160	Natural variant	K	1.0	description:in DENNED; unknown pathological significance
Q8TF50	409	Natural variant	H	1.0	description:in DENNED; unknown pathological significance
P37840	30	Natural variant	A	1.0	description:in PARK1; no effect on oligomerization; dbSNP
P37840	46	Natural variant	E	1.0	description:in PARK1 and DLB; significant increase in binding to negatively charged phospholipid liposomes; increases oligomerization; dbSNP
P37840	50	Natural variant	H	1.0	description:in PARK1; no effect on protein structure; no effect on phosphorylation of the protein; no effect on membrane- and lipid-binding; increases oligomerization; increases fibril formation; increases secretion of the protein; impairs copper-binding; dbSNP
P37840	53	Natural variant	A	1.0	description:in PARK1; no effect on osmotic stress-induced phosphorylation; increases oligomerization; dbSNP
Q96RU8	371	Natural variant	F	1.0	description:in a lung large cell carcinoma sample; somatic mutation
P17861	12	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
P17861	232	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q8NAP8	181	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UJT2	19	Natural variant	G	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9H0D2	712	Natural variant	S	1.0	description:in a breast cancer sample; somatic mutation
Q8IYB0	129	Natural variant	D	1.0	description:in a colorectal cancer sample; somatic mutation
Q9UHD9	155	Natural variant	S	1.0	description:in ALS15; uncertain pathological significance; dbSNP
Q9UHD9	282	Natural variant	A	1.0	description:probable disease-associated variant found in a patient with frontotemporal dementia; dbSNP
Q9UHD9	283	Natural variant	A	1.0	description:in ALS15; dbSNP
Q9UHD9	425	Natural variant	Q	1.0	description:in ALS15; dbSNP
Q9UHD9	487	Natural variant	T	1.0	description:in ALS15; dbSNP
Q9UHD9	497	Natural variant	P	1.0	description:in ALS15; leads to defective ubiquitin-mediated proteasomal degradation; reduces binding to HNRNPA1 and FAF2; increases translocation of HNRNPA1 to the cytoplasm; adversely affects ERAD; dbSNP
Q9UHD9	497	Natural variant	P	1.0	description:in ALS15; reduces binding to HNRNPA1; increases translocation of HNRNPA1 to the cytoplasm; dbSNP
Q9UHD9	506	Natural variant	P	1.0	description:in ALS15; leads to defective ubiquitin-mediated proteasomal degradation; reduces binding to HNRNPA1; increases translocation of HNRNPA1 to the cytoplasm; dbSNP
Q9UHD9	509	Natural variant	P	1.0	description:in ALS15; reduces binding to HNRNPA1; increases translocation of HNRNPA1 to the cytoplasm; dbSNP
Q9UHD9	525	Natural variant	P	1.0	description:in ALS15; reduces binding to HNRNPA1; increases translocation of HNRNPA1 to the cytoplasm; dbSNP
Q9NZR4	17	Natural variant	L	1.0	description:in KTCN1; dbSNP
Q9NZR4	159	Natural variant	L	1.0	description:in KTCN1; unknown pathological significance; dbSNP
Q9NZR4	160	Natural variant	G	1.0	description:in KTCN1; unknown pathological significance; dbSNP
Q9NZR4	166	Natural variant	R	1.0	description:in KTCN1; sporadic; dbSNP
Q15649	31	Natural variant	S	1.0	description:in PEHO; increased protein degradation; decreased protein abundance; does not affect localization to cytoplasm and nucleus; dbSNP
Q9BUG6	146	Natural variant	E	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q96NL3	178	Natural variant	L	1.0	description:de novo variant found in a patient with intellectual disability; dbSNP
Q92574	246	Natural variant	R	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	305	Natural variant	G	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	305	Natural variant	G	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	336	Natural variant	R	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	362	Natural variant	P	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	411	Natural variant	L	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	417	Natural variant	T	1.0	description:in TSC1; unknown pathological significance; does not affect interaction with TSC2; dbSNP
Q92574	448	Natural variant	P	1.0	description:no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	500	Natural variant	R	1.0	description:in TSC1; dbSNP
Q92574	509	Natural variant	R	1.0	description:no effect on expression; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	523	Natural variant	A	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	567	Natural variant	A	1.0	description:no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	654	Natural variant	Q	1.0	description:in TSC1; dbSNP
Q92574	1035	Natural variant	G	1.0	description:no effect on expression; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	1043	Natural variant	S	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling
Q92574	1097	Natural variant	R	1.0	description:no effect on expression; no effect on inhibition of TORC1 signaling; dbSNP
Q92574	1146	Natural variant	D	1.0	description:in TSC1; unknown pathological significance; no effect on expression; no effect on subcellular localization; no effect on inhibition of TORC1 signaling; dbSNP
Q969Q1	5	Natural variant	S	1.0	description:rare variant; found in a patient with hypertrophic cardiomyopathy; unknown pathological significance; dbSNP
Q7Z4V0	381	Natural variant	K	1.0	description:in a breast cancer sample; somatic mutation
Q86UE3	15	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q86VR7	769	Natural variant	G	1.0	description:found in esophageal adenocarcinoma; somatic mutation; unknown pathological significance; dbSNP
Q96CV9	26	Natural variant	H	1.0	description:in GLC1E; dbSNP
Q96CV9	213	Natural variant	K	1.0	description:requires 2 nucleotide substitutions
Q96CV9	295	Natural variant	V	1.0	description:in ALS12; no effect on Golgi subcellular location; no effect on protein expression level; increased Golgi fragmentation; decreased Golgi ribbon formation; increased susceptibility to endoplasmic reticulum (ER) stress; dbSNP
Q96CV9	545	Natural variant	R	1.0	description:in GLC1E; unknown pathological significance; dbSNP
Q8TEW0	783	Natural variant	D	1.0	description:in NTD; reduces interaction with PRKCA, disrupts tight junction formation in epithelial cells; dbSNP
Q8TEW0	913	Natural variant	P	1.0	description:in NTD; reduces interaction with PRKCA; increases phosphorylation; disrupts tight junction formation in epithelial cells; dbSNP
P19224	7	Natural variant	S	1.0	description:in allele UGT1A6*2, allele UGT1A6*3 and allele UGT1A6*4; dbSNP
P35916	1235	Natural variant	S	1.0	description:in LMPHM1; recessive form
P02788	22	Natural variant	R	1.0	description:associated with lower plasma lactoferrin concentrations; dbSNP
P25445	25	Natural variant	A	1.0	description:in non-Hodgkin lymphoma; somatic mutation; dbSNP
P25445	28	Natural variant	T	1.0	description:in ALPS1A; associated with autoimmune hepatitis type 2
P25445	198	Natural variant	T	1.0	description:in non-Hodgkin lymphoma; somatic mutation
P00734	200	Natural variant	E	1.0	description:in FA2D; prothrombin type 3; variant confirmed at protein level; dbSNP
P00734	314	Natural variant	R	1.0	description:in FA2D; Barcelona/Madrid; dbSNP
P00734	314	Natural variant	R	1.0	description:in FA2D; Padua-1; dbSNP
P07951	2	Natural variant	D	1.0	description:probable disease-associated variant found in patients with undefined congenital myopathy; dbSNP
P07951	3	Natural variant	A	1.0	description:in NEM4
P07951	7	Natural variant	K	1.0	description:in NEM4
P07951	14	Natural variant	D	1.0	description:in NEM4; dbSNP
Q13488	141	Natural variant	A	1.0	description:in OPTB1
O95409	36	Natural variant	Q	1.0	description:in HPE5; 2-fold increase in luciferase activity; dbSNP
O95409	37	Natural variant	D	1.0	description:in HPE5
O95409	128	Natural variant	D	1.0	description:in HPE5
O95409	152	Natural variant	D	1.0	description:in HPE5; requires 2 nucleotide substitutions; 50% reduction of luciferase activity
O95409	415	Natural variant	H	1.0	description:in HPE5; dbSNP
O95409	470	Natural variant	A	1.0	description:in HPE5; near-complete loss of luciferase activity
O60281	2354	Natural variant	N	1.0	description:in MRD64; unknown pathological significance
Q96K58	66	Natural variant	A	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P45379	38	Natural variant	A	1.0	description:in CMH2; dbSNP
P45379	80	Natural variant	F	1.0	description:in CMH2; dbSNP
P45379	89	Natural variant	I	1.0	description:in CMH2; dbSNP
P45379	151	Natural variant	R	1.0	description:in CMD1D; dbSNP
P45379	170	Natural variant	E	1.0	description:in CMH2
P45379	173	Natural variant	E	1.0	description:in CMH2
P45379	189	Natural variant	S	1.0	description:in CMH2; dbSNP
P45379	210	Natural variant	K	1.0	description:in CMD1D
P45379	288	Natural variant	R	1.0	description:in CMH2; dbSNP
P45379	288	Natural variant	R	1.0	description:in CMH2; dbSNP
P45379	296	Natural variant	R	1.0	description:in CMH2; dbSNP
Q15672	83	Natural variant	G	1.0	description:found in a patient with non-syndromic ventricular septal defect; unknown pathological significance; loss of function in negative regulation of transcription from E-cadherin promoter; dbSNP
Q15672	95	Natural variant	S	1.0	description:no effect on negative regulation of transcription from E-cadherin promoter; dbSNP
Q13207	20	Natural variant	R	1.0	description:in VETD; unknown pathological significance; decreased transcriptional regulatory activity; no effect on localization to the nucleus; dbSNP
Q13207	305	Natural variant	R	1.0	description:in VETD; de novo variant; decreased transcriptional regulatory activity; no effect on localization to the nucleus; dbSNP
P10636	5	Natural variant	R	1.0	description:in FTD; reduces the ability of tau to promote microtubule assembly and promotes fibril formation in vitro; dbSNP
P10636	5	Natural variant	R	1.0	description:in PSNP1; delays assembly initiation and lowers the mass of microtubules formed; but the assembly rate is increased compared to normal tau; dbSNP
P10636	285	Natural variant	D	1.0	description:risk factor for PSNP1; dbSNP
P10636	289	Natural variant	V	1.0	description:risk factor for PSNP1; dbSNP
P10636	574	Natural variant	K	1.0	description:in PIDB; reduces the ability to promote microtubule assembly by 70%; dbSNP
P10636	583	Natural variant	L	1.0	description:in FTD; less able to promote microtubule assembly than wild-type tau; dbSNP
P10636	589	Natural variant	G	1.0	description:in FTD; dbSNP
P10636	590	Natural variant	G	1.0	description:in FTD; increased aggregation propensity and altered binding affinity towards microtubules and F-actin; dbSNP
P10636	596	Natural variant	N	1.0	description:in FTD; with parkinsonism; dbSNP
P10636	597	Natural variant	K	1.0	description:in FTD; dbSNP
P10636	613	Natural variant	N	1.0	description:in FTD; reduced the ability of tau to promote microtubule assembly without having a significant effect on tau filament formation; effects at both the RNA and the protein level; dbSNP
P10636	613	Natural variant	N	1.0	description:in PSNP1/atypical PSNP1; heterozygosity may be a risk factor for both a PSNP1-like syndrome and Parkinson disease; reduced the ability of tau to promote microtubule assembly without having a significant effect on tau filament formation; effects at both the RNA and the protein level
P10636	618	Natural variant	P	1.0	description:in FTD; most common mutation; reduction in the ability to promote microtubule assembly; accelerates aggregation of tau into filaments; dbSNP
P10636	618	Natural variant	P	1.0	description:in FTD and CBD; reduction in the ability to promote microtubule assembly; dbSNP
P10636	620	Natural variant	G	1.0	description:in PSNP1; dbSNP
P10636	622	Natural variant	S	1.0	description:in FTD; minimal parkinsonism; very early age of onset; dbSNP
P10636	634	Natural variant	K	1.0	description:in FTD; dbSNP
P10636	637	Natural variant	S	1.0	description:in PIDB; markedly reduced ability of tau to promote microtubule assembly; dbSNP
P10636	654	Natural variant	V	1.0	description:in FTD; ultrastructural and biochemical characteristics indistinguishable from Alzheimer disease; accelerates aggregation of tau into filaments; dbSNP
P10636	659	Natural variant	E	1.0	description:in FTD; dbSNP
P10636	669	Natural variant	S	1.0	description:in fatal respiratory hypoventilation; unusual apparent autosomal recessive inheritance; reduced binding to microtubules as well as increased fibrillization and aggregation; dbSNP
P10636	686	Natural variant	K	1.0	description:in PIDB; 90% reduction in the rate of microtubule assembly; dbSNP
P10636	706	Natural variant	G	1.0	description:in PIDB; in vitro the mutation reduces the ability of tau to promote microtubule assembly by 25 to 30%; dbSNP
P10636	723	Natural variant	R	1.0	description:in FTD/Alzheimer disease; accelerates aggregation of tau into filaments; reduces tau phosphorylation in cells compared to both the wild-type and other mutant forms; dbSNP
Q15915	400	Natural variant	G	1.0	description:in CRS6; dbSNP
Q9H9D4	126	Natural variant	S	1.0	description:in EVR6; unknown pathological significance; does not affect localization to the nucleus; dbSNP
Q8N1G0	242	Natural variant	S	1.0	description:in PDB6; unknown pathological significance; dbSNP
Q8N1G0	937	Natural variant	P	1.0	description:in PDB6; enhances nuclear localization; increases expression levels; R-937 containing osteoclasts induced by treatment of peripheral blood mononuclear cells with CSF1 and TNFSF11 exhibit a greater number of nuclei, as well as a larger surface area than did those from the control individuals; dbSNP
O15527	12	Natural variant	G	1.0	description:found in a kidney cancer sample; no effect on activity; abolishes mitochondrial localization; dbSNP
O15527	46	Natural variant	R	1.0	description:found in a clear cell renal cell carcinoma sample; somatic mutation; diminished activity; dbSNP
A3KN83	889	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
Q15772	1178	Natural variant	E	1.0	description:in a gastric adenocarcinoma sample; somatic mutation; dbSNP
Q15772	1903	Natural variant	R	1.0	description:in an ovarian mucinous carcinoma sample; somatic mutation; dbSNP
Q15772	2757	Natural variant	G	1.0	description:in CNM5; dbSNP
O43818	8	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
O95935	524	Natural variant	H	1.0	description:in CAKUT2; results in decreased transcriptional repression through a dominant negative effect; does not affect nuclear localization; no effect on DNA binding; no effect on interaction with SIX1; no effect on interaction with TLE3; dbSNP
Q9H808	130	Natural variant	D	1.0	description:in PREMBL1; unknown pathological significance; dbSNP
Q9H808	240	Natural variant	A	1.0	description:in PREMBL1; unknown pathological significance
Q96Q45	155	Natural variant	D	1.0	description:found at heterozygosity in a patient with Bardet-Biedl syndrome also carrying BBS6 mutation A-57 in MKKS; hypomorphic variant
Q5SV17	149	Natural variant	E	1.0	description:in SCA21; dbSNP
Q5SV17	170	Natural variant	P	1.0	description:in SCA21; dbSNP
Q5SV17	171	Natural variant	R	1.0	description:in SCA21; dbSNP
Q8IWU9	36	Natural variant	L	1.0	description:the property of the variant is indistinguishable from the wild-type; dbSNP
Q8IWU9	36	Natural variant	L	1.0	description:the property of the variant is indistinguishable from the wild-type; dbSNP
Q8IWU9	41	Natural variant	S	1.0	description:the property of the variant is indistinguishable from the wild-type; dbSNP
Q8IWU9	55	Natural variant	R	1.0	description:the property of the variant is indistinguishable from the wild-type; dbSNP
Q9BX84	1663	Natural variant	Q	1.0	description:no effect on function or cell membrane localization; dbSNP
Q9BX84	1754	Natural variant	S	1.0	description:in HOMG1; loss of function; no effect on cell membrane localization
P22309	15	Natural variant	L	1.0	description:in CN2; mutant protein rapidly degraded by the proteasome owing to its mislocalization in the cell; dbSNP
Q9Y462	139	Natural variant	G	1.0	description:in XLID97; unknown pathological significance; dbSNP
Q9Y462	244	Natural variant	I	1.0	description:in XLID97; dbSNP
Q9Y462	274	Natural variant	H	1.0	description:in XLID97; unknown pathological significance; dbSNP
P78424	192	Natural variant	Q	1.0	description:in WT5
Q8IZ69	604	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
O43914	2	Natural variant	G	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance; associated in cis with L-55 in some patients; dbSNP
O43914	23	Natural variant	R	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance; dbSNP
O43914	47	Natural variant	V	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance; dbSNP
O43914	50	Natural variant	D	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance; causes reduced expression; also leads to reduced expression of TREM2
O43914	55	Natural variant	V	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance; associated in cis with E-2 in some patients; dbSNP
O43914	80	Natural variant	R	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance; dbSNP
O43914	84	Natural variant	I	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance
O43914	89	Natural variant	S	1.0	description:found in patients with early-onset Alzheimer disease; unknown pathological significance; dbSNP
Q70EL1	505	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q9NRM2	445	Natural variant	L	1.0	description:in a breast cancer sample; somatic mutation
Q8N8E2	339	Natural variant	C	1.0	description:in RP58; cannot bind to promoters of retinal-specific genes; dbSNP
Q07955	89	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q86UE8	173	Natural variant	F	1.0	description:in a gastric adenocarcinoma sample; somatic mutation; dbSNP
P40818	718	Natural variant	S	1.0	description:in PITA4; somatic mutation; unknown pathological significance; dbSNP
P40818	718	Natural variant	S	1.0	description:in PITA4; somatic mutation; unknown pathological significance; localizes to nucleus instead of cytoplasm; dbSNP
P40818	718	Natural variant	S	1.0	description:in PITA4; somatic mutation; unknown pathological significance
P40818	720	Natural variant	P	1.0	description:in PITA4; somatic mutation; unknown pathological significance; dbSNP
Q96E52	69	Natural variant	H	1.0	description:in a patient with amyotrophic lateral sclerosis; dbSNP
Q15319	64	Natural variant	D	1.0	description:in DFNA15
Q15319	164	Natural variant	P	1.0	description:in DFNA15; unknown pathological significance; dbSNP
Q15319	281	Natural variant	I	1.0	description:in DFNA15
P07204	486	Natural variant	D	1.0	description:in THPH12 and AHUS6; cells transfected with the mutant are less effective in converting C3b to iC3b on the cell surface after complement activation; dbSNP
P07204	495	Natural variant	P	1.0	description:in AHUS6; cells transfected with the mutant are less effective in converting C3b to iC3b on the cell surface after complement activation; dbSNP
P07204	501	Natural variant	P	1.0	description:in AHUS6; cells transfected with the mutant are less effective in converting C3b to iC3b on the cell surface after complement activation; dbSNP
Q9UNS1	1008	Natural variant	Q	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
Q8TBZ6	82	Natural variant	P	1.0	description:in a breast cancer sample; somatic mutation
Q00341	939	Natural variant	D	1.0	description:in a breast cancer sample; somatic mutation
Q92889	490	Natural variant	R	1.0	description:in XP-F; dbSNP
Q92889	502	Natural variant	E	1.0	description:in XP-F
Q92889	513	Natural variant	G	1.0	description:in XP-F; dbSNP
Q92889	529	Natural variant	I	1.0	description:in XP-F
Q92610	1046	Natural variant	G	1.0	description:found in a patient with clinical features of Galloway-Mowat syndrome; unknown pathological significance; dbSNP
Q8TD43	844	Natural variant	G	1.0	description:in PFHB1B; right bundle-branch block; dbSNP
P35968	2	Natural variant	Q	1.0	description:in a lung adenocarcinoma sample; somatic mutation
Q969T9	160	Natural variant	A	1.0	description:in DFNB107; dbSNP
Q969T9	163	Natural variant	M	1.0	description:in DFNB107; unknown pathological significance; dbSNP
Q969T9	224	Natural variant	A	1.0	description:in DFNB107; unknown pathological significance; dbSNP
Q96NG8	65	Natural variant	W	1.0	description:found in a patient with mild intellectual disability and eye movement disorder; unknown pathological significance; dbSNP
Q9BVV6	403	Natural variant	R	1.0	description:in JBTS23; unknown pathological significance; dbSNP
Q9BVV6	566	Natural variant	D	1.0	description:in JBTS23
Q9HBL0	1197	Natural variant	F	1.0	description:in a breast cancer sample; somatic mutation
Q13432	22	Natural variant	G	1.0	description:in IMD13; impairs interaction with LCK; impairs LCK activation; induces LCK mislocalization; dbSNP
Q8IWV7	1102	Natural variant	Q	1.0	description:in JBS; strong decrease in activity in a yeast-based assay
P51814	153	Natural variant	P	1.0	description:rare variant found in patients with X-linked intellectual disability; unknown pathological significance; dbSNP
Q6ZVT0	130	Natural variant	A	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q9ULK5	84	Natural variant	S	1.0	description:in NTD; dbSNP
P56705	12	Natural variant	L	1.0	description:in MULLAPL; unable to suppress steroidogenesis in an ovarian adenocarcinoma cell line resulting in increased androgen production; dbSNP
P19544	131	Natural variant	A	1.0	description:in a patient with hypospadias
P19544	181	Natural variant	P	1.0	description:in WT1; dbSNP
P19544	223	Natural variant	S	1.0	description:in WT1
P19544	253	Natural variant	G	1.0	description:in WT1
P19544	273	Natural variant	S	1.0	description:found in a mesothelioma sample; somatic mutation; dbSNP
P19544	281	Natural variant	L	1.0	description:in RNA edited version
P19544	312	Natural variant	R	1.0	description:in NPHS4
Q9H4T2	137	Natural variant	R	1.0	description:in a colorectal cancer sample; somatic mutation; dbSNP
Q14643	2554	Natural variant	G	1.0	description:in GLSP; dbSNP
Q3KP66	333	Natural variant	Y	1.0	description:in IBD29; decreases protein stability; dbSNP
Q96RR4	127	Natural variant	P	1.0	description:in a lung neuroendocrine carcinoma sample; somatic mutation
P48634	1087	Natural variant	T	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P48634	1152	Natural variant	R	1.0	description:in a breast cancer sample; somatic mutation; dbSNP
P08575	230	Natural variant	E	1.0	description:in a breast cancer sample; somatic mutation
